{\rtf1\ansi\ansicpg1252\uc1 \deff28\deflang1033\deflangfe1033\deftab360{\fonttbl{\f0\froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f2\fmodern\fcharset0\fprq1{\*\panose 02070309020205020404}Courier New;}{\f3\froman\fcharset2\fprq2{\*\panose 05050102010706020507}Symbol;}{\f4\froman\fcharset0\fprq2{\*\panose 00000000000000000000}Times;}{\f14\fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f28\fswiss\fcharset128\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f29\fswiss\fcharset128\fprq2{\*\panose 00000000000000000000}@Arial Unicode MS;}{\f128\froman\fcharset238\fprq2 Times New Roman CE;}{\f129\froman\fcharset204\fprq2 Times New Roman Cyr;}{\f131\froman\fcharset161\fprq2 Times New Roman Greek;}{\f132\froman\fcharset162\fprq2 Times New Roman Tur;}{\f133\froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f134\froman\fcharset178\fprq2 Times New Roman (Arabic);}{\f135\froman\fcharset186\fprq2 Times New Roman Baltic;}{\f144\fmodern\fcharset238\fprq1 Courier New CE;}{\f145\fmodern\fcharset204\fprq1 Courier New Cyr;}{\f147\fmodern\fcharset161\fprq1 Courier New Greek;}{\f148\fmodern\fcharset162\fprq1 Courier New Tur;}{\f149\fmodern\fcharset177\fprq1 Courier New (Hebrew);}{\f150\fmodern\fcharset178\fprq1 Courier New (Arabic);}{\f151\fmodern\fcharset186\fprq1 Courier New Baltic;}{\f354\fswiss\fcharset0\fprq2 Arial Unicode MS Western;}{\f352\fswiss\fcharset238\fprq2 Arial Unicode MS CE;}{\f353\fswiss\fcharset204\fprq2 Arial Unicode MS Cyr;}{\f355\fswiss\fcharset161\fprq2 Arial Unicode MS Greek;}{\f356\fswiss\fcharset162\fprq2 Arial Unicode MS Tur;}{\f357\fswiss\fcharset177\fprq2 Arial Unicode MS (Hebrew);}{\f358\fswiss\fcharset178\fprq2 Arial Unicode MS (Arabic);}{\f359\fswiss\fcharset186\fprq2 Arial Unicode MS Baltic;}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red221\green221\blue221;\red153\green153\blue153;\red222\green222\blue233;\red102\green51\blue204;\red150\green150\blue150;\red254\green248\blue217;}{\info{\title Factiva RTF Display Format}{\author Factiva, from Dow Jones.}{\operator Factiva, from Dow Jones.}{\creatim\yr2005\mo2\dy5\hr12\min00}{\revtim\yr2005\mo2\dy5\hr12\min00}{\version2}{\edmins4}{\nofpages1}{\nofwords16}{\nofchars93}{\*\company Factiva, from Dow Jones.}{\nofcharsws114}{\vern8279}} \paperh15840\paperw12240\widowctrl\ftnbj\aenddoc\noxlattoyen\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\hyphcaps0\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin1800\dgvorigin1440\dghshow1\dgvshow1\jexpand\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule \fet0\sectd \titlepg \linex0\endnhere\pgbrdropt32\sectlinegrid360\sectdefaultcl\margr1440\margl1440 {\headerf\pard\plain \s21\qc \li-1008\ri-1008\widctlpar\tqc\tx4320\tqr\tx8640\aspalpha\aspnum\faauto\adjustright\rin-1008\lin-1008\itap0 \fs20\lang1033\langfe1033\loch\af28\hich\af28\dbch\af28\cgrid\langnp1033\langfenp1033 {\f0\fs16\qr\ri0{\*\shppict{\pict\jpegblip\picw117\pich70\picscaley100\picscalex100\picwgoal1755\pichgoal1050
FF
D8FFE1001845786966000049492A00080000000000000000000000FFEC00114475636B79000100040000003C0000FFE1031F687474703A2F2F6E732E61646F62
652E636F6D2F7861702F312E302F003C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A7265537A4E54637A6B6339
64223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F626520584D5020436F7265
20352E362D633036372037392E3135373734372C20323031352F30332F33302D32333A34303A34322020202020202020223E203C7264663A52444620786D6C6E
733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E203C7264663A446573637269
7074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F22
20786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D
6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E7449443D22786D702E646964
3A41323833444137413541454331314535423730414642454331423332443443442220786D704D4D3A496E7374616E636549443D22786D702E6969643A413238
33444137393541454331314535423730414642454331423332443443442220786D703A43726561746F72546F6F6C3D2241646F62652050686F746F73686F7020
43432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D2243353942433442
41323033324339414238413541444443363033343137334630222073745265663A646F63756D656E7449443D2243353942433442413230333243394142384135
41444443363033343137334630222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F7870
61636B657420656E643D2272223F3EFFEE000E41646F62650064C000000001FFDB0084000604040405040605050609060506090B080606080B0C0A0A0B0A0A0C
100C0C0C0C0C0C100C0E0F100F0E0C1313141413131C1B1B1B1C1F1F1F1F1F1F1F1F1F1F010707070D0C0D181010181A1511151A1F1F1F1F1F1F1F1F1F1F1F1F
1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1F1FFFC00011080046007503011100021101031101FFC4007C00010003
01010100000000000000000000000306070405080101010101000000000000000000000000000102031000010303030203070403010000000000020001030405
061112072113314122513223141516086142331752433618110101010101000203010101000000000000010211213112415103226113FFDA000C030100021103
11003F00FAA501010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101010101
01061F985B723C9F9CA6C669328BAD86DF15942B986DF532C62F20CCC0FF000C4C47AB1F57FD1749E471D4B75CEBB78BAEF9759793EFBC757CBCCB7FA4A3A20B
8505C2AB579C59DE26702277227D5A7F327F77A69AA9AE73A62D9AE556305B4E7DCA768BBE5D2E6B73B219554D05B2DB412C915344D10898EF0030DCDEB61F6F
4D5DDF556F278CE65D7BD1F36CCB26FC6BACBF0DCAA69AFD67A91092BE9253A79658E290189CCA270FF54DEAF6EDD539268FB5B8EA3CBF9AEE1167D814D49592
C7678E8E8EAEFD1C6643097D4C4589A7067DA5DA8DD8877783BF45667CA6BFA7B176E31BCDE6FBCABC8359357D4CB67B64F15B68684A590A980E377090A389DF
6096B4FABBB37EEFD56753C8DE2DBAAD6161D593E417ABCC5F9218CDA22AFA88ED551679659EDE329B539C8DF37A19C4CFB08BD03D5DBC996E4FF2E56DFBC576
829B32E4CE42CC69DF2BB8E3D69C66ABE9F47496B90A1DE4C7206F37021DDD61727D757EBA368CCAF92333BAB7DF8498565D969F1EF26D96EB7396B6E787C771
A5A3BCB11054176E19C44F7B3EFDC2706E12D7775F1E8964EC33ABCB3F4AD71BF2C647271E64B8FE415D54D7BFA3575D31CBACD29BD44D13432396C99DF7B944
60E40FAEBD1DBA6D5759F59C6EF2CAECCBB2ACA20FC68C6EF105E2BA2BB4F5318CF710A9986A4C5CAA3563998B7937A5BC5FC924FF004BAD5FA45838ABEDAAAC
C602B57275E3279E9A29653B4561D53C060E1DB723697417D8523137EAA6BE3E1AC73BF3D52EFD94DCABF9072AB76599D5D70CA8A4A93871FA6A6EFC74650B11
768E4ECBB7420602DCFA6BAF8F92B279E462EBDBDBC6C5BF28FEA1DDF75DBFEADF2FFF005BAB7CAF67B9FCDBBDDDDD9F4EEFF2EAB1F975F7EBF2AE66566E51B6
72F4997E298EC77AA596D216F779AAA9E0162797B85D0E58CF56DADE5A755659CE56753535D91DDC6584E71F7D5E7903348E9E86E972A61A1A6B5D29B4831422
F1BBB910918EBF0474D09FCFC13567391719BDED5631CC6F9C38EA8EEB8D63362A3BE59EA2A25A8B6DCCEA6288A2EE8B036F8E492322D0405DC74F1D7ABB2B6C
ACC9ACF916EC1F8A6AEC5C395F8757184D71BA53D5BD4F6DF58C26A98DC00449F4D76330F5F6A975EF5BCE399E33DC33813286E33CBE8F20A3ED649730863B54
273432930D00B490334A06602D21FC3EA5D19BD8B577EB9E7F95FADEFCB45E00C1EFF89E1F57164503C17BB857CB5754252473168E2003B8E32317D76B978F9A
C6EF6BA7F2CD93D5AB3F87349318A9FB3278A0BFC6E274CD30810482CFEB8FE23388B90F83BF9FB149CFCB5AEF3C6738962DCA17CE57B7E6D995A69EC91DA2DC
5451C314F14EF399B48CE4CD11CBB7ACE4EFABB79375F15AB67391CF39D5D76A27C6796706CEB26BAE2166A5C8AD193CFF003A612D4474F24136E33767EE1C7D
374A5E1AEADA783A7659E9CD66DE7E5D387F19E6141C7F9EC978088F2BCCE2AE98A82031ED84D3C32B471EF72EDB3949317EEDACDA754BA9D8671797F75E25EB
83EFD75E16B0DBDA95A9736B0C530C50B4B133C91CF29F7698A51378F4303D5BD5A6BD3A6AEACD7A97F9DB9FFA9728E31CE6B7F1FAC189D2DB7B990515404955
45DFA71D82253BBBF70A4689FF00907C0926A77A6B17E922CD811F22864D4ED75E3BB5E3D6E90241A9BA51CD4852836C72116184C8DD88C459FA2979FB6B3DEF
C3C3CC31FE622BBDE2927C76D99E586B1CCAD12D6BD2412D101B938C7EA780DDC7769AB78E8CEC4CACB13535FAEA4FEA1CB7FF003CFD91BE2FAFEEF98EC773E1
6BF35F31D9EE7BBAEDF3F77779E9D54FB4FB74FF00CEFD38DB161D84040404040404040404040404040404040404040404040404040404040404040404040404
040404040404041FFFD9}}
\par }{\fs20\lang1024\langfe1024\noproof {\shp{\*\shpinst\shpleft1440\shptop2070\shpright10800\shpbottom2070\shpfhdr1\shpbxpage\shpbxignore\shpbypage\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz2\shplockanchor\shplid2049{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn shapePath}{\sv 4}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fFilled}{\sv 0}}{\sp{\sn fArrowheadsOK}{\sv 1}}{\sp{\sn posrelh}{\sv 1}}{\sp{\sn posrelv}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxpage\dobypage\dodhgt8194\dpline\dpptx0\dppty0\dpptx9920\dppty0\dpx1190\dpy2070\dpxsize9920\dpysize0\dplinew15\dplinecor0\dplinecog0\dplinecob0}}}}{\f0\fs16  \par }}{\footerf \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }{\footer \pard\plain \s22\ql \b\f354\fs18  Page {\field{\*\fldinst PAGE}{\fldrslt 1}} of {\field{\*\fldinst NUMPAGES}{\fldrslt 1}}{     }\'a9 2019 \uc2 Factiva, Inc.  All rights reserved.\par }\pard\plain \ql \li0\ri0\nowidctlpar\faauto\rin0\lin0\itap0 {\fs20 {\par\fs20\b \uc2 Summit Medical, Inc. Summit Medical, Inc. Expands InstruSafe Portfolio with New InstruSafe(R) Care + Maintenance Products\b0\par\par\uc2 506 \uc2 words\par \uc2 30 December 2016\par \uc2 Medical Devices & Surgical Technology Week\par \uc2 MDST\par 122\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Medical Devices & Surgical Technology Week via NewsRx.com \par \par \uc2 2017 JAN 8 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Summit Medical, Inc. increased its presence and impact in the health care industry on Wednesday, Dec. 14 with the \b \highlight22\uc2 launch\b0 \highlight\uc2  of its new InstruSafe(R) Care + Maintenance Products. The \b \highlight22\uc2 new product\b0 \highlight\uc2  line, which is an extension of the InstruSafe brand that manufactures InstruSafe(R) Instrument Protection Trays, offers a variety of protection, cleaning and identification solutions such as assorted tip protectors, brushes and identification tapes.\par \par \uc2 This Smart News Release features multimedia. View the full release here: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20161220005015/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20161220005015/en/}}}\uc2  Summit Medical, Inc. increased its presence and impact in the health care industry on Wednesday, Dec. 14 with the launch of its new InstruSafe(R) Care + Maintenance Products. (Graphic: Summit Medical, Inc.) The development of this new line was a natural and progressive step for Summit Medical to take in expanding the reach of its InstruSafe brand and increasing the number of solutions it offers to its customers. And although the InstruSafe brand experienced growth, its main goal has remained static - to increase surgical instrument longevity throughout the sterilization cycle.\par \par \uc2 "The InstruSafe team is made up of multiple individuals, including myself, that have a great deal of experience in the health care industry, specifically in sterile processing departments," said Marcus Super, director of sales and marketing at Summit Medical. "We are familiar with the frustrations and inefficiencies that occur when the right tools aren't available to properly care for and maintain your instruments. This is why we released our line of InstruSafe Care + Maintenance Products - to provide sterile processing professionals with the solutions they need to help create a more effective central service process."\par \par \uc2 Along with making the care of surgical instruments easier and more efficient, the InstruSafe Care + Maintenance Products are meant to serve as a part of a preventative maintenance plan to help minimize the need to replace costly instruments. To learn more about how InstruSafe products protect instrument investments, and to see the complete offering of InstruSafe Care + Maintenance Products, visit instrusafe.com. About Summit Medical, Inc.Summit Medical, Inc. - headquartered in St. Paul, Minnesota - is a medical device manufacturer that has been serving the global health care community for over 30 years through designing, engineering and manufacturing numerous health care solutions. The company is dedicated to staying on top of industry demands and developing the solutions to meet them. The areas the company specializes in include ENT products, plastic and cosmetic surgery products, and instrument protection trays and care and maintenance products under the InstruSafe(R) brand. For more information about Summit Medical, visit {\field{\*\fldinst{HYPERLINK "http://www.summitmedicalusa.com"}}{\fldrslt{\cf2 \uc2 www.summitmedicalusa.com}}}\uc2 . View source version on businesswire.com: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20161220005015/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20161220005015/en/}}}\par \par \uc2 Keywords for this news article include: Summit Medical Inc.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC\par \par \uc2 Document MDST000020161230eccu00062\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Health Care Down as Traders Make Regulatory Hedge - Health Care Roundup\b0\par\par\uc2 116 \uc2 words\par \uc2 30 December 2016\par 16:43\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Shares of health-care companies fell as traders hedged their bets on the outlook for regulations and drug approvals in 2017. After a two-year surge in \b \highlight22\uc2 new product launches\b0 \highlight\uc2  in the U.S., the \uc2 Food and Drug Administration\uc2  approved 22 new prescription drugs this year, down more than 50% from last year, The Wall Street Journal reported. \uc2 OPKO Health\uc2  slid after the drug developer said a weekly injection to treat growth hormone deficiency failed to achieve its primary goal in a late-stage trial.\par \par \uc2 -Rob Curran, rob.curran@dowjones.com\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 30, 2016 16:43 ET (21:43 GMT)\par \par \uc2 Document DJDN000020161230eccu002ca\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 16:28 EDT Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of Janssen's Concerta tablets Mylan...\b0\par\par\uc2 202 \uc2 words\par \uc2 29 December 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 16:28 EDT Mylan \b \highlight22\uc2 launches\b0 \highlight\uc2  generic version of Janssen's Concerta tablets Mylan (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's (JNJ ) Concerta Tablets. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated for the treatment of Attention Deficit Hyperactivity Disorder. Mylan CEO \uc2 Heather Bresch\uc2  commented, "The \b \highlight22\uc2 launch\b0 \highlight\uc2  of generic Concerta Tablets demonstrates Mylan's leadership in complex development and manufacturing and in bringing to market a broad portfolio of high quality generics. This \b \highlight22\uc2 launch\b0 \highlight\uc2  also further strengthens our robust portfolio of central nervous system medications, which is the largest in the U.S. with more than 100 products.\par \par \uc2  We're excited about bringing another generic in this therapeutic area to market and expanding access to help patients." Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, had U.S. sales of approximately $1.59 billion for the 12 months ending October 31, 2016, according to \uc2 IMS Health\uc2 .\par \par \uc2 Document FLYWAL0020161229ecct008y9\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 07:03 EDT Mylan  \highlight22\uc2 launches \highlight\uc2  generic version of \uc2 Pfizer\uc2 's Cerebyx injectionMylan...\b0\par\par\uc2 111 \uc2 words\par \uc2 29 December 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 07:03 EDT Mylan \b \highlight22\uc2 launches\b0 \highlight\uc2  generic version of \uc2 Pfizer\uc2 's Cerebyx injectionMylan (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Fosphenytoin Sodium Injection USP, 75 mg/mL, a generic version of \uc2 Pfizer\uc2 's (PFE) Cerebyx Injection. Mylan received final approval from the \uc2 FDA\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, for the treatment of certain types of severe seizures. Fosphenytoin Sodium Injection USP, 75 mg/mL, had U.S. sales of approximately $36.3M for the 12 months ending October 31. Currently, Mylan has more than 240 ANDAs pending \uc2 FDA\uc2  approval representing approximately $95.6B in annual brand sales. \par \par \uc2 Document FLYWAL0020161229ecct00209\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw300\pich25\picscaley100\picscalex100\picwgoal4500\pichgoal375
47
49463839612C011900F7FF00009CBA55C0D9DCF1F631ACC59BD9E8E5F5F9F8FCFDA4DAE53EB0C832B5D1009EC307A9CAF1FAFC5DBCD10086ABEEF8FA00A2C687
CDDD80D0E3A0DCEAC2E9F12AA9C4FAFDFE3FB9D458BBD1D3EDF2F4FAFC17A2BF92D6E6CCEAF072CADFA3DDEAAADCE746BBD5B0DFE80099C0009AB9ABE0ECC0E5
EDD8F1F6BBE6F000A2C5E3F2F6E0F4F87CCDE0009AC1059EBC009CC27BC8DA24A6C2B8E5EF6AC8DE00A5C800A3C63EADC6D4EEF492D1E0ECF7F91DA5C1D0EEF5
C4E6EEF0F9FBB4E0EA4CBDD74CB5CCADDEE90095BEECF8FBF6FCFDE9F6F98BD3E596D7E772C4D717ADCC81CADB00A0C51DAECDB0E2ED0EA1BE96D3E100A0C5D7
EFF498D9E800A4C744ADC61BA4BF8FD5E643B1C96AC1D5E8F6F857B8CEB7E1EA9BD6E3169EBC94D7E7009BC2C8E8EF04A6C9D5F0F60081A748B4CBA5DEEB22A2
BECCECF42BB3D0E4F4F80094BE0093BCEBF7FA0094B50097B694D3E1B5E4EE49B4CC63C5DC0094BD0CA7C984D1E3F2FAFB0095B68CCFDE65C6DC76CCE0008CAF
D2EDF2CAE9F0F6FBFC25A8C3E8F7FAC6EAF200A0C466BFD37CCADF6CC3D62FA7C20090B226B1CFA1D8E464BCD187D3E438B6D28FD0DF56B6CC0C97B7B4E3EE7C
CDE172C2D55BC2DA7CCDE0DDF3F765BACFCEEBF191D1E00098B8F0FAFC68C0D4CBECF30090BB0FACCBBDE4ED74C5D8BBE3EC61C4DB5DC3DA3AAFC80094B40096
BF00A1C5EBF8FB13A8C90093B4C9E7EE12ACCC00A1C645B2CA4BB3CA36AEC719ACCB00A8C900A2C7009EC3009CC2009AC1009FC4009DC3009EC4009CC2FEFFFF
FCFEFE009CC3FDFEFFFFFFFFFDFEFE0097BF009DC2FBFEFEF9FDFD009BC1009FC4FAFDFD79CCE0009DC4009FC5C8EBF3C2E3ECFEFEFF79CDE19DDBE900A3C7E3
F3F7009DC376C6D8009DC2009AC20099C0E1F3F74DB5D150BED7009FC37CCEE19FDBE9B2E3EE62BED3C0E2EBACDFEB009FC4BEE7F0009CC2B9E2EBE7F5F8EAF5
F8C6E7EE4FB6CD00A2C500A1C536A3C049B1CE7CCBDF3BA6C1007EA627A4C096D8E739B7D37CC3D678CDDF54BFD8A7DFEB03A4C80092B387D2E351C0D913ABCC
17A9CA6FC3D69ED7E4FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34423839384231373531444631314536383342314337334644453946314437322220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3442
383938423138353144463131453638334231433733464445394631443732223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3442383938423135353144463131453638334231433733464445394631443732222073745265663A646F63756D656E744944
3D22786D702E6469643A3442383938423136353144463131453638334231433733464445394631443732222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000002C01190040
08FF00FF091C48B0A0C18308132A5CC8B0A1C38710232EDC25828BC48B18336ADCA8704AAE70B472850C17CEDAA4515FC249833061203D5B2AA519E1102C5C2E
534604DAA1412B1C146B73E6AC092A34580D0EBC2E8CCB252D9DBD81C4428CA3D5939DC000D6487E91316369AE5E28FEAD40638DAA9A650467080169ADCEB081
4398C00C67ABD2C05F17B2862B46818DB58F3669259325638A349222BFC43A3170C5BD625455CA0AD470178837066FC42882D002192A029FFC213610530C0BFF
7A3868F04B603937A1FE19F81361A0AF4C070476706240839B4FFFC891E823F040265F03239CFEF74407691366FE98903DE0C9BF0C24FCD8CE21100429D21D62
C0FFB3F86F4003819BAA0CECE2C6C0401864086A1974E35F9967139E95416D5B9C94FC4DA0E0C504F959018841451080DF33F69C801F81104248803D69FC6301
0AFF4518A1148110C3C011042AA881413B2C42E0331FF0C246370448584602D6F492803D3D1444CC0D2D6AF88C0C2BF862800C5E10E0458D02156005016809C4
40091942B8880004F5304186F1A0C0DF41966186102FC4B8C7D02E234A048C971219004C46BC1840264705ED62079B70C629E79C74D669E79D782A54434F2A99
328397C3E4F3572FD0B434102F33A8815849CE1064413DC1F00992A4208D53891F17A434A94D24F5948B10D0A03290053FE84592106510148F1ABD2046554F91
59FF538D5D04F9C2881087F129694FD664F38F2F89F6D4CB02F5FD5ACF1CCAEC458306BFC8634B4FB6A8B3C23FCF08F18532E38CD3C43F058C32C3B40359665D
413DB8704E9445EC62211957309403095A4224C01E7B70269009008091679E5390148E3ABCFC130F2DE340C1692FB4A46A8F29914D4A29146B88F30F1BF57880
CCC5C83883CC363F84448D2C9048451535057F248D3450103CCE3225ACD1E9CB808164CB32469842D24FE3F8648D2D06872344580349300755508C731849E324
F3513047CCD0AA10F6F8E24CCE360573CF301A4063CB170B00328C5A0627630DD5E35443C197971974890E6C10948113E5AC0BDA3F5A00E1B6139CE570873F03
69FFE00412131FB205421DE8602F2F7F7401C025024D731E42410C00030C02C1B0C900C41964001E9940F98F000328F1381EA06090C840A0A8275015800B74CC
06B5ED2B3B9CBB7890CE02613042EBEC6CEEE2C3E9BC072F3C437544B24D247510512B05ED441289043B14C44B3CED1C4FC907EA16B48204941CEFFCF7C653D2
830513740FBEF3DE1BC158411AA01F0921322047D0105294C18117F8E74FC084F21BD4431D47CA1FFE38F0010E9C4D207ED80625DE97A481D8A379943082069E
D13C05D6216002F9453C8C17897658A112F1C8C795FE21AE831820113A4000199CA088F5F102138D60880636319D88A46113711B4814B0E0B9E115440B7118A1
43FFFAE5AFAA790035825249A108B28D9A88441A22B1851706D2831A204D1447F00207B6C801296CC3034360805242928B055C2001F24043CFA4D10A2B643004
9A42584F8A518281C8C1141FC9852C12C0087920020AD2088929E05090009C8C245348802213A00E6AF4641CA2D84520E6F0919EA88190C4580064A8F2052688
4120525883C168218D2F7CC416C120A4424A5810CDE4D0201688832B06D2810654C11000100106DF75805AEA00074412081F2A10032738E24D02B904027C7087
F57D0200ABA0A2239C10830A6440374E8886400C1081067849005DD04E140A810145C0C211153200297CF01E2C20F30103D017171EF78F7E44210354D0D73FA2
80FF810D54A1025118881525630528688A942021D4110462045B88641CD928C0099C059235A8F20101A00314A0A08E5674541D5030992C9AF08394F4620ADB1A
C80FE6A28648FC630643CB852D4491861BF08460B6E0842F98F0179F456F201E5003AFDC321023CCC291C54043FF76208BA9108C0D4A51C928A0819840967214
4CA0463116231062780026919146121E5019108C8B20AEFC0731FAB0857E6CA06D9E991B125497CC2A90F55DC0FBC703622089D46462035740000260E10E1024
530759F88706EEC08372A822738D28052C044B0A52D860447EF8431488E1864AA4C105BF8802006A040C3C74C1053168C439CEF40F5E00C02257E84311DC9083
22FF540099A91B48152827100B342013B020C5606DA0041EFC431D461B872082190F2814831AD2B085357640814E48831A29A9C70CE420873CFC401AC5086430
CEB0026B9C4C1AE3E8C5C9D4DB8B7158230969C80B7AE76BB45EA8B718C18845082215DD29E4410EA2E8EE0554D6DEAC8E8DBEEAE553B4C83A906D74E20BF4A5
AF7B85A0072968631C42080069FC50836C052300AD39832C6C318E2920C21AE1CD0A6304108CF08E630D01E81F96CC7A90271CE209458806285451430B90621D
0219C600F2C5861DD7D01C2E7005064480874744A035FF38412960108D1BE8E00A61EA03DE6C838E3D7440200FA8002CA290062C3CA2420381452618EC873DD0
D3FF0F8678C235A2C186D065EF1F6F180391FC100312B0F61F9B70C1405C80058268800403884234AEA0831BACC9879016C82E4681C76224617D9196489632CD
E94E7BFAD3A00EB5A8474DEA52EFCB323848480E3A70896B14444D0DF183101B32A68200C30F7FCEB4018209113EE5621C33505E90F5F097714083030511832D
5A150E6A08E24004A9041340524449FDFA041A6042310023127FE5221750E0870C0AC2093C7EBB1834B0974000918D1713452843194A3A8E30EB1530020AA618
4A50D630944E58830E3F0D84290E638A7A904900E9A54B0D865006A391721CA922A1144692AD12EC401DB228004158591018DC21141DE0031FAA4086331DA302
40FF5E88390E810789DCE01D8580F23FB6C0584F27820B6F89C8407B220D21788034BC48E24A0C251001B4F765D2980503A828886E5B4308423085D4A15E8C62
9C0053540BC73882618D9DE5CAD829FDC70E4C451269C8229872A0A45682C175F3767B0D071CC83200F9C8AE73BD922A09C03F3441326A0B21E073E894A5A1B4
82F092C41AF5B0C2D8A0205D55FEA20005B83309695C103EB0AD33EC2288013AF08D57FE230799B0480FDA66901C30E31CA4D1210954310828E34B9F5D3D0733
B8834001DCD90FC8FC551A58AB812D6C8107A9E7C503AE6480DCFFA31CDAE90D1551E387D4CB8607CC089340065AC47098C2030688473098B2448154622EE89D
42FF48ACB12C81F480AA04DB060A64C07EF68BE3031233803C8AA175691040136C18C235D090750C08240D5AF711060512D2100BA841043F1029E1100C65F000
6C907FFA50132561047FB60B8C102904F30C6C800A8060071700135F214163E429B69007BBF001646769EB030C09600A3D032DC1D00D68132F039156071157E6
E70466D0073D10047BC04E7A950908E00D6FB0056E30085E1205AA800759100D96E002A9573844000A1BD01A5B004DDB0400969006E5800777A02F1AA0037CB3
4FF8B0074482036DB00BBCE0024FD00C8A6509B1030085B04DAA7008E7F20FFEB00135E20D82261031A0050D300F01C5002E600302F00011B0070FD01AE21733
B9FF220D659150D02005E6370B87310EACB00B43200887110C0BA01DBC9007C1300ED0250DBD005D4EA575E1B00322230DD0C00D7071019B140ED8F00F80005E
2AB10F60B214B4600D09C00B43002396243192466922610D8B8041FF100834604AE1F0054330106C9004F4B7179550066065784CC10A36815E5A7169034104F2
50168FB4080EC17135B8197AD500F0600618405638F80F0D304B35F8569FB707E4601B2ED05739E00678500E2AA00245700573F80F1D50059C01034EE00B3C30
1C95A305451090E5A0048A781D150904222002E8A0577B501FE5B0075860018FD6036E301D4A00033C000BBFB00B2E003C73B51E4A302A0810070F100D2AD003
79FF88197B02120B400C13400B5FD0330438056E64000B602AB4600B73F111D68008A8F10BC410081F5006F65095F650021E903366D70D21407FD2300533000E
25000ECFC07F36310732300CE9508D2A510C5F002B3E2307BE30094E140C1C0007E0100414500F91680A5ED03F93508D5F70011F2096E02007357089092003B2
1048B2A001F230159C3207DB500049600BC5E04916E20178D46C9CF20521A08C09B169AD140389351019A003DC114B73D30F1540106B735724401E9FF707FC88
0F0790266A6200185438A7E90F15600224A04F4AE00A1AB09B6A02659BD00851701ABC000BD7A004AD23104580097160080EE003D9130148106676600115C003
3EFF101F02F192AB339D16000BFDE00B7E6000C7C09BEAD288B95003447204EA001936310EB6B003C0C00A36431556454A72F46B4CC00B95A0066C670DA6600D
6CB7A065470325D0959B426D9CA2750BB00D8DC973EA655550140ECA2004A2C09720C16D14FA116BC009041154DE566D9D620DF6C0080E150C1AA76C0FF50512
73024DF505AC9006F9200489210BE2609625B100A4379A94676855906A03E10D577026F108023AC060FFC0A467D2037B8001DAF10FC2391D061003D330107620
02ACB53645CA070E7008D7F40F89D006C72010BC100AB967074E900940D80787300044D20CE5702545A00AB4A2015D968FFFC003007007526A9EFFC03AE10203
A4FFE0253DD803675203D030A953B0740321053430A9EA4003562015933A0E8B6000C36001A46A0172300E10000D82F003672008D090AAAF3AA9B05A03FC5002
067001AE0AABB21AAB3470011CB000EAF0A904E00BA58A3593600BA94A0B3F30034C3005B10A0D1EA195E90034351802F7A0ABA99AAA53900A21A00975600B5A
0309412601B4A00E442A1062E009AE0A0D50D00AD0A00E74F0490C85AAAA3A0E67207306818EE19208F0E00A8C56431682058A30100C8001AF80005500B03900
045970091530003E80AF601003408000A41005AC15053449103C000FC5F20F69800036000431100A927700D3D90C710084FFF00B37E00A076B033030427D0004
7F5B16012D371078409EFF4006393B1069400AAF60031BD001F86A6A78E2016B110C34F0B148BB7147FAB4523BB5C3B30BF5B006A8240BF24AB52474003FCBB5
601BB674E2B2250007DD4001590AB64D28B66CDBB66EFBB670AB110101003B}}
\par\par \b \uc2 ZS Pharma\uc2  selects TikaMobile as their Mobile Intelligence and Analytics Platform\b0\par\par\uc2 439 \uc2 words\par \uc2 21 December 2016\par 12:40\par \uc2 GlobeNewswire\par \uc2 PZON\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 GlobeNewswire, Inc. All Rights Reserved. \par \par \uc2 ZS Pharma\uc2  selects TikaMobile as their Mobile Intelligence and Analytics Platform\par \par \uc2 NEW YORK, Dec. 21, 2016 (GLOBE NEWSWIRE) -- TikaMobile, Inc., a cloud-based mobile and analytics software provider for the life sciences industry, today announced that \uc2 ZS Pharma\uc2 , a member of the AstraZeneca Group, focused on using its proprietary ion-trap technology to develop new treatments addressing unmet needs in the pharma and medical community, will deploy the TikaPharma solution to help \b \highlight22\uc2 launch\b0 \highlight\uc2  their \b \highlight22\uc2 new product\b0 \highlight\uc2  ZS-9 as a new therapeutic option for hyperkalemia. TikaPharma will provide the \uc2 ZS Pharma\uc2  sales team with actionable intelligence and analysis at the customer and territory levels accessible via both iPad and web to help them drive revenue.\par \par \uc2 With its world-class team and extensive requirements, \uc2 ZS Pharma\uc2  required a robust solution to deliver on its vision to have a profound impact in the hyperkalemia market. This relationship with TikaMobile helps address \uc2 ZS Pharma\uc2 's unmet analytics and mobility needs.\par \par \uc2 Yasser Ali, Vice President, Business Analytics at \uc2 ZS Pharma\uc2  said, "At \uc2 ZS Pharma\uc2 , we're dedicated to leveraging innovative approaches to transform patient care. We've adopted this mindset within the Commercial team when it comes to the analytics we provide to our sales team. In TikaMobile, we found a partner equally dedicated to innovation in mobile intelligence and analytics. New Biopharma drug launches require near real-time insights on new diagnoses, reimbursement challenges, source of business, etc. We feel that the TikaPharma platform is ideal to deliver this intelligence due to its agile nature and exceptional user experience."\par \par \uc2 Implementing TikaPharma will help maximize the effectiveness of \uc2 ZS Pharma\uc2 's go-to-market efforts by providing their sales reps the actionable insights they need to stay one step ahead of their competition. "We are excited to work with the \uc2 ZS Pharma\uc2  team," said Manish Sharma, CEO at TikaMobile. "Our vision is to be the leading provider of mobile intelligence and analytics solutions that deliver real-time, on-demand access to the business insights that life sciences sales teams need to drive revenues and be market leaders."\par \par \uc2 About TikaMobile\par \par \uc2 TikaMobile Inc. is leading innovations in cloud based mobile and analytics SaaS solutions for the life sciences industry. Dedicated to customer success, TikaMobile's real time recommendation analytics go beyond CRM to give commercial teams and field sales ongoing actionable intelligence. Our powerful, yet agile applications for Pharmaceutical and Medical Device organizations are easy-to-use, easy to deploy, and can accommodate companies of all sizes. For more information visits us at {\field{\*\fldinst{HYPERLINK "http://www.tikamobile.com"}}{\fldrslt{\cf2 \uc2 www.tikamobile.com}}}\uc2 . \par \par \uc2 \f2 \par Contact \par Cliona Barry \par info@tikamobile.com \f28 \par \par \uc2 \f2 (MORE TO FOLLOW)\f28 \par \par \uc2 Document PZON000020161221eccl0002l\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 ANI Pharmaceuticals \highlight22\uc2 Announces  \highlight \highlight22\uc2 Launch \highlight\uc2  of Authorized Generic of Lithobid(R) Extended Release Tablets\b0\par\par\uc2 615 \uc2 words\par \uc2 21 December 2016\par 08:30\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 BAUDETTE, Minn., Dec. 21, 2016 /PRNewswire/ -- \uc2 ANI Pharmaceuticals, Inc\uc2 . ("ANI") (Nasdaq: ANIP) today \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Lithium Carbonate Extended Release Tablets, 300mg, an authorized generic of Lithobid(R) , which is used in the treatment of manic episodes of Bipolar Disorder. The annual US market for lithium carbonate is approximately $19 million, per \uc2 IMS Health\uc2 .\par \par \uc2 Arthur S. Przybyl, ANI's President and Chief Executive Officer said, "We are pleased to announce the \b \highlight22\uc2 launch\b0 \highlight\uc2  of an authorized generic of our mature brand product Lithobid(R) . This generic \b \highlight22\uc2 launch\b0 \highlight\uc2  represents ANI's 11th \b \highlight22\uc2 new product\b0 \highlight\uc2  introduction in 2016 capping a substantial commercial portfolio expansion for the company this year. We look to continued commercial portfolio growth in 2017."\par \par \uc2 About Lithium Carbonate Extended Release Tablets\par \par \uc2 Lithium Carbonate Extended Release Tablets are indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-IV) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium Carbonate Extended Release Tablets are also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur.\par \par \uc2 About ANI\par \par \uc2 ANI Pharmaceuticals, Inc\uc2 . (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website {\field{\*\fldinst{HYPERLINK "http://www.anipharmaceuticals.com"}}{\fldrslt{\cf2 \uc2 www.anipharmaceuticals.com}}}\uc2 .\par \par \uc2 Forward-Looking Statements\par \par \uc2 To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company's future operations, products financial position, operating results and prospects, the Company's pipeline or potential markets therefor, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will, " "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates.\par \par \uc2 Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; increased competition; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the \uc2 U.S. Food and Drug Administration\uc2 ; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.\par \par \uc2 More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the \uc2 Securities and Exchange Commission\uc2 , including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.\par \par \uc2 For more information about ANI, please contact:\par \par \uc2 Investor Relations\par \par \uc2 IR@anipharmaceuticals.com\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-authorized-generic-of-lithobid-extended-release-tablets-300382207.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-authorized-generic-of-lithobid-extended-release-tablets-300382207.html}}}\par \par \uc2 SOURCE \uc2 ANI Pharmaceuticals, Inc\uc2 .\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.anipharmaceuticals.com"}}{\fldrslt{\cf2 \uc2 http://www.anipharmaceuticals.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020161221eccl0007o\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 CytoSorbents Announces First Sales of New CytoSorb(R) CPB Procedure Pack for Cardiac Surgery\b0\par\par\uc2 957 \uc2 words\par \uc2 20 December 2016\par 08:00\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 MONMOUTH JUNCTION, N.J., Dec. 20, 2016 /PRNewswire/ -- \uc2 CytoSorbents Corporation\uc2  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb(R) blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, \b \highlight22\uc2 announces the launch\b0 \highlight\uc2  and initial sales of its new CytoSorb(R) Cardio-Pulmonary Bypass (CPB) Procedure Pack for cardiac surgery. This \b \highlight22\uc2 new product\b0 \highlight\uc2  provides all of the necessary components, including the CytoSorb cartridge, to rapidly and seamlessly integrate CytoSorb into the majority of heart-lung machines used in open heart surgery today. CytoSorb has been used intra-operatively in thousands of heart operations in Europe to either help stabilize unstable patients during surgery or to prophylactically treat patients at risk of severe inflammation caused by the surgery.\par \par \uc2 Mr. Vincent Capponi\uc2 , Chief Operating Officer of CytoSorbents stated, "The CytoSorb CPB Procedure Pack was developed by our product management and engineering teams with key input from cardiac surgeons and perfusionists. It is the first of a series of value added procedure kits that we plan to introduce into the market in 2017 to improve the end-user experience."\par \par \uc2 Mr. Capponi continued, "We are also delighted to count our partner, Terumo Cardiovascular Group, among the first customers to have ordered the CytoSorb CPB Procedure Pack. We have worked closely with Terumo, a global leader in cardiac and vascular surgery, to finalize all documentation, marketing material, and sales force training, and are pleased that they have now officially launched sales of CytoSorb in their exclusive market territories of France, Denmark, Sweden, Finland, Norway, and Iceland."\par \par \uc2 The CytoSorb CPB Procedure Pack is now available for volume purchase by direct customers and distributors worldwide.\par \par \uc2 About \uc2 CytoSorbents Corporation\uc2  (NASDAQ: CTSO)\par \par \uc2 CytoSorbents Corporation\uc2  is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb(R) is approved in the \uc2 European Union\uc2  with distribution in 42 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb(R) is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents has completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a multi-center, randomized controlled study that has demonstrated the safety of intra-operative CytoSorb(R) use in a heart-lung machine during complex cardiac surgery. In 2017, the company plans to initiate a pivotal REFRESH 2 trial intended to support \uc2 U.S. FDA\uc2  approval. CytoSorb(R) has been used safely in more than 17,000 human treatments to date.\par \par \uc2 CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding in excess of $20 million from \uc2 DARPA\uc2 , the \uc2 U.S. Army\uc2 , the \uc2 U.S. Air Force\uc2 , the \uc2 U.S. Department of Health and Human Services\uc2 , the \uc2 National Institutes of Health\uc2  (\uc2 NIH\uc2 ), \uc2 National Heart, Lung, and Blood Institute\uc2  (\uc2 NHLBI\uc2 ), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend(TM), ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at {\field{\*\fldinst{HYPERLINK "http://www.cytosorbents.com"}}{\fldrslt{\cf2 \uc2 www.cytosorbents.com}}}\uc2  and {\field{\*\fldinst{HYPERLINK "http://www.cytosorb.com"}}{\fldrslt{\cf2 \uc2 www.cytosorb.com}}}\uc2  or follow us on \uc2 Facebook\uc2  and \uc2 Twitter\uc2 .\par \par \uc2 Forward-Looking Statements\par \par \uc2 This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict, " "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the \uc2 SEC\uc2  on March 9, 2016, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.\par \par \uc2 Please Click to Follow Us on \uc2 Facebook\uc2  and \uc2 Twitter\par \par \uc2 \f2 \par  \par Cytosorbents Contact: \par  \f28 \uc2 \f2 Amy Vogel\f28 \uc2 \f2  \par  Investor Relations \par  (732) 398-5394 \par  avogel@cytosorbents.com \par  \par  Public Relations Contact: \par  Amy Phillips \par  Pascale Communications \par  412-327-9499 \par  amy@pascalecommunications.com \par  \f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/cytosorbents-announces-first-sales-of-new-cytosorb-cpb-procedure-pack-for-cardiac-surgery-300381836.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/cytosorbents-announces-first-sales-of-new-cytosorb-cpb-procedure-pack-for-cardiac-surgery-300381836.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 CytoSorbents Corporation\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 (END)\f28 \par \par \uc2 Document PRN0000020161220ecck0008l\par }\page {\par\fs20\b \uc2 Business News; Regulus  \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Drug \highlight\uc2  Development Candidates\b0\par\par\uc2 301 \uc2 words\par \uc2 16 December 2016\par \uc2 Obesity, Fitness & Wellness Week\par \uc2 OBWK\par 105\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Obesity, Fitness & Wellness Week via NewsRx.com \par \par \uc2 2016 DEC 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- - \uc2 Regulus Therapeutics Inc\uc2 . (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced two \b \highlight22\uc2 new drug\b0 \highlight\uc2  development candidates at its R&D day, held in New York. The first candidate, RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for the treatment of cholestatic diseases. The second candidate, RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for the treatment of autosomal dominant polycystic kidney disease (ADPKD).\par \par \uc2 "We are delighted to announce the addition of two new drug candidates to our growing portfolio of potential microRNA therapeutics. We believe both RGLS5040 and RGLS4326 have very favorable preclinical profiles with the potential to fulfill meaningful unmet medical needs," said \uc2 Paul C Grint, M.D\uc2 ., President and Chief Executive Officer of Regulus. "We are currently conducting IND-enabling work and finalizing development plans for RG5040 and RGLS4326 and expect to file INDs for both drug candidates in the second half of 2017. The announcement of two new drug development candidates underlines the confidence we have in our rigorous targeting and validation process, which we believe should enable us to identify at least one new drug development candidate per year moving forward."\par \par \uc2 For additional details on Regulus' two new drug development candidates as well as other information detailed at Regulus' R&D day, please visit the investor relations section of Regulus' website HYPERLINK "{\field{\*\fldinst{HYPERLINK "http://www.regulusrx.com/"}}{\fldrslt{\cf2 \uc2 http://www.regulusrx.com/}}}\uc2 " \\n{\field{\*\fldinst{HYPERLINK "http://www.regulusrx.com"}}{\fldrslt{\cf2 \uc2 www.regulusrx.com}}}\uc2  where a replay of the webcast presentation is available for a limited time.\par \par \uc2 Keywords for this news article include: Therapy, Business News, Drug Development.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document OBWK000020161216eccg000qs\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Agios Pharmaceuticals Files 8K - Other Events >AGIO\b0\par\par\uc2 227 \uc2 words\par \uc2 15 December 2016\par 16:37\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Agios Pharmaceuticals Inc\uc2 . (AGIO) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 15, 2016.\par \par \uc2 On December 15, 2016, \uc2 Agios Pharmaceuticals, Inc\uc2 . (the "Company") issued a press release announcing that it is no longer developing AG-519 and withdrew its investigational new drug application for AG-519 on December 14, 2016, following a verbal notification of a clinical hold from the \uc2 U.S. Food and Drug Administration\uc2 . This announcement does not impact the Company's ongoing global phase 2 study for AG-348.\par \par \uc2 The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1439222/000119312516794518/d290043d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1439222/000119312516794518/d290043d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1439222/000119312516794518/0001193125-16-794518-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1439222/000119312516794518/0001193125-16-794518-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 15, 2016 16:37 ET (21:37 GMT)\par \par \uc2 Document DJDN000020161215eccf0044p\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Eagle Pharmaceuticals Files 8K - Other Events >EGRX\b0\par\par\uc2 207 \uc2 words\par \uc2 14 December 2016\par 06:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Eagle Pharmaceuticals Inc\uc2 . (EGRX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 13, 2016.\par \par \uc2 On December 13, 2016, \uc2 Eagle Pharmaceuticals, Inc\uc2 . issued a press release announcing positive results from its pivotal animal study conducted under the \uc2 U.S. Food and Drug Administration\uc2 's so-called "Animal Rule," for RYANODEX(R) for the treatment of exertional heat stroke, an investigational new indication for the product.\par \par \uc2 A copy of the press release referenced above is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/827871/000110465916161955/a16-23138_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/827871/000110465916161955/a16-23138_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/827871/000110465916161955/0001104659-16-161955-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/827871/000110465916161955/0001104659-16-161955-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 14, 2016 06:01 ET (11:01 GMT)\par \par \uc2 Document DJDN000020161214ecce00198\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Omnicell Files 8K - Regulation FD >OMCL\b0\par\par\uc2 710 \uc2 words\par \uc2 6 December 2016\par 06:03\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Omnicell Inc\uc2 . (OMCL) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on December 05, 2016.\par \par \uc2 During an analysts and investor briefing on December 5, 2016 at the American Society of Health-System Pharmacists Midyear Meeting, \uc2 Omnicell\uc2  discussed the launch of the Omnicell XT Series Automated Dispensing System, the Omnicell Performance Center, the \uc2 IV Solutions\uc2  suite of products, and \uc2 Omnicell\uc2 's pending acquisition of \uc2 Ateb, Inc\uc2 . a leading pharmacy software solutions provider. \uc2 Omnicell\uc2  also disclosed that, given its new product launch of the Omnicell XT Series in the first half of 2017, it expected different revenue growth rates in the first half and second half of 2017. Specifically, \uc2 Omnicell\uc2 's preliminary expectation for revenue for the first half 2017 is flat with that of the first half of 2016 (before adding in revenue from the pending acquisition of Ateb), and preliminary expectations for the second half of 2017 are a return to year over year organic revenue growth rates in the long term 8% to 12% range.\par \par \uc2 A replay of the call is now available and will be continue to be available until 8:59 p.m. PT on December 15, 2016. The replay access numbers are 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, Conference ID # 27141322. Details of the product announcement are included in an investor presentation found in the investor relations section of our website and can be accessed at: {\field{\*\fldinst{HYPERLINK "http://ir.omnicell.com/index.cfm"}}{\fldrslt{\cf2 \uc2 http://ir.omnicell.com/index.cfm}}}\uc2 .\par \par \uc2 This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.\par \par \uc2 Forward-Looking Statements\par \par \uc2 To the extent any statements contained in this Current Report on Form 8-K deal with information that is not historical, these statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. As such, they are subject to the occurrence of many events outside \uc2 Omnicell\uc2 's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such statements include, but are not limited to \uc2 Omnicell\uc2 's expected revenue growth and growth rates for 2017. Risks that contribute to the uncertain nature of the forward-looking statements include \uc2 Omnicell\uc2 's ability to take advantage of the growth opportunities in medication management across the spectrum of healthcare settings from long term care to home care, bookings and installations of \uc2 Omnicell\uc2 's XT Series Automated Dispensing Systems, unfavorable general economic and market conditions, risks to growth and acceptance of \uc2 Omnicell\uc2 's products and services, including competitive conversions, and to growth of the clinical automation and workflow automation market generally, the potential of increasing competition, potential regulatory changes, the ability of \uc2 Omnicell\uc2  to improve sales productivity to grow product bookings, to develop new products and to acquire and successfully integrate companies. These and other risks and uncertainties are described more fully in \uc2 Omnicell\uc2 's most recent filings with the \uc2 Securities and Exchange Commission\uc2 . Prospective investors are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. \uc2 Omnicell\uc2  undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/926326/000110465916160709/a16-22756_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/926326/000110465916160709/a16-22756_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/926326/000110465916160709/0001104659-16-160709-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/926326/000110465916160709/0001104659-16-160709-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 December 06, 2016 06:03 ET (11:03 GMT)\par \par \uc2 Document DJDN000020161206ecc6001b8\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Amicus Therapeutics Files 8K - Regulation FD >FOLD\b0\par\par\uc2 157 \uc2 words\par \uc2 28 November 2016\par 16:47\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Amicus Therapeutics Inc\uc2 . (FOLD) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 28, 2016.\par \par \uc2 On November 28, 2016, \uc2 Amicus Therapeutics, Inc\uc2 . (the "Company") hosted a conference call and webcast to discuss the U.S. Regulatory Pathway for Migalastat for Fabry Disease.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/a16-22245_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/a16-22245_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/0001104659-16-159334-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/0001104659-16-159334-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 28, 2016 16:47 ET (21:47 GMT)\par \par \uc2 Document DJDN000020161128ecbs003pp\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Amicus Therapeutics Files 8K - Other Events >FOLD\b0\par\par\uc2 253 \uc2 words\par \uc2 28 November 2016\par 16:47\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Amicus Therapeutics Inc\uc2 . (FOLD) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on November 28, 2016.\par \par \uc2 On November 28, 2016, the Company issued a press release announcing the U.S. Regulatory Pathway for Migalastat for Fabry Disease. A copy of this press release is attached hereto as Exhibit 99.1.\par \par \uc2 In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/a16-22245_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/a16-22245_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/0001104659-16-159334-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1178879/000110465916159334/0001104659-16-159334-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 November 28, 2016 16:47 ET (21:47 GMT)\par \par \uc2 Document DJDN000020161128ecbs003ny\par }\page {\par\fs20\b \uc2 CEL-SCI Corporation\uc2 ; CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid Arthritis\b0\par\par\uc2 657 \uc2 words\par \uc2 25 November 2016\par \uc2 Obesity, Fitness & Wellness Week\par \uc2 OBWK\par 207\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Obesity, Fitness & Wellness Week via NewsRx.com \par \par \uc2 2016 DEC 3 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- \uc2 CEL-SCI Corporation\uc2  (NYSE MKT: CVM), a biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, \b \highlight22\uc2 announced new\b0 \highlight\uc2  preclinical data that demonstrate its investigational \b \highlight22\uc2 new drug\b0 \highlight\uc2  candidate CEL-4000 has the potential for use as a therapeutic vaccine to treat rheumatoid arthritis. CEL-4000 has been developed using CEL-SCI's patented LEAPS (Ligand Epitope Antigen Presentation System) technology. Data were presented by \uc2 Daniel Zimmerman, Ph.D\uc2 ., CEL-SCI's Senior Vice President of Research, Cellular Immunology, at the \uc2 American College of Rheumatology\uc2 's Annual Meeting in Washington DC.\par \par \uc2  The poster presentation titled, "A Therapeutic Peptide Vaccine Reduces Pro-inflammatory Responses and Suppresses Arthritis in the Cartilage Proteoglycan G1 Domain-induced Mouse Model of Rheumatoid Arthritis," was presented on November 14, 2016.\par \par \uc2 This study was supported in part by funding of a Phase I Small Business Innovation Research (SBIR) grant in the amount of $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (\uc2 NIAMS\uc2 ), a part of the \uc2 National Institutes of Health\uc2  (\uc2 NIH\uc2 ). The study was conducted in collaboration with Drs. Katalin Mikecz and Tibor Glant, and their research team at \uc2 Rush University Medical Center\uc2  in Chicago, IL.\par \par \uc2 "These findings, in conjunction with the results from earlier animal studies with LEAPS vaccines, support the potential that LEAPS vaccines may be useful as a therapeutic treatment for different types of rheumatoid arthritis. LEAPS vaccines may be advantageous to other therapies because they appear to act early on the immune system and inhibit the production of disease-promoting inflammatory cytokines. This is a significant step forward in the development of the LEAPS technology," said Dr. Zimmerman.\par \par \uc2 This efficacy study evaluated the LEAPS vaccine's effect in both the Proteoglycan (PG) induced arthritis (PGIA) and the closely related recombinant huG1 domain of PG (GIA) both in animal models of rheumatoid arthritis (RA) having a dominant T helper 1 (Th1) cytokine profile. These animal models were developed and have been studied extensively in Dr. Glant's laboratory for over 25 years and are considered to be closely related to the human condition of many RA patients. The PGIA and GIA model also exhibits rheumatoid factor (Rf), RA-specific antibodies ACPA (anti citrulline peptide antibodies) and tend to develop spondylitis not usually seen in other RA models.\par \par \uc2 Disease severity, as determined on the basis of the Arthritis Index and histopathology, was suppressed in mice treated with the LEAPS vaccine when compared to controls. As initially reported based on preliminary data in the PGIA model only, the reduction in disease (RA) severity following LEAPS vaccination with CEL-4000 (DerG-PG70 treatment) correlated with up-regulation of T regulatory cells (Treg) and Th2 cytokines (IL-10, IL-4 and TGF-b), reduced proliferation of PG specific T lymphocytes, and decreases in the production of Th1 and Th17 cytokines (IFN-? and IL-17). About Rheumatoid Arthritis RA is a chronic inflammatory disease that mainly targets the synovial membrane, cartilage and bone. It affects about 1% of the global population and is associated with significant morbidity and increased mortality. Non-steroidal, as well as steroidal anti-inflammatory medicines and now more commonly the use of anti-TNFa related therapies are the current standard treatment of patients with advanced RA, but information suggests that over half of the RA patients treated do not respond to current anti-TNFa drugs such as etanercept (Enbrel(R)) and infliximab (Remicade(R)).\par \par \uc2 Keywords for this news article include: Vaccines, Cytokines, Immunology, Technology, Immunization, Therapeutics, Biological Products, \uc2 CEL-SCI Corporation\uc2 , Rheumatoid Arthritis, Hemic and Immune Systems, Joint Diseases and Conditions, Autoimmune Diseases and Conditions, Musculoskeletal Diseases and Conditions.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document OBWK000020161125ecbp0001c\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw237\pich40\picscaley100\picscalex100\picwgoal3555\pichgoal600
47
4946383961ED002800F70000CBDBF0211C1DF2F1F0A3C2E6B1ACAC0174A8BEBABAB6B2B25387B16B6564D5D2D20075B5DAE5F5524C4B1E191A86B2DF3891CF27
76994896D1445A63191415288DCD386576599CD4DCD9D98AB4E0467A930079C1BAB6B57AACDCC1BDBC28242481AFDE456675AAB9C7E4E2E239333302729C4A44
44FDFDFDB6C1CCE3EAF6959090016A88317BA3869AA91A8BCCC9C6C5312C2C252121CDC9C96BA4D89BB3CF413B3BC2D5EEAAA5A5E8E6E595BAE2E6E4E4435359
A6A1A02D2929006E93EAE8E7D4E1F39ABDE4D9D6D6605A598FA3B3F5F4F42C667BF2F5FBEBE9E995AEC78F8989888282E5E4E3EFEDEC9E9899B5CDEB837C7C3B
494D363131EFEEEE375965585252E0DEDEDFDDDC645E5ED7DEE6D1CECE74A8DA746D6E5199D3928C8CC2CCD6706A697495ACC3C0C05C56558079793E38384F49
48E3E0E0BCD1ECECF1F99C96964741408C8686787272FBFCFE82919D7C7676F6F8FC51819B65A1D7A8A2A28A84840081C6B0CAEAA09A9A777170D0DEF2D7D4D4
EDEFF2FAFAFD171213FBFBFB0189CBD3D0D0868080908A8A7F7878736C6C97919170A5D9A49F9F0D8ACBAFAAA9EDECEBA7C5E7A29D9DC7D8F0857E7E007EC50D
73A5F3F2F19B95950085C8CDD7E55750503F92D0948E8EDAD8D80070A61B1617C6C3C3676161ADC8E9E8EEF76F8493D3D0CFD1D9E1608CA9F8F8F9DEE7F6007C
C34A8CC35F9FD6F7F6F6ABA6A67B7575ABC6E8DEDBDB68737A318FCEE2E0DF1D6B84625B5BFAF9F9CAC7C76D67678FB6E10B06070077BF95979940606D5B5454
100B0CF1F0F0E1E6ECDAD7D7CED3D7CFCCCCB7CEEB618FB6CBC8C82C2727231E1FB4AFAE00657E443E3E5E5757130E10F8F7F7F1EFEFA9A4A3C5C2C1E9E7E792
8C8B76706F342E2F999393554F4E817B7BC5C2C286807F5A535367A2D8726B6BA8A3A3FAFAF9CECBCBA0B1BE3E4D5285A4BEF3F3F34D4747779AB9C7C3C3ACC7
E78A8383B3CBEAC9CBCEE7EAEDBCBCBE0080BBC6C2C1635C5CC3D1E690B0D6958F8F0F708D9FC0E53C37379D9FA3DEE1E497989A2D8FCE616668E8ECF169A3D8
ACA7A77A7373767A7DFFFFFF21F90400000000002C00000000ED0028000008FF00FF091C48B0E0BF60380C2A5CC8B0E13F242F14EA50E0B0A2C58B168B302338
E507C68F20438ABCB8078FA025CE30283CD6A015C1457F460ABC92C74C833607C42859F4AF888A1A31F2882348A7C634020363CA5C6AF0579B2A5854ECD14200
911882586A34BA82C48007A615FFF41AC8CC23D8B33F6A150BB06953801E260A11E02910478C04030DC9DA381247325E7E286C32E6A0D0BF030DFCB8DD6482D6
3F31D536397010A34A1B2C5004EA2872B6A2A48405F7D05B468142800FC654A83220D08A2C076E7BF408A0A6F3C22909BC0C2423850E58370CEEE478D0E1418E
27A5DC5C1CE2C74180E7CF611B93A2EC91A1210E92FD6B568B8289A5700224FFA3F7A16D3631DBA81930E1DCD8261809DA20EAE127807B3FBC742B28C365A8ED
856DD4F04C41583820C55A7EF881C53F88B0F68F13EE19630C5B43FC67900C262CC3C63F3A58D2D607DCC8A447072E40B2C106B8A4782224AF3CC080432FC4B0
C9073D1423A35BD0B535D926E388D3806066C8540417AC49E2011B981082C92A7BFC23401D1F04E0800907E8460B1630D817402D3DAD916035161A644869311C
33900E9DB4534420861442CD0D07D0E1E03F0AC011035BCA8449D0013D48A6C43FD0142865314881A4C705A6E072E2A28C2E6AC73E003084C8960AFC80C10175
5802C38DD03940C139FF74428103418E940A68023533863157A840D17665B0FF858515BA09248D693D8C20D0393148C1819E0461E80017530C24C91904310386
035E10302787B3519007B002292085947F0A0487730EF460E645717480A2A28D326ACAB9909862C71669AC440F12043DD3041207ACD2C03431F490CC39A4FC03
455BA59E35C6321F9CE16AAA65C0366BADFFE4812B13031DF02CB54C3422494360D477003FCF3211EDB4D4FE63869F044129A5B716D900882912CC20811D27DA
51012A8DDAF2002576D801C9052F16244E02420864C01A5C1424041CB0F0E52FC09D714058C107C3AAB015D10CE47000C5401CB24842F4409907AB11E47100D2
6E3DB203D90EC4CD5A0EC030B14177980248A40295C2081A1D40F000B91B3CFF50B7270308E3082A7A1884012CFF281180194AD1A2C53F4C3CC2D940FF6E526A
302E3104CBAB0B2DE116D4AF3693F026B3562DD0D5590B24C90B4A19E4CDE305B512F440A4D072F140AD7C5590025734C4CF843180DDF1C70A31C17913D71014
08AA033563C0ED049D9DF6402A70EB36436898E2420A06A56087DEE41EA2102397CC508A4282BC17341E0D7C40CD3F23484E50E54172004319BF2AC441193558
C1D0BFA731D8AB7A31BA8559CD34A9FB471D62200DBA0C441C75900D1CA0D70C33F84A20CC90460CDCA1AB7F18801E31A8850E0682813294E16D6A039E07F8A1
3B818CAD6C052947329221006D85B009FFE08414CCC081C9FD4306D5084036FF663710E91544154A10C49DDAD642829402674138421032E0894FFC430F2EC085
04F676A20AA0413903F144175071085B1CA12062F8801F3A518E6C78CA01B5899F0F97B6890678A04F9B28C624E6F88FB56D82026D50481198B0ACD38CC00B37
78C10B0C4002599D010EC1B88602448535881D20069E1A47EB5A9180B6904D19A011D57B38F0875A2CC35366C0C13360501FEFC0CE12A38A013F0CD28C3DD441
85AA50032DAE710D5A70602D301CC8316030AAF771434A14C04228922119F1E88A1F655806D9E8719522924C207BA8C2389AE12FFBF8012F06D106242430006D
2482129470C125763603F0316A1F0361C025BA30031074000D0569C06064A1FF8A55388736F0931FE5DC4202280C2147799AC910D66009E7F460400479C11A3E
1083097D0009DBFA80462B4A3A016C6AA3132AC608119125430A44091FD8051EA6619A4D90C0007F7087840210032CA8E2A05222C12AD8400207B8871ECC4042
15EC43014214647F31A8284DC5C083A46A54A3120A6630B0400F654C861ED050C36C26B4861808C60F85E00050D4D089E87C6010D6449B40BCD083655862201E
A200380902004A5C600EA89080045E010848D8011DFFB84005B8B8280880910112B8C0211E600B5B5851208A90123D46A8847FC651A002F957768A8589D96427
158F91C2324C508ED958AE75FFA8C632DC72A78BAE82176D718B7BB0200E35FF7AF24E0924436CB466825BB8834EBBA8E8320CF38F7EB4A750E131D00817C105
294DC3233898065B3293946428C6A74B45446C631B5590F1A0187E908237A4009B4E7870894A384635CCB0847F14821731F8D524B2E49DB4662B319BA8C240DC
519AB90E04047300C116B4818A2E5CC205941086405ED122BE6DE012871DE3163210045B005620A26CC0492D1BD039D26F204390CC1A36620811FF631592A100
1E8C450F0794A191A781061448B0861A1763B68BA8418D4D20DD4A6676B70219C732643190C8F801644E78CE073821106710A60CDC3C0C26A5002F24907713D4
15C80F60608C649401784C2D438D6B9C8C8AC2701BD29442E2A4538E66B06DFF7AFF90861F6270805DC1266046FC4715DAA25F81C8A2BF056100089EC088070C
F8021248C41C06828F06330AC20261C0183B608B01302208562C423260938D0D3FE7B21E669A40DC21E28DA8414A6BF847748BB10407FEA316D6585A0055100A
D5AD616A7FDAC8AD7C2CEB1E686D1CB720B240F67C64819CFA341075B28BA37C490355F9CA5916C810DE4707E019206CCCD8082C88D730D348610AA428C3346A
83833717A40DB730469DFF31883BDB77D87C1EC89FE55A90273C210D7A1840070E91D744E480D18E5E14A4FF216954509A114F18800DFEF103E96E024C6B7E8E
133A3C3F51FFE3CF0E18F13F4E3D252B60820CB07BC9C500083A0CDE9A7454FF3B20AF01E86BA199C01D481042873651EC8D2B39D94F66F6949F0D9B683F6423
DC0073D806F242905D4D0A1898043632C7047313E4175C20013FCEF08325B85B2079DE737EE50DE881C4611E0C880303CC01027E4B0010410038614F347049CF
A10339F0840DD0308038341CD51BA96C00FC4006C861968E01C3B8C68F2D0542E4EF7F9F13A0C9A766BA6EAF1CC8027102093AB10428C40A86C7FE00CE972D90
6653F921D05E48D0BB850439898DDB57EB413FD6ED42A713040396480621D86009B6E0F99A5AEFF3C5BB5EB70794E213406045D911ED82B40BA4D119D8C0B9CE
2581080738077770041082908226D0E3393D508912EAB30633452ED496E37AFFC64D2DA51A8CD0219A5533265EC58C93974EE50964B9D6BA6306BE78A8E699DF
3C943BBF73D0F75CF4C6F04D0C323C646374A6010344D47AD85210D4F0010EB062FFC006572732B8176F7EC67BFF200C5BA00740E008030002FB00028EC000ED
727C8990027A908229D8330477012118044F000029C0088EF00FFA4418F11067C9E00CFE21470211131F7681E3677343E81068B6091B3208ECE77E29773A08A4
35F2C76E8291367B867937D76439C77FCEE67F58B61086B00CE390108D4080307474F02236AEF70FB4F001144002745159E1877515B87517486F03610B17E008
36800E41D0011D508204810F80805A8146460F300FC2A00769606F2736182EFF760E8830473EF80F7880019E1387BB37841CA7710DB10752300D9820104AB878
28D778A80385B19110E3601AB5016F56886C58C87952B68556F67F06010DB2C00538F40F63787A05E88401F07968B880034108A3520635B46698987516B87B76
28105B7009C2700703900133607C05C15760A410A5F076958606407004E8600EFFE034F6B109D260103EC801E3F00F8F607182477E45C81007C0060EA4044B38
350C937AA8F816D0F00F9BE600A0026FF87785FFA06CFB378B9F578B5D681048B00741351688D04445078CC248749E8556039100DE768670787B0EA0917BE600
E33039EEE007C345105B00018C3000390060FFA607395083C7E7028EF00019FF909319C0082750378B1504721776E6C00872083C50300B62B3047FE00C3DF008
80276F9251033C410D0EF53EFFC00FBFC0110460083C80014A51049D900902C10D252505436054FFE00135E01C31B0049C0140C5D024E3001B6300577F948E36
771AE5108B653016B308032E81040E87977BA20C35201B65D0096040008AC0193250081C3506F05208F5F1016C70027FA00A1E310251E20096A012FEB30AA641
670221813C9256D4F523136206DEF00F63100079F08F03B1052E9003C3B105A83003E8F00A7D3310A7700AF0A0090B9022B8500160540A9436004FE008A51007
8C700702515AD89571E7700018800306A00CD5E0078CF30FD6302AF4F02ACAFFE00712920C1CC001E5F11CE3901BADA3056B001D1F400FBBD009264002C5D209
9E3421141003D5600D50B096E7B8068BF008CB30215280076D309A37A0006400036E310D7F3209CF610C564907CF713D8731A12480074500033E55192AB12B7B
D74CB0E100F4F02BD61003F5610C77D20362E00493816AB51022DB5103A6D13663106BC7101D66A003FCB006A6F10109E03F264001C6F001B230022A501EEED1
0385D009DF421037030202360706860F94B0011920106E8000C390049A100905B0001BF00A6094022090038103000C7004F3B07002314CA6411894510C3DE080
BC300EFE933882F10185720C52201830701543D316313071D1730B812119B0FF4101B7B020FE743FF8E21C1400032BD60B093019C6B021DEB00692110304D00A
D3F0473D600DA1400024407379724C92B10D71CA1601B021AA3606B0510CBF420698440155C017DC4019D3F089E5E11C93C08B08D4999B60093CA10A9BE616C3
3A1056D00FE5E107E3707EDBB9770DC00DDEA04F6DE812D4500C7F34069CE101ECE129D5B0A705C1087670013350601050019400090B000F02A10F11300CC159
000510090B609C0281A6B6300F7760037AC00039C082FF400CD5E05592F1478A0103ABE04019D40388401099900D3070785300063DE00C05410B3D50055CD009
E3C065F66106AD2009D2C0018B20095D0106C5D00021BA2B3D6095FFB00809FFF001AD384C65A008039109666006BBB8043DA091A5D9038250108200033C3010
042005E3502C024108E710088B800448500EFD000381F40F09C0051CB00781A00665D0000E240EFDD003885A106A390E66F10F186006779139CC500852504DFF
F00C35500D73C45660C0107A000915A057AF704EF0AA0934201034A0095F5A022590AF9A700A7D50375B90A603E00968800E19008803E10170B00B3FDB009D80
09313B10A9900984580459992C424088B45028AD41007860009CF1074A3310A1D0B63FF80BB54B0A0AE0437BD04103B108C0FB0742005A14CB47278001C62B10
67D03B3FE81F05810138145405A103C09BBBB52B3688C3115A805A45E0BC67FF72BD02F10B51A6107190087690082E000876600A0B10092570B895C0023EB0B8
8C5B009A8000914B70640402B610041F680B5B33C0045CC0060C125B800B90902E0BE0B81150092840BF3E300A49E0038CCBB8FA1B698935031D40A512C00A07
1CC2223CC2030C00A67022EFCBB83E100108E0032EBC0214BC02168CC1FB0B0489000163340783CB3D24DCC33EFCC323D105B890AF2ACC02E120025FF0052210
0661100EF220072E1C01E13010409033157060B8203E40BCC502C10184D024E30B05DE800409D08A20E10CD2500492F008D5A4058460B71F61008F50BEFF4000
D6209B7AE20805A0C22B10067C60106E200ADFA00130EC0B05312239B30176FF60B05CECC360700B59C606BC80072FC00BDF111263E007ADF0030170B40CB20C
ED1512C675BD58E007811032E4F0C272D02F0B1106C8A001FAA010EF70C2B8D0018DCCC579C00B6BA014AB3871DC101121110A6632023150070241070E20AB20
41083170BD0910009CA327BEA001AFAC0EE2A0C4228002F6201027D00246600428F00F59F005A260BCF33B9C2EA0B9B7DCC379306766E201773271D670036E2B
0DD590072AC10C4B8009F1D006A160005C700EC87218EDA5039679CCC9FC0F92407B5C2096DED00F1C4006AAC00CD860090900CCCCAC2BB4D00F983004C610CD
3A400696000632D079EE900D86809493E0058840245AD00F84506B0BF10516FF000A2D10021690D3161002A0000C44600416A001DF200746100BF2A001229005
2C50029AC00E85B3CE40CC0531900C1592006560A9B0E0079DF69E0D10036B300B45300D7E0003C500031FC0656B002FCFDC0CD0F00185E00DB460757FD209C6
D0003D5003CC40079BE035859031660003D34011CC3C05CF5023D7520CD11C44664051626000BDE2A97DD700CBD003665D231F300DC1C01028100254A00B9EFD
D95410029F8DD316F0CDB120C311E0C22C500950BDC5522D0852500E24600D30E00423100015D20875860701506724500C5A10081F50037F80080E307185500C
CDF0033662D90E100F4C600C8671039B800707F070382000C7E01BB41000EDFFC5CCCCD0091FB00702D0559C23030160541CB0049270B32ED10024A0679BC00F
925006C52004E85D340C910EAEB00313F0DF00FEDF9FEDD9396DDAC8B002729005ADEDDA0E303435400FDE80B6B75D21570007B2D000C6C0B124500302410F75
A90031002AC9CDD61FB00DDE400C56170F8110033040028D64080790D035CB064370507DC7CCBDB00BA9C6B5D0BCB931D0AC02B10B65B01160300D7D60093130
4242DE13D3B0200D5104B9B003E0B003FE1DE0003EDA3ADD027FBCE051ED000A2008B750089C69DB01406435200509500DC6A00AFFB0E10251061F1E031B32E2
6D2DABC88C09A110036D60001CE0018BA00A6AE59AC58005B21000B186E363FFB0E365C539F00CE4FF20E4443E0DA480E423340665C0E4E6551181E00F3B1005
E030E5544EE5004E05A1FD06C0C0E55CCC059BF00C424002628001877ADBEE000B0E605484E0006C2E051CFE0FF249279BFA0FDBF0016C5DCCC7BC095EA00301
908E8A1048CE8084FFD00B30D0697A7DE331C00CB51003CF70056510030AF00757110A0150343CD00957000631506BF5F90F94FEE8F4C0E44E6E110AA002F920
E55150EF9EEEDFAE500FE08BEA408C6666022FC4401B67B0097599B0D3E0801C3B0DEDDEE66FA5000ED05ED7DE0C38E0DD02C1037EB02105727DF4D00DCEE007
030906D3E1AD46B50A01B008C120052CCEA26780071430B1AF112B302003329850233DB5210D1000236409F15D043DF05B1FD10DADC001F5900BB9700FDCB00E
23D093FCDEC806500799F30F673008A12009E90528D4B0041E400D4DA2068D201078801448300811610098C00CE2E005C0AC006C101192400D0900052AA1F68E
D1133CF00807D008572106D1703118E005D63D0802A000AB4011CD600809800DCE2B036D500BB3F40F8A30081703BBFFF007D4C07A051C10003B}}
\par\par \uc2 health_care\par \b \uc2 OPKO to begin shipping  \highlight22\uc2 new drug \highlight\uc2  for kidney disease next week\b0\par\par\uc2 By Nancy Dahlberg \par \uc2 Miami Herald\par \uc2 170 \uc2 words\par \uc2 23 November 2016\par \uc2 The Miami Herald\par \uc2 MHLD\par \uc2 English\par \uc2 (c) Copyright 2016, The Miami Herald. All Rights Reserved. \par \par \uc2 OPKO Health\uc2 , the biopharmaceutical company founded by \uc2 Phillip Frost\uc2 , announced Wednesday that it will begin shipping of its \b \highlight22\uc2 new drug\b0 \highlight\uc2 , Rayaldee extended-release capsules, to distributors in the United States on Tuesday as part of its nationwide rollout to retail pharmacies. Rayaldee, which treats secondary hyperparathyroidism in patients with chronic kidney disease and/or vitamin D deficiency, should be on pharmacy shelves next month, the company said.\par \par \uc2 The Miami-based OPKO \b \highlight22\uc2 introduced\b0 \highlight\uc2  Rayaldee to thousands of nephrologists attending the American Society of Nephrology Kidney Week Meeting last week in Chicago. Rayaldee was approved by the \uc2 U.S. Food and Drug Administration\uc2  on June 17.\par \par \uc2 "The RAYALDEE launch represents a major milestone for OPKO," said Frost, CEO and chairman of OPKO. "RAYALDEE is the first product developed by OPKO to be commercialized by our own marketing and sales teams, and represents an important contribution to the care of patients with chronic kidney disease."\par \par \uc2 Document MHLD000020161123ecbn0040h\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Ajanta Pharma \highlight22\uc2 Announces the Launch \highlight\uc2  of Aripiprazole Tablets\b0\par\par\uc2 272 \uc2 words\par \uc2 16 November 2016\par 12:13\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 BRIDGEWATER, N.J., Nov. 16, 2016 /PRNewswire/ -- \uc2 Ajanta Pharma USA Inc\uc2 ., a wholly owned subsidiary of \uc2 Ajanta Pharma Ltd\uc2 , announces today the \b \highlight22\uc2 launch\b0 \highlight\uc2  of Aripiprazole Tablets (2.5mg, 5mg, 10mg, 15mg, 20mg, 30mg), a bioequivalent generic version of Abilify(R)(1) , into the US market.\par \par \uc2 Aripiprazole Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the \uc2 United States Food & Drug Administration\uc2 .\par \par \uc2 About \uc2 Ajanta Pharma\par \par \uc2 Ajanta Pharma Limited\uc2  is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, finished pharmaceuticals across 30+ countries.\par \par \uc2 For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at $261 million and net profit of $61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.\par \par \uc2 For more details about \uc2 Ajanta Pharma USA Inc\uc2 ., please visit us at {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 www.ajantapharmausa.com}}}\uc2 .\par \par \uc2 (1) Abilify(R) is a registered trademark of \uc2 Otsuka Pharmaceutical Co\uc2 .\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20161116/440192"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20161116/440192}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-aripiprazole-tablets-300364320.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-aripiprazole-tablets-300364320.html}}}\par \par \uc2 SOURCE \uc2 Ajanta Pharma USA Inc\uc2 .\par \par \uc2 /CONTACT: For more information, please contact: John Adams, john.adams@ajantapharma.com, 908.252.1165\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 http://www.ajantapharmausa.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020161116ecbg000or\par }\page {\par\fs20\b \uc2 Pharmaceutical Companies; \uc2 Fluxion Biosciences \highlight22\uc2 Announces the Launch \highlight\uc2  of IonFlux Mercury, Its Next Generation Automated Patch Clamp System. The System Will Be Sold Directly by \uc2 Fluxion Biosciences\uc2 .\b0\par\par\uc2 319 \uc2 words\par \uc2 14 November 2016\par \uc2 Pharma Business Week\par \uc2 PHBW\par 95\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Pharma Business Week via NewsRx.com \par \par \uc2 2016 NOV 14 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 Fluxion Biosciences\uc2  announced the release of a second generation of its IonFlux automated patch clamp family of products. IonFlux Mercury will replace and update the existing IonFlux product family. While IonFlux systems were previously distributed by \uc2 Molecular Devices\uc2 , the \b \highlight22\uc2 new product\b0 \highlight\uc2  line will be sold directly by \uc2 Fluxion Biosciences\uc2  and its partners.\par \par \uc2 IonFlux systems are used all over the world in industry and academic laboratories and are leading systems in ligand and voltage gated ion channel screening. Unique in-plate perfusion provides continuous compound flow, allowing for assay simplification and speed, even for otherwise complicated and long assays. With IonFlux Mercury, Fluxion takes the platform to a new level by enhancing all aspects of its operation. The platform adds new features such as remote and touch screen experiment execution, highly extended recording times, new streamlined fluid exchange, standardized temperature control, and integrated current clamp.\par \par \uc2 IonFlux Mercury is the most compact yet full featured stand-alone high throughput automated patch clamp instrument on the market. "We believe that the new updates to the IonFlux system will greatly enhance all aspects of an otherwise well proven and unique automated patch clamp system", explained Dr. Ali Yehia, VP IonFlux Product at Fluxion. The IonFlux Mercury will replace the IonFlux 16 while the IonFlux Mercury HT will replace the IonFlux HT. Both systems will be sold exclusively by \uc2 Fluxion Biosciences\uc2  and are available for pre-ordering now. All IonFlux 16 and HT system sold within this year are upgradeable to Mercury. Please contact \uc2 Fluxion Biosciences\uc2  for more information.\par \par \uc2 Keywords for this news article include: Pharmaceutical Companies, \uc2 Fluxion Biosciences\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document PHBW000020161114ecbe0004t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Ajanta Pharma \highlight22\uc2 Announces the Launch \highlight\uc2  of Voriconazole Tablets\b0\par\par\uc2 263 \uc2 words\par \uc2 7 November 2016\par 07:00\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 BRIDGEWATER, N.J., Nov. 7, 2016 /PRNewswire/ -- \uc2 Ajanta Pharma USA Inc\uc2 ., a wholly owned subsidiary of \uc2 Ajanta Pharma Ltd\uc2 , India, announces today the \b \highlight22\uc2 launch\b0 \highlight\uc2  of Voriconazole Tablets (50mg, 200mg), a bioequivalent generic version of Vfend(R)(1) , into the US market.\par \par \uc2 Voriconazole Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the \uc2 United States Food & Drug Administration\uc2 .\par \par \uc2 About \uc2 Ajanta Pharma\par \par \uc2 Ajanta Pharma Limited\uc2  is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, finished pharmaceuticals across 30+ countries.\par \par \uc2 For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at $261 million and net profit of $61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.\par \par \uc2 For more details about \uc2 Ajanta Pharma USA Inc\uc2 ., please visit us at {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 www.ajantapharmausa.com}}}\uc2 .\par \par \uc2 (1) Vfend(R) is a registered trademark of PF Prism CV\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20161104/436377"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20161104/436377}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-voriconazole-tablets-300357848.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-voriconazole-tablets-300357848.html}}}\par \par \uc2 SOURCE \uc2 Ajanta Pharma USA Inc\uc2 .\par \par \uc2 /CONTACT: John Adams, john.adams@ajantapharma.com, 908.252.1165\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 http://www.ajantapharmausa.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020161107ecb70005r\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Ajanta Pharma \highlight22\uc2 Announces the Launch \highlight\uc2  of Amlodipine + Olmesartan Medoxomil Tablets\b0\par\par\uc2 285 \uc2 words\par \uc2 2 November 2016\par 09:57\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 BRIDGEWATER, N.J., Nov. 2, 2016 /PRNewswire/ -- \uc2 Ajanta Pharma USA Inc\uc2 ., a wholly owned subsidiary of \uc2 Ajanta Pharma Ltd\uc2 , India, announces today the \b \highlight22\uc2 launch\b0 \highlight\uc2  of Amlodipine + Olmesartan Medoxomil Tablets, (5mg+20mg, 5mg+40mg, 10mg+20mg, 10mg+40mg), a bioequivalent generic version of Azor(R)(1) Tablets into the US market.\par \par \uc2 Amlodipine + Olmesartan Medoxomil Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 29 Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications (ANDAs) of which it has 16 final ANDA approvals; 2 tentative approvals; and 11 ANDAs under review with the \uc2 United States Food & Drug Administration\uc2 .\par \par \uc2 About \uc2 Ajanta Pharma\par \par \uc2 Ajanta Pharma Limited\uc2  is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, finished pharmaceuticals across 30+ countries.\par \par \uc2 For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at $261 million and net profit of $61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.\par \par \uc2 For more details about \uc2 Ajanta Pharma USA Inc\uc2 ., please visit us at {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 www.ajantapharmausa.com}}}\uc2 .\par \par \uc2 (1) Azor(R) is a registered trademark of \uc2 Daiichi Sankyo Inc\uc2 .\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20161102/435278"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20161102/435278}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-amlodipine--olmesartan-medoxomil-tablets-300355868.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-amlodipine--olmesartan-medoxomil-tablets-300355868.html}}}\par \par \uc2 SOURCE \uc2 Ajanta Pharma USA Inc\uc2 .\par \par \uc2 /CONTACT: John Adams, john.adams@ajantapharma.com, 908.252.1165\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 http://www.ajantapharmausa.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020161102ecb2000cl\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Fortamet\b0\par\par\uc2 Steve Duffy \par \uc2 144 \uc2 words\par \uc2 1 November 2016\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2016 Haymarket Media. All Rights Reserved. \par \par \uc2 Mylan announced that it has received final approval from the \uc2 Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Metformin Hydrocholoride Extended-Release Tablets USP, the generic version of Fortamet (Watson).\par \par {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-pharmaceuticals/manufacturer/19076/"}}{\fldrslt{\cf2 \uc2 Mylan}}}\uc2  announced that it has received final approval from the \uc2 Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Metformin Hydrochloride Extended-Release Tablets USP, the generic version of Fortamet (Watson).\par \par \uc2 The treatment is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available in 500mg and 1000mg dosage strengths.\par \par \uc2 [HMICMS RELATED ARTICLES]\par \par \uc2 Metformin hydrochloride, a biguanide, reduces hepatic glucose production and intestinal glucose absorption. It also improves insulin sensitivity and peripheral glucose uptake and utilization.\par \par \uc2 For more information call 724-514-1968 or visit {\field{\*\fldinst{HYPERLINK "http://newsroom.mylan.com/2016-09-30-Mylan-Launches-Generic-Fortamet-Tablets"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020161102ecb100005\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw112\pich40\picscaley100\picscalex100\picwgoal1680\pichgoal600
47
494638396170002800E60000004A8E5989B62B66A19BB8D300146DE3ECF3ABC2DA326BA4F5FAFCB8CFE16487B5DAE9F11C5B9A739BC13B73A9A5BAD5D7E3EEFA
FEFE26619EB3C7DD4677AB135193D3DCE9004D900041896792BC013A855475A996A9C9CCDBE9EDF5F9015294002B7B175B99215C9A7AA3C6134D91899CC13658
98193B85E9F0F68BABCB7794BD0B448B17468C83ABCB456CA4F1F6F9BFD3E4E4F4F818539599B0CE386DA600448A013481233A8500478C718CB80D4C9009498E
001F74EDFAFC002F7EE5EFF5CED4E521478D37609C8BB0CE2B5E9C8398BF90A1C544599980A0C54B639E82A5C8CCDFEC07478C1A5998172779234D91C8CFE12B
51931F609CC5DAE80026785B7FAF556AA2093A85C2C6DC3167A26C78AB3B66A1C0D7E7013E8704418920509305448B0D35820B2E7D364D91CAD8E71758973040
890F1D7010559688A5C82D70A7222C7B004088396FA70005625181B191B2D00D40891B5697EEF2F70924772757974B7EAFC9E6F0E8F8FBDFEFF59FC0D903448A
E1E6F0403C84366FA7FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633133382037392E3135393832342C20323031362F30392F31342D30313A30393A30312020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D6536323166353162393836332220786D704D4D3A
446F63756D656E7449443D22786D702E6469643A42434235393642363343433231314538424441434143323846354633383935442220786D704D4D3A496E7374
616E636549443D22786D702E6969643A42434235393642353343433231314538424441434143323846354633383935442220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313720284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265
663A696E7374616E636549443D22786D702E6969643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222073745265
663A646F63756D656E7449443D22786D702E6469643A31333464646664372D333863352D343931342D393763642D653632316635316239383633222F3E203C2F
7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFD
FCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBD
BCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D
7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D
3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F9
0400000000002C00000000700028000007FF80026521650C522188884D87898452528388858C9265520C918E94848B8D8E0C8D6522908993A196A0A58F99658B
A9928FA18684026817353A5965350017381812123800C41872073A3817B74C82C3BE35120238CA00181559C9BD354C590CBCC4350C124CBDD6150715BCBECDDF
CBD622593BD5B85915CAB7350222CF00354D02983CC3A0E3009A616842D4D87140C43A006C24C81B664D461B19EBB86511D6EB978403F32E9CA3212723930302
6A54C3C000D9CA0A6D9AACC3D18CA32F0C22DAE800878B64C63D02048059D9C4A54882341C12235450049B8E110F300187C1620536CBB81D9080A163341A606A
2CBBE60063D69302BA8A6423C2CF0EB1E7FF1CC8E9D2114C16017BA0E6DC9955871F3918B2DA15E0852832B117083A1041576488261B9FFA8AE867EA51AB586F
813940C44B470C52A43E05D08544D92EC3306C16D0A5711711A2C75638BDCDCB5D2F544538D08141250EBF7224D7F022200B866A6C9AF8E10B51C7E2C6D44230
403393F2D45E55DB54089C588784153CA880C0C0A48C8E3D357C80A062034D05F5EB41A03960833D081F521C84E1E1838A0F190EB0C0C3051FD440451D6AD4D7
1F154DEC660308F5D9E0871436F850CC0E6558465A133A21C686732268E095250A41254165DC5D43830CDC71F3110523B4E0021568BCF1461732B4D0C01B030C
E05C0B1928F0801220D091010C2AACC0C0FF0E4264D0420E41348106116F5CA0811719D861431D01B450C4163ABC27460606CCD0461C1A48F106001A1C800411
1A88D4851C0E90C0DD878B89F8010E6C04D5440826B6C1448A30B178961F1A54F187056420A042176FF450C70913F0F1071F09301000141144B004123C341081
012FC0B01F177F60814002E0C1F1030B6EB8F0470604CC906A01085441800D03FC31010A2F3CC1430605A0C186037F703060170DDA39168874EDD9C547E501EA
118AB25DA4163734084040117F1CE186AA363880C016E1A9F0C706037A4107107C884185097F94E0461A7F5841C012069C4141040AB831C0025EF8E007020D10
F0EB155F2C3105011BFC91030F24F03101FF010AA0E0000651FC31030FCCD69919063BB4C15847D31E101622D69C38E85824B401D836274950030FE08E410012
7380E1800744D8D00505EB125083061AC00004153C2421B11B22E8B105151D4CD04518733CE0C6100550A8C30F09CFF0830EC32E00420E7F4CCD430E23D04101
0A6D50D1B11104349BD9427E9C3C19B56211B207DFB2AD080E4D5B754585BA148010C00F4C383087411A58F1870220E8A383011660A041184B2CE1030F1A6060
43070910E0C41F46B8D102024410408207093FF08318048C000115689B00C2075D6860430305784180191194E083C8DB30C4805A7C0A20155C8F496459628532
DF0D57CAACFD870B0A7BE0C3BF5568C043FFC4555021800420180081066CB0F1EF046280DC85051D68318301715031F00A04C8E04106549840019E6082511100
0E08F802847800820B200105346081152200071CD8297907F8C6678A139665E0403A22B845B630420C1CEC200B2238CE3278A0803F00010805A0000FDEF0822D
80000411DBC00EF0E2830958C0062DA1C2113C00812080A00C309803145E900210306102106042FF5090021BA4E1050BC81A0B343080089CE00A70484300E240
0104A0800F28F803122A87410DFA022859408F0775008A7E5C435B1D69865244723425A0AE0A4D0041171A300722A827620D500D0E6C30810E9040003B10DF13
16000111F8A003067042107EF0002AA4A0FF00FC23C10F52C083194060031E78830D6AD0803F9C200C5D5CC219EC80020A3CA1854518D02D94373838CA313165
D807A02E834776A07026C0F082BAC6003A1DA021031EC8827A2497032A28C30706E0431976E08530E0800092D355D58A340120F04009A02400111040AB0740C0
0964E8407F94108127F827010B70421582C7832CA08E0A89511EF37C0997AAD0A0028320268B68B611649E487B4200013A86F6822C88076D1B682000B0C907DF
1D20014250670432C0034CD2E10A4AE3C11020F03901BC2076F11A41015840801678F10A1A30000AF45900484601011CA002C9F236D0E2A8102232F0833A5856
95B208E77A79B9890468B0039CFDC1041AFFF0830C7C40432280000019F84315BECA062F58C0021AF081ACECB585C911C0027AF0010B16000502B492086E686B
000820BB0A0801756E68A10278C00328C87203B5A4C218924500BFA4B02340494B35E6E480ED000011D991C1DD362301CF4895062BC0010F8C90363904C70601
F08000481087882940A80CA840070A80341BE821024800420F9E40800EFCE10130F0000508F0D305E4000231E0ED042210073A4C610954A003AA8A6080080C37
033F68020FE8A5ACE74056227B982C9DAEB20C4260E62C28290C34A63A950FD8600B0FB0C35B1223801450000D2010821EB20082B65C210023C00006BAC08007
E0810B51A082064690001818C0053ED843FF17DA00831E4CC09E714082127AE70738D401471C88C102D8C5820CA4C14A3248411544E014007C0000BEC4C18B29
7B958E14421023EB820088102D6B30200B2BE0450D7A538632F4AE2BD70811352054949D54A8062450431C40D71F26A88104E1518F0624A0062A10C07754708E
0E40308CF570D906A0437305A4FCD50F68800A2190401754326011E08518BE2B03052AD0050F7E30046F814A05C04305F6EC410415608F9B41A7063430B04220
78447F6C00001B5CE1033EA046A1652080377B990756C672A1A9A0E303C487003C98CDF2E043EA82B917D55210C0E77CF0010C44387417500F153CD3E737FBC0
0B158803627021011184E01935B001051EFF908614A4400157685C03D240011FD861002920020FA29086090C40013B28D7001AA08127E861008913808EA44001
0DB7000E0D38000682A08404E8C1052B38800FA230002E0C40085F68C280DF900225C0E10133B043170230EE3AD000092978830F4800070334200E2C1881B30D
900209F8E00A2A98000C7220C802AD800612904308B2328F3744E00F308F00192AF00504FC960043F8031E6E208629C0FC0F08D840EDFED083281CE1E53D5883
A2681B809FC3FC085480C1CF3DA0021E08C1E63F7700997D0004A7FF61003630C01FA67006B42D4A7130EF8119CC807598BF810E62FF39127CA00126A0BC0609
255C1C84E0013566E0057F38C009E6803AFF1EE8E10F0B10430B110681450DEB0F1138C209F20073131C00011040FB0BE0908211680F010A20830B55FA8704BC
A1F170A03B1BEC30044B8D720B61FF83010860F60234A1953A37C30D62E02B1534400644F8C3FF52407413F0C00F36FB334DEE62F5BE1FC1060BF8831D4E5080
3FA440030FF803046C00AE39ACC1050998810FC21A831BDC80F27F68801D5EF0C3A67B807BFD81C31F0AE0840D24800339FD3A0B21308238D0650757D02B5C00
026ED030B2B7362F870202807B79700263607301E00685D6740DB80677600026F005C9770184703D3500025BD0772E200269E40771507D1FD3028827065A0073
45400727E503AD547EBB077309F077ED07FF74426720EAE23162400796D62BB3420074B003B7506C62907D53501F02E05B0680807F30076F9073C2570726D077
00F46B4D277B61400057A0065270548F713EBC00827D47492F9006364002D5473739B700611005BC372AC2B202B6428331800073300703800016E0034D17017C
C0077BF505D1277BF6C4553F370361604D41E1055720766480067B000613207B181301C0024508D0296330797FF00316300015C00252B72842100765400D22F1
41527010BD905F7DF7022FF03F54200384E786F3E70754B00196327F5BB0607F40833D600170300780D7013610567F00780DC00336A000D5377F86440245F072
7F400641F048831289DA97053C80527FA0FF075695008D87020FF0023B5783088000301007205007BE0573002416D4800687D00F54E00236B762D517004D9046
BA380734C00304100409007350F07834E88707308F64A00348207C0A100415606C3C700209F90730200257E00644D0785F4702228203DEB80455B5025297001A
002E157729F4D403E6C77B03B022FEC00362602BDAF7043E708402000A75C1066F607349D05BB2F70596622F2A58442BE000271040DA875A7F90072C402F1E40
027117454D170363E0062BA006592078E9337F0CF0050E40079CF3071D700236700B6120765370337120755CA078113002616501ADB48EBC472B3C500321E007
4F60031C00731B4005D19005D522552440FF043FF00749C0034BF00770307880A5820BA00185C90567002E10C0064D870042C002BC770355F0721D807631607C
632676B2A42816000097C801F7F2074B100471A2012420751D205A5790907A407B11D0007EF0072D40033A677E94B757FD11567960037D60983CC03788E01171
73043637032960732A7006A8020169107D30400025007329207A164005618500BA87077F60062BF0982C159A133001091006E5F90745909040000287370501E0
5B7A10061A500315C00009B90452C4023E37013CA02E29200008F0067FB5736CA7963D92056DF5024850983F100571E0071D4408C040553CE002D8087330C002
FB984631F706041007F3287C42B7973740FF3C57A50193C907E3E7755640051B297CBAB20584077335E403C9910594A2965DD04FD1573AEA020375F00314D056
1EF0044EE374231006419A7ED1305F1CD804EC55033520036FD00070A0021B802638000214900270A0045EA50138B0051910A733B202671A002BB0020110004A
950519F0066CC0004AA0040A90011910023CF0052D30004AE00236800120D0064300A975E00304A6131A40010D40014C20014DE0A914B0256274050E80066590
030D40032410008A9AA801C00461A0000330042EB00352C01B1E640912C0AB6E466B6F062100B003120006FEA11E362001FA91AC54B00375C21F2FC6033BB403
EAE10350A603FD711F6C400232A00137E4FF0324F3ABE2711F1AC021242016E22306C8D705CA8A03DB64038B74343E8006C6724385E64C9586AF5EB0ABC3B603
75840FDDAA55742A127B701760206035C016BB41671AE0174DC006BC8003D38217F6382754851AA4B10213D21ABC0006C5C1046CD01B18C02196951827A13747
E33C1D8454CB411710611B2DB6275BE21629C269C6860F18601A02E7158F881CBAA10399F11B7ED0B393C1B288610CCBF1AF26A31630561CE1B50C6C305EDBB2
037923197C0238155159C2C159510B632E43282B3208E10013C1610E3810144371147BC11DBF7100320159503B6C724003CCD1134E510D38200D6BEB0F72A01D
CCD314CC130DCFC347327050D65338D5F0843785EB0F8502986800006F1BB1682B05C7AAB7C7C0AB22B143462BB9D2F04B38800D3BD11127F45825C40001410F
E870B20010AA8FC547F1A021A16B0F6E9BB652A012AD0819D3F3B6248406821002ABE00952D00491300897C00AC12B09E340BCAA400ACA0B099900BCCC9B08C9
8B088610BDD21BBDD56B09D09B08AE80BCA4104C8100003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic versions of hypertension treatment\b0\par\par\uc2 Patty Tascarella \par \uc2 102 \uc2 words\par \uc2 27 October 2016\par \uc2 Pittsburgh Business Times Online\par \uc2 PITBJO\par \uc2 English\par \uc2 \u169\'00\'A9 2016 American City Business Journals, Inc. All rights reserved. \par \par \uc2 Mylan NV{\field{\*\fldinst{HYPERLINK "http://www.bizjournals.com/prnewswire/press_releases/2016/10/26/NE27692"}}{\fldrslt{\cf2 \uc2 announced U.S. \\b launches\\b0 }}}\uc2  of the first generic versions of Benicar and Benicar tablets, which are used to treat hypertension to lower blood pressure.\par \par \uc2 Mylan (Nasdaq:MYL), whose executive team is based in Southpointe, received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its abbreviated \b \highlight22\uc2 new drug\b0 \highlight\uc2  applications for these products and said it has 237 ANDAs awaiting regulatory approval.\par \par \uc2 Did you find this article useful? Why not {\field{\*\fldinst{HYPERLINK "https://secure.bizjournals.com/subscribe/selectTerm?market=pittsburgh&ana=cstpd&csrc=6355"}}{\fldrslt{\cf2 \uc2 subscribe}}}\uc2  to Pittsburgh Business Times for more articles and leads? Visit bizjournals.com/subscribe or call 1-866-853-3661.\par \par \uc2 Document PITBJO0020161027ecar0002w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 13:28 EDT Mylan  \highlight22\uc2 launches \highlight\uc2  generics of Benicar, Benicar HCT tabletsMylan (MYL)...\b0\par\par\uc2 142 \uc2 words\par \uc2 26 October 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 13:28 EDT Mylan \b \highlight22\uc2 launches\b0 \highlight\uc2  generics of Benicar, Benicar HCT tabletsMylan (MYL) announced the U.S. \b \highlight22\uc2 launches\b0 \highlight\uc2  of the first generic versions of \uc2 Daiichi Sankyo\uc2 's (DSNKY) Benicar and Benicar HCT, Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg, and Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg, respectively. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications for these products. Olmesartan Medoxomil Tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents, to lower blood pressure. Olmesartan Medoxomil and Hydrochlorothiazide Tablets are indicted for the treatment of hypertension to lower blood pressure, and are not indicated for the initial therapy of hypertension.\par \par \uc2 Document FLYWAL0020161026ecaq008y9\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 07:08 EDT Baxter reports Q3 adjusted EPS 56c, consensus 45cReports Q3 revenue...\b0\par\par\uc2 85 \uc2 words\par \uc2 25 October 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 07:08 EDT Baxter reports Q3 adjusted EPS 56c, consensus 45cReports Q3 revenue $2.56B, consensus $2.55B. ''We are pleased with the continued strength across our core franchises as well as our improved financial performance, both of which are reflected in our third quarter results. Given this progress, we are intensifying our focus on portfolio management and innovation to accelerate our efforts to \b \highlight22\uc2 introduce new products\b0 \highlight\uc2  and therapies,'' said Joe Almeida.\par \par \uc2 Document FLYWAL0020161025ecap0039j\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw64\pich40\picscaley100\picscalex100\picwgoal960\pichgoal600
47
494638396140002800F70000000000FFFFFFEFA3A5F3A6AB39292AF6A8B2352F30D94A65EC58811E1115ED6391D2CFD0D23475F099BC756B6FE34288EA91BD50
484CB1AFB0B2A9AFE399D1A73694D39ACC6E666DD2C9D19F8E9ED6A9D6604F60070607241F24968F969E989EFFF7FFFFFBFFFEFBFE535253FFFDFFC0BEC07A79
7A6E6D6EFFFEFFF7F6F7F5F4F5D3D2D39291927F3988A05BAB484249AEA7B01F1C20B9B4BB3430365A565C4D4B4EF1EEF4B8A6D0A8A6AB716F754F4D59ADACD2
0101031A1A1C1D1D1E2D2D2E333334474748FDFDFFF3F3F4C6C6C7C1C1C25E65A6999A9FB2B5BEA0B2D3111419313843000204BABFC4D7DADDE3E4E5A4C4E249
4C4E9AA0A44C4E4F8688892A6E8C616C71131F244596B4BDC5C85C63658DBDC92D35373C40410A0F1038939914232496C9C94F5656272A2ADCE3E3ACB1B17F82
82FBFFFFFBFEFEFDFFFFEFF1F1A8A9A98FC2BBF9FFFE0C1412C6CECC141F1BF8FFFC379C6C111915646A67FBFFFD92C9AA1D2520A6ACA8A4A7A5FCFFFD55A76E
9BD2AB555956D6DAD7F9FEFA191F1A97CB9E373E385B635B8A948A111211868C864A4D4AB1B5B1CBCECB646564BABBBA3A4739BDE0B7CED4CDC4C9C392B989B3
D3ABD4E9CEF0F8E8AEB4A612140CFDFFF4060605C1C1AC161615747470FEFEF9454544FBFBF9CECECD9898978C8C8B4443315C594B9C998AB3B2AD34332F1C1B
18413F39ADACA9FFEFCDE7DECBCEC9C03C3832FCC175FFDAACE9B57DF4C693DE9347040302201F1EFEF7F0A89F97090400F6BF98F6B791ED8E59F8B795131110
FDBC9DE67C51F3B299EC8461CCC9C8D96854FEB9ACFFB9B70A0808B4B0B0302F2F4D4C4C5E5D5DB8B7B7B6B5B5FEFEFEFDFDFDFBFBFBF9F9F9F2F2F2EEEEEEEC
ECECE8E8E8E6E6E6E5E5E5E2E2E2DCDCDCD5D5D5CBCBCBC8C8C8C4C4C4B5B5B5B3B3B3B1B1B1ADADADAAAAAAA2A2A2A0A0A09D9D9D9A9A9A9494948F8F8F8989
896060605C5C5C5B5B5B4F4F4F4949493E3E3E3939393737373434343232322C2C2C2929292525252424242222221919191313131111110F0F0F0D0D0D0C0C0C
040404020202010101FFFFFF21F904010000FF002C00000000400028000008FF0003081C48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2C58B18336ADCC8
B1A3C78F20438A1C49B2A4C99328232E1BB832C0B2972D5B3664E692A54C97346DD63CE8CC5AB24529023C2BF16419B3664699BD64A654E0B268DEA831358A73
EAB26A459432ABA6CDD952A634A986651A806C117BC6E2CDF2440D8038824D092AF316C01B80713B03342BC802801981E532412378D3A9C09C02B901D0160DDE
3B6C003E15DC4B30539000CE4A48437CB01C0062D50294BB37582FC46DFCB205F8A6CF5B3F6ED8DCC5E3642DC00A4EF3CA7DCA370F5D1113D7022C7247EFEFB9
7A419E0530C18E9E3AD1F802A850276FC4B4747FAD8D504D2E5DB511F5CE2DFFDB06C04F8077F3AEF9EB96CD0C111FF2A0D98327EE9B377D3F407D0350C21A00
77E42CB20E006B50314400278C000E00D27C738F0AEFC8C30D3EEAB4034000E100604E00FB18134426E098C38C3200C4430F07D948135900D088D3CE259EE8C3
CE403EF41100642BA4B3CF40F65C32CD4027C4C34C21EAAC014F1E0028138039009CC0410A261073CE100084630C3D41055006008A88234D000B00200137C41C
C3C93E3614010000380410430D0110014032635C26826D3134D949009A641280045C9E03CA2540FC200F2079DC81471F741C82CA2ECF2C400C00E56809801303
6100C0113C2013002200D416C014003C11430401000300115DF45090190090FFC2A7290219230B327D95A0821A01FCE18E3B23902186205D0CA408009EC00080
0C032502C0071DCC304107006032CA2AA20030092BB684530C000B2403C020882062C8228400D044005A30215016002841861B5C64D1041201E400000D014401
00150150D18415C896600030014CB289248C3CE2C81D5C98A1C51B6228B104BE59807145133A6010800770CC6182030910908140196C00824017BC10801FA754
32CB09013C520A2501D442802A9684E2C5155204B0C924924402C91E48CBB1871C4ACBF1C517557C8145155818518511581BE1820B2D6C5D41050A30C0C0030F
88CD0002081CA080020704F34B30BDF4928BDCB9C4124B2BAFB812C0199658A34274239104C2472082F361871D6C84A1F8168C4301451249ECB0C30D1A686081
0514640E01040D74DEF900050C20C000C308E3CBE9BCE882CB2DB0B4EE4A2AA9D072461C75E8911244699C9146002804404208C0070F3C09C4176F7CF1C18B80
061A420884C2329B440F130A28102F04F569E8A1C719DC9FD1C619010CBF4961CE534F3DEFBD976F7EFA05B1BF91FBB7C72FFFFCF4D76FFFFDF8E7AFFFFEFCF7
7F5140003B}}
\par\par \b \uc2 PolyOne\uc2  shows  \highlight22\uc2 new products \highlight\uc2 , technologies\b0\par\par\uc2 Frank Esposito \par \uc2 299 \uc2 words\par \uc2 21 October 2016\par \uc2 Plastics News\par \uc2 PLCN\par S013\par \uc2 English\par \uc2 (c) 2016 Crain Communications, Inc. All rights reserved. \par \par \uc2 3-D surfaces, metallic colorants and cricket helmets are all part of \uc2 PolyOne Corp\uc2 .\u8217\'20\'19s presence at K 2016.\par \par \uc2 Avon Lake, Ohio-based \uc2 PolyOne\uc2  recently \b \highlight22\uc2 launched\b0 \highlight\uc2  IM3D, a technology developed with German science and technology firm \uc2 Merck KGaA\uc2 . With IM3D, manufacturers can create surfaces that appear to have depth and structure, even though they are perfectly flat, officials said.\par \par \uc2 Several processing steps were previously necessary to generate this effect in a polymer surface. Now, the 3-D impression is created in just a single step during injection molding, they added.\par \par \uc2 Also new for \uc2 PolyOne\uc2  are Impress-brand ultra-glossy metallic colorants: This new technology enables packaging manufacturers to realize new combinations of color and gloss to create packaging with a brilliant, attention-grabbing appearance. The new Impress metallic effect materials add value to packaging made with semi-crystalline polymers such as PET, polycarbonate and ABS, officials said.\par \par \uc2 The firm\u8217\'20\'19s OnColor BIO masterbatch concentrates now are certified for at-home composting. Officials said this step is important because of two new laws in France, and the likelihood such laws also will be introduced in other countries. At-home composting is at lower temperatures and pressure than industrial composting.\par \par \uc2 PolyOne\uc2 \u8217\'20\'19s GLS thermoplastic elastomer unit is focused on a host of new products, including Versaflex VDT (Vibration Damping Technology) materials and OnFlex LO materials, which feature reduced levels of volatile organic compounds (VOCs) for vehicle interiors.\par \par \uc2 The \uc2 PolyOne\uc2  stand at K 2016 is displaying a cricket helmet that includes protective safety pads made with Versaflex VDT.\par \par \uc2 The firm\u8217\'20\'19s Specialty Engineered Materials unit recently added a new extrusion line in Pune, India. The site already offers solid and liquid color concentrates from the facility. The new line should be up and running in January.\par \par \uc2 Document PLCN000020161103ecal0001u\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 ENOVACHEM PHARMACEUTICALS  \highlight22\uc2 LAUNCHES \highlight\uc2  ADYPHREN(TM) KITS EPINEPHRINE EMERGENCY INJECTION KITS\b0\par\par\uc2 203 \uc2 words\par \uc2 19 October 2016\par 08:10\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 TORRANCE, Calif., Oct. 19, 2016 /PRNewswire-iReach/ -- Enovachem Pharmaceuticals has \b \highlight22\uc2 launched\b0 \highlight\uc2  their \b \highlight22\uc2 new Product\b0 \highlight\uc2  Adyphren(TM) Kits. The kits contain epinephrine and syringes for use when signs or symptoms of a life-threatening allergic reactions occur such as anaphylaxis.\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20161018/430012"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20161018/430012}}}\par \par \uc2 As low as $85 per single use kit\par \par \uc2 Designed for use as an emergency kit for: \par \par \uc2 \f2 \par    -- School nurses \par  \par    -- Healthcare practitioners \par  \par    -- Emergency responders and \par  \par    -- Individuals trained to use a syringe and give an injection. \f28 \par \par \uc2 \f2 Enovachem Pharmaceuticals is a creative team of healthcare professionals, with experience in academia, finance, pharmaceuticals, and regulatory affairs. We interact daily to further our research, to develop, and manufacture products that will change the landscape of healthcare and create solutions for issues being observed today. We are committed to working together with medical providers and health insurance payers to help to ensure quality outcomes, by limiting the circulation of disease and allowing for increased compliance.\f28 \par \par \uc2 \f2 The Pharmaceutical Leader in Single Use Injection Kits (SUIK(TM))\f28 \par \par \uc2 \f2 Media Contact: Aprile Haynes, Enovachem Pharmaceuticals, 310 320-0100, aprileh@enovachem.us.com\f28 \par \par \uc2 \f2 News distributed by PR Newswire iReach: \f28 {\field{\*\fldinst{HYPERLINK "https://ireach.prnewswire.com"}}{\fldrslt{\cf2 \uc2 https://ireach.prnewswire.com}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE Enovachem Pharmaceuticals\f28 \par \par \uc2 \f2 (END)\f28 \par \par \uc2 Document PRN0000020161019ecaj00071\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: Alphatec Spine to Showcase New Minimally Invasive (MIS) and Complex Spine Products at the Upcoming 31st Annual North American Spine Society (NASS) Meeting in Boston\b0\par\par\uc2 1,226 \uc2 words\par \uc2 18 October 2016\par 16:15\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Alphatec Spine to Showcase New Minimally Invasive (MIS) and Complex Spine Products at the Upcoming 31st Annual North American Spine Society (NASS) Meeting in Boston\par \par \uc2 CARLSBAD, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- \uc2 Alphatec Holdings, Inc\uc2 . (Nasdaq:ATEC), the parent company of \uc2 Alphatec Spine, Inc\uc2 ., a provider of spinal fusion technologies, announced today that it will \b \highlight22\uc2 introduce\b0 \highlight\uc2  several \b \highlight22\uc2 new products\b0 \highlight\uc2 , as well as its current comprehensive portfolio at the upcoming \uc2 North American Spine Society\uc2  (NASS) meeting at the Boston Convention and Exhibition Center in Boston, Massachusetts, which will be held from October 26th -- 29th, 2016. Alphatec Spine will be located in booth number 1523. In addition, today the Company announced that it has received 510(k) clearance from the \uc2 U.S. Food and Drug Administration (FDA) \uc2 for its Battalion(TM) Lateral Spacer System featuring the Alphatec Squadron(TM) Lateral Retractor.\par \par \uc2 "We are excited to demonstrate our newest products at NASS this year, including our new lateral system, the Battalion Lateral Spacer System, which features a unique and innovative retractor that we believe offers surgeons improved functionality and better patient outcomes," said \uc2 Leslie Cross\uc2 , Chairman and interim Chief Executive Officer. "Our new XYcor(R) Expandable Spinal Spacer System and Arsenal(TM) Deformity systems will also be showcased. Each of these new products leverage and complement our robust Arsenal Spinal Fixation platform - providing comprehensive and compelling solutions for our surgeon customers and their patients. With our revitalized product pipeline and portfolio, we are increasing our market opportunities in the U.S., including our new offerings in the MIS and complex spine markets, two of the fastest growing market segments of spine."\par \par \uc2 Alphatec will be showcasing its broad portfolio of spinal fusion products, including the Company's newest spinal fusion products:\par \par \uc2 Alphatec Spinal Fusion Technologies Technical Exhibit Booth #1523: \par \par \uc2 \f2 \par    -- Battalion Lateral Spacer System and Squadron Lateral Retractor:  The \par       Battalion Lateral Spacer System with the Alphatec Squadron Lateral \par       Retractor provides surgeons with a next-generation lateral system with \par       unrivaled, unique design characteristics - total blade control technology \par       that allows the surgeon to maintain approach aperture throughout the \par       procedure, including in-situ blade height adjustment and blade \par       replacement, combined with the Battalion Lateral Spacer will be available \par       in 0degand 15deg lordosis with a variety of width and height options for \par       lumbar and thoracic approaches. \par  \par    -- XYcor Expandable Spinal Spacer System:  The XYcor system provides \par       surgeons with a minimally invasive inspired solution for PLIF and TLIF \par       procedures by utilizing a smaller, more compact ALIF sized implant that \par       can accommodate a variety of patient pathologies. The system provides \par       nearly five times the amount of bone graft potential compared to standard \par       PLIF and TLIF cages. \par  \par    -- Arsenal Deformity Spinal Fixation System:  The Arsenal Deformity System \par       was thoughtfully designed to provide surgeons with a complete solution to \par       address complex deformity pathologies.  The system features unique \par       uniplanar and monoaxial screws, providing the surgeon with easier screw \par       positioning and rod placement through a tulip that has 360 degrees of \par       rotation while restricting motion in the medial/lateral plane for \par       derotation correction. \f28 \par \par \uc2 \f2 Alphatec Workshops and Presentations: \f28 \par \par \uc2 \f2 \par    -- "Alphatec Spine Complex Solutions:  Avoiding Pitfalls in Complex \par       Deformity" by Dr. Kirkham Wood and Dr. Saechin Kim: \par  \par           -- Wednesday, October 26th -- 8:00am EDT, The Learning Place \par  \par    -- "Discover XYcor the New Expandable Spinal Spacer System" by Dr. Henry F. \par       Fabian, Jr.: \par  \par           -- Wednesday, October 26th -- 3:15pm EDT, Alphatec booth #1523 \par  \par           -- Thursday, October 27th -- 9:45am EDT, Alphatec booth #1523 \f28 \par \par \uc2 \f2 About Alphatec Spine\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Alphatec Spine, Inc\f28 \uc2 \f2 ., a wholly owned subsidiary of \f28 \uc2 \f2 Alphatec Holdings, Inc\f28 \uc2 \f2 ., is a provider of spinal fusion technologies for the treatment of spinal disorders associated with trauma, congenital deformities, disease and degeneration. The Company's mission is to combine innovative surgical solutions with world-class customer service to improve outcomes and patient quality of life. The Company markets products in the U.S. via a direct sales force and independent distributors.\f28 \par \par \uc2 \f2 Additional information can be found at \f28 {\field{\*\fldinst{HYPERLINK "http://www.alphatecspine.com"}}{\fldrslt{\cf2 \uc2 www.alphatecspine.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 About the \f28 \uc2 \f2 North American Spine Society\f28 \uc2 \f2  (NASS)\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 The North American Spine Society\f28 \uc2 \f2  is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value- and evidence-based spine care for patients. The society is comprised of almost 9,000 members worldwide from disciplines including orthopedic surgery, neurosurgery, physical medicine and rehabilitation, pain management, physical/occupational therapy, anesthesiology, radiology and other health care professionals focused on the spine.\f28 \par \par \uc2 \f2 Additional information can be found at \f28 {\field{\*\fldinst{HYPERLINK "http://www.nassannualmeeting.org"}}{\fldrslt{\cf2 \uc2 www.nassannualmeeting.org}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Forward Looking Statements\f28 \par \par \uc2 \f2 This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include references to the Company's belief that certain of its products offer competitive functionalities in the marketplace. In addition, forward-looking statements include the Company's ability to successfully develop and commercialize its current products and new products, including the products discussed in this press release. The words "believe," "will," "should," "expect," "intend, " "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to; the uncertainty of success in developing new products or products currently in Alphatec Spine's pipeline, including without limitation the products discussed in this press release; the uncertainties regarding the ability to successfully license or acquire new products and the commercial success of such products; failure to achieve acceptance of Alphatec Spine's products by the surgeon community, including without limitation the products discussed in this press release; Alphatec Spine's ability to develop and expand its U.S. revenues; continuation of favorable third part payor reimbursement for procedures performed using Alphatec Spine's products, including the products discussed in this press release; unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec Spine's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; Alphatec Spine's ability to compete with other competing products and with emerging new technologies; product liability exposure and patent infringement claims and claims related to Alphatec Spine's intellectual property. Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. \f28 \par \par \uc2 \f2 \par CONTACT: Investor/Media Contact: \par  \par Christine Zedelmayer \par Investor Relations \par Alphatec Spine, Inc. \par (760) 494-6610 \par czedelmayer@alphatecspine.com \f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 October 18, 2016 16:15 ET (20:15 GMT)\f28 \par \par \uc2 Document DJDN000020161018ecai0038n\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Ergobaby  \highlight22\uc2 Introduces New Products \highlight\uc2  And Styles This Winter\b0\par\par\uc2 746 \uc2 words\par \uc2 18 October 2016\par 09:00\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 \f2 \par The Winter 2016 Collection Includes the \f28 \b \highlight22\uc2 \f2 Launch\f28 \b0 \highlight\uc2 \f2  of Diaper Bags, a Customizable Swaddler + Sleeping Bag Set and New Prints and Styles for Existing Product Line \par  \f28 \par \par \uc2 \f2 LOS ANGELES, Oct. 18, 2016 /PRNewswire/ -- Ergobaby(R), the award-winning maker of ergonomic baby carriers, swaddlers and nursing pillows, announces its expansion into a \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  category, Diaper Bags, the \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of an customizable Sleeping Bag + Swaddler Set, and a number of new prints and styles to be added to its existing product line.\f28 \par \par \uc2 New Product Category -- Diaper Bags\par \par \uc2 Ergobaby proudly announces their new Diaper Bag Collection. Featuring backpack (in two sizes) and messenger style bags, each available in three different color options, this nine-piece collection marks the brand's expansion into a whole new product category and will be available in February of 2017.\par \par \uc2 New Sleep Products -- Customizable Sleeping Bag + Swaddle Set\par \par \uc2 Ergobaby's Baby Sleeping Bag + Swaddle Set is a versatile and adjustable Baby Sleeping Bag with separate Swaddle. It's a customizable sleep solution designed to grow with babies and their changing sleep preferences and needs. The easy-to-use swaddling solution within the Ergobaby Baby Sleeping Bag + Swaddler Set offers customizable options to swaddle a newborn, help baby transition out of swaddling, and then ultimately into a sleep sack. The Sleeping Bag + Swaddle Set will be available in three colors and prints this December.\par \par \uc2 In addition, Ergobaby is introducing two new print and color options in the Original Swaddler design, a peaceful sheep print, as well as a new blue color option in the Lightweight Swaddler.\par \par \uc2 New Carrier Designs\par \par \uc2 Ergobaby is introducing a number of new styles to their carrier collections, including two new styles to the award-winning Four Position 360 Carrier collection, Dewy Grey and Azure Blue. These two new styles draw inspiration from weather symbols, mixing playful and whimsical interpretation with style and sophistication. The Dewy Grey baby carrier is an elegant grey hue with a raindrop print lining. The Azure Blue features a light blue color and classic striped lining. The Four Position 360 Carrier's unique, structured bucket seat, padded shoulder straps, and wide supportive waistband offer exceptional comfort and ergonomics in all four carry positions.\par \par \uc2 The Ergobaby ADAPT carrier offers the renowned comfort and ergonomics that the brand is known for, in an easy-to-use, 3 position carrier that adapts to a growing baby, from newborn to toddler (7-45 lbs.), with no infant insert needed. This winter, Ergobaby is introducing two new designs to the ADAPT carrier line: Azure Blue and Admiral Blue. The Admiral Blue baby carrier draws on a nautical inspiration with a navy blue color, and a vintage lace patterned lining, while the Azure Blue features the same classic light blue and striped lining as the Four Position 360 Carrier.\par \par \uc2 One new style is being added to the award-winning Ergobaby Original Collection, Moonstone, which is a monochromatic earth toned carrier inspired by elements in nature. The International Hip Dysplasia Institute has acknowledged all Ergobaby Carriers (Four Position 360, ADAPT & Original), as "hip healthy" products.\par \par \uc2 New Nursing Pillow Designs\par \par \uc2 The award-winning Ergobaby Natural Curve Nursing Pillow is made from solid foam, with a unique contour designed to help position baby tummy-to-tummy at a good height that saves moms from slouching. Firm and ergonomically structured, it maintains its shape over time for lasting support. The Nursing Pillow will now also be available in a new peaceful sheep print.\par \par \uc2 Ergobaby(R) is a registered trademark of The ERGO Baby Carrier, Inc. and its affiliates.\par \par \uc2 About Ergobaby\par \par \uc2 Founded in 2003, Ergobaby is dedicated to building a global community of confident parents with smart, ergonomic solutions that enable and encourage bonding between parents and babies. Ergobaby offers a broad range of award-winning baby carriers, swaddlers, nursing pillows, and related products that fit into families' daily lives seamlessly, comfortably and safely. Ergobaby is headquartered in Los Angeles and is sold in more than 650 retailers and online sites in the United States and in more than 50 countries.\par \par \uc2 For more on Ergobaby, please visit: {\field{\*\fldinst{HYPERLINK "http://www.ergobaby.com"}}{\fldrslt{\cf2 \uc2 www.ergobaby.com}}}\uc2 .\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20161018/429637"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20161018/429637}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ergobaby-introduces-new-products-and-styles-this-winter-300346515.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ergobaby-introduces-new-products-and-styles-this-winter-300346515.html}}}\par \par \uc2 SOURCE Ergobaby\par \par \uc2 /CONTACT: \uc2 Nicole Daley\uc2 , Daley PR, 415.408.8664, nicole@daleypr.com\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.ergobaby.com"}}{\fldrslt{\cf2 \uc2 http://www.ergobaby.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020161018ecai000dq\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 07:32 EDT Vascular Solutions announces IND submission for RePlas Vascular...\b0\par\par\uc2 116 \uc2 words\par \uc2 18 October 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 07:32 EDT Vascular Solutions announces IND submission for RePlas Vascular Solutions announced the submission of an Investigational \b \highlight22\uc2 New Drug\b0 \highlight\uc2 , or IND, application to the FDA for RePlas, a freeze-dried plasma product being developed in collaboration with the U.S. Army Medical Materiel Development Activity, or USAMMDA. Pending \uc2 FDA\uc2  approval of the IND application, Vascular Solutions expects patient enrollment to commence in December. Upon successful completion of the clinical study, a Biologics License Application is expected to be filed, followed by commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  in the U.S. in 2019-2020 and initial production devoted to meeting the battlefield needs of the \uc2 U.S. Army\uc2 .\par \par \uc2 Document FLYWAL0020161018ecai003k5\par }\page {\par\fs20\b \uc2 Trinity Partners\uc2 ; Trinity Partners  \highlight22\uc2 Launches New Products \highlight\uc2  to Help Optimize the Commercialization Process for Biopharmaceutical Clients\b0\par\par\uc2 539 \uc2 words\par \uc2 17 October 2016\par \uc2 Biotech Business Week\par \uc2 BTBW\par 778\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Biotech Business Week via NewsRx.com \par \par \uc2 2016 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- \uc2 Trinity Partners\uc2 , a global life sciences consulting firm, announced that it has \b \highlight22\uc2 launched\b0 \highlight\uc2  formalized products around six key areas of expertise focused on the necessary foundational work to support the successful commercialization of a product in today's dynamic environment.\par \par \uc2 These pillar programs, termed Cornerstone projects, are based on proven approaches that the company has been employing for the past twenty years to assist biopharmaceutical clients in the process of activities such as expanding portfolios, gaining market insights, launching and/or pricing \b \highlight22\uc2 new products\b0 \highlight\uc2 , and many more. These \b \highlight22\uc2 new products\b0 \highlight\uc2  come at a challenging time for biopharmaceutical companies. In fact, according to a 2014 study by Tufts Center for the Study of Drug Development the cost to receive approval for just one drug is $2.6 billion USD.\par \par \uc2 The Cornerstone projects systematize \uc2 Trinity\uc2 's best practices and multidisciplinary expertise to create a consistent work product so that clients know exactly what to expect when they work with \uc2 Trinity\uc2  on their strategic commercial engagements. Please see each project and its area of focus below: TRek - Integrated patient journey research:A holistic, data-driven research tool that incorporates both claims analysis and primary market research to identify and characterize key leverage points in the patient journey. TRailblazer - Analytical launch planning:A set of products offering a clearly defined analytical plan to optimize product value via sequencing and execution of critical pre-launch activities. TRaject - Strategic forecasting:A gold-standard forecasting methodology centered on innovative, standardized forecasting solutions that provide transparent, actionable insights for our clients. TaRget - Business development and licensing: A menu of tools optimized for integrated quick-turnaround BD assessments, including \uc2 Trinity\uc2 's proprietary QuickQuant market research survey tool and forecast model. OpTimizeR - Strategic pricing and reimbursement research:A strategic pricing research offering that applies a balanced, rational, and evidence-based approach, incorporating \uc2 Trinity\uc2 's multidisciplinary research capabilities. ConTRact - Contracting offerings:A comprehensive suite of specialized tools and methodologies to support a wide range of contracting projects for both medical benefit and pharmacy benefit products.\par \par \uc2 "At \uc2 Trinity Partners\uc2  we have always taken great pride in delivering innovative insights that enable our clients' success via unique methods and tools," said David Fitzhenry, Managing Partner at \uc2 Trinity Partners\uc2 . "We are excited to offer comprehensive compilations of our key learnings regarding the commercialization of a product in today's shifting drug development landscape."\par \par \uc2 To see more information on each of the Cornerstone projects, please click here: {\field{\*\fldinst{HYPERLINK "http://trinitypartners.com/index.php/cornerstone-projects/"}}{\fldrslt{\cf2 \uc2 http://trinitypartners.com/index.php/cornerstone-projects/}}}\uc2 Trinity Partners\uc2  is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about our Partners, click here: [{\field{\*\fldinst{HYPERLINK "http://www.trinitypartners.com/index.php/our-team/our-partners/"}}{\fldrslt{\cf2 \uc2 http://www.trinitypartners.com/index.php/our-team/our-partners/}}}\uc2 ] View source version on businesswire.com: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20161005005201/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20161005005201/en/}}}\par \par \uc2 Keywords for this news article include: \uc2 Trinity Partners\uc2 , Biopharmaceuticals, Drugs and Therapies.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document BTBW000020161017ecah0003f\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Lipocine Files 8K - Regulation FD >LPCN\b0\par\par\uc2 176 \uc2 words\par \uc2 17 October 2016\par 08:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Lipocine Inc\uc2 . (LPCN) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on October 17, 2016.\par \par \uc2 On October 17, 2016, \uc2 Lipocine Inc\uc2 . issued a press release announcing the completion of the post action meeting with the \uc2 United States Food and Drug Administration\uc2  ("\uc2 FDA\uc2 ") for the LPCN 1021 new drug application. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1535955/000114420416128259/v450633_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1535955/000114420416128259/v450633_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1535955/000114420416128259/0001144204-16-128259-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1535955/000114420416128259/0001144204-16-128259-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 October 17, 2016 08:00 ET (12:00 GMT)\par \par \uc2 Document DJDN000020161017ecah001fi\par }\page {\par\fs20\b \uc2 ANI Pharmaceuticals, Inc\uc2 . \uc2 ANI Pharmaceuticals \highlight22\uc2 Announces  \highlight \highlight22\uc2 Launch \highlight\uc2  of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL\b0\par\par\uc2 244 \uc2 words\par \uc2 10 October 2016\par \uc2 Pharma Business Week\par \uc2 PHBW\par 33\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Pharma Business Week via NewsRx.com \par \par \uc2 2016 OCT 10 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- \uc2 ANI Pharmaceuticals, Inc\uc2 . ("ANI") (Nasdaq: ANIP) \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections. The current annual U.S. market for this product is approximately $78 million, according to \uc2 IMS Health\uc2 , and is representative of two brand products. ANI will immediately \b \highlight22\uc2 launch\b0 \highlight\uc2  the product.\par \par \uc2 Arthur S. Przybyl, ANI's President and CEO stated, "This is the first product that we are launching from the basket of 22 previously marketed generic products that we acquired in July 2015 and it represents another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA product. ANI has added nine \b \highlight22\uc2 new products\b0 \highlight\uc2  to our commercial portfolio in 2017 and we continue to forecast the \b \highlight22\uc2 launch\b0 \highlight\uc2  of at least one additional generic product this year."\par \par \uc2 About Erythromycin Ethylsuccinate for Oral Suspension\par \par \uc2 Erythromycin Ethylsuccinate for Oral Suspension is indicated in the treatment of infections caused by susceptible strains of selected diseases. For more information, including the complete list of indications and usages, please see the accompanying Full Prescribing Information.\par \par \uc2 Keywords for this news article include: Antibiotics, \uc2 ANI Pharmaceuticals Inc\uc2 ., Drugs and Therapies, Topical Acne Agents, Dermatological Agents, Macrolide Derivatives, Ophthalmic Preparations, Ophthalmic Antiinfectives, Erythromycin Ethylsuccinate.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document PHBW000020161010ecaa00003\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Aspen Veterinary Resources Debuts First Environmental Preventative for Mastitis at World Dairy Expo\b0\par\par\uc2 433 \uc2 words\par \uc2 6 October 2016\par 13:23\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2016  Business Wire. All Rights Reserved. \par \par \uc2 \f2 \par GREELEY, Colo.--(BUSINESS WIRE)--October 06, 2016-- \f28 \par \par \uc2 \f2 Aspen Veterinary Resources Ltd. today at the World Dairy Expo \f28 \b \highlight22\uc2 \f2 introduces\f28 \b0 \highlight\uc2 \f2  a \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  line of stall and feed additives that reduces mastitis in dairy cows. The revolutionary product line is the first of its kind in the U.S.\f28 \par \par \uc2 The products, called Easy Cow and Gold Pro Cow, are made with all-natural carrier ingredients and imprinted with a contrasting electromagnetic frequency. This creates an opposing force to the specific frequency created by each pathogen that causes mastitis. The technology is similar to noise-canceling headphones, which use an opposing frequency to cancel out noise.\par \par \uc2 "We are always looking for new, innovative products that provide effective solutions to our customers, and Easy Cow is one of those solutions," said Kevin Pohlman, senior vice president of sales and marketing for Animal Health International. "Easy Cow is a unique approach to preventing mastitis, which is the leading cause of milk loss, and therefore revenue loss, for our dairy customers. It's good for herd health and the fiscal health of their operation."\par \par \uc2 Easy Cow is applied to bedding to kill 96 percent of the pathogens that cause mastitis, reducing SCC and leading to higher production. It also works to increase beneficial bacteria for a better environment. Gold Pro Cow works similarly once added to food.\par \par \uc2 For more information, please visit goodnightmastitis.com.\par \par \uc2 About Aspen Veterinary Resources Ltd.\par \par \uc2 Aspen Veterinary Resources Ltd. offers a range of products to prevent and treat animal illness and optimize their health and performance. Aspen focuses on all aspects of health from improved feed, nutrition intake, disease prevention, calving, milking, growth and performance.\par \par \uc2 Aspen Veterinary Resources is part of \uc2 Animal Health International Inc\uc2 ., which is owned by \uc2 Patterson Companies\uc2 .\par \par \uc2 About \uc2 Patterson Companies Inc\uc2 .\par \par \uc2 Patterson Companies Inc\uc2 . (Nasdaq: PDCO) is a value-added distributor serving the dental and animal health markets.\par \par \uc2 Dental Market\par \par \uc2 Patterson's Dental segment provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists and dental laboratories throughout North America.\par \par \uc2 Animal Health Market\par \par \uc2 Patterson's Animal Health segment is a leading distributor of products, services and technologies to both the production and companion animal health markets in North America and the U.K.\par \par \uc2 View source version on businesswire.com: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20161006006229/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20161006006229/en/}}}\par \par \uc2 \f2 \par  \par     CONTACT: \f28 \uc2 \f2 Patterson Companies Inc\f28 \uc2 \f2 . \f28 \par \par \uc2 \f2 Jennifer Joly, 651-681-3487\f28 \par \par \uc2 \f2 Corporate Communications Manager\f28 \par \par \uc2 \f2 jennifer.joly@pattersoncompanies.com\f28 \par \par \uc2 \f2 \f28 {\field{\*\fldinst{HYPERLINK "http://www.pattersoncompanies.com"}}{\fldrslt{\cf2 \uc2 http://www.pattersoncompanies.com}}}\uc2 \f2 \f28 \par \par \uc2 \f2 \par  \par     SOURCE: \f28 \uc2 \f2 Patterson Companies Inc\f28 \uc2 \f2 . \par Copyright Business Wire 2016 \par  \f28 \par \par \uc2 \f2 (END)\f28 \par \par \uc2 Document BWR0000020161006eca6000cf\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Wellnext Opens New State-of-the-Art Facility to Meet High-Growth Gummy Vitamin Market\b0\par\par\uc2 550 \uc2 words\par \uc2 5 October 2016\par 06:00\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 SUNRISE, Fla., Oct. 5, 2016 /PRNewswire/-- Wellnext, with its family of leading brands curated to meet the health needs of consumers throughout every life stage, announced today the opening of a new, state-of-the-art gummy vitamin plant in its Sunrise, Florida facility. The new Wellnext plant uses the latest technology, including non-starch molds and fully robotized equipment to deliver industry-leading purity and quality in a gummy product.\par \par \uc2 Consumers have wholeheartedly embraced the gummy delivery format as a delicious, convenient way to enjoy their nutritional supplements. Sales of gummy vitamins grew 45% from 2012 through 2014 and now comprise 18% of \b \highlight22\uc2 new product launches\b0 \highlight\uc2 .\par \par \uc2 "The opening of our state-of-the-art gummy manufacturing facility is a direct response to consumer enthusiasm for the gummy vitamin format," said \uc2 Jose Minski\uc2 , Chief Executive Officer for Wellnext. "Our new gummy plant showcases Wellnext's focus on always leveraging the best in new technologies as we continue to deliver outstanding nutritional products."\par \par \uc2 Wellnext is currently the only manufacturer in the United States producing gummies using non-starch technology, which significantly reduces contamination risk. Legacy starch technologies require recycling of the starch material posing a higher risk of cross contamination. The new Wellnext facility will be able to eliminate any and all cross-contamination via the advanced technology used in this plant. Wellnext's new plant produces both vegetarian and gelatin based gummies.\par \par \uc2 The existing 225,000 square foot Wellnext facility in Sunrise, Florida has the capacity for large-scale projects and complex formulation processes, producing 84 million bottles per year and delivering more than 8 billion doses--with room to grow. This new gummy plant is a welcomed addition to Wellnext's long-term commitment to create the best quality products for consumers for every stage of health. To learn more about Wellnext and its premier portfolio of nutritional supplement brands, please visit {\field{\*\fldinst{HYPERLINK "http://www.wellnexthealth.com"}}{\fldrslt{\cf2 \uc2 www.wellnexthealth.com}}}\par \par \uc2 About Wellnext\par \par \uc2 WELLNEXT LLC, family of brands delivers research-backed nutritional supplements for every consumer life stage. Anchor brands within the Wellnext portfolio include Nature's Products(R), Inc., a GMP certified manufacturer with 30 years of leadership in supplement manufacturing, Rainbow Light(R) and Natural Vitality(R), leading natural channel brands, Champion Nutrition(R), a leader in the sports nutrition category and Stop Aging Now(R), an innovator in the direct-to-consumer channel. Other hallmark brands include Iceland Health(R), Blessed Herbs(R), Nutri-Health Supplements(R), \uc2 Sedona Labs\uc2 (R), Sedona Pro(R), Vitamin Research Products(R), True Health(TM), Health Resources(TM) and VitalStyle(R). Guided by three generations of family heritage, Wellnext is committed to the highest standards of corporate social responsibility including product quality and purity testing, sustainability practices, and corporate giving programs to help foster a vibrant state of health in families everywhere. To learn more about Wellnext, visit {\field{\*\fldinst{HYPERLINK "http://www.wellnexthealth.com"}}{\fldrslt{\cf2 \uc2 www.wellnexthealth.com}}}\uc2 .\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20160202/329007LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20160202/329007LOGO}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/wellnext-opens-new-state-of-the-art-facility-to-meet-high-growth-gummy-vitamin-market-300339346.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/wellnext-opens-new-state-of-the-art-facility-to-meet-high-growth-gummy-vitamin-market-300339346.html}}}\par \par \uc2 SOURCE Wellnext\par \par \uc2 /CONTACT: Annette Banca, \uc2 5W Public Relations\uc2 , 212.999.5585, abanca@5wpr.com\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://wellnexthealth.com/"}}{\fldrslt{\cf2 \uc2 http://wellnexthealth.com/}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020161005eca50002x\par }\page {\par\fs20\b \uc2 Leading BioSciences Inc\uc2 . Leading Biosciences  \highlight22\uc2 Launches \highlight\uc2  Gastrobiome Focused Product Development Strategy to Harness Microbiome Ecosystem in the Gastrointestinal Tract\b0\par\par\uc2 543 \uc2 words\par \uc2 3 October 2016\par \uc2 Clinical Trials Week\par \uc2 CTRW\par 211\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Clinical Trials Week via NewsRx.com \par \par \uc2 2016 OCT 3 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- \uc2 Leading BioSciences Inc\uc2 ., a pioneer in therapies for gastrointestinal (GI) mucosal barrier breakdown related diseases, \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of a \b \highlight22\uc2 new product\b0 \highlight\uc2  category of novel therapeutics and diagnostics for targets within the GI tract category called the Gastrobiome(TM).\par \par \uc2 Leading BioSciences\uc2  defines the gastrobiome as the entire ecosystem of the gastrointestinal tract, including the environment, barriers, tissues, mucus, mucin, enzymes, nutrients, food and communities of microorganisms that reside in the gastrointestinal tract. Of critical importance is how the integrity and permeability of the intestinal mucosal barrier impact health.\par \par \uc2 The company is focused on treating the effects of intestinal mucosal barrier breakdown within the gastrobiome, which includes leaking endogenous enzymes and bacterial toxins that have a daily impact on acute and chronic human health conditions such as severe shock, multi-organ failure, ileus, adhesions, obesity, diabetes, hypertension, insomnia, metabolic syndrome and autism. Currently, there are no FDA-approved products designed to restore the microbiome, nor any component of the gastrobiome, to a healthy state. \uc2 Leading BioSciences\uc2  is currently advancing three Phase 2 clinical trials in acute conditions and is now preparing to launch multiple chronic related therapeutics into the clinic during 2017.\par \par \uc2 "This new product strategy is about speeding up the timing of clinical development for \uc2 Leading BioSciences\uc2 ' existing long-term product pipeline and expanding into new opportunities within the gastrobiome. Our company has been pioneering research on the 'gut-motor hypothesis' for more than a decade now. This move is about defining a new ecosystem and then advancing our product pipeline within that category in the clinic as appropriate," said \uc2 Greg Doyle\uc2 , CEO of \uc2 Leading BioSciences\uc2 . "With our gastrobiome product development strategy, we are making aggressive moves expanding our product development efforts into areas of high value that have potential for treating serious chronic conditions. This focus will create a depth and breadth to our pipeline that is currently unmatched in the field."\par \par \uc2 Thomas Hallam, Ph.D\uc2 ., senior vice president, Clinical Development and Regulatory Affairs, added: "The most important aspect of the gastrobiome is the permeability of the mucosal barrier, which traps the disease causing elements in the small intestine while allowing essential nutrients to cross the barrier for absorption by the body. Our research has demonstrated that the barrier can become leaky, allowing small amounts of disease causing elements through the barrier and driving chronic diseases such as diabetes and hypertension. Furthermore, the barrier can fail suddenly, like water breaking though a levee, causing a medical crisis such as multiorgan failure. Given our unique understanding of the intestinal mucosal barrier, we can develop gastrobiome-focused drugs to improve patient lives."\par \par \uc2 As it expands its gastrobiome product strategy, \uc2 Leading BioSciences\uc2  will continue to advance its lead, product candidate, LB1148, through Phase 2 clinical studies for ileus and adhesions, cardiovascular surgery complications, severe shock and multi-organ failure.\par \par \uc2 Keywords for this news article include: Ileus, Chemicals, Chemistry, Hypertension, Gastroenterology, Intestinal Obstruction, Cardiovascular Diseases, \uc2 Leading BioSciences Inc\uc2 , Digestive System Diseases, Gastrointestinal Diseases, Clinical Trials and Studies.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document CTRW000020161003eca30000m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Pall Life Sciences to  \highlight22\uc2 Introduce \highlight\uc2  Continuous Bioprocessing with Single-Use Technologies\b0\par\par\uc2 940 \uc2 words\par \uc2 28 September 2016\par 16:52\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2016  Business Wire. All Rights Reserved. \par \par \b \highlight22\uc2 New Product Launches\b0 \highlight\uc2  Planned for Biotech Week Boston, Oct. 4-7 \par \par \uc2 \f2 \par PORT WASHINGTON, N.Y.--(BUSINESS WIRE)--September 28, 2016-- \f28 \par \par \uc2 At next week's first annual Biotech Week Boston (October 4-7, 2016), \uc2 Pall Corporation\uc2 , a global leader in filtration, separation and purification, will officially launch new production-scale technologies and preview upcoming technologies that enable fully continuous biopharmaceutical processing using single-use formats. These solutions will be formally introduced at the BioProcess International Conference & Exhibition (BPI), October 4 - 7, 2016 at the Boston Convention and Exhibition Center (BCEC), Booth #521.\par \par \uc2 As manufacturers of biotherapies seek to incorporate continuous technologies in production to improve efficiency over batch methods, and to enable process intensification, \uc2 Pall\uc2  is forging ahead by offering biopharmaceutical companies an "end-to-end" continuous processing option with integrated single-use technologies. Single-use systems enable manufacturers to reduce costs by eliminating cleaning and validation requirements, as well as hardware infrastructure.\par \par \uc2 Last year \uc2 Pall\uc2  introduced the Cadence(TM) BioSMB PD System, the first disposable flow path, continuous multi-column chromatography system that is scalable from laboratory process development to GMP manufacturing. Earlier this year, \uc2 Pall\uc2  introduced the Cadence Acoustic Separator (CAS)(1) , a groundbreaking invention that incorporates acoustic wave separation (AWS) technology to continuously harvest biologic drug substances from cell culture processes. At BPI Pall will continue to advance its pipeline of products that enable continuous manufacturing by launching production-scale continuous chromatography solutions, a new single-use stirred tank bioreactor, single-use sterile genderless connectors, and other equipment and materials. In addition, \uc2 Pall\uc2  will feature filtration technology for consistent and robust small virus retention.\par \par \uc2 "At \uc2 Pall\uc2  we are helping the industry move continuous bioprocessing from theory to reality," said \uc2 Michael Egholm, Ph.D\uc2 ., VP and General Manager, Pall BioPharmaceuticals. "Our continuous-ready products and integration expertise help manufacturers of biotherapeutics achieve high-quality products with smaller production footprints and shorter lead times."\par \par \uc2 Egholm will introduce \uc2 Steve Wozniak\uc2 , Apple Co-Founder as the keynote speaker for the conference program at Biotech Week Boston on Friday, October 7, at 9:15am. Wozniak's presentation will cover innovation and customer centricity. (Please find details below)\par \par \uc2 As the Presidential Sponsor of Biotech Week Boston, \uc2 Pall\uc2  also will host, present and participate in a number of activities at the BCEC, including the following: \par \par \uc2 \f2 \par    -- Tuesday, Oct. 4 - 9:00am -- 5:00pmSymposium on Continuous Processing -- \par       sponsored by Pall Life SciencesTopics will include GMP implementation, \par       regulatory and quality considerations, and making the business case for \par       continuous processing. The symposium will include case studies presented \par       by Merck, \f28 \uc2 \f2 Merrimack Pharmaceuticals\f28 \uc2 \f2 , \f28 \uc2 \f2 CMC Biologics\f28 \uc2 \f2 , \f28 \uc2 \f2 Biogen\f28 \uc2 \f2 , Just \par       Therapeutics and others.Pall speakers at this daylong workshop will \par       include: \par  \par           -- Marc Bisschops, Ph.D., Principal Scientist, , \f28 \uc2 \f2 Pall Life Sciences\f28 \uc2 \f2 , \par              Holland \par  \par           -- Mark Schofield, Ph.D., Principal R&D Engineer, Pall Life Sciences \par  \par           -- Peter Levison, Senior Marketing Director -- Downstream Processing, \par              Pall Life Sciences \par  \par    -- Tuesday, Oct. 4 - 7:30pm -- 10:30pmBPI "Bio Brew" Networking Event at the \par       Harpoon BreweryPall will co-sponsor this event with \f28 \uc2 \f2 Kaneka Corporation\f28 \uc2 \f2 . \par       Pall and Kaneka recently entered into a collaborative agreement for \f28 \uc2 \f2 Pall\f28 \uc2 \f2  \par       to supply Kaneka's Protein A chromatography resin (KANEKA KanCapA). A \par       shuttle outside the BCEC will be available to transport attendees \par       (pre-registration is required). \par  \par    -- Wednesday, Oct. 5 - 9:30am -- 10:30amPall Presentation"An update on \par       significant technology advances enabling integrated continuous \par       bioprocessing," presented by \f28 \uc2 \f2 Martin Smith, Ph.D\f28 \uc2 \f2 ., Chief Technology \par       Officer, Pall Corporation and \f28 \uc2 \f2 Michael Egholm, Ph.D\f28 \uc2 \f2 ., VP and General \par       Manager, Pall Life Sciences. \par  \par    -- Wednesday, Oct. 5 - 11:30am -- 12:00pmPall Presentation"End-to-End \par       Integrated Continuous BioProcessing Platform for Biologics Manufacturing, \par       " presented by Engin Ayturk, Ph.D., Senior Manager R&D, BioPharm \par       Applications R&D, Pall Corporation. \par  \par    -- Friday, Oct. 7 - 9:15am -- 10:15amKeynote address by Apple Co-Founder \par       Steve WozniakTopic: Innovation & Customer Centricity. Steve will be \par       introduced by \f28 \uc2 \f2 Pall\f28 \uc2 \f2 's \f28 \uc2 \f2 Michael Egholm\f28 \uc2 \f2 . \par  \par    -- Friday, Oct. 7 - 10:15am (Pall's Lounge, Booth #621)Steve Wozniak Meet & \par       GreetSteve will be available for a brief period to meet with expo \par       attendees. \f28 \par \par \uc2 \f2 In addition to finding \f28 \uc2 \f2 Pall\f28 \uc2 \f2  representatives at the company's main booth (#521), show and conference attendees can also enjoy free refreshments at \f28 \uc2 \f2 Pall\f28 \uc2 \f2 's neighboring lounge, Booth #621 and visit Booth #1355 for \f28 \uc2 \f2 Pall\f28 \uc2 \f2 's technologies and services dedicated to cell and gene therapy, and vaccines. A highlight of the Cell and Gene Therapy sessions at the BPI conference will be "Achieving Large-Scale GMP Production of Adenovirus in the iCellis 500 Fixed-Bed Bioreactor." This presentation by FinVector Vision Therapies will detail the use of the Pall iCELLis single-use perfusion bioreactor system. It will take place on Wednesday, October 5, at 2:15pm in the Gene Therapy Development & Production -- Manufacturing Strategies and Solutions for Gene Therapies track.\f28 \par \par \uc2 \f2 About \f28 \uc2 \f2 Pall Corporation\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Pall Corporation\f28 \uc2 \f2  is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. \f28 \uc2 \f2 Pall Corporation\f28 \uc2 \f2  serves customers worldwide. For more information visit \f28 {\field{\*\fldinst{HYPERLINK "http://www.pall.com"}}{\fldrslt{\cf2 \uc2 www.pall.com}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 Or follow us on social media:\f28 \par \par \uc2 \f2 Google+ YouTube LinkedIn Twitter Facebook\f28 \par \par \uc2 \f2 (1) On June 15, 2015, \f28 \uc2 \f2 Pall\f28 \uc2 \f2  announced an exclusive licensing agreement with \f28 \uc2 \f2 FloDesign Sonics\f28 \uc2 \f2  for acoustic wave separation, a disruptive technology for cell culture clarification for both fed-batch and perfusion applications.\f28 \par \par \uc2 \f2 View source version on businesswire.com: \f28 {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20160928006492/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20160928006492/en/}}}\uc2 \f2 \f28 \par \par \uc2 \f2 \par  \par     CONTACT: Pall Life Sciences Marketing: \f28 \par \par \uc2 \f2 Erin C. Bush\f28 \par \par \uc2 \f2 Senior Manager, Global Product Marketing\f28 \par \par \uc2 \f2 erin_bush@pall.com \f28 \par \par \uc2 \f2 \par  \par     SOURCE: Pall Corporation \par Copyright Business Wire 2016 \par  \f28 \par \par \uc2 \f2 (END)\f28 \par \par \uc2 Document BWR0000020160928ec9s000hr\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 08:32 EDT \uc2 ANI Pharmaceuticals \highlight22\uc2 announces  \highlight \highlight22\uc2 launch \highlight\uc2  of Erythromycin Ethylsuccinate...\b0\par\par\uc2 144 \uc2 words\par \uc2 27 September 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 08:32 EDT \uc2 ANI Pharmaceuticals\b \highlight22\uc2 announces \b0 \highlight\b \highlight22\uc2 launch\b0 \highlight\uc2  of Erythromycin Ethylsuccinate ANI Pharmaceuticals \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections. The current annual U.S. market for this product is approximately $78M, according to \uc2 IMS Health\uc2 , and is representative of two brand products. ANI will immediately \b \highlight22\uc2 launch\b0 \highlight\uc2  the product. Arthur Przybyl, ANI's President and CEO stated, "This is the first product that we are launching from the basket of 22 previously marketed generic products that we acquired in July 2015 and it represents another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA product. ANI has added nine \b \highlight22\uc2 new products\b0 \highlight\uc2  to our commercial portfolio in 2017 and we continue to forecast the \b \highlight22\uc2 launch\b0 \highlight\uc2  of at least one additional generic product this year." \par \par \uc2 Document FLYWAL0020160927ec9r0058y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 ANI Pharmaceuticals \highlight22\uc2 Announces  \highlight \highlight22\uc2 Launch \highlight\uc2  of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL\b0\par\par\uc2 601 \uc2 words\par \uc2 27 September 2016\par 08:30\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 BAUDETTE, Minn., Sept. 27, 2016 /PRNewswire/ -- \uc2 ANI Pharmaceuticals, Inc\uc2 . ("ANI") (Nasdaq: ANIP) today \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections. The current annual U.S. market for this product is approximately $78 million, according to \uc2 IMS Health\uc2 , and is representative of two brand products. ANI will immediately \b \highlight22\uc2 launch\b0 \highlight\uc2  the product.\par \par \uc2 Arthur S. Przybyl, ANI's President and CEO stated, "This is the first product that we are launching from the basket of 22 previously marketed generic products that we acquired in July 2015 and it represents another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA product. ANI has added nine \b \highlight22\uc2 new products\b0 \highlight\uc2  to our commercial portfolio in 2017 and we continue to forecast the \b \highlight22\uc2 launch\b0 \highlight\uc2  of at least one additional generic product this year."\par \par \uc2 About Erythromycin Ethylsuccinate for Oral Suspension\par \par \uc2 Erythromycin Ethylsuccinate for Oral Suspension is indicated in the treatment of infections caused by susceptible strains of selected diseases. For more information, including the complete list of indications and usages, please see the accompanying Full Prescribing Information.\par \par \uc2 About ANI\par \par \uc2 ANI Pharmaceuticals, Inc\uc2 . (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website {\field{\*\fldinst{HYPERLINK "http://www.anipharmaceuticals.com"}}{\fldrslt{\cf2 \uc2 www.anipharmaceuticals.com}}}\uc2 .\par \par \uc2 Forward-Looking Statements\par \par \uc2 To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company's future operations, products financial position, operating results and prospects , the Company's pipeline or potential markets therefor, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will, " "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates.\par \par \uc2 Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; increased competition; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the \uc2 U.S. Food and Drug Administration\uc2 ; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.\par \par \uc2 More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the \uc2 Securities and Exchange Commission\uc2 , including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.\par \par \uc2 For more information about ANI, please contact:\par \par \uc2 Investor Relations\par \par \uc2 IR@anipharmaceuticals.com\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-erythromycin-ethylsuccinate-for-oral-suspension-200mg5ml-300334595.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-erythromycin-ethylsuccinate-for-oral-suspension-200mg5ml-300334595.html}}}\par \par \uc2 SOURCE \uc2 ANI Pharmaceuticals, Inc\uc2 .\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.anipharmaceuticals.com"}}{\fldrslt{\cf2 \uc2 http://www.anipharmaceuticals.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020160927ec9r000bc\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Ajanta Pharma \highlight22\uc2 Announces the Launch \highlight\uc2  of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension\b0\par\par\uc2 292 \uc2 words\par \uc2 26 September 2016\par 09:00\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 BRIDGEWATER, N.J., Sept. 26, 2016 /PRNewswire/ -- \uc2 Ajanta Pharma USA Inc\uc2 ., a wholly owned subsidiary of \uc2 Ajanta Pharma Ltd\uc2 , announces today the \b \highlight22\uc2 launch\b0 \highlight\uc2  of Omeprazole and Sodium Bicarbonate Powder for Oral Suspension, a bioequivalent prescription generic version of Zegerid(R)(1) Powder for Oral Suspension (20mg/1680mg and 40mg/1680mg), into the US market.\par \par \uc2 Omeprazole and Sodium Bicarbonate Powder for Oral Suspension is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications (ANDAs) of which it has 14 final ANDA approvals; 2 tentative approvals; and 10 ANDAs under review with the \uc2 United States Food & Drug Administration\uc2 .\par \par \uc2 About \uc2 Ajanta Pharma\par \par \uc2 Ajanta Pharma Limited\uc2  is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing, and marketing quality, pharmaceuticals across 30+ countries.\par \par \uc2 For the financial year ended March 31, 2016, Ajanta's consolidated revenue stood at $261 million and net profit of $61 million. For the last five years, Ajanta has posted healthy performance with its consolidated revenue growing at 26% CAGR and net profit at 51% CAGR.\par \par \uc2 For more details about \uc2 Ajanta Pharma USA Inc\uc2 ., please visit us at {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 www.ajantapharmausa.com}}}\uc2 .\par \par \uc2 (1) Zegerid(R) is a registered trademark of \uc2 Santarus Inc\uc2 .\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20160923/411422"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20160923/411422}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-omeprazole-and-sodium-bicarbonate-powder-for-oral-suspension-300333658.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-omeprazole-and-sodium-bicarbonate-powder-for-oral-suspension-300333658.html}}}\par \par \uc2 SOURCE \uc2 Ajanta Pharma USA Inc\uc2 .\par \par \uc2 /CONTACT: John Adams, john.adams@ajantapharma.com, 908.252.1165\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 http://www.ajantapharmausa.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020160926ec9q000bw\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Impax \highlight22\uc2 launches \highlight\uc2  generic version of Metadate CD\b0\par\par\uc2 99 \uc2 words\par \uc2 22 September 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 Impax Laboratories\b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of a generic version of Metadate CD, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg. \uc2 Impax\uc2  is focused on further enhancing its portfolio of 73 solid oral dose and alternative dosage form generic products available. The \b \highlight22\uc2 launch\b0 \highlight\uc2  of methylphenidate hydrochloride is \uc2 Impax\uc2 's sixth \b \highlight22\uc2 new product launch\b0 \highlight\uc2  since the beginning of 2016. Methylphenidate hydrochloride extended-release capsules had annual combined brand and generic sales of approximately $151M in the United States, according to \uc2 IMS Health\uc2  for the 12 months ending in July 2016. \par \par \uc2 Document FLYWAL0020160922ec9m0040h\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Leading Biosciences  \highlight22\uc2 Launches \highlight\uc2  Gastrobiome(TM) Focused Product Development Strategy to Harness Microbiome Ecosystem in the Gastrointestinal Tract\b0\par\par\uc2 1,056 \uc2 words\par \uc2 20 September 2016\par 08:01\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 \f2 \par Pipeline Expanded with Therapeutic Programs and Diagnostics Targeting Gastrobiome(TM) \par  \f28 \par \par \uc2 \f2 SAN DIEGO, Sept. 20, 2016 /PRNewswire/ -- \f28 \uc2 \f2 Leading BioSciences Inc\f28 \uc2 \f2 ., a pioneer in therapies for gastrointestinal (GI) mucosal barrier breakdown related diseases, announced today the \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of a \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  category of novel therapeutics and diagnostics for targets within the GI tract category called the Gastrobiome(TM).\f28 \par \par \uc2 Leading BioSciences\uc2  defines the gastrobiome as the entire ecosystem of the gastrointestinal tract, including the environment, barriers, tissues, mucus, mucin, enzymes, nutrients, food and communities of microorganisms that reside in the gastrointestinal tract. Of critical importance is how the integrity and permeability of the intestinal mucosal barrier impact health.\par \par \uc2 The company is focused on treating the effects of intestinal mucosal barrier breakdown within the gastrobiome, which includes leaking endogenous enzymes and bacterial toxins that have a daily impact on acute and chronic human health conditions such as severe shock, multi-organ failure, ileus, adhesions, obesity, diabetes, hypertension, insomnia, metabolic syndrome and autism. Currently, there are no FDA-approved products designed to restore the microbiome, nor any component of the gastrobiome, to a healthy state. \uc2 Leading BioSciences\uc2  is currently advancing three Phase 2 clinical trials in acute conditions and is now preparing to launch multiple chronic related therapeutics into the clinic during 2017.\par \par \uc2 "This new product strategy is about speeding up the timing of clinical development for \uc2 Leading BioSciences\uc2 ' existing long-term product pipeline and expanding into new opportunities within the gastrobiome. Our company has been pioneering research on the 'gut-motor hypothesis' for more than a decade now. This move is about defining a new ecosystem and then advancing our product pipeline within that category in the clinic as appropriate," said \uc2 Greg Doyle\uc2 , CEO of \uc2 Leading BioSciences\uc2 . "With our gastrobiome product development strategy, we are making aggressive moves expanding our product development efforts into areas of high value that have potential for treating serious chronic conditions. This focus will create a depth and breadth to our pipeline that is currently unmatched in the field."\par \par \uc2 Thomas Hallam, Ph.D\uc2 ., senior vice president, Clinical Development and Regulatory Affairs, added: "The most important aspect of the gastrobiome is the permeability of the mucosal barrier, which traps the disease causing elements in the small intestine while allowing essential nutrients to cross the barrier for absorption by the body. Our research has demonstrated that the barrier can become leaky, allowing small amounts of disease causing elements through the barrier and driving chronic diseases such as diabetes and hypertension. Furthermore, the barrier can fail suddenly, like water breaking though a levee, causing a medical crisis such as multiorgan failure. Given our unique understanding of the intestinal mucosal barrier, we can develop gastrobiome-focused drugs to improve patient lives."\par \par \uc2 As it expands its gastrobiome product strategy, \uc2 Leading BioSciences\uc2  will continue to advance its lead, product candidate, LB1148, through Phase 2 clinical studies for ileus and adhesions, cardiovascular surgery complications, severe shock and multi-organ failure.\par \par \uc2 About the Gastrobiome\par \par \uc2 For decades, researchers have investigated the human microbiome, composed of the bacteria, microbes, genes and genomes that live in and on our bodies, and its role in human health. This includes all areas where bacteria and microbials live, grow and exist, in areas such as the skin, mouth, GI tract, genitourinary tract and lungs. The microbiome focuses on the trillions of species of bacteria and microbials that exist in the body. Most species are harmless, or even helpful, under normal circumstances. There is also a large part of today's microbiome effort that is devoted to sequencing, analyzing, and data storage of the individualized human microbiome.\par \par \uc2 Leading BioSciences\uc2  believes that the most critical and impactful microbiome ecosystem resides in the gastrointestinal tract, which contains a combination of barriers, tissues, mucus, mucin, enzymes, nutrients, food and communities of microorganisms that become the driver of multiple medical conditions when disrupted. Of primary importance is the contribution of these organisms within the small and large intestines, and the barriers that maintain them within the intestinal tract. The intestines comprise the majority of the surface area in the GI tract and represents where the majority of digestion and absorption occurs. \uc2 Leading BioSciences\uc2  refers to this ecosystem, as well as the tissues and barriers that protect the rest of the body from these potent elements, as the Gastrobiome.\par \par \uc2 About the Gastrobiome Product Strategy\par \par \uc2 Leading BioSciences\uc2  Gastrobiome product strategy is rooted in the company's extensive research showing the gastrointestinal tract and the intestinal mucosal barrier are the foundation of human health. Based on proprietary pharmacological knowledge of the intestinal mucosal barrier, as well as the mucin layer within the small intestine, the company's product pipeline targets specific therapeutic opportunities within the Gastrobiome. On the therapeutics side, the company will focus on treating conditions such as ileus, adhesions, severe shock, multi-organ failure, obesity, diabetes, high-cholesterol, hypertension, insomnia, metabolic syndrome, autism and numerous additional conditions. In 2017, the company expects to nominate its first gastrobiome therapeutic candidates for clinical development. To complement its emerging gastrobiome therapeutic pipeline, the company plans to develop and commercialize novel diagnostic technologies, such as blood assays for mucosal barrier integrity and tools for gastrointestinal imaging, to identify patients with gastrobiome-related disorders.\par \par \uc2 About \uc2 Leading BioSciences\par \par \uc2 Leading BioSciences\uc2  is a biopharmaceutical company pioneering new approaches to address conditions and diseases related to gastrointestinal mucosal barrier breakdown. The company has leveraged its deep scientific understanding of the GI tract, the intestinal mucosal barrier and the Gastrobiome(TM) -- a rich ecosystem with numerous druggable therapeutic targets within the human microbiome -- to develop a broad pipeline of programs to address critical-care conditions and chronic, daily-maintenance health issues, complemented by an emerging Gastrobiome(TM) diagnostic platform. The company's clinical development is supported by a robust base of positive preclinical outcomes, $23 million in private capital and more than $22 million in foundational research backed by the \uc2 National Institutes of Health\uc2 . Leading Biosciences is privately held and maintains corporate headquarters in San Diego. Visit {\field{\*\fldinst{HYPERLINK "http://www.leadingbiosciences.com"}}{\fldrslt{\cf2 \uc2 www.leadingbiosciences.com}}}\uc2  for additional information.\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/leading-biosciences-launches-gastrobiome-focused-product-development-strategy-to-harness-microbiome-ecosystem-in-the-gastrointestinal-tract-300330703.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/leading-biosciences-launches-gastrobiome-focused-product-development-strategy-to-harness-microbiome-ecosystem-in-the-gastrointestinal-tract-300330703.html}}}\par \par \uc2 SOURCE \uc2 Leading BioSciences Inc\uc2 .\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.leadingbiosciences.com"}}{\fldrslt{\cf2 \uc2 http://www.leadingbiosciences.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020160920ec9k0008a\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Cardiac Biomarkers Market By Type, By Application, By End Use, By Region And Segment Forecasts to 2024\b0\par\par\uc2 640 \uc2 words\par \uc2 19 September 2016\par 20:04\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 NEW YORK, Sept. 19, 2016 /PRNewswire/ -- The cardiac biomarkers market is expected to reach USD13.3 billion by 2024, according to a new report by \uc2 Grand View Research, Inc\uc2 . The cardiac biomarkers market is anticipated to witness a lucrative growth during the forecast period from 2016 to 2024. Analysis of global market trends focuses on the increasing demand for cardiac biomarkers owing to its increased adoption in cardiovascular disease diagnosis. Furthermore, this growth is attributed to a majority of factors, such as the high prevalence of Acute Coronary Syndrome (\uc2 ACS\uc2 ), continual technological advancements in the development of cardiovascular biomarkers, increasing number of \b \highlight22\uc2 new product launches\b0 \highlight\uc2  by the key market players, rising demand for point of care cardiac testing kits, along with the high specificity and sensitivity of these biomarkers in the detection of cardiovascular diseases, especially acute myocardial infarction.\par \par \uc2 The cardiac biomarkers market has been classified by type into troponin, Creatine kinase-MB(CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide (NT-proBNP), myoglobin, and others. Troponin is a heteromeric protein and comprises cardiac troponin T & I, which are abbreviated as cTnT & cTnI, respectively. The troponin biomarkers segment is expected to grow lucratively in the forecast period at a significant CAGR. The diagnostic efficiency and specificity related to cardiac biomarker testing renders it a universally gold standard test to diagnose cardiovascular disorders worldwide. The market by application is segmented into acute coronary syndrome, myocardial infarction, congestive heart failure, and others. \uc2 ACS\uc2  is expected to be the highest grossing segment according to the study. \uc2 ACS\uc2  is responsible for huge medical costs globally and is responsible for most hospital readmission cases. The increasing efforts to cut down worldwide \uc2 ACS\uc2  prevalence rates are expected to drive the growth of the biomarkers market.\par \par \uc2 The key countries included in the report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South Africa, and the Middle East. North America accounted for the largest market in 2015, whereas the Asia Pacific region is anticipated to be the fastest growing region during the forecast period.\par \par \uc2 Further key findings from the study suggest:\par \par \uc2 North America is estimated to dominate the global cardiac biomarkers market. The high prevalence of coronary heart disease in western countries is one of the major factors contributing to the high demand for cardiac biomarker diagnostics.\par \par \uc2 The Asia Pacific region is anticipated to be the fastest growing region in the study period owing to the large population, especially in China and India. Apart from that, there exists a high prevalence rate of myocardial infarction in the region. This prevalence rate is expected to fuel the demand for cardiac biomarker diagnostics.\par \par \uc2 The troponin biomarker segment is expected to grow at a significant rate, and is expected to grow at the highest CAGR compared to others and accounts for the largest market share in 2015.\par \par \uc2 The sector comprises of several local as well as global players. Some of the major players of this vertical include \uc2 Alere, Inc\uc2 ., Siemens Healthcare GmbH, \uc2 Roche Diagnostics\uc2 , \uc2 Beckman Coulter, Inc\uc2 ., \uc2 Thermo Fisher Scientific, Inc\uc2 ., \uc2 Becton, Dickinson and Company\uc2 , and \uc2 bioMerieux SA\uc2 .\par \par \uc2 Read the full report: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com/p04144336-summary/view-report.html"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com/p04144336-summary/view-report.html}}}\par \par \uc2 About Reportlinker\par \par \uc2 ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.\par \par {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 __________________________\par \par \uc2 Contact Clare: clare@reportlinker.com\par \par \uc2 US: (339)-368-6001\par \par \uc2 Intl: +1 339-368-6001\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/cardiac-biomarkers-market-by-type-by-application-by-end-use-by-region-and-segment-forecasts-to-2024-300330574.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/cardiac-biomarkers-market-by-type-by-application-by-end-use-by-region-and-segment-forecasts-to-2024-300330574.html}}}\par \par \uc2 SOURCE Reportlinker\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020160920ec9k00001\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw91\pich40\picscaley100\picscalex100\picwgoal1365\pichgoal600
47
49463839615B002800F70000D3868A777777E4CED3FFF9FEE60003D8C3BDD6B3B7E9E8DCF3F2F2FDFDFDF1FFFFD95666E8FDEAD694A1D8D4C9FEF4FED8142BCC
CCCC373737C05A62D39593E4E3E44B4B4BE4BAC6D63749E05B68606060646464CB7C85C98485ACACACE17D86D81C39FBFFFFD50627E80113BBBBBBCC001DC972
77CC4B5CC53746B4B4B4E63856E56770F4FAF3D2D2D2E3A9B3CD5468F0C7D4C72938FAECF3DA8593C3C2C1E61022F3EAEEFBFAFAE298A9F9FFFFD30001D3445D
939393D96368D77984F8FDF5FEFFF8DA8177EEE4E2D27574F8FFFFCC5A5AEBDEE4DA6A77DD2A3C292929515151D59FA3F3D7D6EDFFFE000000BC00008E8E8EDD
C8CADC0001C967765E6261BB293EC60726C794925C5C5CE6D3D9E7EEFCBC0F2B848484E3FFF9E492ACD30013F5FFFFFFFCFFF4FFFFFBF3F5E5B4BBF9FEF8BD34
3FF5B8B6DBB9C3161616F6F2ED434343616665D8D8D8CA1D27E2999BD62943F0ADB8E7D7CCE4D6D2CA0000C20000DB4D5DF5DAF2FBF9FFE2C1C5CD6466C98993
DB000B625F61EBD4D2E55472FEFAF8C2454DFFFCFCEEB7B7EAFFFFD3A697EAC4C1E1AAABE7B7ADCB2E45EBCCCEE4B1B3E3A0A3EA4655A4A4A4E6D9DCD0000DEB
D9DBE19CB6E6828BE3EFE29A9A9AD90013FEFFFCF0ECE5CF55556D6D6DF5F5F6FAFCFEE4AA9DB60319F4FEFBDF021CCB000BEBE9E4C96D82E9173FC41A32E14B
65DA0E2EE4A4AEFBFFFCEFEFEFE38C97D81F31EEC6CBF2E2E4EADDD7FCFEFBD20B1CCE2630FCFCFFD0434FF1FFFBF5FAFEF3A6ABE7C6CDBF7884F7FDFFF7FCFC
AD0001D60517FBFDFEF8FBFEF1FBFFC3000FFFFFFF646363FEFEFEFFFEFFFDFFFFFFFEFEFEFEFFFEFFFEF9FDFBDF6688DC0D20DFC1BC616564F30115FFFFFDD9
584FDA1D20ECE3ECE0E1DAE65C7FEEAAA1E1F4F9DFDEDFEDF6F8F9FFFCF290B3CEA8AFDCB5A5F3D1D2E05D75CC0F1FD23259E5DBD7E02026E9D3D8E5CBC3E0CF
CBF25E7ECB343BDED3E0DDDCCEFEE8F2FEE7E9F5FCFFF6FFFBDA908BF7FFFEE6CDDF5F605FF7CEE0F7F8F8E0B9B3E0FAFFC1090DD62F36E78FA1F4BECCAF1618
EDB1BFD11030EEACA8EEC1D521FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E74
49443D22786D702E6469643A45363645313337443531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E636549443D22
786D702E6969643A45363645313337433531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241646F6265
2050686F746F73686F702043432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E6365
49443D223032464134343642333944393332433443304537303538434136414236414542222073745265663A646F63756D656E7449443D223032464134343642
333944393332433443304537303538434136414236414542222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D
706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDB
DAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B
9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B
5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B
1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000005B0028004008FF004960D1D04783C18307A950E9C35003
157908234A9C68B021C1821AE43D94071123458B14116A1C8625458E19754AFCC1014016817E42E00D502125439C2375126D2272099EB00C9030E8993001C488
2F518401AAF54058BD50046270008082C017433910900AD64D1821424484C103236C961861E6ACF4A3264C9802314D063C18004F4C0E2260C20C10A60EDCA92C
C268D4915228993063627AF0D9E10E0301340A8CE5B0030AD21B61097ED2E91122471331617CA5F235008F1855AC08BCE82C2C1B8A6770DC7D0241A080B0067C
F031683B434A8C64E4627942D3D6C8293A91B649C96458D8323A2B84A513C14C48DBEB6D13DC48A0BD2D31ECE0C38BFF1F4FBEBCF9F3E0035810B69D1E893412
DAF25022EC3B142CD8D55FD7B401BC924AD8A541C375AA58A00A7A0826185E31C528E86079C608134618E731D860730886D1608406784280145F5811C3098A80
91835B18F06109049D2800002D2870F3930E0B78A3080CAB40504707C2E872E22475A8804C08E50C31C9241F5C018B1A207C718830174002CA120A50428B142F
0823C029A04C01063C7B80124C05C604228B1C6D01A043745988D00F39C2F892407321603821856D89E11378215C37E131C74CD8563221341842848781970C9E
6D8511963060F49943087B61D7A79F6D3D8A21A26D69821F762438118130F35D474C66D771F79D304AAC575F5B1270FF912A77A6AEFAE0ADE9ADC75D02C4F46A
1F7DECA531EA751268F0AA06FD6167010F9811138123E0A5E141B3B8E22AD006CEB0A1ED06DC76CB6DB66C38E3EDB8E496DB6DB8CE0CC3ADB6DB9AEB2DBBE20E
A3AEBBDD3AE34C4982B4E5CD121CCC80CA18C21011462A218872C5280030914C328250980C2E872CB2481C8BE4B1495B211C238831A9F88409230074F0860DC2
F43906072608A0B120D068434408975C728C304670C0812BC784304BC3C9A442CC314040630C2CC7E8E28B11B9E422C4314C3023C51993B65540072E24A34055
8C84E04228A7C870689F19D0518D18940A73050118C0B5573396C4E28030395018C5287BC0C3022B90DC1242133F0CFF01812523D062CEA1FA80828F1EE08002
8109B3ECCDC210A740128A2CA8BCF50F28FD00765D135A30A18F17B2601902073AD851C1103AC8224E23A034B38E310B7C81040618A01348073208038C180F84
90CF1770B020C63CAB741204288900630F29A12C22CC374F443780027E8062C53A07E8808F0D9C1002841D3A7C90031928F0F2042FBD8CF00D118AF40201366D
B912C81704E84007019E70900A21D94CA0C3FF3A90421102F1842A54A0093BD0C10942400805DCA0166248463108D52722F8A0044FB01F8DCCE0091B18C30401
9C80300A200229D0014445F8019474200D37D02180FBC8430E1810082948E1094F38410DEAC00163EC800F74F041B5FF8648C4220A830416588312D7B0811678
A712C35050AFC8F31D5B191157FA39156658B59E524DB10512484218A1D0961448200D69B040125AE0813326610D1268435B36F0C62460E106577C1017244083
3ED20001D8F1E277022081352861184908C07536F0A9EB58808CC4B8013136A18424585213D9E1551ED1B381F888C75969C0C2A81C918600F0A093014803B484
D102276C20001EC88C239C10800038B11269D8000FB8900679D407559B344F009C40CC621AF398C84CA63297C9CC663AB399980CA634A7090D6888C742C54805
78528121051DE312E32146A530330B64B4059B824800A28A81AA062D884182D858A312300031ECE10B52D0411D2011FF03438440348A704306A5708F0B106117
0320820FE9600929D4EF0B31789218000188599481102E7021004B6180492100838C10C6279421087AFC62003710C4592E408027BC0D0C0348C02F6051066DF8
02107329834A43F00F3A044300C2B0416A3E4004C3C8011C75988230ECD10F025022042C48DC3C8461CE9FD4E10864230435AAB29A327C62009BC00701026104
B28822745550000B48C1076B08A31D11528339C47198B0384004A7C0841A044089C3E8A52DAA98833AE851326138C02F80194322F8808225E4411F77B80E2746
280D088C4204756880022203361D9C236AC238821402010F42ECE50D7580C300EAE416B2B5851DAC681E3C92D10386FFD222063A8885398CF18F58D420281808
850E96610C302C800EE058015020418610C4437180695C1EEC10033788800F3AF004506D90084B540114E3D80D1208C08B1EEAC17D5F2841305E980835F8E217
709D841454D00461CC80173AE0C308B6408F5D800012FE1006079ED0887F0A63107C28C52C22018A2D4C0331D080830E56010F225C231D71B8450F82F107303C
97198F104633EC700405B465B3931841389A108850F8C12D999002124A8101B724E30F7558813236318621810110F09845EFC8F08558CC210460881422089008
0534010E5F888330AA019D64E0010CE2E8C516C6F00A3EB0821214BA840AE8800A4C04430AD1A080018EA0831EF025FF16A708B13B12E8061F2CE21045C06748
7B330E46B4220FA6D0AF1D6E600C05F4A0CD2198CB007256A83020E32CEFD0C1084EC0883760A06D891843172030824CCC0113A5204011EA4181534801005AAA
81254A1107445CA90A3990041DF0410645F8C00A23C08028EE600566648009BF108B017CB0003DBC03176028862DE0018F069C00057AC001180EF00E13E00219
0678C72206008C265CC216781046314220866220635268E88029A6B0047818620F9B08C32C0A11047ED4330B4128C21124410898BEE20A17C004075EE0834808
A3166150C30C5E5084431803152668853064408121487C9A180FE614BDE32B2D66FCE30FEAD5AEAC08F292B725953CFF8042CAB1E0046609638FD851D5A978E5
AB1478408BDF71C480683EF25D995C3C597C9530D6E0CB5279A72D342001614FF51D4D18CBE74A70B92685818D14C8F1E7400716769C002041B68196079AE5B4
2AE0010B5880041E500536DAA88914A400907494631BC48847AC5F87076980A304C2682CF9E80A559BA8400452B0064C7E8791BFFCCE233193994AB600909924
79C903A0758EFB7D91C2AA0061B9D048C42B8B8CB46A4B0568500931D25CF21FD7CFD1B1C3853564270D2E17460A9C20ABCC68C293EC11860414D99608382105
D7B9411A48402DACA37DEA310FCCD9DB82440B6CA0022FAFC41423A00425EC5C1865974705BE437D254A1D983F0F08003B}}
\par\par \b \uc2 PRESS RELEASE: Southern California Commercial UAV Company Teams Up With a \uc2 Radiation Detection Company\uc2  to Create a Groundbreaking UAV\b0\par\par\uc2 655 \uc2 words\par \uc2 19 September 2016\par \uc2 Platts Commodity News\par \uc2 PLATT\par \uc2 English\par \uc2 Copyright 2016. Platts. All Rights Reserved. \par \par \uc2 London (\uc2 US Nuclear Corp\uc2 .)--19Sep2016 11:10 This press release is published as it was received CHATSWORTH, CA -- (Marketwired) -- 09/19/16 -- You may have seen FlyCam UAV's aerial production work, but the UAV company that's known for its stunning cinematography recently partnered with \uc2 US Nuclear Corp\uc2  (OTCBB: UCLE) to create a \b \highlight22\uc2 new device\b0 \highlight\uc2  that's right out of the movies -- and can save real lives. FlyCam UAV \b \highlight22\uc2 launched\b0 \highlight\uc2  the Cypher 6, a commercial-grade hexacopter, and The NEO, an all-weather commercial co-axial octocopter. The platforms are designed for use with \uc2 US Nuclear Corp\uc2 's DroneRad aerial radiation detection system. DroneRad detects particles that contain alpha, beta, gamma and neutron radiation. A gas collection option tests for the presence of chlorine, biological particulates, and aerosols such as anthrax and poison gases, making the FlyCam UAV/US Nuclear Corp UAV suitable for radiological, chemical and biological detection missions.\par \par \uc2  Future upgrades to the DroneRad package will detect methane and diesel. The UAVs can be used to detect radiation leaks in nuclear power plants or flown into plumes of smoke from a burning building to give first responders immediate data about what kinds of hazards might be present. It can also be used for to monitor public events, seaports or geographic areas to detect possible dirty radiological bombs or the use of chemical and biological agents. The DroneRad with the Cypher 6 and NEO UAV configurations acquires and relays data to the operator in real-time. The data can be tagged with GPS coordinates and stored on-board for post-flight download and viewing, or it can transmit data to a base station for live monitoring. The data consists of a series of measurements of radioactive intensity tagged with GPS data for color coded display on a map. The data can be displayed as a full gamma spectrum, allowing the identification of radioactive isotopes. "Sensors mounted on UAVs is the perfect marriage of two technologies that will be a game changer for a variety of different industries," Jeri Donaldson, CEO and owner of FlyCam UAV, said. "In addition, the need for security is at an all-time high and our technology can remove the human element from a potentially dangerous situation. The practical and potential applications of the Cypher 6 and Neo with \uc2 US Nuclear Corp\uc2 .'s DroneRad sensor package is enormous and we have yet to see all of the use cases of the devices." The Cypher 6, Neo and DroneRad are available now through FlyCam UAV. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.flycamuav.com"}}{\fldrslt{\cf2 \uc2 http://www.flycamuav.com}}}\uc2 . About FlyCam UAV: FlyCam UAV utilizes aerial imaging systems to deliver stunning footage for film and television to agricultural and industrial inspections. From 10 feet off the ground to 400 feet in the air, FlyCam UAV gets it done on time and on budget. The company recently partnered with \uc2 US Nuclear Corporation\uc2  to create the Cypher 6 and NEO UAV platforms and the DroneRad sensor package, which can detect radiological threats. With a gas collection option, it can also find chemical and biological agents. Safe Harbor Act This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. \uc2 US Nuclear Corp\uc2 . \uc2 Robert I. Goldstein\uc2  President, CEO, and Chairman Rachel Boulds Chief Financial Officer (818) 883 7043 Source: \uc2 US Nuclear Corp\uc2 . \par \par \uc2 Document PLATT00020160919ec9j0015x\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw39\pich40\picscaley100\picscalex100\picwgoal585\pichgoal600
47
494638396127002800F700000000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC002BFF0055000055330055660055990055CC00
55FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D56600D59900D5CC00D5FF00FF0000FF3300FF
6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF3355003355333355663355993355CC3355FF
3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633D59933D5CC33D5FF33FF0033FF3333FF6633
FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655006655336655666655996655CC6655FF6680
006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D59966D5CC66D5FF66FF0066FF3366FF6666FF99
66FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF9955009955339955669955999955CC9955FF99800099
80339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5CC99D5FF99FF0099FF3399FF6699FF9999FF
CC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533CC5566CC5599CC55CCCC55FFCC8000CC8033
CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCCD5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCC
FFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF5566FF5599FF55CCFF55FFFF8000FF8033FF80
66FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FFFFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF
00000000000000000000000021F904010000FC002C00000000270028000008FF00F7091C48B0203D7AED88257447AFA0C3871005BA53486CD8398BBC78D9B2C5
AB61C48F03DD296BE76E58BB73BDCE650CC70B9C2D58B5DC8184484F64C976BD7A69B4E572A3AD5A3F5FD99A6990DEC8922859F6FC59ABD62BA74EFD789C6913
A9CEA54E5FBD4AA5B5AB563FCAA82A7367F59CCF9FB0BC6E5DAB1595D48F368759ECC591A7AD57DFD4A272B51715AA576EFD441C3BCC1D4E73747BD68299B6ED
5A54A95CF901ECA7D0C39A09519A05D7D26ED76C5DF7A6EAEBD78FE9610E0B9BECC5A810A345860AC9FE532B5BA12DA673E71EEDD72D9582F5DACDB505E3868C
1B316EE0B881BC4A711CD0972F8FA1A2B46F6204E5A274890362BD4C62EAEDFFD357309AB230A54D6F218852A74F8225A72A9BEA8E974C81CB7AFBA1F25B603D
5E2AF5F4CA2403D9E2C77A02D143A040065211CD406E0546452609DAD28B4B40BDD29D4099AC70C340ED3032D03031C410D63EF5A4B79F88FB0CB35350AF8841
9032CB0C14E383022973223D7CA5A74218025DC85356310E74504DBD0006A440ED0C35901F2A52B1C58374A1F5D592FB1402A57E310CC4082A140A34C996FB51
B14243BC64D8D501690CA4CC229145B6021A6EBA45901881F9A1C216D0EC932491A8C848902D7FF9352541804962646954EC19D6307A4952D3A4E0F486CA2264
21440F60A830A4506E8D8AD190325CBDE24A9CBD35DA282AAAEEA7027F2A98FFF6AA7EB03282E3645B9DDAA30A6940A323156F2C03CD245BE89889329AE0A063
84AEAA90097959FAA12B64A6C9684E2AC350F88D88BCD4F88A40B5844519AC301053638B5B527B83188A4EA28218A831D2E530614DB8CF1F142EE25BA8270A64
5A2AD2FA81DD2BEDEC33162AA8EDE3CE220D5DB44F3B8AD253A60ACEF6BB8F24A6596A9DC61AA7CB68A30088815D4154E416A1A5646EEC578FA6354AF1B10E29
5372C627736C33212D53CCEB30381634097F19A77CF29692499633C562C00C1123FCCD2C34CA79C2AA020061281D111A4D3BADDBD613531C7226C488075226AF
36CDF57E13BB0C8024601325103161E8AC6AD62EEB0CC00D931CDBA7DBFB2C3D33CC163A071E38002AE00DB6C57CEBB34C2693840183D714C710061A99543E32
DF0F29430C319A54EEB926C3108338E60FF5391F8D4691AEFAEAFB0404003B}}
\par\par \b \uc2 Pharmaceutical Drug Analog Screening and Forecasting Online Portal.(Drug overview)\b0\par\par\uc2 448 \uc2 words\par \uc2 15 September 2016\par \uc2 PR.com (Press Releases)\par \uc2 PRCOM\par NA\par \uc2 English\par \uc2 2016 Content Enterprises, Inc. \par \par \uc2 Houston, TX, September 15, 2016 --(PR.com)-- The web based portal allows a subscriber to select over 30 critical parameters in order to screen appropriate analogs that can be further reviewed in detail alongside U.S. sales data right from their \b \highlight22\uc2 launch\b0 \highlight\uc2  year up to 2015 as historical data and 2016-2022 as forecast period.\par \par \uc2 In terms of pharmaceutical jargon, analogs or analogues are drugs of varying similarity. These similarities may be in terms of numerous parameters such as order of entry in market, pharmacologic class, epidemiology, molecular similarities, days of therapy, formulation type and/or disease specificity. Forecasting the demand of a \b \highlight22\uc2 new drug\b0 \highlight\uc2  is tricky because it has no history/historical commercial data that can be used to predict the future. Analogs play an important role in helping the forecast teams build a forecast model to estimate the sales of the \b \highlight22\uc2 new drug\b0 \highlight\uc2 .\par \par \uc2 For further details, please click the link: sa-brc.com/pukka-analog-forecast-tool.php\par \par \uc2 This tool provides access to qualitative and quantitative (U.S. sales) data of over 100 brands for United States market with more brands being added every year. Comparison models frequently present inaccurate predictions if the brands being considered have multiple indications or if brands being considered are only top selling prescriptions, however Pukka considers only those drugs that are \uc2 FDA\uc2  approved for single indication only and comprises of both top selling brands as well as those performing below par thus presenting an extremely realistic view of the comparison result.\par \par \uc2 Pukka currently offers analog forecasting for major disease categories such as oncology, metabolic disorder, cardiovascular, central nervous system, skin disease, respiratory, pain management, hematology, urology, autoimmune and autoinflammatory diseases. The database also presents market revenue for United States from approval to 2015 and a forecast of sales to 2022 for all 100 brands! It provides qualitative information on over 36 parameters such as adherence, persistence, molecule, order of entry, efficacy rate, disease condition, clinical manifestation, treatment type, formulation type, orphan designation, pharmacologic class, indication, disease category, route of administration, indication specificity, days of therapy, dosing frequency, cost per day, reimbursement tier, current ownership and others. The market forecast has been estimated using the most accurate prediction systems using base values gathered from annual reports and patient based forecasting techniques.\par \par \uc2 For free demo access, please mail us at: sales@sa-brc.com; john@sa-brc.com\par \par \uc2 SA-BRC Team\par \par \uc2 Contact Information:\par \par \uc2 SA-BRC\par \par \uc2 John Whitmore\par \par \uc2 +1(832)-426-3701\par \par \uc2 Contact via Email\par \par {\field{\*\fldinst{HYPERLINK "http://www.sa-brc.com"}}{\fldrslt{\cf2 \uc2 www.sa-brc.com}}}\par \par {\field{\*\fldinst{HYPERLINK "http://sa-brc.com/pukka-analog-forecast-tool.php"}}{\fldrslt{\cf2 \uc2 http://sa-brc.com/pukka-analog-forecast-tool.php}}}\par \par \uc2 Read the full story here: {\field{\*\fldinst{HYPERLINK "http://www.pr.com/press-release/687536"}}{\fldrslt{\cf2 \uc2 http://www.pr.com/press-release/687536}}}\par \par \uc2 Document PRCOM00020160917ec9f00020\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 16:32 EDT \uc2 Neptune Technologies \highlight22\uc2 introduces \highlight\uc2  NKO Omega Plus \uc2 Neptune Technologies\uc2  &...\b0\par\par\uc2 257 \uc2 words\par \uc2 15 September 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 16:32 EDT \uc2 Neptune Technologies\b \highlight22\uc2 introduces\b0 \highlight\uc2  NKO Omega Plus \uc2 Neptune Technologies & Bioressources\uc2  announced that NKO Omega Plus will now be one of the highest omega-3 concentration of pure krill oil product available on the market. Neptune's proprietary extraction process enables NKO Omega Plus to contain up to 30% more Omega-3 than krill oil products typically on the market today. \uc2 Michel Timperio\uc2 , Head of Strategic Development stated, "We see this \b \highlight22\uc2 new product\b0 \highlight\uc2  as a great opportunity to further support our customers in their work to differentiate their brands while delivering great quality and value to their consumers. Prelaunch experience has shown an exceptionally strong level of consumer interest for a pure krill oil with improved omega-3 levels than has been available until now and NKOOmega Plus fills that need".\par \par \uc2  Neptune, the Krill Oil market pioneer, continues in its commitment to science-based innovation with the addition of NKO Omega Plus to its growing proprietary specialty ingredients portfolio. In addition, through the recent acquisition of Biodroga, a leading solutions provider of Omega-3s in the nutrition industry, Neptune Wellness Solutions offers a variety of turnkey solutions with a focus on unique delivery forms. "With the rapid pace of consumer driven innovation which characterizes today's market, there has never been a greater need to work together. Our goal is to partner and collaborate with manufacturers in developing new and innovative products to expand their current offerings to consumers", states Marc Vaugeois, Vice-President of Sales for North America\par \par \uc2 Document FLYWAL0020160915ec9f00c6y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: Blueprint Medicines  \highlight22\uc2 Announces  \highlight \highlight22\uc2 New \highlight \highlight22\uc2  Drug \highlight\uc2  Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference\b0\par\par\uc2 1,199 \uc2 words\par \uc2 9 September 2016\par 08:59\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Blueprint Medicines \b \highlight22\uc2 Announces \b0 \highlight\b \highlight22\uc2 New\b0 \highlight\b \highlight22\uc2  Drug\b0 \highlight\uc2  Discovery Program Targeting PRKACA Kinase Fusions for the Treatment of Fibrolamellar Carcinoma at 10th International Liver Cancer Association (ILCA) Annual Conference\par \par \uc2 PR Newswire\par \par \uc2 CAMBRIDGE, Mass., Sept. 9, 2016\par \par \uc2 CAMBRIDGE, Mass., Sept. 9, 2016 /PRNewswire/ -- \uc2 Blueprint Medicines Corporation\uc2  (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase medicines for patients with genomically defined diseases, today disclosed a new drug discovery program targeting protein kinase cAMP-activated catalytic subunit alpha (PRKACA) fusions for the treatment of fibrolamellar carcinoma (FLC). The announcement was made during an oral presentation on September 8, 2016 at the 10(th) ILCA Annual Conference in Vancouver, Canada on Blueprint Medicines' efforts to develop targeted therapies for patients with hepatocellular carcinoma.\par \par \uc2 "Patients with liver cancers have historically suffered from a lack of genomically defined therapeutic options. Our new drug discovery program represents our commitment to patients with orphan cancers," said \uc2 Christoph Lengauer\uc2 , Chief Scientific Officer of Blueprint Medicines. "The addition of this program is a testament to the strength of our scientists and genomics platform, as well as to the quality of our unique library of kinase inhibitors and continued momentum of our discovery efforts."\par \par \uc2 FLC is a rare and distinct subtype of liver cancer that typically arises in young adults. Currently, there are no approved therapies, and surgery is the only available treatment option for some patients, but most patients inevitably progress. Research published in 2014 by the laboratory of Dr. Sanford Simon, Professor and Head of the Laboratory of Cellular Biophysics at \uc2 The Rockefeller University\uc2  in New York in Science (Honeyman J.N. et al., Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma) and Blueprint Medicines in Nature Communications (Stransky N. et al., The landscape of kinase fusions in cancer) identified PRKACA kinase fusions in FLC. Blueprint Medicines estimates that more than ninety percent of patients with FLC harbor the PRKACA fusion, which is the only known recurrent genomic event in FLC and is considered to be the driver gene of the disease. Given the high medical need and the opportunity for a potentially transformative therapeutic impact, Blueprint Medicines is developing drug candidates for the selective inhibition of PRKACA.\par \par \uc2 "FLC is a devastating disease, and patients are in great need of effective therapeutic options," said Dr. Sanford Simon. "Targeting PRKACA represents a promising opportunity to develop innovative therapeutics that could make a difference in these patients' lives."\par \par \uc2 The unveiling of the PRKACA program expands Blueprint Medicines' existing pipeline, which includes Phase 1 clinical programs for its drug candidates BLU-554, a selective inhibitor of FGFR4 for patients with hepatocellular carcinoma, and BLU-285, a selective inhibitor of both exon 17 mutant KIT and D842V mutant PDGFR<ALPHA> for patients with advanced systemic mastocytosis and unresectable, treatment-resistant gastrointestinal stromal tumors. Blueprint Medicines expects to report preliminary data from the dose escalation portion of each of these Phase 1 clinical trials by the end of 2016. Blueprint Medicines' existing pipeline also includes preclinical programs for its drug candidate BLU-667, a selective inhibitor of RET activating mutations, fusions and predicted resistant mutants found in non-small cell lung cancer and thyroid cancer, a rare genetic disease program in collaboration with Alexion Pharma Holding and cancer immunotherapy programs in collaboration with \uc2 F. Hoffmann-La Roche Ltd\uc2  and \uc2 Hoffmann-La Roche Inc\uc2 .\par \par \uc2 About Blueprint Medicines\par \par \uc2 Blueprint Medicines is developing a new generation of highly selective and potent kinase medicines to improve the lives of patients with genomically defined diseases. The Company's approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing three programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma and systemic mastocytosis, as well as multiple programs in research and preclinical development. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.blueprintmedicines.com"}}{\fldrslt{\cf2 \uc2 www.blueprintmedicines.com}}}\uc2 .\par \par \uc2 Cautionary Note Regarding Forward-Looking Statements\par \par \uc2 This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the estimated number of patients with FLC that harbor the PRKACA fusion; and the timing of clinical data or proof of concept for preclinical and clinical programs, including, without limitation, the timing and type of preliminary clinical data for Blueprint Medicines' Phase 1 clinical trials for BLU-285 and BLU-554; and Blueprint Medicines' strategy, business plans and focus. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate, " "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the delay of any current or planned clinical trials or the development of Blueprint Medicines' drug product candidates, including BLU-285 and BLU-554; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the efficacy and safety of its drug product candidates; the preclinical and clinical results for Blueprint Medicines' drug product candidates, which may not support further development of such drug product candidates; and actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to develop and commercialize companion diagnostics for its current and future drug candidates, including a companion diagnostic for BLU-554 with \uc2 Ventana Medical Systems, Inc\uc2 . and a companion diagnostic for BLU-285 with QIAGEN Manchester Limited; and the success of Blueprint Medicines' rare genetic disease collaboration with Alexion Pharma Holding and its cancer immunotherapy collaboration with \uc2 F. Hoffmann-La Roche Ltd\uc2  and \uc2 Hoffmann-La Roche Inc\uc2 . These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, as filed with the \uc2 Securities and Exchange Commission\uc2  (SEC) on August 9, 2016, and other filings that Blueprint Medicines may make with the \uc2 SEC\uc2  in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.\par \par \uc2 Logo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20150605/221118LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20150605/221118LOGO}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/blueprint-medicines-announces-new-drug-discovery-program-targeting-prkaca-kinase-fusions-for-the-treatment-of-fibrolamellar-carcinoma-at-10th-international-liver-cancer-association-ilca-annual-conference-300325390.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/blueprint-medicines-announces-new-drug-discovery-program-targeting-prkaca-kinase-fusions-for-the-treatment-of-fibrolamellar-carcinoma-at-10th-international-liver-cancer-association-ilca-annual-conference-300325390.html}}}\par \par \uc2 SOURCE \uc2 Blueprint Medicines Corporation\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.blueprintmedicines.com"}}{\fldrslt{\cf2 \uc2 http://www.blueprintmedicines.com}}}\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 09, 2016 08:59 ET (12:59 GMT)\par \par \uc2 Document DJDN000020160909ec99001m7\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Fate Therapeutics\uc2  Files 8K - Other Events >FATE\b0\par\par\uc2 185 \uc2 words\par \uc2 7 September 2016\par 16:03\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Fate Therapeutics Inc\uc2 . (FATE) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on September 07, 2016.\par \par \uc2 On September 7, 2016, \uc2 Fate Therapeutics, Inc\uc2 . issued a press release announcing the launch of a partnership with \uc2 Memorial Sloan Kettering Cancer Center\uc2  for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines, as further described in the press release. A copy of the press release is attached as Exhibit 99.1.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1434316/000156459016024981/fate-8k_20160907.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1434316/000156459016024981/fate-8k_20160907.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1434316/000156459016024981/0001564590-16-024981-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1434316/000156459016024981/0001564590-16-024981-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 September 07, 2016 16:03 ET (20:03 GMT)\par \par \uc2 Document DJDN000020160907ec970037w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 07:35 EDT Insulet to establish highly-automated manufacturing operation in...\b0\par\par\uc2 94 \uc2 words\par \uc2 6 September 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved. \par \par \uc2 07:35 EDT Insulet to establish highly-automated manufacturing operation in U.S.Insulet Corporation announced plans to establish an automated manufacturing operation in the United States and to build product beginning in 2019. The new U.S. operation is intended to provide manufacturing redundancy and additional production capacity to support growth and \b \highlight22\uc2 new product launches\b0 \highlight\uc2 . The new operation will enable further improvements of manufacturing reliability and the lowering of production costs, in line with the company's previously stated objectives, Insulet said.\par \par \uc2 Document FLYWAL0020160906ec96003v5\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw95\pich40\picscaley100\picscalex100\picwgoal1425\pichgoal600
47
49463839615F002800F7FF00ACD19CD5E8F3A5A6A9E0EEF6C8E1EEB2D4A3C4DEB975B25BFDFEFEFAFCF9B3D6E82C8DC03391C289898D66666BD1D0D2E1EEDCB6
B6B8A3CB78A3CC91D2E6C9CEE4F0DDDDDE929296A1A1A462A74484BCDAEDF5FAD0E6F191C3DE757579C9E2F09595999B9B9EF5FAFCC5E0EE858589E6F1E168AD
D2F0F7EE3E96C58DC2DD818185BABABC8D8D914C9ECAB8B8BB6D6D71C6C6C8CDCDCFF9FCFD4299C7B9D9EAD9E9D1529E32C2DEED0E7CB70276B4ACD3E7E6F1F8
A0CCE3F7FAF5CFCFD1D4D4D598C5857CB8D892C27DD8D8DAAAD1E6BCBCBE59A23AEDF5EA95C6E05CA43D9D9DA1FAFAFA69AB4D9AC8E1E8F3F8F7F7F7117FB818
82BA6CAD50469BC81480B965ACD1E1E1E2EAF3E6E3F0F87EB765EAF4F90578B578787CB2B2B5BEDCED72B3D551A1CBC7E0BC88BC71717176D6E8CEBEBEC081B9
69F8F8F92589BEF4F4F4C9C9CAF2F2F2AAAAAC49992661A9D078B35EDEEDD8C0C0C2E6E6E6DDECD6097AB6A5CFE41E85BCB4B4B77BB561D5E7CDECECEDBAD8AD
8DBF77B7D7A9AFAFB1F8FBFDF3F8F0F0F7FB9FCBE2DFEEF7ACACAE60A6420071BD56A03564A846A9CF995AA6CEA0CA8EC4C4C68AC0DCD0E5BFBCDBEBC3DDB871
AF563A94C488BFDC9EC88B96C482A7A7AAE4F0DFE2EFF78ABD745FA540DAEAD386BB6F57A4CD288BBF8EC0795FA8CF7B7B7F67AA4B509D2F0076B10075B3DFEE
F5A0A0A3DEEDF597C7E0E5E5E6EBF4E7DADADB2086BD9CC9E1CACACC76B5D6EFF6ECF5F9F4C3C3C5DBDBDC9DCAE2CDE3C39BC788DBECF4D8EAF3A4A4A7E3E3E4
FBFDFBD3D3D472B057A7CE96AFD29FDCEBD52F8EC11A83BBBDDAB054A2CCE7E7E8E8E8E9F2F8FB98989BCAE1C0E4E4E5B6D7E9CDE3C49EC7EA78B6D77BB5DDDC
DBDCC5DEF0DEDEDFEFEFF0D9EAF4DDECCDF1F7F0F4F3F36CB0D39CC8E6EDF5F0CBE3F0B6B8BBDDEBB79FCBDE0072B8B7D7AAA2CBE7A2CDE3D0E5C7D3E6CB87BC
700C7BB7F8FBF753A2CCB2B2B4EBEBECF9FBF8E1EED5F5F5F5F6F5F5EBF4E890C07A93C37F97C57B9B9B9FDDEDF582B6E5D8D8D9E8F2E3DBEBC571B2D3D7D7D8
5DA6D1AED3E7CFE4C5FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F626520496D61676552656164792220786D704D4D3A496E7374616E636549443D22786D702E6969643A3142304236354442353046303131453639
3838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A314230423635444335304630313145363938384645
4531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22786D702E6969643A3142304236
354439353046303131453639383846454531364331343335353638222073745265663A646F63756D656E7449443D22786D702E6469643A314230423635444135
3046303131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D70
6D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDA
D9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A
999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B5A
595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B1A
191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C000000005F0028004008FF00FF091C48B0A0C18308132A3468EB9FBF
70F0566D5A48B1A2C58B0365919B902583478F59801430400ECE2500470CC4E2255059128F9A34650056A0D01B60B130EA24C80BC001299420EC1C4AF4DF1B31
0A71942A35C5C4962D60FE4933540AC73F3B4BBD68588A6229121A4B5BE05A4A76E9BF5C4BE92C9DF20FD452494B053979ABB4D48E7F41967650546A060E1CB5
942A0A40F69F27B2A4B40D00476ACBD26245234B9E4CB9724565323300F188E04AA443496C24096399F29CCD19442D9A5894429251870A5CC20707C2112136E6
1C3C2226C3A28AB552094FD544C70682C438CD6B575AE70041E388FCDB30AE7A857F23AADF4858200F42B25BD42EFF9D34B7548E0564EB2CC00106139A520C9A
2C75836A69AB7F3396D69BB474442A4FAD10D00A156EECD00A538D94D20A2AE32C358E406E9015C53F5F48F80F61A550F14F57A5E820105C5B5490C202ADDC95
D0340EDC310606FF2801822E242473813A2C0CC182032E10A2C20B6AC431861F0DFC50840A212CF1CF0B67C4F182121E4460893A4AA8C1C6055CB05086034538
5086002FA8E383034FFC330417EAD0430221BA701141115D14D1801F1160008207C990100706B38C914C737CFEB38A1419BC51093EFF20C08728854871429F8C
52144B3061149048098518914112661820D0047BCC01071C7C18D1E864BC9473CB474CDC12C62A155D234F1827C4FF524209918C62840D9A2092410102959088
AE5278372A41C164E25125BA35D7C31EB77CB2071964B04A1131199046590200BC614643C396360125099D13D6176A81C3CF358E6CD3AD45C32C25422A644962
D852DB21248B370655F1455D41A0925F29D960C8007E4B7103EF526898B081024B9930C0520377B2542DEF3946560AAE90B580099804D06E588208A4C55254A8
C5C114A54491432923C860DF3F2897D2CF854B59BC540AFF38B1C3CE3B388100411F7C50282698FCF14F20043CC28DD1C810BD01025860E2C43F5A101D884001
78318216036931020DDCC8305000343C820A410898A236D77F0C32882957FF61CA2058E43CB708045540C30DC751FF3484032CFE73CA05244440CD1D7A0CC106
178CC0D04B0C023810871C1158A0CE3D2BFC20D018AF5C70012D654CE34117178030CD132B3CEE0E0C6B0C0143113E0CF1040CFF3CE0810F18ACE1070C4BACE0
C22C2E9C110321AAA4E1821C72ECAEC63B1658B06E69AFA871910B0915E1CEF392C5F2061305B4110F3A79BCF1C611D8974FD0011E5D41862CFF8413C6279A14
8287F9E59B93994700F0120E1E35005080F8F4B3CC250CB0888E7CC423063083108CF00B8218C0178790820D3251807204238018810000F0F0114450B01CE43B
481F0AD083125C4116808884A53EA2093E4080131FC91F0609D20C63794408B0DA091FDA208F725C211635C80227FF80F186244821010449401FF057BE6B14C0
171960C2229235993C40B00D3690C726CA418E5B40422100C840031B65803764000F5F1C1602D0C10E8C24220348AC4C027E218503EC61861801440684121900
98A112ACC1E34E00B108961CA42C6481420010900F0948C01A82E44061FA4116B6086329554888233485B69DD56504FF804B29F4F1876F68C319FF1087063430
B5261443186E904E2E56C98C40D012176E50C42304928B20A0A0054818482AD2C10013CCEC1F15800503663089BEC5EC0379411826DA458500346212A9F80711
26910202D88300FFE0003466D0893AFCA3094DA80B7840F18F0F406C430E82422984518D0E0882007568D8C3AAD2FF0F062C85006028051444A0030751A11428
40450A9A908B672C8519DC68842BB8C68CA580E19229B8A422D492823F2CC50E305B0A0E5040047F464106192BC575EAE28A7F486C9E0C830F3C4BA18040A422
08B058D90252EAB0A52CE01F2D588A0E2E4985472820151D18C1063A10047D2C6518C8F0022C1AC1211E08043D69F9075FC82283F2DC2766CCF8C70E96120566
1001091DE0C63FA09083959967182610485011FA2F0E30C3AD29AB8017F4E953A02EE53AFF6AD83F9050962854E00F58B5A8D8FE2108B20C8CB016FD07379E4A
3099096407FE244B3604C9D98A80E00102C19D25A2511001FC4C203DFAC73BBA711036D4EE0E03C1C63F5660248CD9C060468DA2920AAE478853B02102F40885
004870810638A0172CB8000694E0B908808004200805098C44821090C0122E1883254000B90B9C22062A60810AB8440F42B0610C0DD0050B4EF10F0C9040200D
B0C4702FC08206AC37192E084111B830B80684C003BA00012D14120DD01E837672B84304FE91605544C318CB88C60AD410831FA862193EB0C23EF4708608F840
203158821C1E108322AC63082B60C531AC00BA18BC03066778C51A1E50045594C1030361050658F10F36C0001BACD88515761103E1EAC1184518422F54B10F77
7061169DE56C4000003B}}
\par\par \b \uc2 Innovus Pharma\uc2  to Present at Rodman & Renshaw 18th Annual Global Investment Conference\b0\par\par\uc2 593 \uc2 words\par \uc2 31 August 2016\par 06:00\par \uc2 Business Wire\par \uc2 BWR\par \uc2 English\par \uc2 (c) 2016  Business Wire. All Rights Reserved. \par \par \uc2 \f2 \par SAN DIEGO--(BUSINESS WIRE)--August 31, 2016-- \f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Innovus Pharmaceuticals, Inc\f28 \uc2 \f2 . ("\f28 \uc2 \f2 Innovus Pharma\f28 \uc2 \f2 ") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that \f28 \uc2 \f2 Dr. Bassam Damaj\f28 \uc2 \f2 , President & Chief Executive Officer will present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference, on Monday, September 12(th) . Dr. Damaj will present an update on the Company's growing revenues, FlutiCare(TM), the \f28 \b \highlight22\uc2 \f2 launch\f28 \b0 \highlight\uc2 \f2  of \f28 \b \highlight22\uc2 \f2 new products\f28 \b0 \highlight\uc2 \f2  and plans to up-list to a higher national exchange.\f28 \par \par \uc2 Event: Rodman & Renshaw 18th Annual Global Investment Conference\par \par \uc2 Date: Monday, September 12, 2016\par \par \uc2 Time: 3:00-3:25 PM EDT\par \par \uc2 Location: Louis Room, 4th Floor, Lotte New York Palace Hotel, 455 Madison Ave, New York, NY\par \par \uc2 Dr. Damaj and Robert Hoffman, \uc2 Innovus Pharma\uc2 's in-coming Chief Financial Officer, will be meeting with members of the investment community during one-on-one meetings at the conference. The presentation will be available for download on the \uc2 Innovus Pharma\uc2  web site ({\field{\*\fldinst{HYPERLINK "http://www.innovuspharma.com"}}{\fldrslt{\cf2 \uc2 www.innovuspharma.com}}}\uc2 ).\par \par \uc2 About \uc2 Innovus Pharmaceuticals, Inc\uc2 .\par \par \uc2 Headquartered in San Diego, \uc2 Innovus Pharma\uc2  is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH(R) Testosterone Booster, (b) BTH(R) Human Growth Agent, (c) Zestra(R) for female arousal and (d) EjectDelay(R) for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+(R) for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide(R), (g) Vesele(R) for promoting sexual and cognitive health, (i) Androferti(R) (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, (l) RecalMax(TM) for brain health among others and eventually FlutiCare(TM) OTC for Allergic Rhinitis, if its ANDA is approved by the \uc2 U.S. FDA\uc2 .\par \par \uc2 For more information, go to {\field{\*\fldinst{HYPERLINK "http://www.innovuspharma.com"}}{\fldrslt{\cf2 \uc2 www.innovuspharma.com}}}\uc2 , {\field{\*\fldinst{HYPERLINK "http://www.zestra.com"}}{\fldrslt{\cf2 \uc2 www.zestra.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.ejectdelay.com"}}{\fldrslt{\cf2 \uc2 www.ejectdelay.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.myvesele.com"}}{\fldrslt{\cf2 \uc2 www.myvesele.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.sensumplus.com"}}{\fldrslt{\cf2 \uc2 www.sensumplus.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.myandroferti.com"}}{\fldrslt{\cf2 \uc2 www.myandroferti.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.beyondhumantestosterone.com"}}{\fldrslt{\cf2 \uc2 www.beyondhumantestosterone.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.getbeyondhuman.com"}}{\fldrslt{\cf2 \uc2 www.getbeyondhuman.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.trybeyondhuman.com"}}{\fldrslt{\cf2 \uc2 www.trybeyondhuman.com}}}\uc2 ; {\field{\*\fldinst{HYPERLINK "http://www.recalmax.com"}}{\fldrslt{\cf2 \uc2 www.recalmax.com}}}\uc2 .\par \par \uc2 Innovus Pharma\uc2 's Forward-Looking Safe Harbor:\par \par \uc2 Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, "up-listing" to a higher national exchange, additional acquisitions, commercial partnerships, and to achieve its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the \uc2 SEC\uc2 's website or without charge from the Company.\par \par \uc2 View source version on businesswire.com: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20160831005258/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20160831005258/en/}}}\par \par \uc2 \f2 \par  \par     CONTACT: Brokers and Analysts \f28 \par \par \uc2 \f2 Chesapeake Group\f28 \par \par \uc2 \f2 Kevin Holmes, 410-825-3930\f28 \par \par \uc2 \f2 info@chesapeakegp.com \f28 \par \par \uc2 \f2 \par  \par     SOURCE: \f28 \uc2 \f2 Innovus Pharmaceuticals, Inc\f28 \uc2 \f2 . \par Copyright Business Wire 2016 \par  \f28 \par \par \uc2 \f2 (END)\f28 \par \par \uc2 Document BWR0000020160831ec8v0001m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Clovis Oncology\uc2  Files 8K - Entry Into Definitive Agreement >CLVS\b0\par\par\uc2 324 \uc2 words\par \uc2 31 August 2016\par 05:00\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Clovis Oncology Inc\uc2 . (CLVS) filed a Form 8K - Entry Into a Definitive Agreement - with the \uc2 U.S Securities and Exchange Commission\uc2  on August 30, 2016.\par \par \uc2 On August 30, 2016, \uc2 Clovis Oncology, Inc\uc2 . ("Clovis") entered into the First Amendment to License Agreement (the "First Amendment"), between Clovis and \uc2 Pfizer, Inc\uc2 . ("\uc2 Pfizer\uc2 "). The First Amendment amends the existing License Agreement, between Clovis and \uc2 Pfizer\uc2 , dated June 2, 2011, to permit Clovis to defer payment of the milestone payments payable upon (i) \uc2 FDA\uc2  approval of an NDA for 1 st Indication in US and (ii) EMA approval of an MAA for 1 st Indication in EU, to a date that is 18 months after the date of achievement of such milestones. In the event that Clovis defers such milestone payments, Clovis has agreed to certain higher payments related to the achievement of such milestones.\par \par \uc2 The above summary is qualified in its entirety by reference to the First Amendment, a copy of which will be filed as an exhibit to Clovis' next applicable periodic report or registration statement. Clovis intends to submit a Confidential Treatment Request to the \uc2 SEC\uc2  pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, requesting confidential treatment of the specific milestone payment amounts payable in connection with such deferment disclosed in the First Amendment.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1466301/000119312516696895/d248592d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1466301/000119312516696895/d248592d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1466301/000119312516696895/0001193125-16-696895-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1466301/000119312516696895/0001193125-16-696895-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 31, 2016 05:00 ET (09:00 GMT)\par \par \uc2 Document DJDN000020160831ec8v0014m\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw51\pich40\picscaley100\picscalex100\picwgoal765\pichgoal600
47
494638396133002800F700004040406A6A6A9F9F9F6B6B6BF7F7F7747474E8E8E8FEFEFE7272721E1E1EE4E4E4525252D1D1D1323232F6F6F6FDFDFD2929298A
8A8A6D6D6D686868E9E9E97171710E0E0E7C7C7C3E3E3EA5A5A5C5C5C5FCFCFC242424040404101010E0E0E0020202A0A0A0C4C4C4E5E5E5ABABABD9D9D99393
93D5D5D58181819D9D9DF5F5F55F5F5F3C3C3C9999999E9E9E2B2B2B1D1D1DEBEBEB0D0D0DD4D4D4545454D6D6D6DBDBDBA1A1A1DDDDDD989898E6E6E6B8B8B8
9C9C9C626262929292A2A2A2D3D3D3515151252525F8F8F8656565AFAFAFC7C7C7C2C2C2BABABAB7B7B7FAFAFA424242A3A3A3B4B4B47A7A7A8B8B8B01010163
63635050506F6F6F3F3F3F8282827676766969692A2A2A444444565656E1E1E16C6C6C3636364A4A4A2C2C2C343434303030CACACAF4F4F40B0B0B1212124D4D
4D080808030303FBFBFBF9F9F9D7D7D7B9B9B9A9A9A9161616B1B1B14C4C4C1C1C1CC9C9C9D2D2D2C6C6C6111111EEEEEEB2B2B2494949ADADAD333333181818
070707C8C8C8B0B0B0ACACACA6A6A67B7B7BF2F2F2F0F0F0CFCFCFCECECEE2E2E2DEDEDE2020208C8C8C9797977070704343438686863838381B1B1BCCCCCCBC
BCBC1919193D3D3DA7A7A79B9B9BB6B6B65A5A5A7878784848488787874E4E4EC0C0C05C5C5C1414142727278F8F8FBDBDBDD8D8D82D2D2DEDEDEDE7E7E7EFEF
EF2828283737374545457E7E7E1A1A1ADCDCDCDADADA262626AEAEAECDCDCD7D7D7DC3C3C3919191B5B5B5AAAAAA3939391F1F1F5E5E5E353535BBBBBBE3E3E3
313131848484BEBEBE7373733B3B3B3A3A3A8E8E8E222222949494777777F1F1F1C1C1C1DFDFDF8383834B4B4B6161610606068888885959590C0C0C0A0A0A47
4747BFBFBF131313808080A8A8A85858581717178585854F4F4F0909092E2E2E8D8D8D2323235757572F2F2F676767F3F3F3909090000000FFFFFF0000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
00000000000000000000000021FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E332D633031312036362E3134353636312C20323031322F30322F30362D31343A35363A32372020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F702043533620284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969643A4136
3333313334303635413031314534383039454641434334344137384341392220786D704D4D3A446F63756D656E7449443D22786D702E6469643A333143343745
3038363541313131453438303945464143433434413738434139223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E63654944
3D22786D702E6969643A4136333331333345363541303131453438303945464143433434413738434139222073745265663A646F63756D656E7449443D22786D
702E6469643A4136333331333346363541303131453438303945464143433434413738434139222F3E203C2F7264663A4465736372697074696F6E3E203C2F72
64663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9
E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9
A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A69
6867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A29
2827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C00000000330028000008FF00C9
51F0A1AC41AA4404C8295CC8706124610E1A2A0CE7025798172C569810237121A41C25F88C1B39D2919D8E0AD5FCC834CE4BC722DD48CA1CA7E7021089862465
D1B60084CC641D6B3CC945D28A445D68662A25A385890D8576ACBDB874881C3699DF1E344C116766818606DC281D3B52062A291CC66158C8406699110D7D1901
271341431E23F5A068D128880CB2335B2C142153068E8E15EA3694306E93D685AD46011EC948C9C223323D7CE8784531C340E352488423B34E079216240C62C8
466682181D03C8FCCA70048471371A029019624EA5599458492C225388B1D8322B48B46106946E99AF502EF423B3411AE424AF487F4ED2C576728064AEFFC53E
72C0F785BB490AF89E43E61294B2499A3F4F2EFDC8F5DB5BC80C025FE67C853AF461404307D427137ED245209333FDC9A7902913EC31CE2312D420101E8618A8
DE7755C8C445832305408E0360CCE40926DBAC12917DE32088922AB381388E72528CA38A2D4ADDA4E17DDF71112379E31865462DE40C11C10BE39C818706E81D
F8DD04326122E37F0B0DA1C109DCF1B81D11324D30257D3BB6F8DD1432B1809213FE81C9A28B1D8923D319A248F4C01269D2B7E6777324455218163AD4C54C22
D247854CA27D47C34C6E0CA049150B40A15431607A21931FE76D51C764AE2C20130D831428DD06367C21532F097D87C4236441704222337990C176179CFF3653
1CB09C674020A3F8340E1F544490D022D020924002D78CE39D74134071CBB0C37A008211601220022D9614E2293906943082020AE810830ADB5160C3B6DC2AF0
012B966D57838EF43DF0066C6082A984093480D140336A9C27820753F4D045038A90030A061CC5DB1002186C70C0021F9EE7C00AC370C082A879FC3100960633
64820C05304182421A64F0439C4940E282080D85A209B6E344F100270BE5718C422A447098420214211105124CD1C038202C40402742C0F0090E647070CA3839
2C44010C211840C738DCF8308E0904A4F0CC38967CD0D91E6CA8914319E314702D3982BC008114DEA0D03229487841C6185940504A19542C24C73822B0FFD1C8
3828F4318E226D40F107163738124D09E34490C138A5F032CE636C05E3C9190B2CB2C90CB1088105395A40B00118CB2C3443072494D0C438D4EC324E13D28C83
C08092D040CE384C00020239704C2351133C90D34A1759F03009214EC0404E36610C714A140BAD61011DE4A8302332E3EC6044F60A71B0C218B8656001391878
205128410CB04521158430CE180858600A2310AC81C80A119183192A17DC314E156DA94435C6C1800D7C80192CD8C238DE4082713860121D381B09BE40A771F4
40070AE8C027B4300E4A20601C7730C33838F2814B7422152321461ADA82050D70000D0558C305C6F1B327C4C002309840081842001FC8811C339000034B1422
8B5F1CA20D8220856066F084841C21090AF9416E1492841D906304564082423841884CAC821C27B800B818B2818C29E46CDF4983137A900122ECD08C70EC8806
50400460DCAC230101003B}}
\par\par \uc2 Business\par \b \uc2 Mylan launching a cheaper, generic version of its EpiPen;  \highlight22\uc2 New product \highlight\uc2  will cost $300 per set of injectors, should be available within weeks\b0\par\par\uc2 TOM MURPHY \par \uc2 596 \uc2 words\par \uc2 30 August 2016\par \uc2 San Diego Union-Tribune\par \uc2 SDU\par \uc2 Final ME\par 3\par \uc2 English\par \uc2 Copyright 2016, San Diego Union-Tribune. Distributed by NewsBank, Inc. \par \par \uc2 Mylan will start selling a cheaper version of its EpiPen after absorbing waves of criticism over a list price for the emergency allergy treatment that has grown to $608 for a two-pack, making it unaffordable for many patients.\par \par \uc2 The drugmaker says it will \b \highlight22\uc2 launch\b0 \highlight\uc2  in several weeks a generic EpiPen version that is identical to the branded option but will have a list price of $300 for a two-pack.\par \par \uc2 It will be available in both 0.15-milligram and 0.30-milligram strengths, like the current version on the market.\par \par \uc2 EpiPens are used in emergencies to treat severe allergies to insect bites and foods like nuts and eggs that can lead to anaphylactic shock. People usually keep a number of EpiPens handy at home, school or work. The syringes, prefilled with the hormone epinephrine, expire after a year.\par \par \uc2 Consumers and politicians have accused the company of price-gouging, since the list price for a pair of EpiPens has climbed repeatedly from around $94 in 2007, when Mylan acquired the product.\par \par \uc2 Mylan CEO \uc2 Heather Bresch\uc2  defended the price hikes last week, saying the company only received $274 of the total price for a twin-package, while insurers, pharmacies and other parties divvy up the rest.\par \par \uc2 Last week, Mylan said it was expanding programs that help people pay for EpiPens. It doubled the limit for eligibility for its patient assistance program, so a family of four making up to $97,200 would pay nothing out of pocket. It also said it will offer $300 copay cards, up from the current $100-per-prescription savings.\par \par \uc2 A company representative said Monday that the $300 cards would be available only for the branded version, but patients could use its assistance program for both the branded and generic versions of the medicine.\par \par \uc2 How much an individual pays for an EpiPen prescription can depend on insurance coverage.\par \par \uc2 Pharmacy benefits managers, which negotiate drug prices for insurers and employers, often get discounts off a drug's list price, and patient out-of-pocket costs can vary by plan. For instance, customers of \uc2 Express Scripts Holding Co\uc2 ., the nation's largest prescription benefits manager, pay $73.50 on average, a price the company has kept fairly stable for a couple of years.\par \par \uc2 Mylan said that last year, nearly 80 percent of its patients with commercial insurance paid nothing out of pocket for an EpiPen prescription due to its savings card.\par \par \uc2 Uninsured patients or those with high-deductible coverage might be stuck paying the full price for the prescription, if they are unaware of Mylan's savings options. High deductible coverage can require patients to pay thousands of dollars toward medical care or prescriptions before most coverage kicks in.\par \par \uc2 Mylan specializes in selling generic drugs, which are lower-priced equivalents to branded medications. Launching a generic version of the EpiPen can help the drugmaker protect its market share from competition.\par \par \uc2 Mylan's announcement Monday comes a few days after the compounding pharmacy \uc2 Imprimis Pharmaceuticals\uc2  said it might be able to sell a version of the allergy treatment in a few months and would likely charge around $100 for two injectors.\par \par \uc2 There is currently little competition for EpiPen, with the only rival product being Adrenaclick, which carries a list price of $461. But that could change.\par \par \uc2 Mylan is creating a generic version of its EpiPen that will be be identical to the existing product. KAREN KASMAUSKI new york times \par \par \uc2 Document SDU0000020160830ec8u00005\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw171\pich40\picscaley100\picscalex100\picwgoal2565\pichgoal600
47
4946383961AB002800F7FF00DACBCB9624288F6B6BBDA3A4C2999AD3C4C4CCBBBBF1F1F1BA151BA78687712023C11E24EEEDEDD1B9BAE5DEDEA71E22A43E42C4
ABABFCFCFCDDDBDBCDC4C4ECE9E9F1EDEDCBB3B4FAFAFAC4A4A5B81E24E9E6E6BD1E24BE9293AB0C12B37A7CAE8081CAAAABE5E1E1A62C30AB1419E1D4D5BCB7
B7B16769E2DDDDC6B3B3B59293B91A20B3898BB28485EAE8E8A30C12BA181EB91C229C0D12E0D9D9F4F2F2A26163BA2026BC9B9BAA696CBE1C22B62025DDD5D5
9D8B8BF6F6F6A13135981E22BD1920B10D14BD2026D2C9C9A35A5DB720269A5254BA8B8DA97375F8F7F7E6E5E5B6161CF4F4F4B5181EA44144D4D1D184191CA1
9FA0C6C3C3AB242ABB1E249C595AB2141AAD9A9BA25255A56C6DA05F61982B2FAA7B7CCCCBCBADACACA3292DAB595CA31419DAD1D19A313596080D885B5CD5CD
CDD7C4C5B21016E2E1E1A34649A21016A27476B5141AF0EAEAB51218DED1D29A14199D4A4DA74D50AB1016AC2126F8F6F69B4143A27C7DAC4A4E96393CDAD6D6
A3050A9B4E51B38E8FB9818296151AB12025C7AFAF8437399B1016A23438F6F4F4B87B7EA45558AD5D6093191EFBFCFC9C3B3FB012188C0204AC181E9C353899
5F61A4393CAC6163EAE3E3B47779B31F24954A4DA4252AE7DDDDB46D70B2161CAA34397D4749AA6E70F4F7F69C191EA34B4EAB292DAB5356A84549F8FAFAAC56
59DCCFCFA84246B05256BA8688ECE6E6B27274955052D5C8C9B01D23A4191EEDECEBA93135B15F62AD6668963134A12125AA3B3FBA1F25B41F24B61C22882528
B61A20FCFAFAF2F4F4B11A20B12E33AB7678B996979B4649B81F25943639F9F9F99C5658F6F8F8BA1017E6E3E3935B5CD9D3D4961217933F42BC2127C2BABAB6
8688ECE3E3E8E3E4B92025A67778BA1D23B81D23A56668B71F25BB2025FEFEFEB61F25FFFFFFFEFFFFFDFEFEB61F24B71E24FCFCFBF8F9F9B71F26B61E24FBFB
FBFDFDFDBFA8A9900D12E3D9D9B99FA0D8CFCFE5DFDFD0BFBFDFCDCDB23C3FC09F9FE3E3E3D2C7C78E474AD8C7C8EFEFEFDFD3D3F5F8F7B87577DDD8D8D9C9C9
D2CDCCE7E7E7D8CCCCFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A32323246443135333530464231314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3232
324644313534353046423131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3232324644313531353046423131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3232324644313532353046423131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AB00280040
08FF00FF091CF8CF98190A43120E993744998481C64420543884C21E0C04336ADCC8B1A3C78F2039764BC26FA2427E6652326BB7A1021373C642CA14D88DC981
0349CC6DFBB7CD5CC61E82C2F0A296AD68B6222B7E05A3F40F052318C48C0A91D16111C124FAB8DC193125D0AB5796024DF161045D8F810ED86CF1C1966D002E
18FFB5AB62ABAD8F11BB0074FB87CCCF962F76035489F5EF80811A92BED4F90A36509D2F7754F43B37904686472B8A18CDC641571F754C6E84E1B0391B104E82
28FC0D9CE58040667D02D8F5114005E19915882CD150DA282E0ECE3A895A609418902D3BFE9500B4C286D122401EB190D08D800CD29B81485AF92306AEA24510
70FF72652EDE03189A8DC6B0F2A1C73D4039A216CD218A4D825FD6E44387754360BC30C9AC00C3800890E1CE3F15C801036F9B5111C8187214620915C454488C
3540C81001466EB0F04A66D9D8B0C2303C1462CD77D93CD3860F62EC359340EE3493C366391452C625F1F576D47A2D5850C1218D3008DE0A3EF851403DFB00A0
E49200D4730F133D6440470CE9091188020A08A14D3642FC00C503B8E0A28D220A80B200374569B0422D0E0CF44D3F6C00B20407159656042E40D0D1870B025D
4008719B69E3C12C1BFCA38C136838075E0C6B444083403DA880597ABDE510C7052F12C484261E0861D4356DD460C13F1638B36069362C818918DBE8430B1AF2
15FF25C40B7F9CE502048D785A9488A0F8F3D03E889CDA9B354BF461813273B4A123528F7091C43F06E481C066B8BCD00132FFD873C7261CA0998D3656F8A00C
13F9745A1A073284B04D1282D4B104A5DA2C61CB0CFFE8A3461BF269F0C60752A882869045C0F08501996E644E165680980D37DA34B18532026D734633F915C5
0D0C234450F0C61C773C10325A58416569DC94ECADC5452CC0C707B7792C1049C618F384175E48214546EAFCB00215BDE1B2421C25F8A28A072866434D109AB4
F38F39C2AC01C333DEE2A2C117A14858F4B71E7C70402677AC608D51408491814029C88200A51AC0A0871BFF6C7087B09CE910090FB6E46083B736E882892910
04FF5274111A34E209612528B2C2D5365851483BDB1C5089B946D9E0C121E318A24713280A3ACB4BC1909083B7542C714705993241C00BB8C47A940ED45E7D21
210D20580B0C571F458C151EFC4B6951D512F00900841CBE2B1A9A3CD1422E0A17454C0C8F0CE0C714331A9543AF9FFCD18835BB17C1C1123260E38E123B6564
4F0744AB7E271008E4F01D31D4BCA2C8250380EFE60E982CA12837B9500A1D2803849FA9187378437A8841851784001F0D9041C54A133A3D58A01B21B88EEA80
000A4108A400F048C60236C8415094E01F22388415AE41296A50232AC4C88124AEC0057C29AF34D668421F68D08D76C4230438CCA13BD28002157C411744314A
0CFFB160811D90E26CA541800F0AF08F45742E079422D6305C738E7DC027884278C00FB8112B217840137CCAD4396E000B20B02E1B3E0B409BFE41830808457F
3078851F9EF50F1718C1030B700EE872A0BE92154108C95843300A3590120420479B418A1CCFE28E42C0A0373A80C10332E0A21E08830C0B784611D0C40D5CF0
F16EDC28820D16108400B8A31BDEF04318A2571C3A7C8001200C4013147594254C4110F6F840A74A468D1510C21DE670C311E8A0812EBEA01231F1580F52B086
202CC10A56D8C41B3C60844F0CC402C508421BA0690504F0C11371719938C7A91143A0230CCEE4A63AB9D90812B87304443000B6C6D90D1A4881014C8882148C
E1FF85286884125BC0DC66A8D1840718E0592E18663177158459A0802312308405DC40510BF4C07F19D9864637BA0D170D84A31BCD284835EA8D8C60800613AD
A8211EA2916E644296B58B4A201EC18BDA99C61604E309483532D29046CC1CDDE8C639CC618EA166A4023568420C7AD684628CEA021204DB1698281076E0009D
4010820D8AC0D5AE5243080B40800CB8004B386021071CB0C1339EB100121CE11B4BFBC30BF2B856B006401D4DDC471C72F00CB53E0301F04881AB5EF0861C68
B5AB5E7D861010E0814B40EC1F86C0C26E1229C90158C54FAC2C0A0248B10711FC20AB7545C32C46150B53A041AB6BE5000C6A00CB173121036B18999D624082
01FF40C314D3320ABA32E00D090883042B082297AC3006D2D5E3B3A5014221F451812D08EF2830C084C67A80083A08E164D7580211A691840ED06181C6518300
18A10D9E1585037420826B869007012AEF1A7438023EE331A5DDE580044858C439063002F4D0081000F84726B4A08BA572A9A169B880289610440E580112D3C0
A84CDEA1083AE9281BC4E8D20F2C81226268000D7FD8801BA221B2122EE10B2938C01EB090A8CD10E30D89E84726E2F05C6AA0211528A88024ACB0A5E7D03603
13384410FE86864350E00F6D902D1A37510803942216997043055CB00A2AAF02A8FB9091EA94A70D0E68A34E5A84042D042102CAFCA30717780083D1A8034540
21FF1CBA0ACFC04A5A303180E10D9BC922141421842D1B256DB57860024F94489FB5E1D0884E74814EF18D06C43688B8E0C53178F0054213A36468D40626CAE0
0C446643037488866B62710C0F0061ABBDB1410E1AA108166CC0CCFF70C51C729B9D11E0011D59A8430CE4D3492028E21EFE8B0524AC705D1D718010F1B0CAC6
98A08A17E8EAD36DC847173A703D3F8B280EF5F00600C60004D579511367C1C0055AD0817297FB082D6086396271844690B028DAD022982AA48D41282017A923
C657B858945E364AD904C18032E2B1053A2C40B8426C82162CFA07C81965013220C0363050B635F36E058080C34ECC718135049777B59BD511C6B13108EEB538
39FF50C40797E31D3B25850507B0C7213C404BA3DDD80CFFF8860ACA18C525B0F61FF7C0C1647B538418D0E102410E829F43242F769C6303F9088297B5D1E564
CC821DFF48420B7EA13066A9401C0D20446643F445D25560D8CF66963046358F2D745B568118C4203850341BA7C2150593802BDA1B447F0BE22C1508C62694CC
192BC8E1510C68F8B3D1D8045280C01385B88679B9F18C2580C21DE1ABC0538414B926D86207E768C011752484464060033B8916AD31CC0B527021186AD0C5D7
C0038329AC23090540451B76970D188C610FFFE80536AC30FBF35A81083DB0472282F08C34E5600B28F0C50782442364D37926FD200209741088EEBFE211AD89
D8FF3D14F10BEE775F07242804E807328E21D4401681C805A6B3018E72E42210C040440AECA19153284217DD178081C00D24D007AEF10FFBF003BC2080DD5704
6B400B4C4010DE2002D52009756009E5500E9C647F96300592E0093BA06CB180056B607E01080ECDD000DBC004E7F40B02A8039BE00452500D0F0080DDF70BB0
A0026761011DB0066111803AB0066010461D730E33D00792800A4AA8848CE00724271034000292E0044B880A63C0058F424E5A484EE2B00372908455880AA430
86A1300A603009ACC002EBA0042C454FFD000D4FA00452003E287033196107C2F00A40F00C54870B0B203A07286087A425DAE087614000D7B7858AC83134B075
7BFF487590088961D2651C90038CA507EC20611D23017B600E12600226200F5E000DE5340C9B605EBBE2796240194910026BB04045F0067970208B588B1B6301
8CB004A8E81B7C840BE4602708E004B4284EE6200FE68001B1C00F5DD00F139011E7E00FA0304B8994146BF70F3380036D100E52E10195108802710E867000EC
10012C0002E6A80229800234904C02B16E28E000ED108FED8002B1E02212500128208FF188023DB0172B388FFA8802CA904CC64003B1300F03508EE6E807E860
0607006B02810167108D3527355F1009913002BA503B40800917D00322008FF2986366660E2E908F01B90174841B47005CBC1743C7C03670A0089E9603841002
1EFF85027E00018FD0086DB0042B109441B9046FD0085F500DA4A31C4610046FC04DDE9405CA7601E9900CDCD406C9900EFB2010B1904DDB044DC9F04D58810D
B2D0936D000342199430D0068D000B7D3004CA6608205062CFB102CD821105000840501A30700B0630043280065DE94D73C07FE7E007644095D06495E9500010
1912B1A00730B08B17F70394700EA75334E4800073E00F02B101D8B00608A049DCA003BDF4061F071EDA0004E99002E7F00E72E035D2B30604B01769600A41D0
639FB6025BC01407C0028D60604C370A2690058DB08725439A2B8006B4931EDCA06A6490013E5101B5F05CBB72628C790E1DE06C89840689500116105028E245
B3FFF090293002481422BE6400002713E7500084D072A5E16FEE80029A002B462128AA800C13B8056D506C46B3020FA00213A0020F307608A0064AC00090B033
E001040FA031DBD002AB74469F060372B00ADD9065EA233D9C200091400DD8F19FA2200CCCB00E9C00157F66059EE002DB1076F0292B8D100A8FB20760D06252
F10219B00D6E20074D307B9A630FB1400AA78526D40003B0707B05E3022DE06E4B1743D59000B79097CA9303CDC04434300C4B507C9C41024480110D2023C9A5
7E1BE05C0C121E9C7001E6C00C9260A345710D56800334E0027D800042126955800753400545930361E007702508B7800052A301B8600D389A04ABF00123541A
39FFF008D5C000FA800824B078B8F00658D00FFF400948C0759A61036D900814E009E0307BD0410220D09832210DDCC679D4220450000575F06CE1B004888002
E610011EA73F4B200AAC390E1FA09D9BB159138002868322B1880A33600CD8D008DDE2638DD001F61002C05A1430900757D0024A45236170AADD200C50E00390
10AE3EB005838057D210006FD71BBA6005494614B8005662850461440303F00A4DD0A9DAB00B0A10AB51C10D3940079E500A1B730E506561CA933AC5610996C0
6F185640048001ABA01B5ABA3C7580087F3009A2B06B2E5664F6500234862236D05013E00E0B8670CB430282000DD2422D06A404959064FA830B9BB005C2200F
1DFF610E1164B02EB64968820B45000A0A5006CCC08E4B330FB6603F68940B0F0026E1E90193E08D2FA20C42162BB860094B6B53BE610D2AA71C346953D4B056
7D6542626B0353D1008B70068FB62B6D400B26100A31C033C480B0045407095003BC809BC470A065760164706A27D36F0B8006E9800DA7B092023103AC609F9B
61039630029CF008D7804561450620108103B10163C063C5513436800660A0341C730A63F04852610B0AB00B0B80B5D9905D88400396F9020B6514D4900B7520
0A533005A290BBBA2B0A75500C0E700EAE285BB8500E83D00913824681600B7510265DA200017026BC832E0DF010DFA00F97E0341C8070CA430540B00646A00F
66FFE60AE86A27B2380FE6B00788424BD4C028117016FFE00D33B0054B809B8C0A08C35830E7100F32B07830300A57100C43179FB4150176E00F6040A78B8B06
A6800218B00D434554107C8CE7B00D164000F5252B0FB06742F01D0B00050AF00A6162038AA008AF1067EBE109FC47109F90027AF00259D51B9487006B3000C6
6099FB5B1AB352093D700E3B700B6C2A9F71B101C5A08B17C619C886AA3221029CA2281EE6011DD00F21F05D7EA60D2BF0034A530FF0A13A0BB0064740192250
0C8EF0023230C632F0028E2008F7180DEE961E553B80F4560702B00C350572545BC5EAD00D138701C75854DBE00BEE5003C1430DBB630DBC70A11B700241A0BD
14FF644118A00275E05FBC030301300D02C100C790A59A410C45A0037F3B2B87E00B1C73065F00C9C4802E67F00DF5F09E3615034D500307600ED97935E1D164
FF700EE8609E94E233B5403A33E0096D700D2E261FD9C50A52F0078AEB728FA0024980012D10C62FF0CC2FC007BB90028551039B9059D6B00938600EA7600B52
FA1C6F3007F4D203586005219A0D31B00928DC36D3E7B318860B1E6C039C2BB2037B046B0028B9A9074CF152D4D96F05250849A00C9A1004BB232827004BE680
0D7410A2484102C2C07F7030094B00CC3DB3028A8002FD30096FE0670C630577C07FEC90086F906F713B397C920459B009C557044B50074E763AE7CC252F7004
49FF700E70F0056DA0BE05650018D05DCE86423900013C8004015C046D800A399529CA000641A02845D70847403A8650056DA0A55CB209635028F4890608372B
20400376B00E530003C2650D56D0078620105C033773F908376008A7902C3A420DBBCAD3FF207AAB870B1E7004078001EE600BD2B8300E867CFD609B35970D39
00084C640C7E3029F7F960F6E00DF1F027CA63A80DD00FC6CC798B9C7765739ED7560F7055012AE092CF715FE054CB828049A882830F80399A11C361C002962B
60B590AECFC1019B2007AE11011040BAE74202DB5C55CB577336C0DA9B80B00BE345A1C000DB300098F0CD46F1068860B3347007443C24BFD002E36000DE8C26
45FF670548C000B91424B1B2C5D180C41E9104D3B7001CD0DE967807AD650CEEB00640C0DEED1D56BC4A471240017AE0016D6058856821BF61891EF0052DF050
045102A0000468D5DEF79D0C5F60060F5102B680000EEEE00B900C92B003FEA3045520036F00041CB0C102DE6540F0062FC008291013E370027874E139B0001E
4000355D0F618000F6CD01190E0C05600019C4DE7C84007AC0270CD00141C04718EE0127908533910678D00A5A10E55A5005651188151009C720E55A500397C0
06293C1012600F82A00590F005C070E6C0300290500503100B6D481033D00A44A0E5517E0CC730003EF10F3BB00C594EE744D00A112061DE900414C006CEF005
A23E80E6A23002C3C0051490042EB20D1BC0069750037EBE0C6D720011D00AC760E9525E052020057860049E5E03461009334019CB440F74CEE55C4084321110
003B}}
\par\par \b \uc2 Best Practices, Llc\uc2 ; Study Links Effective  \highlight22\uc2 Launch \highlight\uc2  Training for District Sales Mangers to Successful  \highlight22\uc2 New Product Launches \highlight\uc2  in Pharmaceutical Sector\b0\par\par\uc2 351 \uc2 words\par \uc2 26 August 2016\par \uc2 Investment Weekly News\par \uc2 INVWK\par 80\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Investment Weekly News via VerticalNews.com \par \par \uc2 2016 SEP 3 (VerticalNews) -- By a News Reporter-Staff News Editor at Investment Weekly News -- The success of a new pharmaceutical product \b \highlight22\uc2 launch\b0 \highlight\uc2  historically has been linked to the effectiveness of an organization's sales force.\par \par \uc2 In the past, that meant the sales representatives working in the field. But savvy pharmaceutical companies are beginning to focus more attention on preparing and measuring performance of the front-line District Sales Managers (DMs) - the leaders who oversee \b \highlight22\uc2 launch\b0 \highlight\uc2 -related sales activities in the field.\par \par \uc2 To help sales leaders better understand this rising issue, \uc2 Best Practices, LLC\uc2  conducted a study that identifies the extent, content, channels, venues, and timing of training to prepare DMs for launch. The study also looks at performance metrics companies are using to ensure these front-line managers are accountable for field results.\par \par \uc2 Interestingly, study participants said front-line sales management performance assessments are either conducted frequently (64 percent said monthly or quarterly), or virtually not at all (36 percent said once or twice a year or there is no formal measurement in place). More frequent performance assessments helps reduce complacency and improve overall front-line manager impact, one sales leader said.\par \par \uc2 "I think it is the same thing as the representative. If somebody isn't there to observe and coach you, you fall into bad habits. You forget things, there isn't an awareness of what your areas of opportunity are," said an executive director of sales for a top 20 pharma company.\par \par \uc2 "New & Effective Front-Line Management Training Practices to Optimize Performance & Grow Accountability at Launch" uses external benchmarks and executive interviews to ascertain the most appropriate manager training amount and topics for a new product launch. Likewise, the research gathered qualitative and quantitative data to surface current practices and tactics to make front-line managers more accountable for launch performance.\par \par \uc2 Keywords for this news article include: \uc2 Best Practices Llc\uc2 , Investment and Finance.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document INVWK00020160826ec8q002f4\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: \uc2 ACETO\uc2  Subsidiary, Rising Pharmaceuticals, to  \highlight22\uc2 launch \highlight\uc2  Fluocinolone Acetonide Body Oil, 0.01%, and Fluocinolone Acetonide Scalp Oil, 0.01%\b0\par\par\uc2 704 \uc2 words\par \uc2 23 August 2016\par 11:16\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 ACETO\uc2  Subsidiary, Rising Pharmaceuticals, to \b \highlight22\uc2 launch\b0 \highlight\uc2  Fluocinolone Acetonide Body Oil, 0.01%, and Fluocinolone Acetonide Scalp Oil, 0.01%\par \par \uc2 PORT WASHINGTON, N.Y., Aug. 23, 2016 (GLOBE NEWSWIRE) -- \uc2 ACETO Corporation\uc2  (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced that \uc2 Rising Pharmaceuticals, Inc\uc2 ., its finished dosage form generics subsidiary, has \b \highlight22\uc2 launched\b0 \highlight\uc2  two \b \highlight22\uc2 new products\b0 \highlight\uc2 , Fluocinolone Acetonide Body Oil, 0.01%, an \uc2 FDA\uc2  approved generic version of Derma-Smoothe/FS(R) Body Oil, and Fluocinolone Acetonide Scalp Oil, 0.01%, an \uc2 FDA\uc2  approved generic version of Derma-Smoothe/FS(R) Scalp Oil.\par \par \uc2 According to \uc2 IMS Health\uc2  data, U.S. market sales for Fluocinolone Acetonide Body Oil, which is used in the treatment of atopic dermatitis, were approximately $38.5 million for the twelve months ended May 31, 2016. U.S. market sales for Fluocinolone Acetonide Scalp Oil, which is used in the treatment of psoriasis of the scalp, were approximately $40.3 million for the twelve months ended May 31, 2016.\par \par \uc2 ABOUT \uc2 ACETO\par \par \uc2 ACETO Corporation\uc2 , incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).\par \par \uc2 FORWARD LOOKING STATEMENTS\par \par \uc2 This news release contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this news release may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of \uc2 ACETO\uc2 's plans or strategies, financing plans, projected or anticipated benefits from acquisitions that \uc2 ACETO\uc2  may make, or a projection involving anticipated revenues, earnings or other aspects of \uc2 ACETO\uc2 's operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. \uc2 ACETO\uc2  intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the Company's strategic initiatives including selling finished dosage form generic drugs, and statements regarding the prospects for long-term growth. \uc2 ACETO\uc2  cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond \uc2 ACETO\uc2 's control, which may influence the accuracy of the statements and the projections upon which the statements are based. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in \uc2 ACETO\uc2 's reports filed with the \uc2 Securities and Exchange Commission\uc2 , including, but not limited to, \uc2 ACETO\uc2 's Annual Report or Form 10-K for the fiscal year ended June 30, 2015 and other filings. Copies of these filings are available at {\field{\*\fldinst{HYPERLINK "http://www.sec.gov"}}{\fldrslt{\cf2 \uc2 www.sec.gov}}}\uc2 .\par \par \uc2 Any one or more of these uncertainties, risks and other influences could materially affect \uc2 ACETO\uc2 's results of operations and whether forward-looking statements made by \uc2 ACETO\uc2  ultimately prove to be accurate. In addition, periodic high-margin product sales may have a positive material financial impact in a given quarter that may be non-recurring in future quarters, thereby rendering one quarter's performance not useful as a predictor of future quarters' results. \uc2 ACETO\uc2 's actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. \uc2 ACETO\uc2  undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise. \par \par \uc2 \f2 \par Investor Relations Contact: \par LHA \par Jody Burfening \par jburfening@lhai.com \par (212) 838-3777 \f28 \par \par \uc2 \f2 (END) Dow Jones Newswires\f28 \par \par \uc2 \f2 August 23, 2016 11:16 ET (15:16 GMT)\f28 \par \par \uc2 Document DJDN000020160823ec8n0024q\par }\page {\par\fs20\b \uc2 Instrumentation Laboratory\uc2 ; Instrumentation Laboratory Presents New Innovations In Hemostasis At AACC Annual Meeting\b0\par\par\uc2 904 \uc2 words\par \uc2 19 August 2016\par \uc2 Drug Week\par \uc2 DRGW\par 147\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016, Drug Week via NewsRx.com \par \par \uc2 2016 AUG 26 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- \uc2 Instrumentation Laboratory\uc2  (IL) \b \highlight22\uc2 introduced\b0 \highlight\uc2  several key innovations in Hemostasis at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, Pennsylvania, August 2-4. Giovanni Russi, Vice President of Worldwide Marketing and Service, outlined the \b \highlight22\uc2 new product\b0 \highlight\uc2  offerings in a presentation entitled, "New Innovations in Hemostasis Automation and Service Enhancing Lab Efficiency," on August 3(rd), at the meeting.\par \par {\field{\*\fldinst{HYPERLINK "https://photos.prnewswire.com/prnvar/20140204/NE58020LOGO"}}{\fldrslt{\cf2 \uc2 https://photos.prnewswire.com/prnvar/20140204/NE58020LOGO}}}\par \par \uc2 The presentation described the new ACL TOP(R) Family 50 Series Testing Systems, with advanced automation for routine and specialty testing. Completely standardized, each of the five models integrate pre-analytical sample integrity checks, advanced quality management and lab accreditation tools a true breakthrough. Additionally, the benefits of new HemoHub(TM) Intelligent Data Manager, including unmatched operational performance and clinical decision support from a single workstation, along with HemoCell(TM) Specialized Lab Automation, the first automated workcell solution designed specifically for Hemostasis testing, which optimizes workflow. Complementing the new system offerings are several novel reagents including HemosIL(R) Readiplastin(R), the first liquid PT assay, delivering excellent performance with ready-to-use convenience and HemosIL HIT-Ab ((PF4-H)), the first on-demand, fully automated qualitative immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) antibodies, commonly found in patients with Heparin-Induced Thrombocytopenia (HIT).\par \par \uc2 "For over three decades, IL has been at the forefront of Innovation in Hemostasis diagnostics. Our unique expertise, passion and focus has enabled us to become the market leader in Hemostasis diagnostics worldwide," said Russi. "This year is particularly significant for us with the launches of five outstanding products/product lines, including the ACL TOP Family 50 Series, a broad and standardized platform of systems. Each of our new product offerings will help our customers achieve their goals of delivering better patient care, while reducing healthcare costs."\par \par \uc2 New ACL TOP Family 50 Series Testing Systems These new systems offer all of the standardization benefits of the ACL TOP Family, plus unprecedented pre-analytical quality assurance, risk- management and laboratory accreditation benefits. Automated pre-analytical sample integrity checks identify under-filled sample tubes, abnormal sample aspiration potentially caused by clots, and assay-specific interference from hemolysis, icterus and lipemia. Additionally, the ACL TOP Family 50 Series systems offer enhanced laboratory accreditation tools to automate documentation for compliance with quality standards. Models include: ACL TOP 750/CTS/LAS, ACL TOP 550 CTS, ACL TOP 350 CTS.\par \par \uc2 New HemoHub Intelligent Data Manager\par \par \uc2 For central control of Hemostasis testing, HemoHub delivers unmatched operational performance, QC management and clinical decision support, all from a single workstation. With flexibility to meet specific lab operational needs, HemoHub is scalable for an unlimited number of patient files and analyzer connections, and features a KPI-configurable dashboard and configurable statistical report formats. Simple rerun and reflex processing, sample alert flags, simplified sample-bank inventory and sample routing optimized to each lab's needs, enhances workflow and efficiency. Plus, HemoHub provides easy access to patient result histories, patient-parameter configured rules and integrated accreditation support, to help ensure quality patient care.\par \par \uc2 New HemoCell Specialized Lab Automation\par \par \uc2 The world's first and only automated workcell designed specifically for Hemostasis testing, HemoCell centralizes control of Hemostasis testing. Integrating the Thermo Scientific(TM) TCAutomation(TM) Laboratory Automation System, ACL TOP 750 LAS system and HemoHub Intelligent Data Manager, HemoCell improves throughput, reduces turnaround times and pre-analytical issues. Additionally, operator exposure to biohazards are reduced and Hemostasis expertise in the lab is retained.\par \par \uc2 New HemosIL HIT-Ab((PF4-H)) Assay\par \par \uc2 The first, fully automated, on-demand assay for Heparin-Induced Thrombocytopenia (HIT) on a Hemostasis testing system, HemosIL HIT-Ab((PF4-H)) for use on ACL TOP Family of instruments, detects anti-platelet factor 4/heparin (PF4-H) antibodies associated with HIT. Unlike existing manual processes, HemosIL HIT-Ab((PF4-H)) is a liquid, ready-to-use qualitative immunoassay that delivers results in minutes--on-demand, 24/7--allowing clinicians to make timely, well-informed therapeutic decisions, ultimately minimizing patient risk and reducing costs.(1,2) A severe immunologic adverse reaction to a Heparin complex, leading to venous and/or arterial thrombosis, and potentially death, diagnosis is key to positive patient outcomes and may prompt initiation of alternative anticoagulants.\par \par \uc2 New HemosIL ReadiPlasTin Assay\par \par \uc2 Expanding the Company's growing portfolio of liquid, ready-to-use assays, HemosIL ReadiPlasTin offers high sensitivity, low ISI approx. equal to1.0, and no reconstitution errors. The new Prothrombin Time (PT) assay ensures accuracy and demonstrates excellent performance, comparable to the gold-standard HemosIL RecombiPlasTin((R)) 2G assay. Additionally, the assay requires no acclimation time or pipetting, reducing manual reagent handling, while recombinant human tissue factor and synthetic phospholipids components provide lot-to-lot consistency. HemosIL ReadiPlasTin is fully validated for use and stable for ten days in original vials on ACL TOP Family and new ACL TOP Family 50 Series Hemostasis Testing Systems.\par \par \uc2 Today, IL is the leading manufacturer of instruments and reagents for Hemostasis in vitro diagnostics testing worldwide. IL has continually been at the forefront of innovation in Hemostasis testing for over thirty years.\par \par \uc2 Keywords for this news article include: Heparin, Therapy, Patient Care, Intelligent Data, Machine Learning, Emerging Technologies, \uc2 Instrumentation Laboratory\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document DRGW000020160819ec8j0002b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Study Links Effective  \highlight22\uc2 Launch \highlight\uc2  Training for District Sales Mangers to Successful  \highlight22\uc2 New Product Launches \highlight\uc2  in Pharmaceutical Sector\b0\par\par\uc2 511 \uc2 words\par \uc2 12 August 2016\par 18:30\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 CHAPEL HILL, N.C., Aug. 12, 2016 /PRNewswire/ -- The success of a new pharmaceutical product \b \highlight22\uc2 launch\b0 \highlight\uc2  historically has been linked to the effectiveness of an organization's sales force.\par \par \uc2 In the past, that meant the sales representatives working in the field. But savvy pharmaceutical companies are beginning to focus more attention on preparing and measuring performance of the front-line District Sales Managers (DMs) -- the leaders who oversee \b \highlight22\uc2 launch\b0 \highlight\uc2 -related sales activities in the field.\par \par \uc2 To help sales leaders better understand this rising issue, \uc2 Best Practices, LLC\uc2  conducted a study that identifies the extent, content, channels, venues, and timing of training to prepare DMs for launch. The study also looks at performance metrics companies are using to ensure these front-line managers are accountable for field results.\par \par \uc2 Interestingly, study participants said front-line sales management performance assessments are either conducted frequently (64 percent said monthly or quarterly), or virtually not at all (36 percent said once or twice a year or there is no formal measurement in place). More frequent performance assessments helps reduce complacency and improve overall front-line manager impact, one sales leader said.\par \par \uc2 "I think it is the same thing as the representative. If somebody isn't there to observe and coach you, you fall into bad habits. You forget things, there isn't an awareness of what your areas of opportunity are," said an executive director of sales for a top 20 pharma company.\par \par \uc2 "New & Effective Front-Line Management Training Practices to Optimize Performance & Grow Accountability at Launch" uses external benchmarks and executive interviews to ascertain the most appropriate manager training amount and topics for a new product launch. Likewise, the research gathered qualitative and quantitative data to surface current practices and tactics to make front-line managers more accountable for launch performance.\par \par \uc2 Key topics addressed in the study include: \par \par \uc2 \f2 \par    -- District Manager Training \par  \par    -- Evaluate Training Platforms \par  \par    -- Timing of Sales Force Launch Training \par  \par    -- Measurement of DM Accountability \par  \par    -- Sales Training Operations Metrics \f28 \par \par \uc2 \f2 For this study, \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  engaged 20 sales leaders from 20 biopharmaceutical companies.\f28 \par \par \uc2 \f2 To access the full 58-page report or to download a complimentary summary: \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com/rr1438.htm"}}{\fldrslt{\cf2 \uc2 http://www.best-in-class.com/rr1438.htm}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 For related research, visit our \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  website at \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com/"}}{\fldrslt{\cf2 \uc2 www.best-in-class.com/}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 ABOUT BEST PRACTICES, LLC\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  is a leading benchmarking and advisory services firm serving pharmaceutical and medical device companies worldwide. \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 's clients include all the top 10 and most of the top 50 pharmaceutical companies. \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.\f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/study-links-effective-launch-training-for-district-sales-mangers-to-successful-new-product-launches-in-pharmaceutical-sector-300313044.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/study-links-effective-launch-training-for-district-sales-mangers-to-successful-new-product-launches-in-pharmaceutical-sector-300313044.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 /Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com"}}{\fldrslt{\cf2 \uc2 http://www.best-in-class.com}}}\uc2 \f2 \f28 \par \par \uc2 \f2 (END)\f28 \par \par \uc2 Document PRN0000020160812ec8c0009x\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Zimmer Biomet Holdings Files 8K - Regulation FD >ZBH\b0\par\par\uc2 193 \uc2 words\par \uc2 12 August 2016\par 16:23\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Zimmer Biomet Holdings Inc\uc2 . (ZBH) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on August 09, 2016.\par \par \uc2 On August 9, 2016, the Company issued a press release announcing the launch of the offering by the Selling Stockholders. On August 10, 2016, the Company issued a press release announcing the pricing of the offering by the Selling Stockholders. Copies of these press releases are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1136869/000119312516680760/d189746d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1136869/000119312516680760/d189746d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1136869/000119312516680760/0001193125-16-680760-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1136869/000119312516680760/0001193125-16-680760-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 12, 2016 16:23 ET (20:23 GMT)\par \par \uc2 Document DJDN000020160812ec8c003gd\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Pyrogen Testing Market by Product, Application, Test - Global Forecasts to 2021\b0\par\par\uc2 757 \uc2 words\par \uc2 11 August 2016\par 17:58\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 NEW YORK, Aug. 11, 2016 /PRNewswire/ -- The global pyrogen testing market is projected to reach USD 1086.3 million by 2021 from USD 610.2 million in 2016, at a CAGR of 12.2% from 2016 to 2020. The major drivers for the market include increase in pharmaceutical and biological industries and increasing number of \b \highlight22\uc2 new drug launches\b0 \highlight\uc2 . Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA's Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs) as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the pyrogen testing market.\par \par \uc2 According to \uc2 OECD\uc2  estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain (3,025 biotechnology companies), and France (1,481 biotechnology companies). Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Pyrogen testing is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the pyrogen testing market.\par \par \uc2 This report segments the global pyrogen testing market is segmented based on applications, products, tests, and geographies. In this report, the pyrogen testing market is categorized into three application segments--pharmaceuticals and biologicals manufacturing, medical devices manufacturing, and other applications such as water purification, food and beverages, cosmetics, and plastics and glass products.\par \par \uc2 Based on products, the pyrogen testing market is segmented into kits and reagents, services, and instruments.\par \par \uc2 In this report, the pyrogen testing market is categorized into three test segments-- in vitro pyrogen test, LAL (Limulus amebocyte lysate) test, and rabbit test. The LAL test is further subsegmented in to chromogenic tests, turbidimetric tests, and gel clot tests.\par \par \uc2 In this report, the pyrogen testing market is segmented into four major regions, namely North America, Europe, Asia and Rest of the World (RoW). North America is further segmented into the U.S. and Canada; Europe into France, Germany, Italy, Spain, the U.K., and the Rest of Europe (RoE); Asia into China, Japan, and India, and the Rest of Asia; and the Rest of the World (RoW) into Africa, Pacific and Oceania, and South America, Central America, and the Caribbean.\par \par \uc2 The report provides qualitative insights on key market shares, growth rates, and market drivers for all important sub-segments. It maps market sizes and growth rates of each sub-segment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the pyrogen testing market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.\par \par \uc2 Reasons to Buy the Report:\par \par \uc2 The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.\par \par \uc2 The report provides insights on the following:\par \par \uc2 - Product Development/Innovation: Product portfolios of top players in the pyrogen testing market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the pyrogen testing market\par \par \uc2 - Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the pyrogen testing market\par \par \uc2 - Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various pyrogen testing products across geographies\par \par \uc2 - Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the pyrogen testing market\par \par \uc2 Read the full report: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com/p04053328-summary/view-report.html"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com/p04053328-summary/view-report.html}}}\par \par \uc2 About Reportlinker\par \par \uc2 ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.\par \par {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 __________________________\par \par \uc2 Contact Clare: clare@reportlinker.com\par \par \uc2 US: (339)-368-6001\par \par \uc2 Intl: +1 339-368-6001\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/pyrogen-testing-market-by-product-application-test---global-forecasts-to-2021-300312744.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/pyrogen-testing-market-by-product-application-test---global-forecasts-to-2021-300312744.html}}}\par \par \uc2 SOURCE Reportlinker\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020160811ec8b000p0\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Instrumentation Laboratory Presents New Innovations In Hemostasis At AACC Annual Meeting\b0\par\par\uc2 1,207 \uc2 words\par \uc2 11 August 2016\par 08:30\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 \f2 \par --New Family of Testing Systems, Data Manager, Lab Automation WorkCell and Novel Assays Unveiled-- \par  \f28 \par \par \uc2 \f2 BEDFORD, Mass., Aug. 11, 2016 /PRNewswire/ -- \f28 \uc2 \f2 Instrumentation Laboratory\f28 \uc2 \f2  (IL) \f28 \b \highlight22\uc2 \f2 introduced\f28 \b0 \highlight\uc2 \f2  several key innovations in Hemostasis at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, Pennsylvania, August 2-4. Giovanni Russi, Vice President of Worldwide Marketing and Service, outlined the \f28 \b \highlight22\uc2 \f2 new product\f28 \b0 \highlight\uc2 \f2  offerings in a presentation entitled, "New Innovations in Hemostasis Automation and Service Enhancing Lab Efficiency," on August 3(rd) , at the meeting.\f28 \par \par \uc2 The presentation described the new ACL TOP(R) Family 50 Series Testing Systems, with advanced automation for routine and specialty testing. Completely standardized, each of the five models integrate pre-analytical sample integrity checks, advanced quality management and lab accreditation tools -- a true breakthrough. Additionally, the benefits of new HemoHub(TM) Intelligent Data Manager, including unmatched operational performance and clinical decision support from a single workstation, along with HemoCell(TM) Specialized Lab Automation, the first automated workcell solution designed specifically for Hemostasis testing, which optimizes workflow. Complementing the new system offerings are several novel reagents including HemosIL(R) Readiplastin(R), the first liquid PT assay, delivering excellent performance with ready-to-use convenience and HemosIL HIT-Ab (PF4-H) , the first on-demand, fully automated qualitative immunoassay for the detection of anti-platelet factor 4/heparin (PF4/H) antibodies, commonly found in patients with Heparin-Induced Thrombocytopenia (HIT).\par \par \uc2 "For over three decades, IL has been at the forefront of Innovation in Hemostasis diagnostics. Our unique expertise, passion and focus has enabled us to become the market leader in Hemostasis diagnostics worldwide," said Russi. "This year is particularly significant for us with the launches of five outstanding products/product lines, including the ACL TOP Family 50 Series, a broad and standardized platform of systems. Each of our new product offerings will help our customers achieve their goals of delivering better patient care, while reducing healthcare costs."\par \par \uc2 New ACL TOP Family 50 Series Testing Systems\par \par \uc2 These new systems offer all of the standardization benefits of the ACL TOP Family, plus unprecedented pre-analytical quality assurance, risk- management and laboratory accreditation benefits. Automated pre-analytical sample integrity checks identify under-filled sample tubes, abnormal sample aspiration potentially caused by clots, and assay-specific interference from hemolysis, icterus and lipemia. Additionally, the ACL TOP Family 50 Series systems offer enhanced laboratory accreditation tools to automate documentation for compliance with quality standards. Models include: ACL TOP 750/CTS/LAS, ACL TOP 550 CTS, ACL TOP 350 CTS.\par \par \uc2 New HemoHub Intelligent Data Manager\par \par \uc2 For central control of Hemostasis testing, HemoHub delivers unmatched operational performance, QC management and clinical decision support, all from a single workstation. With flexibility to meet specific lab operational needs, HemoHub is scalable for an unlimited number of patient files and analyzer connections, and features a KPI-configurable dashboard and configurable statistical report formats. Simple rerun and reflex processing, sample alert flags, simplified sample-bank inventory and sample routing optimized to each lab's needs, enhances workflow and efficiency. Plus, HemoHub provides easy access to patient result histories, patient-parameter configured rules and integrated accreditation support, to help ensure quality patient care.\par \par \uc2 New HemoCell Specialized Lab Automation\par \par \uc2 The world's first and only automated workcell designed specifically for Hemostasis testing, HemoCell centralizes control of Hemostasis testing. Integrating the Thermo Scientific(TM) TCAutomation(TM) Laboratory Automation System, ACL TOP 750 LAS system and HemoHub Intelligent Data Manager, HemoCell improves throughput, reduces turnaround times and pre-analytical issues. Additionally, operator exposure to biohazards are reduced and Hemostasis expertise in the lab is retained.\par \par \uc2 New HemosIL HIT-Ab(PF4-H) Assay\par \par \uc2 The first, fully automated, on-demand assay for Heparin-Induced Thrombocytopenia (HIT) on a Hemostasis testing system, HemosIL HIT-Ab(PF4-H) for use on ACL TOP Family of instruments, detects anti-platelet factor 4/heparin (PF4-H) antibodies associated with HIT. Unlike existing manual processes, HemosIL HIT-Ab(PF4-H) is a liquid, ready-to-use qualitative immunoassay that delivers results in minutes--on-demand, 24/7--allowing clinicians to make timely, well-informed therapeutic decisions, ultimately minimizing patient risk and reducing costs.(1,2) A severe immunologic adverse reaction to a Heparin complex, leading to venous and/or arterial thrombosis, and potentially death, diagnosis is key to positive patient outcomes and may prompt initiation of alternative anticoagulants.\par \par \uc2 New HemosIL ReadiPlasTin Assay\par \par \uc2 Expanding the Company's growing portfolio of liquid, ready-to-use assays, HemosIL ReadiPlasTin offers high sensitivity, low ISI .APPROX.1.0, and no reconstitution errors. The new Prothrombin Time (PT) assay ensures accuracy and demonstrates excellent performance, comparable to the gold-standard HemosIL RecombiPlasTin(R) 2G assay. Additionally, the assay requires no acclimation time or pipetting, reducing manual reagent handling, while recombinant human tissue factor and synthetic phospholipids components provide lot-to-lot consistency. HemosIL ReadiPlasTin is fully validated for use and stable for ten days in original vials on ACL TOP Family and new ACL TOP Family 50 Series Hemostasis Testing Systems.\par \par \uc2 Today, IL is the leading manufacturer of instruments and reagents for Hemostasis in vitro diagnostics testing worldwide. IL has continually been at the forefront of innovation in Hemostasis testing for over thirty years.\par \par \uc2 References \par \par \uc2 \f2 \par    1. Caton, S, et al.  Assessing the clinical and cost impact of on-demand \par       immunoassay testing for the diagnosis of heparin-induced \par       thrombocytopenia. Thromb Res. 2016 Apr;140:155-62. \par       \f28 {\field{\*\fldinst{HYPERLINK "http://dx.doi.org/10.1016/j.thromres.2016.01.025"}}{\fldrslt{\cf2 \uc2 http://dx.doi.org/10.1016/j.thromres.2016.01.025}}}\uc2 \f2  \par  \par    2. Warkentin, TE.  Demand on-demand testing for the diagnosis of \par       heparin-induced thrombocytopenia. Thromb Res. 2016 Apr;140:163-4.. \par       \f28 {\field{\*\fldinst{HYPERLINK "http://dx.doi.org/10.1016/j.thromres.2016.02.015"}}{\fldrslt{\cf2 \uc2 http://dx.doi.org/10.1016/j.thromres.2016.02.015}}}\uc2 \f2 \f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Instrumentation Laboratory\f28 \uc2 \f2  (\f28 {\field{\*\fldinst{HYPERLINK "http://www.instrumentationlaboratory.com"}}{\fldrslt{\cf2 \uc2 www.instrumentationlaboratory.com}}}\uc2 \f2 ), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The Company's product lines include Critical Care systems, Hemostasis systems and Information Management systems. IL GEM(R) product offerings, part of the Critical Care line, include the GEM Premier(TM) 4000 analyzer with Intelligent Quality Management (iQM(R) ), GEM Premier 3500 and GEMweb(R) Plus Custom Connectivity. The IL Hemostasis portfolio includes new ACL TOP Family 50 Series Hemostasis Testing Systems, in addition to the original ACL TOP(R) Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers. IL also offers HemoCell(TM) Specialized Lab Automation, HemoHub(TM) Intelligent Data Manager, ACL AcuStar(R) system, ACL Elite(R) system, and other Hemostasis analyzers, along with the comprehensive HemosIL(R) line of reagents. IL is based in Bedford, Massachusetts.\f28 \par \par \uc2 \f2 The \f28 \uc2 \f2 Instrumentation Laboratory\f28 \uc2 \f2  logo, GEM, GEMweb, iQM, Premier, HemosIL, ACL, ACL TOP, HemoCell, HemoHub, ACL AcuStar, ACL Elite, ReadiPlasTin and RecombiPlasTin are trademarks of \f28 \uc2 \f2 Instrumentation Laboratory Company\f28 \uc2 \f2  and/or one of its subsidiaries or parent companies, and may be registered in the \f28 \uc2 \f2 United States Patent and Trademark Office\f28 \uc2 \f2  and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.\f28 \par \par \uc2 \f2 Logo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20140204/NE58020LOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20140204/NE58020LOGO}}}\uc2 \f2 \f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/instrumentation-laboratory-presents-new-innovations-in-hemostasis-at-aacc-annual-meeting-300312234.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/instrumentation-laboratory-presents-new-innovations-in-hemostasis-at-aacc-annual-meeting-300312234.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Instrumentation Laboratory\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 /Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.ilus.com"}}{\fldrslt{\cf2 \uc2 http://www.ilus.com}}}\uc2 \f2 \f28 \par \par \uc2 \f2 (END)\f28 \par \par \uc2 Document PRN0000020160811ec8b000at\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Heron Therapeutics\uc2  Files 8K - Other Events >HRTX\b0\par\par\uc2 238 \uc2 words\par \uc2 10 August 2016\par 08:43\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Heron Therapeutics Inc\uc2 . (HRTX) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on August 09, 2016.\par \par \uc2 On August 10, 2016, \uc2 Heron Therapeutics, Inc\uc2 . (the "Company") issued a press release announcing that the \uc2 U.S. Food and Drug Administration\uc2  has approved SUSTOL (R) (granisetron) extended-release injection for the prevention of chemotherapy-induced nausea and vomiting, as described in the press release furnished herewith as Exhibit 99.1.\par \par \uc2 A copy of presentation materials discussing SUSTOL, all or a part of which may be used by the Company in investor or scientific presentations from time to time, is furnished as Exhibit 99.2 hereto. The attached materials have also been posted on the Company's website at {\field{\*\fldinst{HYPERLINK "http://www.herontx.com"}}{\fldrslt{\cf2 \uc2 www.herontx.com}}}\uc2 . The Company does not undertake any obligation to update this presentation.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/818033/000119312516677624/d240921d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/818033/000119312516677624/d240921d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/818033/000119312516677624/0001193125-16-677624-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/818033/000119312516677624/0001193125-16-677624-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 August 10, 2016 08:43 ET (12:43 GMT)\par \par \uc2 Document DJDN000020160810ec8a0023y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw256\pich40\picscaley100\picscalex100\picwgoal3840\pichgoal600
47
494638396100012800F70000070707EAEAEAD8D8D8F5F5F5E8E8E8EEEEEE181818191919010101FEFEFE1C1C1CFCFCFCF9F9F9FAFAFAFDFDFDF0F0F002020245
45451B1B1BB9B9B9E0E0E0F8F8F8F4F4F4EBEBEBFBFBFB272727D4D4D4D2D2D2161616DFDFDFDADADA797979E9E9E90C0C0C242424232323080808A5A5A5A7A7
A7747474D7D7D7D9D9D9E1E1E14848485F5F5F666666323232E2E2E2ECECECEDEDEDE4E4E4F3F3F30E0E0EB8B8B8050505030303C6C6C6E7E7E7EFEFEF7E7E7E
F1F1F18282823C3C3C6969694B4B4BADADAD2929291313130A0A0A0404049F9F9F3D3D3DB2B2B2E5E5E59E9E9E1D1D1DBBBBBBE3E3E372727206060698989852
5252D6D6D6C7C7C7C1C1C1D5D5D56363633434340909092C2C2C1F1F1F303030F2F2F2F6F6F6B5B5B5C0C0C0BABABAA6A6A6ACACAC8D8D8DC8C8C8B1B1B17878
78A2A2A2F7F7F7D1D1D1B3B3B3D3D3D36060605C5C5C4E4E4E3333330B0B0BABABAB262626A1A1A11E1E1ECBCBCBE6E6E66B6B6B4D4D4DB4B4B48C8C8CCFCFCF
BEBEBE2D2D2D121212A9A9A97C7C7CCCCCCC4444443F3F3F1111113E3E3EAFAFAF505050252525363636C5C5C5101010DEDEDE0F0F0F4242429D9D9D91919140
4040CECECEA3A3A32A2A2ADCDCDC5353536565657373732F2F2F717171494949868686858585616161646464767676BCBCBC2B2B2B5A5A5A5B5B5B0D0D0D9090
905656569494946C6C6C1515152828287F7F7F434343353535585858464646959595929292C9C9C9DBDBDB2E2E2E5555557D7D7DA4A4A4C3C3C36E6E6EA8A8A8
8989894F4F4F5757577070703B3B3B141414C2C2C25D5D5D2121214747474141418181811A1A1AC4C4C4393939B0B0B0878787CACACA373737DDDDDD83838396
9696BDBDBD8484841717177777775959597575758A8A8A4A4A4A4C4C4C9797977B7B7BAEAEAEB6B6B66F6F6F5E5E5E8E8E8E515151BFBFBF6A6A6A3A3A3A8888
883838389A9A9AAAAAAA2020207A7A7AD0D0D06262629999998B8B8B2222223131316767679393939B9B9BA0A0A0808080686868B7B7B76D6D6D5454549C9C9C
CDCDCD8F8F8F000000FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E302D633036302036312E3133343737372C20323031302F30322F31322D31373A33323A30302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F7020435335204D6163696E746F73682220786D704D4D3A496E7374616E636549443D22786D702E6969643A36463546
463938303546443631314530413734313830303934383238413444322220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3646354646393831
354644363131453041373431383030393438323841344432223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E636549443D22
786D702E6969643A3646354646393745354644363131453041373431383030393438323841344432222073745265663A646F63756D656E7449443D22786D702E
6469643A3646354646393746354644363131453041373431383030393438323841344432222F3E203C2F7264663A4465736372697074696F6E3E203C2F726466
3A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7
E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7
A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867
666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827
262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C00000000000128000008FF00FF091C
48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2C58B18336ADCC8B1A3C78F20438A1C49B2A4C9932853AA5CC9B265C51C412AB89C49B3A64D845474089CA7
00D0829030707893A6412742023F52DC5CCA14230576692AC148A0108CAC338FA0F8A33300A48C7C1210F8F3F74442212B3BA050185806913F7D4D5962E857E7
6181090F2A12384366E41C658B204080A3600B9E4B9898ED4A96A2439D1E85BAF4BB01C0DF379028D48DDDCC19918919FF3C90E23C296ECA172BFCC139D101E1
030F02952CD9C100628081E138682310328126CEC081938073C39F897F3D36CF01C9C61F8D118890D9D8FC0BF43F23A4E61CD86C208969937F2470FF56E54403
C1350B781483D6C99F0434114D1413F61BC033916182EB070E4BE087CDDE7C3440067A743043170148A14639B70854410BCA14F04F7E9BB571121AB5D954C03A
85C0111C119694C1C534BAFC84CB66404C94DA587D3820922F8594A0460D6A84814D3E823CA10007107006405DFFE8B219131F11C08241906822101740F8639E
409E6C064128257580076F358D23C4150EE4428716FA49E04486C26C76CA444C6C56CE4856306250014EC021891D87FCA0C436250432D0279BD5F051058FB838
D00900BCF00F036EF893E2400588B0D9113F89D404254F5C40130C664CD79F006D1430890FC0ED401015154EE4C113635D311214790D94032FE2A9FF62E92786
1CD4C666CB8034450E0399E2CF91FFAC331633FF50B087404170C64742313864D44139B8E0CF2232CCC4842F9B45F0CF06510CF44726FE20104B41B96CC6C644
0254E68F101982B4879EFF60A00436848C45874E2D0471902D9B9530D004E47CB150130132E4000602ED51193DFF80B0C858BBFC2386390225E0CC66C01A64C2
129FD0B250385A40D28041175CEC4F08B72194032EAD1AD44015068150C94309DCF2C32C218CA5ED1A6E10A408004618948CB90A217C50BA638D604144964284
F02CAFB8D38028636991D70F651C74C8660CFF33CD74459892D01E94F8C30B44A38CE5E7049BE5F18F09630CC4CB58588861100FA96C360437201CFFC4457363
252246BB3224B259114E9802052E3C10B481B4AB6CD3454101004142690329214108E3320442368930A002093AFFB3C626033172441807E1403442635C1146A4
0421ED0F3CD64953C8313221A4C328F0A411112F5AE42290B4FE2800C33FA9A87150A263CD718125C0D96DD01C586C568D4301A8325632FFC4B29917D7C52D10
DB425061500D830C019C04634838500D5B6CC7D916C72433CE15D38D75033047004636D62290391081336FC89A40D22084B1F8A109FF5800260EE73C85488212
10504A250EE80F6D69A01502D9C00806C1858390E175056980193633083FD54E5D7DA00A2AD4B589121A64167D188B02F8C1BD28F8E31E0339C258FF54618720
B9CD20D9D80C38DAE18E66F462335B18D940ECC0822558833377A0CA4204201604E0E01FC7D80C12FEB10DF3FDC30C2C581E4172D0027F5C8100DCA81767C4F6
0F768CC61F75800235829385294C415D7E90DF40AA7008054CC37E182B612E7A34961310C014BE300077AA85902F782F15026104073D18897FA88103F6828241
9AB1194F18A40AA360E4667A41062DDA4E1B3CB80470AC601028D08133066846434E3116EBFD03166369C45A7E71C482146333AE68CD3F9AF0307F0CA188FFB0
802C14E08F5A2460829B9147570E12031C90E10C62F18730FE0188CDD82D1C71B3C0251C61902FDCD21FA8FB47257E40BAB1F86B015718CB1350F0FF8F177CC3
7D635985C73A903D7F10639BFF08C02F4AE18F3EFC23097750973F6CE0A67F4CA2086381032FAA8582256C0615088181786E3005817420671DFC871480618FE0
58636903A9432909720168D0E0157B10077000200081D80E11564847201CC119F5F99497C388034AFDC101452C4403A882802406D2247F6001364E28264122D0
AF81C4403CC96BD63FD2942A819C8033B838083E24099C65951362FFE0841EA8E00A7F1481059414487BC6620B8220CF1F545AC01BC642829E0A44052650801C
0888827A66A15D79D84C2206320B788CE5007D6B981FC6920529FEE31A9B11E541DE513598AA80A129A58502DCD0862C00C70DEDE2473869594062FF8C4549FF
984024C20900A5FCC3768B6087407800AEB1742E0E726CC13F6A805A7F10E18B09E1C4587A3B106D4CB7A79818A3415AD1558104C07E4A13480D5838905B3867
1E081D0801B2800727E04159FFD8C166E210D7067266094113082A303690041417017A62806B9D3BB38120C107CAFC4715D4E50ADA2161339D1C0851FD61B54C
D2602C852008343673868308762C3E1848131A51BA0DF8422068500240C7628681EC219C9F18883E36F38181746F2C8450814FD59501A3FD831C1C16881E3673
0981188283B648B0412A3088B114016602A92A099472825A19C4189B398E77ED9781DEB16D2CF124C0215C31D583D4201A038945711050D2E48C85FF48D5A847
106A019C1650851E9BF9C1401A5036B248E11F33009373F21A0421342D84FD0BF1400CB1991510E41C6311C1363DC0C1FE0C64AFFEC05C413C50CF624C518EDA
DA8025088283150300CA69288E3F942B103E8D45545B1E0B35B0643B490FA41DF315C81936C3EA7F5881042055481382B119690C84BBFE78E03F4ED08D834422
D7B1F60725A4F8657FF4150CC4B8477A0B9286920AC402D40C818EDD4C0308EA827C5CF8842AE3A904EA0C040D19A01B6C40406CE778E71F5EC002003ED0BB7F
ECA17FEC1C881856E9D7B17459205240953F7A3610666C261D66DE0C0805920380EE8CE103494738FD51E36DA95ACF02B9C3668EA15EB64A408DB5FF46280B36
A340746453209C10047415C288E6CA622075F50722E0030AFA1AA4109BD157B44561B46A838317C480F8423CFB02122BE3276F0585405A50B07F946333DC88CD
664E30100B38EA64337B414111B089187463E3C6F8F33F0281517F585A207FD8CC8905B2801CFA631519DA80AAE70EF3CD54B020C91ACB162275E394AEC1D105
49E25826AE81FE6152204ED84C0F4A6E2FF9A57C20B71A0BF9FE318FCD982109402045CA16128077FA63D4FF80F7585E211050FCE120A01A8B95136A3FA29F6F
333488828E2172427FF87CE5ADD8E630C03010416CE6E6FF78C466A43E5CCD9CEC3EC4E50C350611FBD50BA419AA46BC4028E40F0B098401F66597FF400231D3
816C782CC636881A3643085EFD0306A0F48720FEA1014768912D9B89C74F50D0BFCBF86733D04079146614972710573416C4173E9BE10CCA106C0DE100D4E340
45F45D63A14066A06505517DDA457B63217EB9B51987201109700845C00902A1038DB00282740ACB2210423416F9E50ECBE7551EA51A0526032BE20FA2000209
A05363E17D53104E8BA26B28D40572105019E23A63710704C10A9B310B071108AA744431C056FDA101904239F5860C798102EA820903215F6331790241006CA5
0504A82EB62610BC341654F20F2EC759C203117138169DF00F5EE80FC6603417087B6D63635C061F1FD84811E10025300ABAF40F3A400E1F403BFFFF200EC623
1090361669F50F90B0194E6063C8206F03810167B50A86F20F7CB019B4A508E18407046104E5174D233016723039FFF0055B4710FFE10F37B00107F100D43416
E020100F005690603ACEE05915937323303979C87103310D9B610F02B80496A786081581FE907EF5B019EB201114B054D410038AE00F4B001B02B10E184810D5
870F80186930556DB0F6100EB03405C0048090051FA0460381077D2110833516ACF30F0E37168FF70F39107F3C553B990065BFD53F20572663D10B04A17C6371
2EBEE87C23601D60B0190D321091E70F0579106DA81A3DC505E2E1024BA3016F008B04816C1D9702F5D48ED8B019AC2080C8903205F80F5B838005FFB4194C28
1151B219C3E004B5808BE5153106517D13908E066543D5E68C115106D9506FFE0001C1000467D038FF500C40E2007436165AF656FE106302210300758B036125
7328101AD076BA2010B23816DD321075380A5EB58B0A2056913516263810F24058BE65108CB619DAF00F694061FC447F5B601DFD753189D02A29505064F80FBE
F26A02C801D05493D0E30F9BB70FA43811CFB062FEA00EBB3710ACE07305D1646361541C088EF24356FE600D06C100EE771062B81F1900090FB00265F60F54A3
7921B719AC271014D04CFE005D2FE0023DC00830158B9B815BE3502A99B31970211020603F43706F7FE90FC1381077445D075101F1C019C7700782FF50510AD6
072D2310174002B59057B4C0418F190D3029808B40401EA02E72E05955E50FD6336463913134D56F085102C091054227103D902B050106F1E70FAF176D06D034
E3351634003E03C103D5908F06110A49530E89A0001BB71919400C04A4011C2004D74005327101BBE80F843006A0D101A875043A7601D262034F3002A9B006FF
1077634172FF500D9B317F747747D50441FF6007F1274C0221A03048104F1495427910A1A04A6E945E554009623510A8400979552C1EE20F772810AA38166058
866CE524020106E1240146FA0F9BB0198F3075F98725DE720D56A91063101C91F0083A3606023310A1D00224B619D4C007540102F14703ADB1065CFF857B2D50
171DD003A8591003E002E080030390000EF0008AC00DF1061C9AC004AC700F5E8092FFF00098D03F2C22061E903C4AE0220970999B510A90009F7EF00E79D100
FB3816A080307A005663810C7A30003C70405140062ED2058DAA8782047463E1540E706F058169517904E33010289001A3F70F8A8007F7411041C048BF3010FC
E90FA570021272016C750494F4039C3102CDF60FA9810097E01D0BF057FE900144F20F0E600687608F0B51020BBA198BA00C19700A935002D71009D6A008B370
849BF10632310310EB0FE7900AEFB001935083D3250451A07607F108FE4910333007F9C41982B0AF07F10586C319AB50AF03A106581005ED000C54FF3A04E220
8E083761A96205F850001FC04182C70A594094C039B05B9059C0504A288004B95910E6C51937100548000328200736440B1FF00A4A162F2DEB0F07C00714200B
51D076638108BB9004218008712028B9B505B3340599200A2E24107CB00A9C0101BDD009911005DBB6101E300CF5B41FC6F0860F754CC9E66DFF009F1F35102F
003863B102DB6A1077B07908D10046B09BC4B21015800D9BE50F8D205A03F1011B38052B020014631068F00B9BA100A81908CBEA0F83108A04210593E80F5BE0
7EDCE70F47D09707510F67CA1D7D1002A3400A6FD0138248100E1006032B0748E00064909FAEF80399451003600E72341608A009CF321017900F0AFFB719E470
7F109106D5900912A5330948100DF00DC0304E9D780921E0027F4A1048106F2DE06308A10791A81033800DDBF010CF300AAE702C05B10DE7E900D3E002936A10
CB30026F404003E100FB704B3F408C243B0CFEA00D8274467C45A709A102BA0095C1610B3A9A105230612300244BFA75FED08E07410B1A7C32F98510389083A9
5B112FD30DE10008A0A04010F102ED521020D0A00B210C1DF611433C10B8E0BB0281C10701031D4C102F508E081104C9993974E4102A000596800817E60F2370
0D51AA100DC00A82109A3676021280660CE105C680A00BB10C3E807CDFF1101500B225A103537CC70931009260084190A51841BB7E7CC8889CC88A13BCC88CDC
C88EFCC8901CC9923CC9945CC90101003B}}
\par\par \b \uc2 Shire on track for $20b in sales by 2020\b0\par\par\uc2 Robert Weisman; Robert Weisman \par \uc2 618 \uc2 words\par \uc2 2 August 2016\par \uc2 The Boston Globe\par \uc2 BSTNGB\par \uc2 English\par \uc2 \u169\'00\'A9 2016 The Boston Globe. Provided by ProQuest Information and Learning. All Rights Reserved. \par \par \uc2 [Flemming Ornskov] said Shire is moving forward with the planned \b \highlight22\uc2 launch\b0 \highlight\uc2  of Xiidra, a \b \highlight22\uc2 new drug\b0 \highlight\uc2  to treat dry eye disease that was approved by the \uc2 Food and Drug Administration\uc2  last month. Shire has listed the average wholesale price of Xiidra at $426.73 for a 30-day supply. The price is the same as that for a competing drug already on the market, Restasis from \uc2 Allergan PLC\uc2 .\par \par \uc2 Ornskov said Shire has also been working to consolidate Baxalta -- and its Kendall Square research center -- into the Irish company. "The two teams are integrating well," he said. "They meet one day in Cambridge, and the next day in Lexington."\par \par \uc2 The company also has high hopes for an investigational drug being developed at its Lexington research labs to treat attention-deficit hyperactivity disorder, along with a hemophila drug being develped in Cambridge by the former Baxalta team and a hereditary angioedema drug Shire acquired through a 2015 buyout of \uc2 Dyax Corp\uc2 . of Burlington.\par \par \uc2 Drug maker \uc2 Shire PLC\uc2  is on track to ring up $20 billion in annual sales by 2020, and it is counting on several drug candidates being developed in Massachusetts, its chief executive said Tuesday morning.\par \par \uc2 "People would see this as a stretch goal, but it's absolutely achievable," Shire chief executive \uc2 Flemming Ornskov\uc2  said in an interview after the company posted second-quarter earnings Tuesday. The company reported a 57 percent growth in revenue and a 48 percent growth in net income from the same quarter last year.\par \par \uc2 Shire's shares were up more than 4 percent in mid-morning trading.\par \par \uc2 The quarter ending June 30 was the first in which financial results from \uc2 Baxalta Inc\uc2 . were combined with those of Shire. Shire, which is based in Dublin but run out of Lexington, completed its $32 billion takeover of Baxalta in June. The two companies generated combines sales of more than $13 billion last year.\par \par \uc2 Ornskov said Shire is moving forward with the planned launch of Xiidra, a new drug to treat dry eye disease that was approved by the \uc2 Food and Drug Administration\uc2  last month. Shire has listed the average wholesale price of Xiidra at $426.73 for a 30-day supply. The price is the same as that for a competing drug already on the market, Restasis from \uc2 Allergan PLC\uc2 .\par \par \uc2 To meet its growth plans, Shire will have to successfully advance several other experimental drugs in its pipeline. Next up will be a decision by European regulators on Onivyde, a second-line pancreatic cancer drug developed by Cambridge-based \uc2 Merrimack Pharmaceuticals Inc\uc2 . Shire has the rights to commercialize the drug outside the United States.\par \par \uc2 The company also has high hopes for an investigational drug being developed at its Lexington research labs to treat attention-deficit hyperactivity disorder, along with a hemophila drug being develped in Cambridge by the former Baxalta team and a hereditary angioedema drug Shire acquired through a 2015 buyout of \uc2 Dyax Corp\uc2 . of Burlington.\par \par \uc2 "All eyes are on Burlington" where the drug is being developed, Ornskov said. "This is a potential blockbuster that could be a very significant breakthrough in heriditary angiodema." The disease is a potentially life-threatening genetic condition that causes swelling of the hand, face, feet, and airways.\par \par \uc2 Ornskov said Shire has also been working to consolidate Baxalta -- and its Kendall Square research center -- into the Irish company. "The two teams are integrating well," he said. "They meet one day in Cambridge, and the next day in Lexington."\par \par \uc2 Robert Weisman can be reached at robert.weisman@globe.com. Follow him on \uc2 Twitter\uc2  @GlobeRobW.\par \par \uc2 Credit: By Robert Weisman Globe Staff\par \par \uc2 Caption: Shire CEO \uc2 Flemming Ornskov\uc2 .\par \par \uc2 Document BSTNGB0020161114ec8200jz1\par }\page {\par\fs20\b \uc2 Topix gets financial boost from \uc2 New Mountain Capital\uc2 .(Industry News)\b0\par\par\uc2 63 \uc2 words\par \uc2 1 August 2016\par \uc2 Household & Personal Products Industry\par \uc2 HPPI\par 121\par \uc2 ISSN: 0090-8878; Volume 53; Issue 8\par \uc2 English\par \uc2 Copyright 2016 Gale Group Inc. All rights reserved. \par \par \uc2 * Investment firm \uc2 New Mountain Capital, LLC\uc2  is providing Topix Pharmaceuticals, Inc., Amityville, NY, with "significant financial and strategic resources to support future growth initiatives which include \b \highlight22\uc2 new product\b0 \highlight\uc2  development and acquisitions," Topix recently \b \highlight22\uc2 announced.\b0 \highlight\par \par \b \highlight22\uc2 "New\b0 \highlight\uc2  Mountain is the perfect partner to help Topix execute on its growth plans," said Burt Shaffer, president and CEO of Topix.\par \par \uc2 Document HPPI000020160823ec810002v\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw304\pich40\picscaley100\picscalex100\picwgoal4560\pichgoal600
47
494638396130012800F70000000000FFFFFF0C0708100B0C140F101611121813141A15161C1718201B1C241F202621222823240905060E0A0B110D0E130F1014
10111511121612131713141814151915161A16171B17181C18191D191A1E1A1B1F1B1C211D1E201C1D221E1F231F202420212521222723242622232824252A26
272925262C28292B27282E2A2B2D292A302C2D2F2B2C3531323430313733343632333B37383935364440414945461F1C1D211E1F232021252223272425292627
2D2A2B2B28292F2C2D333031322F30312E2F3532333734353D3A3B403D3E4B48494A4748474445464344545152535051524F50504D4E4F4C4D4D4A4B5F5C5D5C
595A5B58595A57585956575754555653546A6768646162625F60615E5F7E7B7C7A7778777475767374757273737071726F70716E6F6F6C6D827F80817E7F1E19
1B221D1F7F7D7E7C7A7B6C6A6BA8A6A7A3A1A2A19FA0A09E9F9E9C9D9B999A999798989697959394918F90908E8F8F8D8E8D8B8C8C8A8B8A8889888687878586
828081C5C3C4B4B2B3B3B1B2ADABACACAAABFCFBFCFAF9FAF0EFF0EEEDEEE8E7E8E6E5E6E2E1E2E0DFE0DEDDDEDAD9DAD8D7D8D7D6D7D4D3D4CECDCEC6C5C6C5
C4C5BDBCBDBCBBBCBAB9BAB4B3B4B0AFB09B9A9BEFEFF0E5E5E6FBFCFBEEEEEDDADAD91916161B1818454242423F3F4E4B4B5E5B5B6664647B79797876766866
669B99999A9898979595969494959393939191868484848282B8B6B6FCFBFBFAF9F9F8F7F7F4F3F3F2F1F1F1F0F0EEEDEDECEBEBEAE9E9E8E7E7E6E5E5E4E3E3
E3E2E2E2E1E1E0DFDFDEDDDDDCDBDBDAD9D9D9D8D8D8D7D7D6D5D5D5D4D4D2D1D1D1D0D0D0CFCFCDCCCCCAC9C9C9C8C8C3C2C2C2C1C1C1C0C0C0BFBFBCBBBBB9
B8B8B6B5B5B5B4B4B3B2B2B2B1B1B1B0B0AFAEAEAEADADAAA9A9A9A8A8A6A5A5A5A4A4A4A3A39C9B9B898888FFFFFFFEFEFEFCFCFCFBFBFBFAFAFAF9F9F9F8F8
F8F7F7F7F5F5F5F4F4F4F3F3F3F2F2F2EFEFEFEEEEEEEDEDEDECECECEBEBEBEAEAEAE8E8E8E6E6E6E5E5E5E4E4E4E0E0E0DEDEDEDDDDDDDCDCDCDADADAD6D6D6
D3D3D3CBCBCBC7C7C7FFFFFF21F904010000FF002C00000000300128000008FF0003081C48B0A0C18308132A5CC8B0A1C38710234A9C48B1A2C58B18336ADCC8
B1A3C78F20438A1C49B2A4C9932853AA5CC9B2A5CB973063CA9C49B3A6CD9B3873EADCC9D3E0B979C48AED3297521C3432A5E2E8EA39319CBC62B8C211941A20
5D3F6AD3185555C71462BE35DE5EB13B488E1E4173B16632AA038548090D274079691660DDB991E9C65C885080808C635D1FF252B382440B29A884C94276AD1C
1C2220CC6C2061EA4BB2C00CC9B53A6161820619810C42F3414A9A24365A7AC9F463E7913B7791C664A8308103142E88468E6950E1020810059E10BD493522A1
1A022E704860A1C2892022A4A579602003870E1C06ACC2CCB0CE030C1B407CFFC060E1144177342850D0E0C18191E22E998D1154F0DA880D1B2AF819490DD49B
6B506420DE05FB61A44C301CD9A3063212BD21010D32243041061B4860411B800CE0810B30E46081046370B7503A334CC0C20F1F7C004278FE0CF40501BF7DA0
817E3245E1CA41D77430C1762305E28B40842021E0046260440728B96C548E120D0451E04368CC11803ACFA491C40B5048720E12492C930E3A8E8851032E222A
E4CB075FAC33CF0C1AFC4681280241638408116070810777C8B48E0A4A0C57D015A2C007127C6548B0A20C63554487005B74340D110F44C00644C0B8439038E1
1C33473332084310398594A9D03C32E446481654600042071D40120031B53CFFF2C612581833532F265400453E05F1628A6A298952C1AA1C4043913979600041
1C1EE1020528F85874CE1E1AD4D18729A242244E1764B6630A252174000205571464871B34E5D2030715A450C63D028513C63427F1F28A328F8C42437813A041
51241A6C40011C1FA9B394455C3C40013594DC98ED43F5DCD54E16E9686101081E9000D840E7D664C504207040410FA57C658742BB5CD2C75D04C9D3062F0309
A3CD3B0B59B282AA2B04A207C81AD0C032418E04C29540CFBC520E41C19CE0C104041F644C20B514E4C73354C5920D830525631642F06C93C8428E84B001067E
509287429604E2272FB404604EDBE76CE3C840B96C93DB40E774837500B8B0FFB18B41E1F4F37341C3C08C503EF33CD40E14E15092818A13744150C706F5B30E
41FECC4D503F070B644E33830F444E32E430840E2090A47071C81494C0C336E220240E160E78F0093604A1E14010C69E63C503325093903D2250C0C10422E8F2
CC061F74F0C1320689E28013AA35B282014A3422D02EDE8CD0C1055F30130DCD032933430445443390312158D0C538016C33C107A5B42D10302C80F2C841BE58
01C10A74A00F42BA51810E908D12DF108838D4A18E7068427BCBF00004C4209570448108A3484268D6008110B441206118800A5811BB0070F0037200A1035C40
894FDD8103F432C830649004490CC30FED20883D6870046734E20FF64BC8E2FFCE218E27F886032AD0C740F4F0C1A9C881034D0C403D6230823F0C041F2DF884
AD04C28D0A5C011E06894307C8408C3E400F21CAD0C0368C818402B40963F839C21A42170034086003DFAB802A04F20A0F78A002322044291C309E0DB4F020DC
C842339841052704801030E0171E0A02870374E0016260C72720001C1998050C20FB0D08321004796C2F153D80C007EE2489AA30C1021E88003690C1813B3DA0
5C017847287A2302290DC41DD998C1003EB08108E82121A898DF01CFF60A2AFC00085068C525E041840B748002D9084024366001079C401EF298410632508244
784343C5A443008211847186A011E7F480055490A47030A30915A0C011D041FF90726C030507C8800734000A7E06801C8008420532D0014FD4E0680A595C3A02
C00D0BA8880334104317C250846C96AF0A16B0000C72538E285000032B50445DAA5081039C80597D78CB0488F08C8128C800630B0105BA91103614C00C7C68C4
1B8A5001E60DA8023538A440B6F10530040103622B8112C9A0811489A014A8A0429B2AC0044109041706E5C63103A0060A8000034E80C540CA310A0171E005AA
F00628DA0481B30D231025F0C001B6F0084810221BA618C129F43105DF54A00901480610C2738125B0210F29F0400734C08C00184306E1B1402B02208E4A7841
05A900465B577402601844125BA80107C653363B6CA30212D0407690408E5DFF60414017784200FEB0020FC8407DD51081074236863570413C1A88C139B2F181
E16EC014DD0883C04C818F53584105475095015021107ED8E11340286C041ED083CA36820E3538812830305E1F9C1121F24805169C7017421041401A28422316
510B2606001FA9B0420B6A80010550A048EAC8425527802E7D80827915D84300D82002567DC019E1A8861848D00422100002103045E910928D0A7880023060C5
31DC10030458724019986400E4F106F8D1C30AAA9A80370442860AC8085DE9080502909843857061120259C3059A3B02624CC5621E5801AF1C11D90A64412049
5B5AD320B1170A682300ECA881404F600FCB2AED025438DA1B1EC73481AC42FF021E288193E53182074880A7E488C20156F965822819021A08016BFB50031184
A00419804009B0960E027F2003FB91C61EE02710363CCE0263FD02053CB080B9AD817914685400BAC0815EB0A2011388813258B0010DB8E06FA610C0048AD08E
6A6CE10E8B00A100281084774C630B76E095108DF080072001A2AC30EBA3AB21908EB502D52C88840C18AA016904A0187985401D04E206138F0030E190C20532
608400E4E30311D00E3CEA908640D091208780C1B03630012180E10ED810853C3F1082045060C701284E3F2A4C00195F833D1FA04B1D0B8044F2216462841008
2F5AC08171A5A2207988C00684C095721C210316800296953601F368136318FFE8F31DE04C02069DA3081A3040882C3B82A5713700AA80F309726D081470C002
3C8DDF922770F38154610214B880A031408D3E80221B8C2886354691C281AC61CF07A84200EAC00F823C8204F20CFA1B364D82FD0D436912D8E3ABFC85070870
2008E438858F29F085005C01A74430284140C90116049120E32887E07F12004B18E0020E480244E92184CC56412ACE8E4094DF918D25678008F1D8456409A0CE
00B4C1C425288640A270010C2C2100C0C82B01B6FD107FC820B6AC3BC115A0F10C539821032170B5C3EF678258CA981A1BF0C08505C2070970A005964A4834CA
4090510CEB0256800F1E22C0011770851C4F408005B430F2A5991C1228EF33FF1C26903197D320E633C7B6F70592730F9C0041F2E0C1CF830E7C1D993C5E55C8
4029A050D503267020E1001FE7905DCDB30A274310C8007640C76D26D672EB84766A170B34337D7D970EE1005214D001FC100626A603FD601060908121D04A05
110E60000A35500333800501E00713700468A0043FC30A16851DADD4317B207928601658D05211B00DF2B0799DF77971267A01407A18C004A8A73416900525E4
10F27007338001ABD501156003594209448001CDA57001300ED8300A24806E32F60766207CCE407CC6877C0AA1076B501513750A16E50126605A034181D67750
4F0072DCF780EB1700E0E701292710E3577E01700EE7277302A17E25C77E3AFF077FF2B780BB6506F65710655024DEA04C0CF37F09B10D8FC301274017E13062
0918760C68885996760541817E17009450014FD04A65153240A007DA33105D60281E800265A01503E1081910291020003BB60BD0E23BA9400660B0055EB05AE3
320A014007E89283BBF837CBA00146D04ABE2084024184A1377AA5A784BE50732BA2048110710F410B77B0021A6001AC620119A0078C20031AA001CC16007D50
05AE800C2DE07B02618668A886C7977C07210E4B8002430003303004417003E25101E87287D49787D8C787DDD78880187E02710AE4E78088887E8B985718D97E
EF376391187466588904510F4AC491E3310D088410E5500AA25005C2F70122FF9005A2800426578A92D86DA80881AB487D41C00E92D005DC301CAB30001C1002
C7430250300DF0C3060F507127360259400952910A44B0044CE00454500F01F708E3A00E35D00A7FD007AF00074E202019E30BA9308D92B702BDE00C5DC0062C
730FDCE879A0678448A884E5500412A0220760013240064A841091D07503B10DC7300D4A20301D104BD5300711D001FD200E69900129B40B28E08F9318900150
7C039910FA60022A224A22201E2050012C2891D5777D7BB87D17F97D1A19001C69881FA988D7269226479290387FFF48891869101C3999CBF00A9C5810F7A004
55900547101E1E90025140057D20103E197440E980A9A87612D90129100676FF900904910EA4200213209DF9040601500E5B300213D25C065001A41000B4600E
E2909F82225104710C39305C14E00AAAF04139F80127600A79703702A1971EC079DDD897E09884B1B30C49700126464C119002245810F040029F30629030299C
F50C580002172001ADD00D034003B370050D300552C10B9F1901657886C3379A6B489006E10D7BF00BC5F0A3C5E00B7AB0647DD73978289B16E9871819888388
9B1D697E20D99B7F089C26299C93A89206317E1BC002EBF007CB097825B4079FE802623910D9798ADC299404317D71F68107D1085BA0501DE0941C7019A88707
45A01C62F3014E1651503051CD67561EF00251F06539D80122B0A103C1A00EFFCA974518A14C5042E7200D583002AB2301517010EA200313800CE11009AA00A8
66BA040E800776200096E0070600019B1500320A9A0079A3A4C9860811061B43108C9057E30108B04991B3D98759B6A4B7999B1E9988E9E79B8EE87EC1298929
599C9424010FC00501700D5F6A10F73007A5302C7A84800AA89D0DC820DD39947DF77706210F7A4002CEB301AF4010E8C0069FC92A35E5A7A22A10CE20591873
01D71000D488027FC39C7BE98D7E198E4F28109C600A6D92010F75108EA00663D00DD0306205310F31900D47008D3D5800CCE7AA335AA3A239AB3A4A10F4A006
1035154BE01B07D6AB484A9B4A6A729130AC4F7A88C61A925A96AC25990B2BFF60A5CD7A7F05E10A02A0065C010867A3106C1009C5102E194003A27AA601B09D
E0AAA6B0C902E82810949038E662491CB0AE0541070574A342A405F3FA854EE01B8F863BADA0830A1A00CF400F88F0AF107A84A5B704032B108D364E098B10E4
100C7F90075DF005682007CCC04FE8D0066FE004B5100E46304E4F70179E194B410B7CC2A7706490A306D10E8FB007637039F100B1D168561B000360140077A0
711CA78749BA08246772FE803103B391E4170250CA9B8EA003338B733A976BF070B313A076291901CC6210C6A004FB110CDDA005347005A3F005AC100944310E
FC740E79C04F3D381ED660A6DD8AA60C220C4EDB6C927702C33010EBA05F06FFF10A1CC0011A80B504810DD6C101698810E1200C6EF0096EE00C96D20EF0E30D
CA9601B8937188AA0C03610E35F008F3B0031E80B195064B217046A4770146406905613118A0788723062BD065142001B551046F100E8C300A3F120052703119
7023D1D03C14E005498601921543AE20793B909802610B7CE002C4140240D0057930B201800C15361EAD7017AE607C4170085F286468553ADB900032E2045A62
0F4A83014D1035A830001150025DB70E986501A3103B8D507313305676006723F081E650041980004F9043D4F02111109159C30BCF6005C57301F9D119705603
80800AEAC354342309CC630155503AEAA007ACB20154900DE7C0060B850197FFF16932920480F0B901800D167501D22A10D7206AC860076860078EF00A7BD101
C6120CAB800678400CD73001111002D77910B610062280C2CA31045B3007B1F30ED336B626E46317A00625440975470841C0011B400430230D0C650164201053
30001640043483089750067B700DEC9005032001A1A0B90321092D607CACC22ABF710619400154400A2EEC06F3F301165003783004CC1302ACB0093500321920
0389E3202B7204C2F60E4CF01D1C70068F6601AB2C3A04261E114006C2100408D09AD81200A300321B2006E9F005A5170218F0003782053082014F40095B4004
ACF00852C10A12E03C17802EEE1004783402DCB00B32600138E0C752B1070FFF301E47500976C0025B2009435310E71006168053AD1630C2B72A183000A4200C
4D701D41E064AFB42255D00F513098201002174001A0600511D0026040335C50D11AE000A21600EE20033E46C873900663D03674806E11100124400344800797
610926F0D604C000A0500475F008DA2C10E400050FC01ECEF33D1CB03704E401F8CB374370311AC004AB4006A6604A64B5D149B00DA86002CCF3015BD0074B00
057E6016AF100412F0D61720033210058170B603D1082A8074C6D33C02633CAD29032EEC365400681AC00A0190070F9001891A3F2F90746A670F2C401B580051
A4D0001B50023A850113500A073107AAA40142600FE58007D76402AE1200D6FF400119700155F70AA03001158024FF050A04C00170760983430C505001056004
E4530ADF810299B90A25603CD3FB485240001A400110F00549C2BEA670CD19B00331000AA0E002277001EE780135C00B48806A1240046D530D15703CA3A00A0F
302CBF11301100027940B502110DE57DDE944DAF2DA071142000A3D036D8E000527C011A9001699028FA00020210019D70E37CD0D307B10D0E6001245002C763
0613D0AA2E020115E05192B00212901F0D1005F13010C0200397F9002E600C9F87C20E000ADD1D00FBC0E31040011B600043A03E09B11B2CA0066F100DCDF00C
D2E00662C0020F3004085210B850A241770E5FB0016CAC084F804B44230434FFF0B9B8D002A63009C4A00CA8F00941506606910EA21029BC1A273FC0C6013007
20C09E0381095B9002039D0B5BE00323606D06210E76D0E503D10E57C0011E955844E03072CB0A32C001079810D63000252006D6900FB3200BB2B00EC1B006A2
601DC7100D43600A6AE002BB4E06193004B920062DB00527E03C9FD00249B045054108696002955510C210062F80015E2015820005A2900779400529D067CD66
04AD70075950029C8E104A40036B800CC530097BE0022E50E003210B693000B61E0CA500031870050C7C3F588051D1624264BC04261E00648004646007A51003
4F60380FA7026AB0350681086530EE06610E8BF084E2400C834308BB37631DFB1C0093509F04C10EFB8310EAE00D74A0B9F3103ABF700B05210EF7F0F001300F
8C7910E3400FF0310EFB80C3B820E40281F37F5D105800BE0951E7AE9A7CAF0180C9602B792009F880E418900DEE70F1438F0F463F10B6E00F89620EC0120083
E00BC5110E880051E2E00B554F10B780051F8B08635E1094E006F04108CB70E580630CF03210E8A00C04CF59F600B1F1F0F807D10F50B0F627C10F76FA301321
0B56E0ED186129C440F6F26E13EE60BE0EE1552AC10BEBCBF9DC310ED2F06E16A17E14F006AE7FFBB89FFBBD19E0B6AFFBBEFFFB81710CEAACB3C05FFCC65F13
3ED5BBC7BFFCCCEF12E4D005A1D1FCD23FFD27210E5F4BFD201110003B}}
\par\par \uc2 Business\par \b  \highlight22\uc2 New product \highlight\uc2  for wounds from Acelity\b0\par\par\uc2 Peggy O'Hare; Staff Writer; Staff Writer \par \uc2 265 \uc2 words\par \uc2 30 July 2016\par \uc2 San Antonio Express-News\par \uc2 SAEN\par \uc2 State\par B004\par \uc2 English\par \uc2 (c) Copyright 2016 San Antonio Express-News. All Rights Reserved. Distributed by NewsBank Inc. \par \par \uc2 San Antonio medical technology company Acelity has \b \highlight22\uc2 introduced\b0 \highlight\uc2  a \b \highlight22\uc2 new product\b0 \highlight\uc2  nationally that will make it less painful for patients to change their wound dressings.\par \par \uc2 The Biosorb Gelling Fiber Dressing forms a gel when it comes into contact with an open wound. The gel offers increased absorbency and holds its shape, which allows for intact removal of the dressing.\par \par \uc2 It can be used on a wide range of open wounds, such as leg ulcers, pressure ulcers, diabetic foot ulcers, open surgical wounds, partial thickness burns, traumatic wounds and cancer-related wounds. Such chronic and surgical wounds affect more than 10.5 million people in the United States and Europe.\par \par \uc2 The Biosorb product also will be available in Europe in the coming months.\par \par \uc2 Acelity, which employs 1,500 people at its San Antonio headquarters, specializes in advanced wound care and regenerative medicine. The company was founded in San Antonio in 1976 as \uc2 Kinetic Concepts Inc\uc2 . Acelity is owned by a private equity consortium, but the company revealed last year that it is planning an initial public offering of stock.\par \par \uc2 The company has more than 5,800 employees worldwide.\par \par \uc2 pohare@express-news.net\par \par \uc2 San Antonio medical technology company Acelity has introduced a new product nationally that will make it less painful for patients to change their wound dressings. The Biosorb Gelling Fiber Dressing forms a gel when it comes into contact with an open wound. The gel offers increased absorbency and holds its shape, which allows for intact removal of the dressing. \par \par \uc2 Document SAEN000020160803ec7u0000e\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Eli Lilly Revenue Helped by Sales of  \highlight22\uc2 New Drugs \highlight\b0\par\par\uc2 By Anne Steele \par \uc2 433 \uc2 words\par \uc2 26 July 2016\par 07:39\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Eli Lilly & Co\uc2 . reported Tuesday that revenue rose more than expected in the most recent quarter, as sales of \b \highlight22\uc2 new drugs\b0 \highlight\uc2  padded increases in established products.\par \par \uc2 "Lilly is in the midst of one of the most productive periods of \b \highlight22\uc2 new product launches\b0 \highlight\uc2  in our company's history, with new medicines making a substantial contribution to our revenue growth for the first half of the year," Chief Executive \uc2 John Lechleiter\uc2  said.\par \par \uc2 Recently released drugs, including diabetes treatment Trulicity and cancer drug Cyramza, helped push 10% volume growth in the quarter.\par \par \uc2 Meanwhile, sales of Humalog, Lilly's biggest product by revenue, rose 7% to $701.9 million. Revenue for the fast-acting form of insulin in the U.S. advanced 5% on higher demand despite lower realized prices. Sales abroad increased 11% on higher volume, partially dented by unfavorable foreign exchange rates.\par \par \uc2 Blockbuster\uc2  erectile-dysfunction drug Cialis sales shot up 11% to $630.5 million. U.S. revenue jumped 24% on higher pricing, while revenue outside the U.S. fell 4% on currency challenges and lower volume.\par \par \uc2 Sales in its animal-health division, which Lilly bought from \uc2 Novartis AG\uc2  for about $5.4 billion in 2014, rose 2.3% to $859.8 million.\par \par \uc2 In all for the June quarter, Lilly reported a profit of $747.7 million, or 71 cents a share, up from $600.8 million a share, or 56 cents, a year prior. Excluding charges related to the Venezuelan financial crisis and other items, earnings per share fell to 86 cents from 90 cents.\par \par \uc2 Revenue grew 8.6% to $5.4 billion, driven by an 8% rise in volume as realized prices and the impact of foreign exchange rates -- which recently had chipped away at the top line, as Lilly does significant business abroad -- remained relatively flat from a year ago.\par \par \uc2 Analysts projected 86 cents in adjusted per-share profit on $5.15 billion in sales.\par \par \uc2 Gross margin fell 2.6 percentage points to 72.9%, mostly owing to a lower benefit from foreign exchange rates.\par \par \uc2 Lilly backed its earnings guidance for the year, which it had cut down in the previous quarter, citing the Venezuelan financial crisis. The company expects annual earnings per share of $2.68 to $2.78. Revenue is still anticipated to come in at $20.6 billion to $21.1 billion.\par \par \uc2 Shares, inactive premarket, have risen 7.5% over the past three months.\par \par \uc2 Write to Anne Steele at Anne.Steele@wsj.com\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 26, 2016 07:39 ET (11:39 GMT)\par \par \uc2 Document DJDN000020160726ec7q001hr\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Ajanta Pharma \highlight22\uc2 Announces the Launch \highlight\uc2  of Almotriptan Malate Tablets\b0\par\par\uc2 208 \uc2 words\par \uc2 19 July 2016\par 09:04\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 BRIDGEWATER, N.J., July 19, 2016 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of \uc2 Ajanta Pharma Ltd\uc2 , announces today the \b \highlight22\uc2 launch\b0 \highlight\uc2  of Almotriptan Malate Tablets (6.25mg, 12.5mg), a bioequivalent generic version of Axert(R)(1) , into the US market.\par \par \uc2 Almotriptan Tablets is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications (ANDAs) of which it has 11 final ANDA approvals; 1 tentative approval; and 14 ANDAs under review with the \uc2 United States Food & Drug Administration\uc2  (\uc2 FDA\uc2 ).\par \par \uc2 About \uc2 Ajanta Pharma\par \par \uc2 Ajanta Pharma Limited\uc2  is a specialty pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing quality, pharmaceuticals across 30 countries.\par \par \uc2 For more details about Ajanta Pharma USA Inc., please visit us at {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 www.ajantapharmausa.com}}}\uc2 .\par \par \uc2 (1) Axert(R) is a registered trademark of \uc2 Janssen Pharmaceuticals Inc\uc2 .\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20160719/390921"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20160719/390921}}}\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-almotriptan-malate-tablets-300300635.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-launch-of-almotriptan-malate-tablets-300300635.html}}}\par \par \uc2 SOURCE Ajanta Pharma USA Inc.\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.ajantapharmausa.com"}}{\fldrslt{\cf2 \uc2 http://www.ajantapharmausa.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020160719ec7j000cu\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Bricker Labs \highlight22\uc2 Introduces \highlight\uc2  Memory Matters(TM) With Neumentix(TM) - the Natural Way to Support Working Memory and Cognitive Performance\b0\par\par\uc2 568 \uc2 words\par \uc2 18 July 2016\par 07:00\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved. \par \par \uc2 CHANDLER, Ariz., July 18, 2016 /PRNewswire/ -- \uc2 Bricker Labs\uc2 , manufacturer and distributor of nutritional supplements, \b \highlight22\uc2 introduces\b0 \highlight\uc2  a \b \highlight22\uc2 new product\b0 \highlight\uc2  which naturally supports working memory and cognitive performance. Memory Matters(TM) with Neumentix(TM) Phenolic Complex K110-42 is now shipping to retailers and direct to customers from {\field{\*\fldinst{HYPERLINK "http://www.brickerlabs.com/Memory-Matters-p/29060.htm"}}{\fldrslt{\cf2 \uc2 http://www.brickerlabs.com/Memory-Matters-p/29060.htm}}}\uc2 . Memory Matters(TM) provides natural support for working memory, chronic cognitive benefits, and natural sleep support to help the brain function at its best day and night.\par \par \uc2 Photo - {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20160715/390145"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20160715/390145}}}\par \par \uc2 Research suggests working memory can naturally decline approximately 10% per decade, starting in the early 20s. Working memory is the foundation for cognitive abilities such as attention, multi-tasking, and complex thinking.\par \par \uc2 One clinical trial of individuals taking 900mg of Neumentix(TM) showed 15% improvement in the quality of working memory. Those taking Neumentix(TM) also showed 9% improvement in accuracy with spatial working memory, and reported falling asleep faster when compared to those taking a placebo.\par \par \uc2 Neumentix(TM) is a proprietary, spearmint-based ingredient with a unique Phenolic Complex, clinically tested and shown to naturally support working memory in adults. Patent-pending lines of spearmint (KI110 and KI42) used to produce Neumentix(TM) are sustainably grown in the USA.\par \par \uc2 "At \uc2 Bricker Labs\uc2 , we are pleased to bring Memory Matters(TM) with Neumentix(TM) Phenolic Complex K110-42 to market. Brain and memory health are key areas of concern in today's world and we are here to serve the prominent health needs with the development of quality nutritional supplements.\par \par \uc2 Bricker Labs\uc2  is a brand of longevity and one you can count on for innovation, science, high-quality branded ingredients, and award-winning nutritional products for living healthy." -- Charles Heying, President/CEO, \uc2 Bricker Labs\par \par \uc2 ABOUT \uc2 BRICKER LABS\uc2 :\par \par \uc2 Trusted nationwide for more than 40 years in the nutritional supplement industry, Bricker Lab's manufactures and distributes nutritional supplements which can be purchased online at BrickerLabs.com. A full line of nutritional products is also available to retail stores in various nutritional categories, such as Brain & Memory, Immune & Digestion Support, Sports Nutrition, Weight Management, Energy, and Heart/Cardiovascular Health.\par \par \uc2 Memory Matters(TM) is now available at BrickerLabs.com, and soon to be available at \uc2 The Vitamin Shoppe\uc2  stores, and Vitaminshoppe.com.\par \par \uc2 Recognized for innovation, science, and branded nutritional products and high-quality ingredients, \uc2 Bricker Labs\uc2  serves consumers and retailers nationwide with supplements and vitamins offering significant benefit and value in the wellness community.\par \par \uc2 ABOUT KEMIN:\par \par \uc2 Kemin is the supplier of Neumentix(TM) Phenolic Complex K110-42, a company that strives to improve the quality of life by touching half the people of the world ever day with products and services. Kemin is committed to delivering safe, high-quality ingredients backed by science and clinical research. Read more at {\field{\*\fldinst{HYPERLINK "https://www.kemin.com/en/north-america/products/neumentix"}}{\fldrslt{\cf2 \uc2 https://www.kemin.com/en/north-america/products/neumentix}}}\uc2 .\par \par \uc2 Contact: Cyndi D. Giles: 480 889-9452, cdowell@brickerlabs.com.\par \par \uc2 This content was issued through the press release distribution service at Newswire.com. For more info visit: {\field{\*\fldinst{HYPERLINK "http://www.newswire.com"}}{\fldrslt{\cf2 \uc2 http://www.newswire.com}}}\uc2 .\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/bricker-labs-introduces-memory-matters-with-neumentix---the-natural-way-to-support-working-memory-and-cognitive-performance-300299575.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/bricker-labs-introduces-memory-matters-with-neumentix---the-natural-way-to-support-working-memory-and-cognitive-performance-300299575.html}}}\par \par \uc2 SOURCE \uc2 Bricker Labs\par \par \uc2 /Web site: {\field{\*\fldinst{HYPERLINK "http://www.brickerlabs.com"}}{\fldrslt{\cf2 \uc2 http://www.brickerlabs.com}}}\par \par \uc2 (END)\par \par \uc2 Document PRN0000020160718ec7i0004b\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Synergy Pharmaceuticals Files 8K - Other Events >SGYP\b0\par\par\uc2 207 \uc2 words\par \uc2 15 July 2016\par 09:15\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc. \par \par \uc2 Synergy Pharmaceuticals Inc\uc2 . (SGYP) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on July 15, 2016.\par \par \uc2 On July 15, 2016, \uc2 Synergy Pharmaceuticals Inc\uc2 . (the "Company") issued a press release announcing that it has reached the \uc2 Food and Drug Administration\uc2  mid-cycle review milestone for the plecanatide new drug application in chronic idiopathic constipation (CIC). Additionally, the Company is providing an update on the ongoing irritable bowel syndrome with constipation (IBS-C) program.. The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1347613/000110465916132745/a16-14972_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1347613/000110465916132745/a16-14972_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1347613/000110465916132745/0001104659-16-132745-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1347613/000110465916132745/0001104659-16-132745-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 15, 2016 09:15 ET (13:15 GMT)\par \par \uc2 Document DJDN000020160715ec7f001ne\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw39\pich40\picscaley100\picscalex100\picwgoal585\pichgoal600
47
494638396127002800F700000000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC002BFF0055000055330055660055990055CC00
55FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D56600D59900D5CC00D5FF00FF0000FF3300FF
6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF3355003355333355663355993355CC3355FF
3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633D59933D5CC33D5FF33FF0033FF3333FF6633
FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655006655336655666655996655CC6655FF6680
006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D59966D5CC66D5FF66FF0066FF3366FF6666FF99
66FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF9955009955339955669955999955CC9955FF99800099
80339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5CC99D5FF99FF0099FF3399FF6699FF9999FF
CC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533CC5566CC5599CC55CCCC55FFCC8000CC8033
CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCCD5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCC
FFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF5566FF5599FF55CCFF55FFFF8000FF8033FF80
66FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FFFFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF
00000000000000000000000021F904010000FC002C00000000270028000008FF00F7091C48B0203D7AED88257447AFA0C3871005BA53486CD8398BBC78D9B2C5
AB61C48F03DD296BE76E58BB73BDCE650CC70B9C2D58B5DC8184484F64C976BD7A69B4E572A3AD5A3F5FD99A6990DEC8922859F6FC59ABD62BA74EFD789C6913
A9CEA54E5FBD4AA5B5AB563FCAA82A7367F59CCF9FB0BC6E5DAB1595D48F368759ECC591A7AD57DFD4A272B51715AA576EFD441C3BCC1D4E73747BD68299B6ED
5A54A95CF901ECA7D0C39A09519A05D7D26ED76C5DF7A6EAEBD78FE9610E0B9BECC5A810A345860AC9FE532B5BA12DA673E71EEDD72D9582F5DACDB505E3868C
1B316EE0B881BC4A711CD0972F8FA1A2B46F6204E5A274890362BD4C62EAEDFFD357309AB230A54D6F218852A74F8225A72A9BEA8E974C81CB7AFBA1F25B603D
5E2AF5F4CA2403D9E2C77A02D143A040065211CD406E0546452609DAD28B4B40BDD29D4099AC70C340ED3032D03031C410D63EF5A4B79F88FB0CB35350AF8841
9032CB0C14E383022973223D7CA5A74218025DC85356310E74504DBD0006A440ED0C35901F2A52B1C58374A1F5D592FB1402A57E310CC4082A140A34C996FB51
B14243BC64D8D501690CA4CC229145B6021A6EBA45901881F9A1C216D0EC932491A8C848902D7FF9352541804962646954EC19D6307A4952D3A4E0F486CA2264
21440F60A830A4506E8D8AD190325CBDE24A9CBD35DA282AAAEEA7027F2A98FFF6AA7EB03282E3645B9DDAA30A6940A323156F2C03CD245BE89889329AE0A063
84AEAA90097959FAA12B64A6C9684E2AC350F88D88BCD4F88A40B5844519AC301053638B5B527B83188A4EA28218A831D2E530614DB8CF1F142EE25BA8270A64
5A2AD2FA81DD2BEDEC33162AA8EDE3CE220D5DB44F3B8AD253A60ACEF6BB8F24A6596A9DC61AA7CB68A30088815D4154E416A1A5646EEC578FA6354AF1B10E29
5372C627736C33212D53CCEB30381634097F19A77CF29692499633C562C00C1123FCCD2C34CA79C2AA020061281D111A4D3BADDBD613531C7226C488075226AF
36CDF57E13BB0C8024601325103161E8AC6AD62EEB0CC00D931CDBA7DBFB2C3D33CC163A071E38002AE00DB6C57CEBB34C2693840183D714C710061A99543E32
DF0F29430C319A54EEB926C3108338E60FF5391F8D4691AEFAEAFB0404003B}}
\par\par \b \uc2 Alfa Scientific Designs, Inc\uc2 . to  \highlight22\uc2 Introduce New Products \highlight\uc2  and Driven Flow[TM] Technology During Exhibition Events in August.\b0\par\par\uc2 498 \uc2 words\par \uc2 13 July 2016\par \uc2 PR.com (Press Releases)\par \uc2 PRCOM\par NA\par \uc2 English\par \uc2 2016 Content Enterprises, Inc. \par \par \uc2 Poway, CA, July 13, 2016 --(PR.com)-- \uc2 Alfa Scientific Designs, Inc\uc2 ., a leader in the development and manufacture of rapid immunoassay point-of-care tests, will be introducing its newest products featuring Driven Flow[TM] Technology during August at summer tradeshow events across the U.S. While attending the 68th \uc2 American Association for Clinical Chemistry (AACC)\uc2 , ALFA will be introducing new Instant-view-PLUS[TM] products. Instant-view[R] over-the-counter (OTC) home tests with \uc2 FDA\uc2  510(k) clearances will be presented at the \uc2 National Association of Chain Drug Stores\uc2 ' (NACDS) Total Store Expo (TSE).\par \par \uc2 "We're thrilled to attend TSE for the first time," said ALFA's General Manager, Chai Bunyagidj. "TSE presents a great opportunity for us to offer our Instant-view[R] OTC products to the retail market, and also to expand our brand recognition to a wider audience."\par \par \uc2 ALFA will introduce its over-the-counter home tests during the expo's Meet The Market program on August 6. Products being showcased throughout TSE in booth #2929 include:\par \par \uc2 &#8226; Instant-view[R] pregnancy test\par \par \uc2 &#8226; Instant-view[R] ovulation test\par \par \uc2 &#8226; Instant-view[R] immunochemical Fecal Occult Blood (iFOB) test\par \par \uc2 &#8226; Instant-view[R] Push button Multi-drug Urine Test cup\par \par \uc2 Prior to TSE, ALFA, a member of the Pacific Southwest Minority Supplier Development Council (PSWMSDC), will be both sponsor and exhibitor at the Council's "Success through Synergy" Business Conference and Opportunity Fair. Conference attendees can interact with the ALFA team on August 2, at the Talking Stick Resort in Scottsdale, Arizona. "Promoting and supporting minority-owned, small businesses is a core value for ALFA, and we are proud to participate in this event," says ALFA's CEO, \uc2 Naishu Wang\uc2 .\par \par \uc2 Concurrently, ALFA will be showcasing its recently patented Driven Flow[TM] Technology featured in two new products at AACC during the Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, PA, at the Pennsylvania Convention Center. ALFA will exhibit in booth #3913, August 2-4, 2016.\par \par \uc2 To learn more, visit {\field{\*\fldinst{HYPERLINK "http://www.alfascientific.com/"}}{\fldrslt{\cf2 \uc2 http://www.alfascientific.com/}}}\uc2  and {\field{\*\fldinst{HYPERLINK "http://tse.nacds.org/"}}{\fldrslt{\cf2 \uc2 http://tse.nacds.org/}}}\uc2  and {\field{\*\fldinst{HYPERLINK "http://events.jspargo.com/AACC16/Public/Enter.aspx"}}{\fldrslt{\cf2 \uc2 http://events.jspargo.com/AACC16/Public/Enter.aspx}}}\uc2  and {\field{\*\fldinst{HYPERLINK "http://www.pswmsdc.org/calendar/business-conference-opportunity-fair/"}}{\fldrslt{\cf2 \uc2 http://www.pswmsdc.org/calendar/business-conference-opportunity-fair/}}}\par \par \uc2 About \uc2 Alfa Scientific Designs, Inc\uc2 .\par \par \uc2 Celebrating its 20th anniversary in 2016, \uc2 Alfa Scientific Designs, Inc\uc2 ., is a leader in the development and manufacturing of rapid immunoassay point-of-care tests. It offers a broad range of services, including contract product development, technology transfer, OEM services, custom assembly, and packaging with private labeling, all performed in the U.S.A. Established in 1996, ALFA develops breakthrough designs produced to the highest quality standards. The ALFA Product line is \uc2 U.S. FDA\uc2  Regulated and ISO Certified. For more information, visit {\field{\*\fldinst{HYPERLINK "http://www.alfascientific.com/"}}{\fldrslt{\cf2 \uc2 http://www.alfascientific.com/}}}\uc2 .\par \par \uc2 Contact Information:\par \par \uc2 Alfa Scientific Designs\par \par \uc2 Jeanette Christian - Marketing Communications\par \par \uc2 858-413-1276\par \par \uc2 Contact via Email\par \par {\field{\*\fldinst{HYPERLINK "http://www.alfascientific.com"}}{\fldrslt{\cf2 \uc2 www.alfascientific.com}}}\par \par \uc2 Read the full story here: {\field{\*\fldinst{HYPERLINK "http://www.pr.com/press-release/679130"}}{\fldrslt{\cf2 \uc2 http://www.pr.com/press-release/679130}}}\par \par \uc2 Document PRCOM00020160715ec7d0002j\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 InVivo Therapeutics Files 8K - Regulation FD >NVIV\b0\par\par\uc2 274 \uc2 words\par \uc2 12 July 2016\par 08:07\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 InVivo Therapeutics Holdings Corp\uc2 . (NVIV) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on July 12, 2016.\par \par \uc2 On July 12, 2016, InVivo Therapeutics, Inc. (the "Company") issued a press release announcing an update on its INSPIRE study of the Neuro-Spinal Scaffold as well as \uc2 FDA\uc2  approval of expansion of the INSPIRE study to 20 evaluable patients. A copy of this press release is attached hereto as Exhibit 99.1. In addition, on July 12, 2016, the Company posted an updated corporate presentation in the "Investor Relations" section of its website at {\field{\*\fldinst{HYPERLINK "http://www.invivotherapeutics.com"}}{\fldrslt{\cf2 \uc2 www.invivotherapeutics.com}}}\uc2 .\par \par \uc2 The information included in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1292519/000110465916132160/a16-14783_18k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1292519/000110465916132160/a16-14783_18k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1292519/000110465916132160/0001104659-16-132160-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1292519/000110465916132160/0001104659-16-132160-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 12, 2016 08:07 ET (12:07 GMT)\par \par \uc2 Document DJDN000020160712ec7c001ds\par }\page {\par\fs20\b \uc2 Lannett  \highlight22\uc2 introduces \highlight\uc2  generic Paxil tablets in US market\b0\par\par\uc2 148 \uc2 words\par \uc2 11 July 2016\par \uc2 FinancialWire\par \uc2 FNWIR\par \uc2 English\par \uc2 \u169\'00\'A9 2016 FinancialWire. All rights reserved. \par \par \uc2 Pharmaceutical products company \uc2 Lannett Company\uc2  (NYSE:LCI) disclosed on Monday the receipt of approval from the \uc2 US Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) of its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) for Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg in the market.\par \par \uc2 This product is the therapeutic equivalent to the reference listed drug, Paxil CR Extended-Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg, of Apotex Technologies, the company said.\par \par \uc2 In 2015, the total US sales of Paroxetine Extended Release-Tablets USP, 12.5 mg, 25 mg and 37.5 mg, at Average Wholesale Price (AWP), were about USD122m, according to IMS.\par \par \uc2 In conjunction with the \uc2 FDA\uc2  approval, the company said it has begun shipping Paroxetine Extended Release Tablets to patients suffering from depression.\par \par \uc2 ((Distributed by M2 Communications {\field{\*\fldinst{HYPERLINK "http://www.m2.com"}}{\fldrslt{\cf2 \uc2 www.m2.com}}}\uc2 ))\par \par \uc2 Document FNWIR00020160711ec7b002jp\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw130\pich40\picscaley100\picscalex100\picwgoal1950\pichgoal600
47
494638396182002800F72000BFD8E72076AB609DC3106CA5CFE1ED9FC4DB3080B170A7C99F9F9FAFCEE15093BDEFF5F9DFEBF3BFBFBF7F7F7F000000DFDFDF40
4040CFCFCF8FBAD58F8F8FAFAFAF303030202020505050101010606060EFEFEF7070707FB0CF4089B700629FFFFFFF0000000000000000000000000000000000
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
0000000000000000000000002C790000FF00000000000000ECF51200A06AF7770904000000105F2DD8235F2D2C790000FF00000000000000A099010004060403
2CF61200010000002C79000000005F2D010000000300000098F5120070F5120000F61200F4F51200D42CF977F8D4F97767696600B4F512006D89F87700005F2D
2C79000000005F2D0000000004F61200D564F77700005F2D0100000002000000D8F512002C790000FF00000000000000A09901004CF61200D42CF97700105F2D
FFFFFFFFCCF512002966F77754F61200D42CF97770D2F977FFFFFFFF1CF612009964F77700005F2DB0305F2D44F612000000000064F61200BE47F17700005F2D
B0305F2D44F6120064F612000000130019F2F87724000000800C130000001300D80E17003CF61200C4F6120064F71200D42CF97760D8F977FFFFFFFF28F71200
5447F677800C130010031E000800000044FA1200FF000000F8EBFD7F0A00000000ECFD7F6AA9E7770000000000ECFD7F0A000000C4F61200FF00000000000000
10031E00765B4800CAD0470053031E00ABA9420000005F2D2C790000685B4800FF000000C1AA42002C790000685B4800FF00000053031E003DF71200A9DC4100
2C79000010031E00000000005CFB1200885FE877430000000E00000043000000CD0000002A2E6769663B2A2E626D703B2A2E6A70200100006A7065673B2A2E74
74F71200AA28F07700001300080004001801000010031E0000000000000000000000000000000000C4C04400120F170074741500160F170082FA1200FFFFFFFF
D80E17002EC14400120F170021F90401000020002C00000000820028000008FF003F081C28700108101D087EF070B0A1C387100F2AEC10B1A2C58B10132AC4C8
B123088503271CD43890A1C7830904349C78B2A54592035DCA9408F28381910A4D724C3940E04A8214670A85E95368CB9A021920CCD931C1469A03831A7549F4
C3D493483F8824AAF322D1AB60713E0D7B31EB4DAE20527A1868C0C304831DD602ED50A0835DBB000E2E98A0C080C0006E9532B87B37AD5C910D0B08906B5301
5C90643166FD7080AB80C901B2321648773265009E0512D80CD243D5C865B306E04A500000BFA1172ABCAC704066A0B1891E00705BE001C8A82B7A569093B052
A28B2776F6CC6041CF81BDA312984DB8C37182A4AD068F181B3B08001D1478FFF010FD03F8B19E6F82C8FE7473D004E1C747CFBE9DBB42E29AA74F3E4FF0A7E6
83B46575907B0494971370F539045201983DF75779FCC5041552260588D480AD39F8207608263861411A4E46C052044558D44793A9C75E7FEB6535C088BF95D4
A18790593819800A99B890020C1214E2070438479081182215C041B009449F87FEC5E4546C06E057E20435E9F6E382C0AD285094078EC52470577607807E134D
D463560580D6DE90A12DC9248A2CDA58928D490A9457952CF186D400DF650994946C71E8A587D5054540A176150082781EB8069E712028365EA3130C46585E28
1D30A90707247090A5841D54D75D7915C0A800043C9A68A16F0EB8A9078A82FFA0E9AB076CF7EAADE38DD86A822005955D5764C586E9AEDBF55AA477C1094B6C
7DC6B6C854B2A10DBB2C58BCC9E96B690D0130C15D05E8EA1003DB76E0290300945BEE8702396AAE410BC077D70498A66A2E004A954BEEBC06A9AAEBA17679DB
1001E116A0D4A7F3E695EAA10A00AAA45D069A64E00701788A234106D888EE0752E925A7407C9276006CA425409A4A39199456C323EA36100302543519435A7E
A0129C37D24C61CC226BA6509D81B214634D2FBA7C62774AFE9C55026A7A76716DF7012A9ECE44FBF8E44021AE26E0D248F1AC809E43DAD801954F8536C0AB13
020635D546F74CF14660AB8D60D420E5D53674141F5B549BFF9ADB2576E179FFED6C49676605C0D4467620807A36C37D50D214DAAD5D9B2C87295BDD4D62FCB7
928CC34D90C90AB274F9857DBEECF8C5191320B992CF7E4811691E64AEF9899D03E5784D4A115E9349A491EE10A003A4B9B792B173F679EBA1219A3B44CDC62C
90A769DBE4E3E0C055193C651FB23EFDEA39B90ED902D51DFF50F2A54537C00121F2189BEE95473CF7E4255D3FBCEB0A03606379F6C9FEF94291BAA82B696387
DD2C4A401354FB2A873DECB82E7F7B3AD4A05CB5A958CD6A53B5028100CA63800E700E04FCA20BF7DA73AB58352401BD0940011EC8295A39E4558A2221A74643
3610448E62168C540B23532E7F2DAE3A1393D049C835B069E9654C3281C006FF1A20012236000212D88010917810087824738D9AD15410E0000720C02110B062
4310E0C42C5ED12312A0404320F0C52D0AB12216A0C00532308F0C5CA08D08B08005D68881396220021D094D04C3228179A8510314C0C010DFA8810A7020031A
28221B298080405251030888402429108106804003F39040243570010C542002868CC01D1DE0C487484002483422112100810A54A001AE74A52539F2B081CC2C
32F3684004E661815C36E0029414652F1BF0CB7944A097C634261BE7C1CC793860036DE4A4033820C7631ED3020EB8E3B21660AAF9EC663BA4A46205C4484610
18110108A8401629D0000750C00115B0623C25004F07A0928B1460273A11400ACF06A0B39D0E88484000003B}}
\par\par \b \uc2 Elanco offers cost-effective solution for E. coli\b0\par\par\uc2 Cheryl Day \par \uc2 386 \uc2 words\par \uc2 8 July 2016\par \uc2 National Hog Farmer\par \uc2 NHOG\par \uc2 National Hog Farmer\par \uc2 English\par \uc2 \u169\'00\'A9 2016 Penton Business Media. All rights reserved. \par \par \uc2 A major source of frustration and worry, Escherichia coli costs producers big bucks in the form of prevention, diagnosis, treatment, mortality and poor pig performance. Elanco Animal Health \b \highlight22\uc2 introduces\b0 \highlight\uc2  a new swine product, Kavault, for the reduction in incidence and overall severity of diarrhea in the presence of E. coli in weaned pigs.\par \par \uc2 As a solution for pigs up to 14 weeks of age, Kavault can be fed for 21 to 42 days to pigs at risk of developing, but not yet showing, clinical signs of diarrhea, Amanda Kephart, Elanco director of swine marketing, explained to the \b \highlight22\uc2 New Product\b0 \highlight\uc2  Tour panel, \u8220\'20\'1CKavault is an easy, cost-effective way to deliver more thriving pigs out of the nursery.\u8221\'20\'1D\par \par \uc2 [CHARTBEAT:3]\par \par \uc2 Avilamycin, a first-in-class orthosomycin antibiotic, is the active ingredient of Kavault. Kavault is an animal-use-only antibiotic and has never been used in humans. While Kavault is for animal use only, it is required to be administrated under a veterinary feed directive (VFD) because it is a newly approved therapeutic feed additive. Kavault features a zero-day withdrawal period.\par \par \uc2 Performance trials show Kavault significantly reduces the incidence of diarrhea in weaned pigs. Compared to the control, the diarrhea incidence rate for Kavault was 62.44% versus 90.79%.\par \par \uc2 For average daily gain, Kavault was 0.38 pound per day while the control was 0.29 pound per day. Kephart said, \u8220\'20\'1CIn the diarrhea scoring, a 50% reduction in diarrhea for the Kavault pigs was reported.\u8221\'20\'1D\par \par \uc2 As a fairly new product launched into the marketplace in February, it has been evaluated and implemented in production systems, Kephart said. Hog producers are finding Kavault performs well in swine herds with a history of E.coli.\par \par \uc2 As with any medication, the correct timing and dosage is critical to optimize the product. Kavault\u8217\'20\'19s main job is to keep the E. coli from attaching to the villi in the gut of the pig, so proper timing of Kavault medication will help ensure successful implementation.\par \par \uc2 The panel members acknowledge Kavault\u8217\'20\'19s narrow spectrum but identify it as a good solution for E. coli, especially at a time when antimicrobial options in the market are limited due to the new VFD regulations.\par \par \uc2 Visit {\field{\*\fldinst{HYPERLINK "http://kavault.com"}}{\fldrslt{\cf2 \uc2 kavault.com}}}\uc2  to learn more about Kavault.\par \par \uc2 Document NHOG000020160708ec780002y\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 BIND Therapeutics\uc2  Files 8K - Other Events >BIND\b0\par\par\uc2 1,156 \uc2 words\par \uc2 6 July 2016\par 08:01\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 BIND Therapeutics Inc\uc2 . (BIND) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on July 01, 2016.\par \par \uc2 On July 1, 2016, the Company filed a motion with the Bankruptcy Court (the "Stalking Horse Motion") seeking Bankruptcy Court approval of, among other things, (i) the Agreement (or any other purchase agreement between the Company and the prevailing bidder at auction) and the sale contemplated by the Agreement, and (ii) procedures to govern the bidding and auction process. The Stalking Horse Motion also requests that the Bankruptcy Court schedule the deadline for qualified overbids for 4:00 p.m. (Eastern Daylight Time) on July 22, 2016 and the date for the auction (if qualified bids are received) for July 25, 2016.\par \par \uc2 Subject to Bankruptcy Court and other regulatory approvals, if the Purchaser is selected as the successful bidder at the auction, or if no qualified competing bids are submitted, the Company expects that the Acquisition will close in the third quarter of 2016.\par \par \uc2 Forward-Looking Statements Disclaimer\par \par \uc2 This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the sale being conducted under the provisions of Section 363 of the Bankruptcy Code; the anticipated timing of the closing of the Acquisition; and the proposed timing of the bidding and auction process.\par \par \uc2 These forward-looking statements are based on management's current expectations. These statements are\par \par \uc2 neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: that the Acquisition may not be consummated in the timeframe the Company expects, or at all; that the Bankruptcy Court may not approve the Agreement or the sale contemplated thereby; that the timeframe of the bidding and auction process may differ from the timeframe requested in the Stalking Horse Motion; orders and decisions of the Bankruptcy Court; the Company's potential delisting from The \uc2 Nasdaq\uc2  Global Market; the fact that the Company has incurred significant losses since its inception and expects to incur losses for the foreseeable future; the Company's need for additional funding, which may not be available, in order to continue as a going concern; effects of adverse capital market conditions on the Company's liquidity; any default on the Company's credit facility, which could impact its ability to continue as a going concern; adverse effects on the Company's business due to the report of its independent registered public accounting firm on its financial statements for the year ended December 31, 2015, which contains an explanatory paragraph regarding the Company's ability to continue as a going concern; raising additional capital may cause dilution to its stockholders, restrict its operations or require it to relinquish rights to its technologies or drug candidates; the Company's limited operating history; limitations on the Company's ability to utilize net operating loss carryforwards and certain other tax attributes; failure to use and expand its MEDICINAL ENGINEERING (R) platform to build a pipeline of drug candidates and develop marketable drugs; the early stage of the Company's development efforts with only BIND-014 and Accurin AZD2811 in clinical development; failure of the Company or its collaborators to successfully develop and commercialize drug candidates; clinical drug development involves a lengthy and expensive process, with an uncertain outcome; delays or difficulties in the enrollment of patients in clinical trials; serious adverse or unacceptable side effects or limited efficacy observed during the development of the Company's drug candidates; inability to maintain any of the Company's collaborations, or the failure of these collaborations; inability to enter into a collaboration for BIND-014; the Company's reliance on third parties to conduct its clinical trials and manufacture its drug candidates; the Company's inability to obtain required regulatory approvals; the fact that a fast track or breakthrough therapy designation by the \uc2 FDA\uc2  for the Company's drug candidates may not actually lead to a faster development or regulatory review or approval process; the inability to obtain orphan drug exclusivity for drug candidates; failure to obtain marketing approval in international jurisdictions; any post-marketing restrictions or withdrawals from the market; effects of recently enacted and future legislation; failure to comply with environmental, health and safety laws and regulations; failure to achieve market acceptance by physicians, patients, or third-party payors; failure to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities; effects of substantial competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to retain key executives and attract, retain and motivate qualified personnel; difficulties in managing the Company's growth; risks associated with operating internationally, including the possibility of sanctions with respect to our operations in Russia; the possibility of system failures or security breaches; failure to obtain and maintain patent protection for or otherwise protect our technology and products; effects of patent or other intellectual property lawsuits; the price of our common stock may be volatile and fluctuate substantially; significant costs and required management time as a result of operating as a public company; and any securities class action litigation. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-Q filed with the \uc2 Securities and Exchange Commission\uc2 , or \uc2 SEC\uc2 , on May 10, 2016, and our other reports filed with the \uc2 SEC\uc2  could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report. Any such forward-looking statements represent management's estimates as of the date of this Current Report. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Current Report.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1385228/000119312516642027/d146586d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1385228/000119312516642027/d146586d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1385228/000119312516642027/0001193125-16-642027-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1385228/000119312516642027/0001193125-16-642027-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 July 06, 2016 08:01 ET (12:01 GMT)\par \par \uc2 Document DJDN000020160706ec76001d0\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Creating and Executing a Successful  \highlight22\uc2 New Product \highlight\uc2  Market Entry for Diabetes Therapies\b0\par\par\uc2 302 \uc2 words\par \uc2 4 July 2016\par \uc2 Diabetes Week\par \uc2 DBWK\par 20\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Diabetes Week via NewsRx.com \par \par \uc2 2016 JUL 4 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Despite all the pressures facing the pharmaceutical industry, product \b \highlight22\uc2 launches\b0 \highlight\uc2  continue across multiple therapeutic areas - including \b \highlight22\uc2 new drugs\b0 \highlight\uc2  for diabetes. For crowded therapeutic areas like diabetes, the \b \highlight22\uc2 launch\b0 \highlight\uc2  landscape is a particularly difficult one that requires sound strategies and execution to successfully navigate.\par \par \uc2 In a wide-ranging research project that explores the pivotal success factors and failure points facing \b \highlight22\uc2 new product launches\b0 \highlight\uc2 , \uc2 Best Practices, LLC\uc2  established a critical core set of factors that can make or break a market entry for metabolic products as well as other types of therapies.\par \par \uc2 The report, Success Factors and Failure Points in Metabolic Product Launches, examines key launch issues and offers launch leaders two perspectives: a metabolic/diabetes segment and a total benchmark class segment. The study presents a framework for launch success: the ability to differentiate, a defined target patient population, investment in launch activities, engagement of thought leaders, education of key stakeholders, demonstration of value, utilization of new technologies and avoidance of launch pitfalls.\par \par \uc2 In addition to delivering qualitative and quantitative insights on each aspect of this launch framework, the report presents launch leaders' perspectives on the current and future risk levels for an array of pitfall factors that can affect a launch.\par \par \uc2 Best Practices, LLC\uc2  used both field surveys and interviews to complete this study. In all, 44 managers and executives at 38 leading bio-pharma companies participated in the survey. In-depth interviews were conducted with leaders from six organizations who have decades of experience with pharma launches.\par \par \uc2 Keywords for this news article include: Diabetes, \uc2 Best Practices Llc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document DBWK000020160704ec7400003\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Viral Inactivation Market by Product, Application, Method & End User - Global Forecast to 2021\b0\par\par\uc2 715 \uc2 words\par \uc2 29 June 2016\par 19:06\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 NEW YORK, June 29, 2016 /PRNewswire/ -- The global viral inactivation market is projected to reach USD 573.0 million by 2021 from USD 320.5 million in 2016, at a CAGR of 12.3% from 2016 to 2020. The major drivers for the market include increase in pharmaceutical and biological industries and increasing number of \b \highlight22\uc2 new drug launches\b0 \highlight\uc2 . Over the years, the number of drug approvals in North American countries has increased from 2006 to 2015. In 2015, the FDA's Center for Drug Evaluation and Research - approved 45 novel drugs, approved as new molecular entities - under \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Applications - or as new therapeutic biologics under Biologics License Applications - as compared to 22 novel drugs approved in 2006. The increasing number of drug approvals will boost the viral inactivation market.\par \par \uc2 According to \uc2 OECD\uc2  estimates, in 2011, the total number of biotechnology companies in the U.S. was 7,970, followed by Spain -, and France -. Owing to the rise in the number of biotechnology companies, biopharmaceutical production has increased globally. Viral inactivation is carried out at all levels of pharmaceutical and biopharmaceutical manufacturing process to minimize the risk of product contamination. Growth in pharmaceutical and biotechnology industries will drive the growth of the viral inactivation market.\par \par \uc2 This report segments the global viral inactivation market is segmented based on method, product, application, end user, and geography. The method segments included in the report are solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.\par \par \uc2 The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.\par \par \uc2 The application segments included in the report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics.\par \par \uc2 Based on end user this market is categorized into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users.\par \par \uc2 The geographic segments included in this report are Asia, Europe, North America and the Rest of the World -. North America is further divided into Canada and the U.S. Asia is further divided in to China, Japan, India, and Rest of Asia.\par \par \uc2 The report provides qualitative insights on key market shares, growth rates, and market drivers for all important subsegments. It maps market sizes and growth rates of each subsegment and identifies segments poised to see rapid growth. The report also includes company profiles of market leaders. These company profiles include the financial performances, product portfolios, and developments of each company. The report also provides a competitive landscape of the viral inactivation market. The competitive landscape covers the growth strategies adopted by industry players over the last three years. It also includes analyses of industry developments like mergers and acquisitions, agreements and partnerships, and new product launches.\par \par \uc2 Reasons to Buy the Report:\par \par \uc2 The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.\par \par \uc2 The report provides insights on the following:\par \par \uc2 -- Product Development/Innovation: Product portfolios of top players in the viral inactivation market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the viral inactivation market\par \par \uc2 -- Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of leading players in the viral inactivation market\par \par \uc2 -- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various viral inactivation products across geographies\par \par \uc2 Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the viral inactivation market\par \par \uc2 Read the full report: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com/p03940172-summary/view-report.html"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com/p03940172-summary/view-report.html}}}\par \par \uc2 About Reportlinker\par \par \uc2 ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.\par \par {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 __________________________\par \par \uc2 Contact Clare: clare@reportlinker.com\par \par \uc2 US: (339)-368-6001\par \par \uc2 Intl: +1 339-368-6001\par \par \uc2 To view the original version on PR Newswire, visit:{\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/viral-inactivation-market-by-product-application-method---end-user---global-forecast-to-2021-300292407.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/viral-inactivation-market-by-product-application-method---end-user---global-forecast-to-2021-300292407.html}}}\par \par \uc2 SOURCE Reportlinker\par \par \uc2 Web site: {\field{\*\fldinst{HYPERLINK "http://www.reportlinker.com"}}{\fldrslt{\cf2 \uc2 http://www.reportlinker.com}}}\par \par \uc2 Document PRN0000020160629ec6t000mq\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Kitov says on track to file NDA for KIT-302 at end of 2016\b0\par\par\uc2 115 \uc2 words\par \uc2 28 June 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Kitov Pharmaceuticals\uc2  announced that Dexcel Pharma, Kitov's manufacturing partner, has successfully completed an initial stability study for its lead drug candidate KIT-302. This achievement follows Kitov's announcement in May that Dexcel completed manufacturing pivotal batches of KIT-302. Additional stability studies required for the \b \highlight22\uc2 new drug\b0 \highlight\uc2  application, or NDA, are ongoing. "The successful completion of KIT-302's pivotal batch initial stability study brings KIT-302 one step closer to NDA submission and market \b \highlight22\uc2 launch\b0 \highlight\uc2 ," stated Kitov CEO Isaac Israel. Kitov is on track to file NDA for KIT-302 at the end of 2016, the company stated.\par \par \uc2 Document FLYWAL0020160628ec6s004ms\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic Avodart capsules\b0\par\par\uc2 183 \uc2 words\par \uc2 24 June 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan (MYL) announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Dutasteride Capsules, 0.5 mg, the generic version of \uc2 GlaxoSmithKline\uc2 's (GSK) Avodart Capsules. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate. Dutasteride Capsules, 0.5 mg, had U.S. sales of approximately $297.2M for the 12 months ending April 30, according to \uc2 IMS Health\uc2 . Currently, Mylan has 248 ANDAs pending \uc2 FDA\uc2  approval representing $107.6 billion in annual brand sales, according to \uc2 IMS Health\uc2 .\par \par \uc2  Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $37.2B in annual brand sales, for the 12 months ending December 31, 2015, according to \uc2 IMS Health\uc2 .\par \par \uc2 Document FLYWAL0020160624ec6o005eh\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw2\pich2\picscaley100\picscalex100\picwgoal30\pichgoal30
47
494638376102000200F70000000000800000008000808000000080800080008080C0C0C0C0DCC0A6CAF0402000602000802000A02000C02000E0200000400020
4000404000604000804000A04000C04000E04000006000206000406000606000806000A06000C06000E06000008000208000408000608000808000A08000C080
00E0800000A00020A00040A00060A00080A000A0A000C0A000E0A00000C00020C00040C00060C00080C000A0C000C0C000E0C00000E00020E00040E00060E000
80E000A0E000C0E000E0E000000040200040400040600040800040A00040C00040E00040002040202040402040602040802040A02040C02040E0204000404020
4040404040604040804040A04040C04040E04040006040206040406040606040806040A06040C06040E06040008040208040408040608040808040A08040C080
40E0804000A04020A04040A04060A04080A040A0A040C0A040E0A04000C04020C04040C04060C04080C040A0C040C0C040E0C04000E04020E04040E04060E040
80E040A0E040C0E040E0E040000080200080400080600080800080A00080C00080E00080002080202080402080602080802080A02080C02080E0208000408020
4080404080604080804080A04080C04080E04080006080206080406080606080806080A06080C06080E06080008080208080408080608080808080A08080C080
80E0808000A08020A08040A08060A08080A080A0A080C0A080E0A08000C08020C08040C08060C08080C080A0C080C0C080E0C08000E08020E08040E08060E080
80E080A0E080C0E080E0E0800000C02000C04000C06000C08000C0A000C0C000C0E000C00020C02020C04020C06020C08020C0A020C0C020C0E020C00040C020
40C04040C06040C08040C0A040C0C040C0E040C00060C02060C04060C06060C08060C0A060C0C060C0E060C00080C02080C04080C06080C08080C0A080C0C080
C0E080C000A0C020A0C040A0C060A0C080A0C0A0A0C0C0A0C0E0A0C000C0C020C0C040C0C060C0C080C0C0A0C0C0FFFBF0A0A0A4808080FF000000FF00FFFF00
0000FFFF00FF00FFFFFFFFFF21F90400000000002C000000000200020000080600FF09FC1710003B}}
\par\par \b \uc2 Nevro Corp\uc2  at JMP Securities Life Sciences Conference - Final\b0\par\par\uc2 4,209 \uc2 words\par \uc2 21 June 2016\par \uc2 CQ FD Disclosure\par \uc2 FNDW\par \uc2 English\par \uc2 \u169\'00\'A9 2016 by CQ-Roll Call, Inc. All rights reserved. \par \par \uc2 Presentation\par \par \uc2 DAVID TURKALY\uc2 , ANALYST, JMP SECURITIES: Next up -- our next company up is one of my favorites, Nevro. Obviously for those that have spoken to me, you know this is the steepest \b \highlight22\uc2 new product\b0 \highlight\uc2  ramp \b \highlight22\uc2 launch\b0 \highlight\uc2  that I have modeled in my career. So, very pleased to have these guys here.\par \par \uc2 We're going to do a fireside chat. I would certainly encourage people if you have some questions to ask them as well. But to kick it off, we have \uc2 Andrew Galligan\uc2 ; he is the CFO of the Company.\par \par \uc2 I guess I will start off up front here first. You just completed that convert round. You still have a decent amount of cash on the balance sheet. I guess would just like your thoughts on sort of the primary uses of that. Is it primary to build out the selling efforts, or any color on that capital raise?\par \par \uc2 ANDREW GALLIGAN\uc2 , CFO, NEVRO CORP.: Thanks, Turk, and thank you all for being here this morning.\par \par \uc2 Throughout our history, we have always raised cash when we didn't need it. And we have raised cash when we had a lot of cash on our balance sheet, both really as a private Company throughout our history, which has always allowed us to make long-term decisions without really thinking to the balance sheet.\par \par \uc2 And I think we also looked recently -- and clearly a group of gnomes somewhere decided that the medical sector was risk off in the first quarter where you couldn't have raised money. And then suddenly the same gnomes decided that the sector was risk on recently, and it was back to a good financing environment.\par \par \uc2 So, you step back from that, and it reinforces the best time to raise money is when you don't need it. It's because when you need it, the market may not be there.\par \par \uc2 So, that is the basic thing. We never want to be in a situation where we are having to compromise a long-term decision because of the financing need. So we put that away. We are now very well-financed. We have always said that we -- even without this financing, that we had sufficient cash to get us through to cash flow breakeven, albeit that the size of our ramp will put pressure on our cash resources. So, we don't ever want to be in the position where we are compromising between long-term investment opportunities and our need to short-term build the sales force.\par \par \uc2 So, at the end of the day, we actually believe in having a fortress balance sheet and have had the great ability throughout our history to have that. And I think you can see the results of having that ability to concentrate on what is good for the long-term business in our recent performance, and we intend to continue that way.\par \par \uc2 DAVID TURKALY\uc2 : Then as you look at CapEx or additional investments, what are the big buckets? It would seem to me like the sales and marketing might be one of the bigger investments that you need to make given your model. But is there anything else we should be considering as we look at the next couple of years and all that cash that you now have?\par \par \uc2 ANDREW GALLIGAN\uc2 : I think, yes, obviously it will allow us to ramp faster in the sales and marketing area, though I have to caution that the real barrier to growth there is time. Just the ability to hire, train and integrate people into the organization, always remembering that, particularly in our industry, our person in the field is very intricately involved in the doctor's practice. We both help the doctor determine is the patient -- is the right patient for SCS? We educate those patients. We are in the OR. We are programming each individual patient.\par \par \uc2 So, the quality of the person that we hire in the field is incredibly important to our progress and our growth in the market. Because if we put a bad person in that position, that could actually do a lot of long-term damage to our business in that individual account. So, we really have a very disciplined approach to hiring people to make sure that we get the right person into those accounts.\par \par \uc2 DAVID TURKALY\uc2 : And (multiple speakers) -- go ahead.\par \par \uc2 ANDREW GALLIGAN\uc2 : Beyond that -- so, we have only just scratched the surface of what we believe our therapy can bring to patients in leg and back pain. It is very clear from the fact that we have been now commercial internationally for going on six years that our therapy actually has potential efficacy for a broader patient cohort than just back and leg pain.\par \par \uc2 So, I think over the years ahead, we have incredible opportunities to expand our therapy to other groups of patients in desperate need. And those are clinical trials -- both pilot trials, feasibility studies and then finally \uc2 FDA\uc2  trials that we will undertake over time. And we want to continue to invest rapidly in those areas.\par \par \uc2 DAVID TURKALY\uc2 : You mentioned time being sort of a barrier to growth. Just remind us how long you think it takes for you to get a rep up and running. And then are these people still finding you? I would imagine given the story and the trajectory around it, that that would be the case. But any color around how these people are coming into Nevro?\par \par \uc2 ANDREW GALLIGAN\uc2 : Well, one of our first effective recruiting opportunities are our quarterly earnings calls. You may actually think that we are designing what we say for investors, but actually the primary people we're talking to are our competitive reps. And it is amazing how many reps that we interview from our competitors actually come in fully versed on what we said at the last earnings call.\par \par \uc2 DAVID TURKALY\uc2 : I thought it was for us. I thought it was for me. (laughter)\par \par \uc2 ANDREW GALLIGAN\uc2 : (laughter) But you go ahead and believe that, Turk.\par \par \uc2 DAVID TURKALY\uc2 : (laughter) I will.\par \par \uc2 ANDREW GALLIGAN\uc2 : That we are now seeing a lot of the more conservative competitive reps who are turning up for interview who frankly have said, a year ago, a lot of my colleagues moved over to Nevro, but that wasn't a move that I would have felt comfortable making then.\par \par \uc2 And then I think people are now beginning to see that we are real; we are having a real impact on patients' lives. And we appeal to that rep who believes in bringing new hope to patients, that is really bringing the promise of spinal cord stimulation to patients. And those are the people we are interested in.\par \par \uc2 We are interested in people that really feel for the patients because, again, we program individual patients. We want people that are really motivated by the fact that we change people's lives. We take severely disabled people and we give them their lives back. It's important work, and it's a lot of work to do what we ask people to do, and it's important that they are motivated by the right reasons.\par \par \uc2 Your next question was, we've talked about 15 to 18 months for somebody to get upscale. And we've talked about that we believe that a rep in the field can get to about $1.3 million to $1.5 million.\par \par \uc2 I think at the last earnings call we are also very clear that if you look at the waterfall of hirings -- people we have hired -- and you apply those metrics to it, you can't quite reconcile to our revenue. Our revenue is ahead of that. But we have cautioned people that that 15 to 18 months and $1.3 million to $1.5 million is more of a long-term model. And that today we believe that what we are seeing is more of the early-adopter doctors who have taken up our therapy. And they perhaps move faster along the continuum to getting to be 80% of their practice, where we have 80% of their practice. And that as over time when we move into the middle majority of doctor, we believe that some of those doctors, just because they tend to be more conservative, will take a little longer to move along that continuum. And, therefore, I think while we may have overshot those productivity metrics at the moment, we believe in a long-term model that they are the appropriate.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: Do you mean by that -- do you mean those doctors are not (inaudible) right now, or they are -- you said they are familiar with the technology. It seems that that conversion shouldn't be that difficult.\par \par \uc2 ANDREW GALLIGAN\uc2 : No. I'm saying -- as I said, there are doctors that do five to 10 patients and after a month or two are, oh my God, I am all in. It just would be unethical to do any other patient with anything else. I'm all in.\par \par \uc2 Then you have the more middle-majority doctor that is calm, cautious and takes his time. He will do five to 10 patients. He will wait for three months. He will confirm that it is what we said it is and that actually that their therapy is stable.\par \par \uc2 But then he won't go to 100%. He will go, that's very good, those patients worked really well. Now let me make sure that it wasn't patient selection that really got me there. I will do another five or 10 patients.\par \par \uc2 So, a lot of doctors, appropriately, are very conservative. They take time to change. Patients' lives are at stake here. They are cautious. So those doctors take a little longer. We believe from our international experience that they will eventually get to where they are, as we call it, all in. It will just take longer. So those are the difference.\par \par \uc2 But typically we do not -- in our -- we've got a control launch. We don't go after doctors that really don't do SCS. We're going after experienced SCS doctors. Yes?\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: How did you initially come off that 15 to 18 months and 1.3 to 1.5 (inaudible). Can you just walk me through how you kind of got to those numbers (inaudible)?\par \par \uc2 ANDREW GALLIGAN\uc2 : Sure, pretty easy. We have been in the international markets for five years, going on six years, so we actually have the benefit of a lot of experience about what caseload a rep can actually handle and how long it takes to get there.\par \par \uc2 The caveat, of course, is there are international markets that aren't perfect stand-ins for the US market. But that is really where we got our first numbers from. That's why we went out 18 to 24 months -- initially 1.3 to 1.5. Then I think the US market is moving a bit faster, so we brought that down to 15 months to 18 months.\par \par \uc2 So, over time, we will make adjustments to that model for the peculiarities of the US marketplace where doctors, I think, are a little more economically driven perhaps in the US than they are in the international markets.\par \par \uc2 DAVID TURKALY\uc2 : Have you seen, I guess, patients play any role to date? In med tech, we don't usually think of that as being a big driver. But any word-of-mouth recommendations, I guess? We attended that conference recently in New York. They preferred the charging. They preferred that they didn't have to adjust the therapy very frequently. Obvious, the pain reduction benefits are there. I haven't seen any direct-to-consumer efforts as of yet as well, but I'm curious if you are planning on that. And are you seeing any of the patient pull-through come in?\par \par \uc2 ANDREW GALLIGAN\uc2 : Let me put that question aside and go to more of our plan. Our plan is -- this is a stage-control rollout. Our first objective isn't actually to skip over the doctor and go to the patient. It is, in fact, to make the doctors one of our major selling resources.\par \par \uc2 So, our objective there is to take the power of the efficacy from our \uc2 FDA\uc2  trial and replicate it in everyday doctors' hands because that blows them away. Because they all have an expectation that, in their hands, it won't be quite as good as the \uc2 FDA\uc2  trial because those were -- there were inclusion and exclusion criteria that aren't really replicated in everyday life. So they have this expectation that in everyday life, there's a degradation from a clinical trial.\par \par \uc2 So, what we do is we do our best to replicate the \uc2 FDA\uc2  trial efficacy in their hands. We have the ability because we are so involved. We help -- we do the programming under the doctors' direction, but we are very involved with the patients. So we actually do have a hands-on impact on patient outcomes.\par \par \uc2 What we do with doctors is we show them, by showing them their own patients' data, how they are able to replicate the efficacy in the \uc2 FDA\uc2  trial. What that does is it makes those doctors some of our biggest proponents. So the step we are after at the moment is those doctors start talking to their colleagues about how they have to use this therapy, that it really is everything that the sales guys say it is. That is the most effective selling tool that we have is the doctors who are using our therapy become true believers in it and the impact it has on patients, and they talk to their colleagues about it.\par \par \uc2 Over time, I don't want to lose the (laughter), the actual patient point, we do have a major impact on patients. And over time, there will be, I think, a critical mass of those patients where it really does make sense for us to do a direct-to-patient.\par \par \uc2 But before that, we've got to have national coverage, which we don't have at the moment. Going back to our hiring plans, we said that we are going to hire a minimum of another 60 net -- 60 people this year, and we believe that that will allow us to have the majority of the geography of the US covered.\par \par \uc2 The last thing you want to do when you are doing direct-to-consumer is have consumers -- patients turn up at a doctor's office asking for something that they haven't heard of or aren't prepared to deal with. That's a bad thing.\par \par \uc2 So, everything in its time. We believe we are good at execution. We believe we are good at long-term planning because we concentrate on it, we value it. And so, everything in its time. Control launch, that's what we believe in.\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: (inaudible -- microphone inaccessible)\par \par \uc2 DAVID TURKALY\uc2 : That was my secret end-of-the-talk question there. But no, it's a good point. So, this doctor actually said as some of the patients are coming back because their battery has worn out on I'd say one of the three --\par \par \uc2 ANDREW GALLIGAN\uc2 : Key point there. So, the key point here is that in general, as a patient, you only get one SCS. However, at the end of battery life, you do have the ability to get replaced.\par \par \uc2 So it isn't like if you had a Boston SCS and you are three years in and it's not working for you, that you can really go to your insurance company and say, I want a different one. That's very difficult to do. However, if you come to the end of the battery life where the issue isn't that you've lost efficacy, the issue is that the battery has run out of its life, then you are actually able in general to get reimbursement. So this market has a lot of subtleties to it. That would be one.\par \par \uc2 So while it's an important area -- that rechargeables have been in the market now for close to 10 years. So they are -- in fact a lot of them coming up for replacement. So I wouldn't underestimate it as a market but --\par \par \uc2 DAVID TURKALY\uc2 : The other interesting point that -- I don't know -- people may be aware, may not -- you can swap out the cans. And I think the interesting comment was if the electrodes from the (multiple speakers) are in the right spot, you don't have to do anything other than swap the can out, again, at the end of the battery life. But -- and even if they are not exactly in the right spot, the comment was made that depending on where they are, they might be able to adjust it pretty easily.\par \par \uc2 ANDREW GALLIGAN\uc2 : Yes, that depends on scarring and a lot of other issues, yes. Yes?\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: To get to your growth projections going forward, is there a sense that -- do you think about (inaudible)?\par \par \uc2 ANDREW GALLIGAN\uc2 : Sorry, is that -- looking for dedicated and --\par \par \uc2 UNIDENTIFIED AUDIENCE MEMBER: (inaudible) do you think about that going forward?\par \par \uc2 ANDREW GALLIGAN\uc2 : Yes, both Rami and I in our prior history have been involved in direct-to-consumer. I was in the diabetes area for a long time, which is very much a direct-to-consumer.\par \par \uc2 So, yes, at the appropriate time, obviously social media is going to be a big part of that, and other ways of reaching out.\par \par \uc2 The thing that you have to remember is our therapy is not for everyone with back pain. We are talking about chronic, debilitating back pain. Our patients would be on a moderate to severe disability scale. The problem you have with undifferentiated consumer reach-out is everybody -- not everybody, but a huge proportion of the adult population has some form of back pain. And we've had this before where you have a newspaper article -- we have had a couple in the UK -- where a doctor thinks it's a great idea to go out and get his name in the Daily Mail or whatever. And suddenly, 2,000 people turn up in his waiting room, three of whom are appropriate for the therapy. And all of the rest have moderate, intermittent back pain. That's not what we treat.\par \par \uc2 So, there are a lot of subtleties to consumer outreach. But what you don't want to do is have your doctors' practices bombarded with patients that aren't appropriate. So, it has to be a very targeted message, and I think social media is perhaps, I think, specifically attuned to the type of outreach that we will have to do.\par \par \uc2 DAVID TURKALY\uc2 : And we know that the chronic pain is the focus. But it's also been interesting that we've seen data now on people who haven't had surgery. So, not just failed back surgery syndrome, but if you are a non-surgical candidate with back pain -- chronic back pain. So, it will be interesting. I know it's early today, but it sure seems like there's a lot of folks here and abroad that are interested in trying the therapy earlier in the paradigm than, say, the last stop before a drug problem.\par \par \uc2 ANDREW GALLIGAN\uc2 : Right. Dr. [Alkiza] from [Guy's and St Thomas'] in the United Kingdom had a very interesting paper at the World Institute of Pain in New York, I think, three or four weeks ago which showed -- I mean, it's a small cohort. It's only 21, 22 patients. But in the nonsurgical area, it's a younger population. These are working-age adults pretty typically, whereas the average population for mainline SCS is about -- averages about 59 in our trial, so it skews maybe a little older.\par \par \uc2 But so -- for the nonsurgical I think these are people that want to get back to work and it's really interesting, but in Dr. Alkiza's cohort, 75% of those people were able to return to work. Get off opiates and return to work. And that's outstanding.\par \par \uc2 So we have to, of course, replicate that in a much larger study. That was an isolated small number. We also have data from our \uc2 FDA\uc2  trial where there was a cohort of 10% of those patients that also were presurgical. And, in fact, in our European -- initial European trial, about 10% of those patients were presurgical. And they all show the same thing, which is when the patient is unencumbered with debilitating or rather all of the scarring and screws and everything else from a surgery, actually the therapy looks very effective. And it's actually easy to administer because you don't have the scarring and everything else. So that was very encouraging data. We've got a lot of work to do there, but it's, I think, a market with great promise.\par \par \uc2 DAVID TURKALY\uc2 : I guess just when I -- and we talked about capacity in the past. I know you outsource a lot of components. But just any comments on how many of these things you can make or how you see the investments you have with vendors today. Do you need more? Are you good to look out over the next three to five years? Do you think you can meet the demand if it even exceeds your forecast?\par \par \uc2 ANDREW GALLIGAN\uc2 : Right. Ignore us for a moment and just look at the market. The total market in the US today is about 50,000 units. In manufacturing terms, 50,000 units is not big at all. It is tiny. So that's part of the reason that drove us to an outsourced model in the first place, which is we are actually leveraging the investment that the outsource providers have in manufacturing equipment. Just think of a pick-and-place machine. A good one costs a few million dollars. If you are only making 10,000, 20,000, 30,000 units a year, they don't pay for themselves.\par \par \uc2 So, it actually makes sense to be outsourced. And we have a great partner in Greatbatch, and they have the scale to have the appropriate equipment, the investment in quality systems -- and, it is what they do. So they are experts in all of the various manufacturing procedures that we need. As a small company trying to make 10,000 or 20,000, or 30,000, how do you maintain the right area of expertise where they are continually keeping up to date? The way forward really is -- unless you've got massive scale, it really is outsourced.\par \par \uc2 Now, you need to deal with the issue of how do you from a security viewpoint deal with the fact that you have outsources. And it really is to go to dual sourcing to the extent that you can. And that really is where our big effort is in this area is to go dual sourced.\par \par \uc2 So the plain fact is from most of the vendors that we deal with, they would delight if we doubled, tripled, quadrupled our quantities because then we would get into more normal quantities. The great example I like to use is we have a remote control that patients use. Our vendor makes our annual supply of remote controls in one day. That's --\par \par \uc2 DAVID TURKALY\uc2 : That's amazing. I think we are actually -- we are about a minute over right now. Thank you again for coming.\par \par \uc2 ANDREW GALLIGAN\uc2 : Okay. Thank you very much.\par \par \uc2 [Thomson Financial reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.\par \par \uc2 In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in the companies' most recent \uc2 SEC\uc2  filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.\par \par \uc2 THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON FINANCIAL OR THE APPLICABLE COMPANY OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.]\par \par \uc2 Document FNDW000020160622ec6l001up\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Opko Health Files 8K - Regulation FD >OPK\b0\par\par\uc2 206 \uc2 words\par \uc2 21 June 2016\par 08:10\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Opko Health Inc\uc2 . (OPK) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on June 21, 2016.\par \par \uc2 On June 21, 2016, \uc2 OPKO Health, Inc\uc2 ., a Delaware corporation (the "Company"), issued a press release announcing that the \uc2 U.S. Food and Drug Administration\uc2  approved the Company's New Drug Application for RAYALDEE(R) (calcifediol) for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL.\par \par \uc2 A copy of the press release is attached hereto as Exhibit 99.1.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/944809/000129993316002648/htm_53713.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/944809/000129993316002648/htm_53713.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/944809/000129993316002648/0001299933-16-002648-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/944809/000129993316002648/0001299933-16-002648-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 21, 2016 08:10 ET (12:10 GMT)\par \par \uc2 Document DJDN000020160621ec6l001dz\par }\page {\par\fs20\b \uc2 Thermo Fisher Scientific Inc\uc2 . \uc2 Thermo Fisher Scientific\uc2  Strengthens Life Sciences Leadership with New Instruments  \highlight22\uc2 Launched \highlight\uc2  at ASMS 2016\b0\par\par\uc2 831 \uc2 words\par \uc2 17 June 2016\par \uc2 Obesity, Fitness & Wellness Week\par \uc2 OBWK\par 189\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Obesity, Fitness & Wellness Week via NewsRx.com   \par \par \uc2 2016 JUN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- \uc2 Thermo Fisher Scientific Inc\uc2 ., (NYSE: TMO), the world leader in serving science, strengthened its industry-leading analytical instruments platform with innovative systems designed to help pharmaceutical and biologics producers more efficiently discover and develop candidate drugs. These \b \highlight22\uc2 new products\b0 \highlight\uc2  will be on display at the 64th Annual American Society for Mass Spectrometry (ASMS) Conference, June 5-9 in Texas Ballroom D at the Grand Hyatt Hotel.\par \par \uc2 "The success of our innovation strategy is based on continuous collaboration with our customers," said \uc2 Marc N. Casper\uc2 , president and chief executive officer \uc2 Thermo Fisher Scientific\uc2 . "Our mission is to enable our customers to make the world healthier, cleaner and safer, and we are committed to providing them with the most advanced analytical technologies to help them facilitate research and accelerate discovery. This year's ASMS showing is another great example of how we continue to leverage our technology leadership to raise the performance bar and help our customers achieve their goals."\par \par \uc2 The new Thermo Scientific Q Exactive BioPharma MS/MS Hybrid Quadropole-Orbitrap mass spectrometer takes full advantage of the high-resolution, accurate-mass (HRAM) capabilities of the Orbitrap mass analyzer to enable key workflows for protein characterization in a single instrument. Combined with recommended sample preparation and analysis methods using Thermo Scientific reagents, columns, UHPLC and data processing technologies, the Q Exactive BioPharma system provides a comprehensive solution for customers performing biopharmaceutical characterization.\par \par \uc2 At ASMS, \uc2 Thermo Fisher\uc2  will also feature its new Thermo Scientific Vanquish Flex Binary UHPLC system, an ideal complement for pharmaceutical and biopharmaceutical laboratories performing qualitative and quantitative LC or LC-MS analysis. Built for high-speed and fast gradient applications, the Vanquish platform delivers outstanding reproducibility.\par \par \uc2 As part of its focus on innovation, \uc2 Thermo Fisher\uc2  will feature new technology from \uc2 908 Devices\uc2 , a pioneer in purpose-built analytical devices for chemical analysis. Customers using \uc2 Thermo Fisher\uc2 's mass spectrometers can now incorporate \uc2 908 Devices\uc2 ' breakthrough ZipChip microfluidics separation technology to deliver fast, high-quality separations that transform analysis of biomolecules.\par \par \uc2 Thermo Fisher\uc2  will also showcase high-profile collaborations through presentations and posters by notable scientists doing breakthrough work with its mass spectrometry technologies.\par \par \uc2 Dr. Willi Haas, assistant professor at Harvard Medical School, will present the Advances in Accurate, High-Throughput Quantitative Proteomics Breakfast Workshop. His approach combines Orbitrap HRAM MS and synchronous precursor selection (SPS)-based MS3 technology on the Thermo Scientific Orbitrap Tribrid MS system to accurately measure the smallest changes in low-abundance proteins.\par \par \uc2 Dr. Fan Liu from the Albert Heck Lab, Utrecht University, Netherlands, will present the Improved Workflows for Structural Proteomics Breakfast Workshop. Dr. Liu's lab is using Orbitrap technology for proteome-wide cross-linking mass spectrometry to chart the cellular interactome, the whole set of molecular interactions in a single cell.\par \par \uc2 Dr. Jennifer Abelin from the Eli and Edythe L. Broad Institute of MIT and Harvard will present High-throughput Profiling of HLA Allele-specific Peptides by MS for Improved Epitope Predictions at the Thermo Fisher Annual User Meeting. She will discuss her use of LC-MS/MS techniques to improve the understanding of antigen processing to identify peptides in diseases including cancer, inflammatory bowel disease and infectious diseases.\par \par \uc2 Dr. Akhilesh Pandey, John Hopkins University School of Medicine, will present Getting Ready for Clinical Proteomics at the Thermo Fisher Annual User Meeting. Dr. Pandey will discuss the emerging use of proteomics in a clinical setting. Dr. Pandey is best known for his groundbreaking research in the mapping of the human proteome {\field{\*\fldinst{HYPERLINK "http://www.humanproteomemap.org"}}{\fldrslt{\cf2 \uc2 http://www.humanproteomemap.org}}}\uc2 .\par \par \uc2 Finally, \uc2 Thermo Fisher\uc2  will recognize the winners of the 2016 Thermo Scientific Tandem Mass Tag (TMT) Research Awards, an international research grant for scientists and their work in proteomics.\par \par \uc2 Thermo Fisher\uc2  will be exhibiting in Booth 319 at the Henry B. Gonzalez Convention Center and in Texas Ballroom D at the Grand Hyatt Hotel in San Antonio. For more information please visit {\field{\*\fldinst{HYPERLINK "http://www.thermofisher.com/asms"}}{\fldrslt{\cf2 \uc2 http://www.thermofisher.com/asms}}}\uc2 . About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands - Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services - we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit {\field{\*\fldinst{HYPERLINK "http://www.thermofisher.com"}}{\fldrslt{\cf2 \uc2 www.thermofisher.com}}}\uc2 . View source version on businesswire.com: {\field{\*\fldinst{HYPERLINK "http://www.businesswire.com/news/home/20160606005391/en/"}}{\fldrslt{\cf2 \uc2 http://www.businesswire.com/news/home/20160606005391/en/}}}\par \par \uc2 Keywords for this news article include: Drugs, Therapy, Proteomics, Technology, Biopharmaceuticals, \uc2 Thermo Fisher Scientific Inc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document OBWK000020160617ec6h001wx\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw39\pich40\picscaley100\picscalex100\picwgoal585\pichgoal600
47
494638396127002800F700000000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC002BFF0055000055330055660055990055CC00
55FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D56600D59900D5CC00D5FF00FF0000FF3300FF
6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF3355003355333355663355993355CC3355FF
3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633D59933D5CC33D5FF33FF0033FF3333FF6633
FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655006655336655666655996655CC6655FF6680
006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D59966D5CC66D5FF66FF0066FF3366FF6666FF99
66FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF9955009955339955669955999955CC9955FF99800099
80339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5CC99D5FF99FF0099FF3399FF6699FF9999FF
CC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533CC5566CC5599CC55CCCC55FFCC8000CC8033
CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCCD5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCC
FFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF5566FF5599FF55CCFF55FFFF8000FF8033FF80
66FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FFFFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF
00000000000000000000000021F904010000FC002C00000000270028000008FF00F7091C48B0203D7AED88257447AFA0C3871005BA53486CD8398BBC78D9B2C5
AB61C48F03DD296BE76E58BB73BDCE650CC70B9C2D58B5DC8184484F64C976BD7A69B4E572A3AD5A3F5FD99A6990DEC8922859F6FC59ABD62BA74EFD789C6913
A9CEA54E5FBD4AA5B5AB563FCAA82A7367F59CCF9FB0BC6E5DAB1595D48F368759ECC591A7AD57DFD4A272B51715AA576EFD441C3BCC1D4E73747BD68299B6ED
5A54A95CF901ECA7D0C39A09519A05D7D26ED76C5DF7A6EAEBD78FE9610E0B9BECC5A810A345860AC9FE532B5BA12DA673E71EEDD72D9582F5DACDB505E3868C
1B316EE0B881BC4A711CD0972F8FA1A2B46F6204E5A274890362BD4C62EAEDFFD357309AB230A54D6F218852A74F8225A72A9BEA8E974C81CB7AFBA1F25B603D
5E2AF5F4CA2403D9E2C77A02D143A040065211CD406E0546452609DAD28B4B40BDD29D4099AC70C340ED3032D03031C410D63EF5A4B79F88FB0CB35350AF8841
9032CB0C14E383022973223D7CA5A74218025DC85356310E74504DBD0006A440ED0C35901F2A52B1C58374A1F5D592FB1402A57E310CC4082A140A34C996FB51
B14243BC64D8D501690CA4CC229145B6021A6EBA45901881F9A1C216D0EC932491A8C848902D7FF9352541804962646954EC19D6307A4952D3A4E0F486CA2264
21440F60A830A4506E8D8AD190325CBDE24A9CBD35DA282AAAEEA7027F2A98FFF6AA7EB03282E3645B9DDAA30A6940A323156F2C03CD245BE89889329AE0A063
84AEAA90097959FAA12B64A6C9684E2AC350F88D88BCD4F88A40B5844519AC301053638B5B527B83188A4EA28218A831D2E530614DB8CF1F142EE25BA8270A64
5A2AD2FA81DD2BEDEC33162AA8EDE3CE220D5DB44F3B8AD253A60ACEF6BB8F24A6596A9DC61AA7CB68A30088815D4154E416A1A5646EEC578FA6354AF1B10E29
5372C627736C33212D53CCEB30381634097F19A77CF29692499633C562C00C1123FCCD2C34CA79C2AA020061281D111A4D3BADDBD613531C7226C488075226AF
36CDF57E13BB0C8024601325103161E8AC6AD62EEB0CC00D931CDBA7DBFB2C3D33CC163A071E38002AE00DB6C57CEBB34C2693840183D714C710061A99543E32
DF0F29430C319A54EEB926C3108338E60FF5391F8D4691AEFAEAFB0404003B}}
\par\par \b \uc2 Miami Dentist Teams with Top Surgical Instrument Company to  \highlight22\uc2 Introduce \highlight\uc2  New Anglevator Extraction Product at the FDC 2016 Exhibit Hall.\b0\par\par\uc2 298 \uc2 words\par \uc2 16 June 2016\par \uc2 PR.com (Press Releases)\par \uc2 PRCOM\par NA\par \uc2 English\par \uc2 2016 Content Enterprises, Inc.   \par \par \uc2 Kissimmee, FL, June 16, 2016 --(PR.com)-- Dr. Eric Schuetz and GermedUSA Dental will be introducing their \b \highlight22\uc2 new product\b0 \highlight\uc2  known as the, "Anglevator," this year at the FDC2016 Exhibit Hall at the Gaylord Palms Resort & Convention Center in Kissime, Florida; booth 1131. The new revolutionary Anglevators are considered to be highly effective in all extraction procedures and are the workhorses of your reliable dental extraction kit.\par \par \uc2 With experience in over 20 years of dental rehabilitative and reconstructive dentistry and over 25,000 teeth extractions, Dr. Eric Shuetz invented the idea of the Anglevator and GermedUSA Dental skillfully crafted the oral surgery instrument to provide an all around easier experience for both the patient and dentist. The Anglevator is a multipurpose extraction kit that minimizes the time and effort it takes to switch between things like periotomes, chisels, elevators and luxators while also accomplishing an atraumatic extraction. Dr. Shuetz calls it the, "Swiss Army Knife of Oral Surgery."\par \par \uc2 The Anglevator is considered a hybrid of the above mentioned instruments, most importantly facilitates atraumatic extractions through the use of precisely designed widths and angles. This innovative product was created to provide an all around better extraction experience for patients and doctors.\par \par \uc2 If you would like to meet and asks questions to the creator of this game changing product and many other surgical instruments, be sure to visit booth 1131 at the Florida Dental Convention (FDC) 2016 on June 16-18, at the Gaylord Palms Resort & Convention Center in Kissimmee, FL.\par \par \uc2 Contact Information:\par \par \uc2 GermedUSA Dental\par \par \uc2 Kim Lebron\par \par \uc2 1-800-330-1322\par \par \uc2 Contact via Email\par \par {\field{\*\fldinst{HYPERLINK "http://www.germedusadental.com"}}{\fldrslt{\cf2 \uc2 www.germedusadental.com}}}\par \par \uc2 Read the full story here: {\field{\*\fldinst{HYPERLINK "http://www.pr.com/press-release/675436"}}{\fldrslt{\cf2 \uc2 http://www.pr.com/press-release/675436}}}\par \par \uc2 Document PRCOM00020160618ec6g0000t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 KemPharm\uc2  Files 8K - Other Events >KMPH\b0\par\par\uc2 580 \uc2 words\par \uc2 13 June 2016\par 16:21\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 KemPharm Inc\uc2 . (KMPH) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on June 13, 2016.\par \par \uc2 As described above, the \uc2 FDA\uc2  issued a CRL regarding the NDA for Apadaz. The CRL indicated that the review cycle for the Apadaz NDA is complete and the application is not ready for approval in its present form. The Company is currently evaluating the points raised in the CRL and intends to request an End of Review meeting with the \uc2 FDA\uc2  to determine the pathway forward for Apadaz.\par \par \uc2 Caution Concerning Forward Looking Statements\par \par \uc2 This Current Report may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "anticipate," "plan," "believe," "potential," "should," "continue" or the negative versions of those words or other comparable words. These forward-looking statements include statements regarding the Company's plans to work with the \uc2 FDA\uc2  to continue the review process of Apadaz. These forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier studies and trials may not be predictive of future clinical trial results; the protection and market exclusivity provided by the Company's intellectual property; risks related to the drug discovery and the regulatory approval process; the impact of competitive products and technological changes; and the \uc2 FDA\uc2  approval process under the Section 505(b)(2) regulatory pathway, including without limitation any timelines for the review process. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company's business are described in additional detail in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and in the Company's other Periodic and Current Reports filed with the \uc2 Securities and Exchange Commission\uc2 . The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1434647/000156459016020536/kmph-8k_20160613.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1434647/000156459016020536/kmph-8k_20160613.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/1434647/000156459016020536/0001564590-16-020536-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/1434647/000156459016020536/0001564590-16-020536-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 13, 2016 16:21 ET (20:21 GMT)\par \par \uc2 Document DJDN000020160613ec6d003c6\par }\page {\par\fs20\uc2 Business\par \b \uc2 ANI Pharma  \highlight22\uc2 Launches \highlight\uc2  Oxycodone Capsules; \uc2 FDA\uc2  Approves Oxcarbazepine Tablets\b0\par\par\uc2 275 \uc2 words\par \uc2 13 June 2016\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2016 NoticiasFinancieras. All Rights Reserved. \par \par \uc2 (RTTNews) - \uc2 ANI Pharmaceuticals, Inc\uc2 . (ANIP) announced Monday the commercial \b \highlight22\uc2 launch\b0 \highlight\uc2  of Oxycodone HCl Capsules, 5mg. Trailing twelve-month sales for the product are $7.5 million according to \uc2 IMS Health\uc2 .\par \par \uc2 The company noted that it is the third Schedule II narcotic product to the company's commercial portfolio and sixth \b \highlight22\uc2 new product\b0 \highlight\uc2  introduction in the second quarter of 2016.\par \par \uc2 Oxycodone hydrochloride is an opioid agonist indicated for the management of moderate to severe acute and chronic pain where the use of an opioid analgesic is appropriate.\par \par \uc2 Separately, the company said it has received approval from the U.S. Food and Drug Administration of the Prior Approval Supplement for Oxcarbazepine Tablets, 150mg, 300mg and 600mg. The current annual U.S. market for this product, based on trailing twelve months sales, is $145 million according to \uc2 IMS Health\uc2 .\par \par \uc2 Arthur Przybyl, ANI's President and CEO said, "This approval is the result of ANI's ongoing effort to re-activate the discontinued ANDAs that we have acquired in recent years. The PAS included the successful qualification of a new API source for the drug substance as well as the addition of manufacturing and packaging at ANI's Baudette site."\par \par \uc2 Oxcarbazepine is an antiepileptic drug indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4 years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with partial seizures.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2016 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020160613ec6d003bh\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw388\pich38\picscaley100\picscalex100\picwgoal5820\pichgoal570
47
49463839618401260070000021F904010000FC002C0000000084012600870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF0073081C4890E00F81070FE648281047C187391C368448B1A2C58B032546C488
5121438F1C438AB4A870E1C893284D964CC9122443950861A65938E687C234206926AC990367CF85337FD44CF831E8D09E0F8CDAFCF9234D52A03A4DFA0C8AE3
60D58D3E22FEB8FA33A840AF5B23567510312BD98656C3660D5B756B58B70EDD2EAC1A3747561C641DE2D06BF7ECD60712F9EEDD48416C5FAD7CA3E21CCA732D
4C981F117A8C4C19B2E5981F2B27BC7A57ABDD8D9C3D77BE7B30EBE7814B377F866BF2AADCB497334715BA13E8C1993889D2F6D9B4E9429B407C067FA0E6A09A
DF0B75CC3C9E06C818203DA13B2F12BDE70FE7D77F1C2F1E5C47D3EEBD95DFFFD658B7605D1F0F6A8E71ECF0418E0A19DD5F7DE003877BC039DCC7BC5852E3DC
827FFDE05E5E02E5755005ED65E55E619E9D25917EA9DD66924A1A858598409DB135D146A77DE690690499661564FEA1B6D15B1B4E68D0442BA918A28939F567
626B324EF82186A755B813486FC0A812194241379373C9F994C31850DD94DA188BD126216D501DE71B1009E186831A5929F55B4DE269F7570E0EC03622436314
C193540D2526D10F33F8479E7D28A2E8986708719523872266A4278B81E9A9A14D645236D39A27FAA0C36AFB016A1710E7A195A85D258919116E26AD65678BA9
C574E98AE57944A84B6DEDA72288276A5ADA8A980D34157491F9541358BDA9FFB498753461D7A44DCFE9B65C0E459051411A3C018AE46E506AC79470B8397926
43822D8503B014E2FAD256F065852060F081E943B50F2C7521A21B7ABAE28111C1471E82F949842E83EE1D549843F00938D79868525AE77F33C6756389DE4E68
A18A99CE98694E9221D76F5957ED3B6268745926A1A80D5BC89588A1F9A816C06095298694D62149E591124A47EB41C1D904A44E3AF800244FCB35E5DD514D3D
D0E30F4072F75D4D40484925CD8036C92A90DE490C30A045D854746F80129DB4D136BDC1B4D34B331DF50F4514A12F8E2F9976238778BD882ED70DE72774605E
A17119A102C5EB59A402A38D1C4C8EBD8A5C552C7B8B62877EBA28EA6300AEFF1D138276FB8B990C3196FAEFDE8ED55699C141DDE65B8FCCC53413754BE59643
70BF31341553CFA50122B4C276BC259154A681D3E95036E8EFD43DB3EEA54DCDC10EE8CE482F4DFBC12DDE8929570DF35592690E72DD1A6AC1A269E94419BEA8
12BD1C8E387C7F3B166FD2B015DA78EA4B73755BA05BF855FC6F5D750D9B629F20F9E7BCBF9D4E146C953D1D375BD067CE262D638E5B1754714C5A17644291D3
06F3915F41887A2404AB97D1AC3DA8894BD26E77BBDCD42E6A69F855EB76969BD83D505C428B917D360298F3F18E43C2FB4198D2B590EE698E6F0AC95646AAA5
BC47B1ED6E85F3568F4E6730C1A5EA5E764B1F0EBC231FB1EDCD3535D15E0EFFB3879598804835E519489E54322CF1C14E80B379D5E4064840C79D6C5A81EACA
4B7882244AA5CE288F6959979C851E52FDA638B24BA3ED9286469CDC6E8D51A312EDB816990AD5053602290C7AF4529A6EA5AF791BDC900F82453767D18B2C98
3248124FB5C4D3B0E72B506A9CDC2233278025AA4F097B4C62E62411AFE0704605E214AA42C3BC1D21474A60D1C9FFDC6732E0144C95FEEB4A540492BF6921E9
2751111FB4C0C8392285483E4BB3A01A2AB040D72D245E6E6C5D84D4E8C012BA2871846A4F9FC2A51F0E39C03E8901CD67CC35A3990C0F4EFB9958027F87234B
DE10949409963A61D22873DAF05B5761E1B814B21619315253C034A2A3C675FF4798148F3723139264704206A8E0E65000C5A54241264B9A34749001641900FD
D545590AC5434A944CD48002074DC0A18215D44E11D49086A265AE381CED281A89E940670D0F448BAC1E0EBE862FF091B38323D4D3D67853998929C4355C918B
DE9EF710B9B8A663038B955251782F1A49845404A310680846D58CBE725E97FCE97EFE89A625B9844B9EF4E484BCF9933138C42BEAA1895E06A594B4FE400C13
826BE57A32C09810323F7B440DEBDEB08C7DD46319D0D88726D4A08950E480AFD1A88732A2E15765C0216AA0A84734E8110D7D2C43133691A0A2F6D92E01AD09
6D6E9217364BD22E106A2D2C79D1DE69FE25B11E0A043FFA914F35ADD2AEA0FF96505F2A1C48526EB3DBBAFA6845AAFD92BCD8C6220291273FADD19E134513CA
B374289B0DC18F28E994CA9B8CAC78F19B101769E310B301B28BD38CA836AF72A641C50CAE383853856E79D11445AA373E81C33E94E1D137684213CB00EC3216
0207650836131EF5AF267E9386BE82221370504326FABA5FE0586E5A974A835FB0BA959C92250D3DEA21F7AA225D6902A5472CDAC81BDE4095E5CD945652F9C1
0CB98934BC2AD19BF5AB926F7A62262891D874A6438DE706D22311F9E6C18E52D241FC88109C48A4389C31DD52F4B39632CD53AADA711A026CA240591DF35517
2519A548FA91677D14A839F0EEB3C6AA09189B19C3A683A80FD24052D32129FF4B3349AB43CA7C1031E00AC7387E585646E39AECFC40BE98CDD41BFC0B8AA5BC
611F94B3495F05F483C5722C2199986FB7224825E822E601A088866934A18CA8C6651FA0D607882D3426E9E60714A0DE07283638A8FE82BA1E70F84F1AF60187
193C4013D0A0276353BD8CBAC817D4D1C804421230EB37B887AF1216C81B18BB9037D4631F5212CAAE19DBE98D448318029AF524B487EA7D24761FB0C2D1A181
9D89763D60C1DE3C3459D5E05F504383AC3DD9C71B66B0E7392B23D93F48C0B8410D870428A4BFC906C5326625DF245D3B3F70A8479C91428C5413C3ACC0F208
92D0BB6BC1F2250D9A902CA81B1C6F6FEF63196AE0097D4B338607B47BBEB4FF5CC8C9410D40DAC24BC7B7D34734BAB5B46ED9D7260ED004B4890928C1FE40E7
505B5A05E41BEB584DA8020C5288031AAE0387A0DA9B1B9C29602C2B9050809B9EE5BC8A1E673D60F9767A4DF4D8874002EB1484D40314D7D4F94FBDCD240C9B
E4D6D096C1A231A40350B349E75ED139B81D4009501BBB8B1F7F831A3E1A13C666C2DF8255551A1AAE09A7856B206A00770E801E1104E81C0EEE29B67B2A3089
686822BD8B76CD3E28A1DA8568221AEEB34B62DDE35FB9E200EFF969784272BE0F3205F6F3C59E50A441918349CC3752BA4400637BA4F301D7E4F5FAD0C41846
DC9319FC601FC4207126D2E090315C7BE1C56733CA6FA38C657C14C315159EFF8E96A2F6CCB9EECFB5CF5C0E68FD03681083E64B13C83EF4017FE63D353F3A97
88DA276C21C176864E1C944D09A00FFBE00032607903761578870309B07ECAA011DD176F09287FA08000E6910399500F3F80009107077C046A9A400194100D25
17119C9678CAE05F1C7368C2D63C024180FBE07C82A55A709706FEC64E07E27B6AE00063907802215FD47758D0B6110907622938100ED0815127104F77165C07
260A756BD130288B754B932776A8F16CCBD01416671733305F0C387909787CDE9425FB90096D9203FEE51448027B39005720436B32602269405FD3B30FD03003
02715FAAB20CCA00429B312043E663B9B10CD14060E72784418703F25504B3FFF6582D6534396007B5B759D0431008D05762537ECF2510ED367219C5367D2258
53F651FF025848E85FF49179F2D683334316DEA60C99566E0D215F6F8003A82625E92158B4D683D477109A10597F180DF2B583024106DE460CB208620E2158D0
B00C0E90783F05847B531291F7060E006864E10091E68133608B9D046C2048645C9700A6011F9CA60681D157F33560DA830391966AFB400FBCA57361F615DDA7
0C0F176C0D518E6F90095CE619760640F62815F216173AE787D140096B316BD0E779336167CB000A03F9885A215766A586F3D57DCA771056481A5A913415A00F
CAC0522C155B02F131872642EE61042CA76E3C573AD9C188E0B65B5A052277FFF100C9B00FFA47829FE447F8C5604E612862812E1AE100B376787A076D0E9015
47F85A0DA7877BC17570E09303318F9B400C8DF7764B296F58537BCA500FCB567693070DA7376B62E0950282067E050AA1400CBAB87E24056ECBF00938027798
573045218F7F5815DF086DF611694EB11591A70994C057CA302C483983391259C616132788721C567C240558DEC4776247175CB76C193733F126610D377FE107
403E90003B19846350779430173A475F86D91332306B97A509D3F71597754B2C486F56781BCB70769BA00C8E0775C1E3178A2258142093CF278FB49603145009
CAC9720F508CF0F503BFE20302726846903497E41ED491039BC093EE8177F4FFA153F98100FE9606C9D710C1E32E9F9100F39500388000E809758B95033D3003
0D1058E3F9001590827E98470BB10F9B8000F7A11033A076F6784D34B10F25B771C7810314608FCB605940009857718611315BEBA70902E05FC1564D70A78E30
05138756669E447B66A56F72281099100D93609EEBE781B42458076022A7473D6042A007507CFA815F4E6172F590326F688F1ED97E9A9000C4C05893404BCFA7
0916988D957824CF2221F6F800762698B494714271623F719065370648590F9A603547327F09507269307DC37270E9A58762C019423A9EB6F131A620760E0404
B2080A9A50A79DA662020A07C9000A1266132D5A6EB3934C15500C3C993477FF915B61A1A2A0E07C24E95C6F4039F1669737708DEDB2956992513A970949E86D
C6287F8798037DC55E38F097FE97111F3701C7B7103E407BF2F78725D48370209FF3E7183A37062AF888FAF18491B1A115E09ED2C89A0C5A5A7B738D0D68223E
B00FA720208ACA101D681397574285E9526A2896FAA18457386FB1BA8033A00CEFF65AF987240E808C9F17795E29061510AE89279B6F864B032900A0E614BE47
0C0EC1AE67A94A49B10F9580A60EE5875DE04D6B28848B0A7AF7761066A2506A3250074174DDB2330FE000135B7C02A2738531AC3C77101FB728496364DE1626
D7611EA4B61127877A04D1B112C18E204810D1500C61E11E3909262CEB6DC9FFE610FB3683833129F5CA22CF39607BA80F3B58AD9F81856A0872031169390084
B3A68E0AF19C41F803E939032C481070376A70931F91C63113F200A1096A2D88B3304880CAE020395B6D933785751158A9A609CE856EEE2170834A93EFF166C9
07189106B4EBF100350B6E3635110E096A7F487339A08C9F271003E97BE5467DDE9406F48059046175A9461075A89C9EB941D24516D6B9347EB5B9B0031D55E9
73B4E74068741075B09C1F0B1F4F878895D2425F51669E715620C183B4D974FF41622AE25C62A160F6825C7A489BDB531046425B6DA60601695D024152045174
01F416A8743939566424A506B8FBAB0931038F566456B5123F201EFB611A49FF4158605A10D38B521DC2666C3626EA454B1D855C3A7613A9870364F00666A510
CADBBC73D145B0AB10ECD5446CB2B483453700E4660C018739764B63A664197956B08B4BC0F2516A300921D75E78D221C0719DF3952D80B26CDD57684B2B6F9A
B534FEF55811A273A1B0B1D8FA18E3894DAA6527A5821709804847B93DC7455BF059C17BF10016E81FEFE2BE39D55CEA57270791533FC5BD101148A7711F3E34
6402613510624958F74E517C2F8844C550582280312004117544611F84431735A2A0363210DE9528F59B26AE05AB3C31906C611F7285511EF92CBB154083843D
40915D5CB4C5928321A6B61145503236017782E58840300CD0576098F500A7FFAB33F0B533FE450C09F6677DF5800F84101D84365AF51FC4F55AACB55A8E542E
E9821F22942239422D3A05538B8424EB61C49E9C40CCFA282FA211898335A09127D342612ED436A0E4CAC475CBA9923BC16A2159B2439A2C3C121549A6A215AA
5CA46FF824E193BF9362575081B8B3C4C64DA45017B3C299F7B1D43906920B6C85D69F985501197834B9314715707AF2286A342747FD02221A86AC666429ACF1
19A4521E48CC47DA242F76C164D58403E768555F33CBC475449F6530684331C16C22E95347B0BCC51A644EA7B21A2E9C49A715BBE58355D9A4196305571255C7
7DF28BE9A51364E010648A267655A4024C1B4F312C6F15CDE30151B8423775FFC1B87A1C18C644016CF606CC5B3447637E219C34553162632A366A8447F44C27
6CF3C3D5F45AAEAC35FF31A217481EFC7CCF6FA11F8BD424351443243BC6A2882A2EE14E7A9316A012D6E564460FC14991523D8263C74E45CAEB017198E1C2B3
513DAE974AEB2110DE85BC3D8194017415DE354919493DBA44139FB327D8A451CA9459E6A71BDC7C7EF0112F17DC3A7B32C600A8D4FAE22DEC3164FE81D550E8
21433C8813211161A2BBF7372104ED305D162D7DB319112DCC03E17CD5B3D6B75C5538292A5D5CCCFB245496FD123A62C1A9D248A4714B5E415EDA2B3D5671C6
ED251459B13E05611ACBA2CC01D45665E55064B584B475A87E76418FBD33B4FF53BA2D15DE474D6A44863D5B432317E822D1A4214DF5D98601A0978D1E9A22C4
50B4395A0275F30D128F643D6D5DD6C3731912BD378FC1DB7CB367F3AD4F95E43080685507BD106FBC1A59E15D96724B206236CC7C51573128B8945EFED36475
E691669C1E0C4523CB2C3AF092D80A1447E7771D91E840E79C4CBD413B6FC44EBA15273EE41F47141633612D7C3161BD23A7880227A055C453C54444C11431D6
3C257B4EE85D38608D194EBE149B6DCB03EE22F6F410FD04424A3430AB435421C9A471834B56C81420C31568B0125922DDAF61173C1154EA71543F60363321E1
6B7C5111A7120339DAB83D9D8B8D3AA5FBB16F144C53833A1F835C8DF2595859EDCB78733EA496D8F2F14124E4D9FF97D8B4BCD5646EE751EC3CB0413E31F53C
ED24E06BDD5545F5496D4DDF66BDDF47F53661EDDBA8ADC761717C54F616636612E8C5CC4C6A67857DD8ECF513B3BE1A842D386636565FC1E1FF01B421D8D416
536304732AE8B2C32B670447D9D152E607DC3744E00913EAE21217A636B38401DAE70D265837221D36DD3B1230D8B3D0B53D548133237992EAB2B1D5FD74478D
62C45BA35578C4E5665D1EA6D174599472FC2B71A502751725D3EDFD137BAD562D9756624EEB0F7310651C84A6E14D72B68A74C22FE874F17C3310A9C91F9AF4
1F9A3BDA9EA210B5F58E58F51EE4D3101A8C40A8C22073E2201DF4DF5B51636134C5135D8DAE2CC4391154F79E2AE5912CB96C4366BDE54AEDC9E9CE440E45F3
E384D199F4D78D61D8734156AA111504FFF488621A064EC75913CDEC65C023BE63F066217E11365A7E387D332FF777F5067E4F177237555ECAFFBCCCDFA16415
A4A2D0F6611632E23B064120870351B8B15DFA6CCB3742E4ADCBDFF1DEDFB7EC185A02DDAA35F702832F5425CBFB544939B1D962E1D6D6553923AD35E2A35636
616799EFEBAD116725E1158D7B24272D144DE44469AED5F7585615802494FE54923ED73CCF2C18914D2502111AE6101FFFC29B8E2FC11D5D19A1214BAFE72601
1F265421B5B55A45A1E8302FF497DDCB21E6D658E62A4E824B5CAD7E465C55E544E08B5E3CA983DB7CD2E8520AFE50D26471A1DCAAD4CC54BF1A796EE1632671
75EC505981EB3D81CF6465E10C1BBBDA34A2008123478E1F0207FE189810218E823F1CF8788043A08F8439280E642890420E860E081EFC8810FFE4C790233F32
4C68502447830337E678C051A4C00A1823B20C6910C74D9518098EF92132A8C99525491E3D8950A851994D1BE64833308DD21F40A7023D28B020D18414958244
C9B422CA8B5B093EC02A542BCA855F732A9C1955EBC131238B8A59D9B6AED0BA1CA30EDC2B304DCB815EA172952AB52AC2BE1663EE34F898A3648273B362DCDA
B3A2E3C91039C21CE871EC678B9515E6102D9072D9B0864B3FA0581335C598A43D869D38F0C14CD10E964A66FB312AC2E10251329C7952F9D68BA68F5F5EBA99
EAE2E1048953B5FE9669D8E4DC2B17056F383AD2B04D7B9ADDBA728C8F31BE7388A99CF6231A8B7D115E2C5BB5BE5EC553E1039DEB07BC7EBAFF0F2B90A2A2E8
AF856492282597C0FA8822EED6AA2D870A9EC3ECB3E04A7BC9B4C57C0AEE2B8A74D0ACA5E61C5C4942877422C9339F92C3C922AD20C88840E13E5C0EA4AFD2CB
CEA8BCF242B1C7C3AA230EAA07AE5ACCC0A596F4512D92B0330F48928A78D2C78474782AA1A80094EBA331041B8DBEBA8E3C48A4A8D2A88BBDA608AC2B8D13F9
2A32070013530A87A806FC6B321C6A8AC93317299250B9CDC00222A3E6047A08A69D10BA2D870E098228C0D2567A4E25B6026CA9A19D287220A30AABC4813540
5143493687BA22CDC606DD023239F47C1234C5D3EA1C2A48A5869BEA071D8603EA87A9B8DAF049EFAA8C754DA5943CE922E3222C2CA98250122A8344FFAAF201
08ACDCFC5040FDAAC2610C034B230941902E02AAAE72BD1C884AA8BEF2F6302F7D882A20003B}}
\par\par \b \uc2 TIME.com Opinion: How to Stop Superbugs\b0\par\par\uc2 834 \uc2 words\par \uc2 9 June 2016\par \uc2 Congressional Documents and Publications\par \uc2 CONGDP\par \uc2 English\par \uc2 (c) 2016 Federal Information & News Dispatch, Inc. \par \par \uc2 Following the discovery of a bacteria resistant to colistin, an antibiotic of last resort, U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) earlier this week \b \highlight22\uc2 introduced\b0 \highlight\uc2  their bipartisan PATH Act as an amendment to the National Defense Authorization Act for Fiscal Year 2017. The measure would create a \b \highlight22\uc2 new drug\b0 \highlight\uc2  approval pathway to bolster innovation and encourage development of potentially life-saving antibiotic drugs for patients, including servicemembers serving overseas who are particularly at risk of exposure to antibiotic-resistant bacteria.\par \par \uc2 Read more below about how the PATH Act can help combat antibiotic-resistant bacteria:\par \par \uc2 Senators Hatch and Bennet: How to Stop Superbugs @SenOrrinHatch @SenBennetCO\par \par \uc2 Hatch is a Republican U.S. Senator for Utah\par \par \uc2 Bennet is a Democratic U.S. Senator for Colorado\par \par \uc2 The discovery of a superbug on our home soil is a sign that we must redouble our efforts in the fight against antibiotic-resistant bacteria\par \par \uc2 For years, public health experts have warned that it is only a matter of time before we face a "superbug "--a strain of highly infectious bacteria that is resistant to every antibiotic in our arsenal. With the discovery of a strain of E. coli resistant to colistin, an antibiotic of last resort, the threat of superbugs has become even more severe.\par \par \uc2 Colistin-resistant bacteria was first discovered in China at the end of last year; it has since been found on every continent except Antarctica. We now know for certain that this superbug has found its way to U.S. soil. Just last month, a patient in Pennsylvania contracted a strain of this deadly bacteria--a development that had some health experts declaring "the end of the road " for antibiotics.\par \par \uc2 As we work to combat the emergence of a superbug, the worst case scenario is, unfortunately, a very likely one: colistin-resistant bacteria could converge with bacteria resistant to other types of antibiotics, spawning superbugs that are resistant to all antibiotics. This kind of antibiotic resistance occurs via a microscopic "handshake" between bacteria. The easy transference of resistance is what makes the bacteria found in Pennsylvania more significant than other types of superbugs previously encountered in the U.S. Fortunately, the woman in Pennsylvania was treated with the help of other drugs and released. But future patients may not be so lucky. That's why we must act now to stop the next superbug.\par \par \uc2 Today, thousands of people die of infections that, just a decade ago, could have been easily treated with antibiotics. Consider that each year, two million people in the U.S. are infected with antibiotic-resistant bacteria. And each year, more than 20,000 of these patients die as a result of their infections. Without new treatments that can defeat these bacteria, even more Americans will die in the months and years to come.\par \par \uc2 Despite the urgent threat posed by nascent superbugs, it has been more than 30 years since we have developed a truly new type of antibiotic capable of fighting these drug-resistant bacteria. While there is no simple solution in the fight against superbugs, there is more Congress can and must do to address the problem.\par \par \uc2 First, the Senate should encourage innovation and development of new antibiotics by passing the Promise for Antibiotics and Therapeutics (PATH) Act --a bipartisan proposal we introduced at the beginning of this Congress. Our bill allows the \uc2 Food and Drug Administration\uc2  to approve antibiotics for limited populations of patients suffering from serious and life-threatening bacterial infections that are resistant to current treatments. In effect, our legislation jumpstarts the development of antibiotics that could eventually treat superbugs, including the colistin-resistant E. coli recently discovered in Pennsylvania.\par \par \uc2 The PATH Act also calls for the implementation of antibiotic stewardship programs and encourages more robust surveillance of bacterial resistance through the CDC's National Healthcare Safety Network and other national tracking systems that play a critical role in fighting superbugs. The Senate Committee on Health, Education, Labor and Pensions has reported our bill, and similar legislation has already passed the House of Representatives.\par \par \uc2 Earlier this week, we introduced the PATH Act as an amendment to the National Defense Authorization Act (NDAA). Because our men and women in uniform frequently deploy to diverse countries across the world, they face an even greater risk of exposure to superbugs. By including the PATH Act as an amendment in the defense appropriations bill, we can better provide for the health of civilians and service members alike.\par \par \uc2 The discovery of a superbug on our home soil is an unmistakable sign we must redouble our efforts in the fight against antibiotic-resistant bacteria. We urge Republicans and Democrats in the Senate to join our cause by supporting the addition of the PATH Act as an amendment to this year's defense bill. Time is limited, but if we set aside our differences and face this public health crisis together, we can discover new treatments that will save millions of lives.\par \par \uc2 Document CONGDP0020160609ec69000e3\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw134\pich21\picscaley100\picscalex100\picwgoal2010\pichgoal315
47
494638396186001500B30000FFFFFF8989892A2A2AEDEDEDCCCCCC666666A8A8A8DBDBDBBBBBBB000000777777444444111111999999F5F5F555555521F90400
000000002C00000000860015000004FFB0C849ABBD38EBCDBBFF1F208E64699E68AAAE6CEBBEAC04CF23320E07ADEF7C5CF4AEC0E860031A8F33190211281202
06072217051800CFAAA14170180204D193396C34A287F0C09643BA91CA86B51B901A0E57F0D2EBC003140E0053000D0E0E756422078808878236426F923D4A39
4444224201690885070A01500091A1A10798A343454206039193B03B4A364B03727E4C5272B6000E619177580EBCAE65007E59B1CA344AA17256A600C50661D0
9BA9C7A15782010DAF8BA103220A6D3FCBE72A95E8278EEBEE28EA6B4B45336B6D2DD762F482D53A4B240410885B86A0DF08193512284CC0E0D90B04095EB508
248241444509CCE950F86A41827D25FF060249B0C0044211100530613803A2C41505E8296420CE258F85CF3C821C41E0C1119226350A024A402121300FE42078
B020C0C09E0B145CEC96CD86AB050BE404C8B809A2C71F5BAF7C5A50E0D43503579E1030B0E041988509E4E8C45220AAB8010C04740B47280793300DB03EFB5B
400100A2A1449C1C0AD7B047010214A4945AF2000306013C0A016AF36B80B202120858B036A2CEAD022F0760503222DE920B041425BB392E43023A2DEB653D8A
61D4AD4E3302104073EB83075345433EBC6000F16A8B5386AAA6591A7271529FC41DBAB9A4CBA2425167FA788024F2DEA32D0E2FB09501C43B97AB196D1F7A65
13E46F4B4ACBBBD5B690BC2210D79BE24FE29897C03600440714091E8DD0606F2B5D611367114164D808E22598400EFD31D05B13FF14101A72A3897159810928
B6D04AEC45B3606F092870194DCC89D060868741C6C03D0AEAE7608A22349091010016A59254FFA954DD650D20904785073CE81C850B74228790020CA010600D
14F0D161400280DC47463AA95F5EFFE0B5A19791B0B915585F8A4092910709E555090F66621169415A149A104232C02616631A3625030400288201C28DE2675A
5F46A6678C728639A50D0D84A657900A9913804F890E34809719898323506F2A26D43BACB60A0F08B0C62AEBACB4D65A4004003B}}
\par\par \b \uc2 New Data Logger from \uc2 Mesa Labs\b0\par\par\uc2 257 \uc2 words\par \uc2 9 June 2016\par \uc2 ThomasNet News\par \uc2 PNN\par \uc2 English\par \uc2 Copyright (c) 2016. Thomas Publishing Company. All Rights Reserved.   \par \par \uc2 Mesa \b \highlight22\uc2 introduces\b0 \highlight\uc2  its new Micro Flex logger for use in validating surface temperature environments. Its dual probe design provides capability to measure surface and vial temp with one logger or measure two vials or two surface temperatures at one time.\par \par \uc2 The Micro Flex Logger is a small, 2mm diameter probe that can fit inside vials for vial monitoring. To accompany the Micro Flex, we also have the Surface Flex attachment. The Surface Flex goes onto the Micro Flex Probe to allow you to monitor the surface of a lyophilization, or freeze drying, process. Together, these \b \highlight22\uc2 new products\b0 \highlight\uc2  make it easy to have the right probe set for monitoring your product, so you can collect the surface temperature right from the vial.\par \par \uc2 Similar to the thermocouple, the Micro Flex Logger has ideal response time needed in changes to temperature. The puck used for the Micro Flex Logger is made of brass allowing for a very efficient temperature response time. Since the Micro Flex Logger is built from the foundations of our MPRF product line, it allows the convenience of having real-time data as your process is happening. Now, you can make changes or decisions on the fly based on the evidence in front of you - not based on hunches or intuition. If you are monitoring a process remotely, your real-time data will instantly let you know if there is a problem that needs to be addressed.\par \par \uc2 For more information on this innovative logger, learn more at {\field{\*\fldinst{HYPERLINK "http://datatrace.mesalabs.com"}}{\fldrslt{\cf2 \uc2 http://datatrace.mesalabs.com}}}\par \par \uc2 Document PNN0000020160609ec690000a\par }\page {\par\fs20\b \uc2 Stream of new generic products hits the market.(RX: RETAIL PHARMACY: Generic Drugs)\b0\par\par\uc2 345 \uc2 words\par \uc2 6 June 2016\par \uc2 Chain Drug Review\par \uc2 CHDR\par 87\par \uc2 ISSN: 0164-9914; Volume 38; Issue 9\par \uc2 English\par \uc2 Copyright 2016 Gale Group Inc. All rights reserved. \par \par \uc2 NEW YORK -- New generic drugs are arriving on the market by way of Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (ANDA) approvals, authorized generics and supply agreements.\par \par \uc2 Recently, \uc2 ANI Pharmaceuticals Inc\uc2 . entered into a supply and distribution agreement with Aspen Global Inc. for hydroxyprogsterone caproate injection USP. ANI also recently \b \highlight22\uc2 launched\b0 \highlight\uc2  an authorized generic of Rowasa, indicated for the treatment of mild to moderate ulcerative colitis.\par \par \uc2 Aurolife Pharma LLC, a division of Aurobindo Pharma USA, received ANDA approval for oxymorphone hydrochloride tablets, 5 mg and 10 mg. The product is bioequivalent and therapeutically equivalent to Opana tablets (\uc2 Endo Pharmaceuticals Inc\uc2 .).\par \par \uc2 Aurobindo received final ANDA approval for fenofibrate tablets, 48 mg and 145 mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product Tricor (\uc2 Abbvie Inc\uc2 .).\par \par \uc2 Camber Pharmaceuticals launched methylphenidate tablets, (5, 10 and 20 mg tablets) a generic version of Ritalin. The drug is used to treat attention deficit hyperactivity disorder and narcolepsy.\par \par \uc2 Mylan N.V\uc2 . announced the U.S. launch of hydralazine hydrochloride injection USP, 20 mg/mL, which is a generic version of \uc2 Novartis AG\uc2 's Apresoline Injection, 20 mg/mL. Mylan received final approval from the \uc2 FDA\uc2  for its ANDA for this product, which is used for the treatment of severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.\par \par \uc2 Hydralazine hydrochloride Injection USP, 20 mg/mL, had U.S. sales of approximately $63.4 million for the 12 months ended March 31, 2016, according to \uc2 IMS Health\uc2 . Mylan's launch of this product adds to the company's growing portfolio of more than 150 injectable products available to patients in the U.S. across a broad array of therapeutic categories including oncology, anti-infectives, anesthesia/ pain management and cardiovascular.\par \par \uc2 Teligent Inc\uc2 ., a New Jersey-based specialty generic pharmaceutical company, has received approval of its ANDA for triamcinolone acetonide ointment USP, 0.1%, the fifth approval from its internally developed pipeline of topical generic pharmaceutical products.\par \par \uc2 Document CHDR000020160621ec6600037\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Thermo Fisher \highlight22\uc2 announces new \highlight\uc2  instruments  \highlight22\uc2 launched \highlight\uc2  at ASMS 2016\b0\par\par\uc2 168 \uc2 words\par \uc2 6 June 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Thermo Fisher Scientific\uc2  strengthened its analytical instruments platform with innovative systems designed to help pharmaceutical and biologics producers more efficiently discover and develop candidate drugs. These \b \highlight22\uc2 new products\b0 \highlight\uc2  will be on display at the 64th Annual American Society for Mass Spectrometry Conference, June 5-9 in Texas Ballroom D at the Grand Hyatt Hotel. The new Thermo Scientific Q Exactive BioPharma MS/MS Hybrid Quadropole-Orbitrap mass spectrometer takes full advantage of the high-resolution, accurate-mass capabilities of the Orbitrap mass analyzer to enable key workflows for protein characterization in a single instrument. Combined with recommended sample preparation and analysis methods using Thermo Scientific reagents, columns, UHPLC and data processing technologies, the Q Exactive BioPharma system provides a comprehensive solution for customers performing biopharmaceutical characterization.\par \par \uc2  At ASMS, \uc2 Thermo Fisher\uc2  will also feature its new Thermo Scientific Vanquish Flex Binary UHPLC system, an ideal complement for pharmaceutical and biopharmaceutical laboratories performing qualitative and quantitative LC or LC-MS analysis. \par \par \uc2 Document FLYWAL0020160606ec66003xw\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw388\pich38\picscaley100\picscalex100\picwgoal5820\pichgoal570
47
49463839618401260070000021F904010000FC002C0000000084012600870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF0073081C4890E00F81070FE648281047C187391C368448B1A2C58B032546C488
5121438F1C438AB4A870E1C893284D964CC9122443950861A65938E687C234206926AC990367CF85337FD44CF831E8D09E0F8CDAFCF9234D52A03A4DFA0C8AE3
60D58D3E22FEB8FA33A840AF5B23567510312BD98656C3660D5B756B58B70EDD2EAC1A3747561C641DE2D06BF7ECD60712F9EEDD48416C5FAD7CA3E21CCA732D
4C981F117A8C4C19B2E5981F2B27BC7A57ABDD8D9C3D77BE7B30EBE7814B377F866BF2AADCB497334715BA13E8C1993889D2F6D9B4E9429B407C067FA0E6A09A
DF0B75CC3C9E06C818203DA13B2F12BDE70FE7D77F1C2F1E5C47D3EEBD95DFFFD658B7605D1F0F6A8E71ECF0418E0A19DD5F7DE003877BC039DCC7BC5852E3DC
827FFDE05E5E02E5755005ED65E55E619E9D25917EA9DD66924A1A858598409DB135D146A77DE690690499661564FEA1B6D15B1B4E68D0442BA918A28939F567
626B324EF82186A755B813486FC0A812194241379373C9F994C31850DD94DA188BD126216D501DE71B1009E186831A5929F55B4DE269F7570E0EC03622436314
C193540D2526D10F33F8479E7D28A2E8986708719523872266A4278B81E9A9A14D645236D39A27FAA0C36AFB016A1710E7A195A85D258919116E26AD65678BA9
C574E98AE57944A84B6DEDA72288276A5ADA8A980D34157491F9541358BDA9FFB498753461D7A44DCFE9B65C0E459051411A3C018AE46E506AC79470B8397926
43822D8503B014E2FAD256F065852060F081E943B50F2C7521A21B7ABAE28111C1471E82F949842E83EE1D549843F00938D79868525AE77F33C6756389DE4E68
A18A99CE98694E9221D76F5957ED3B6268745926A1A80D5BC89588A1F9A816C06095298694D62149E591124A47EB41C1D904A44E3AF800244FCB35E5DD514D3D
D0E30F4072F75D4D40484925CD8036C92A90DE490C30A045D854746F80129DB4D136BDC1B4D34B331DF50F4514A12F8E2F9976238778BD882ED70DE72774605E
A17119A102C5EB59A402A38D1C4C8EBD8A5C552C7B8B62877EBA28EA6300AEFF1D138276FB8B990C3196FAEFDE8ED55699C141DDE65B8FCCC53413754BE59643
70BF31341553CFA50122B4C276BC259154A681D3E95036E8EFD43DB3EEA54DCDC10EE8CE482F4DFBC12DDE8929570DF35592690E72DD1A6AC1A269E94419BEA8
12BD1C8E387C7F3B166FD2B015DA78EA4B73755BA05BF855FC6F5D750D9B629F20F9E7BCBF9D4E146C953D1D375BD067CE262D638E5B1754714C5A17644291D3
06F3915F41887A2404AB97D1AC3DA8894BD26E77BBDCD42E6A69F855EB76969BD83D505C428B917D360298F3F18E43C2FB4198D2B590EE698E6F0AC95646AAA5
BC47B1ED6E85F3568F4E6730C1A5EA5E764B1F0EBC231FB1EDCD3535D15E0EFFB3879598804835E519489E54322CF1C14E80B379D5E4064840C79D6C5A81EACA
4B7882244AA5CE288F6959979C851E52FDA638B24BA3ED9286469CDC6E8D51A312EDB816990AD5053602290C7AF4529A6EA5AF791BDC900F82453767D18B2C98
3248124FB5C4D3B0E72B506A9CDC2233278025AA4F097B4C62E62411AFE0704605E214AA42C3BC1D21474A60D1C9FFDC6732E0144C95FEEB4A540492BF6921E9
2751111FB4C0C8392285483E4BB3A01A2AB040D72D245E6E6C5D84D4E8C012BA2871846A4F9FC2A51F0E39C03E8901CD67CC35A3990C0F4EFB9958027F87234B
DE10949409963A61D22873DAF05B5761E1B814B21619315253C034A2A3C675FF4798148F3723139264704206A8E0E65000C5A54241264B9A34749001641900FD
D545590AC5434A944CD48002074DC0A18215D44E11D49086A265AE381CED281A89E940670D0F448BAC1E0EBE862FF091B38323D4D3D67853998929C4355C918B
DE9EF710B9B8A663038B955251782F1A49845404A310680846D58CBE725E97FCE97EFE89A625B9844B9EF4E484BCF9933138C42BEAA1895E06A594B4FE400C13
826BE57A32C09810323F7B440DEBDEB08C7DD46319D0D88726D4A08950E480AFD1A88732A2E15765C0216AA0A84734E8110D7D2C43133691A0A2F6D92E01AD09
6D6E9217364BD22E106A2D2C79D1DE69FE25B11E0A043FFA914F35ADD2AEA0FF96505F2A1C48526EB3DBBAFA6845AAFD92BCD8C6220291273FADD19E134513CA
B374289B0DC18F28E994CA9B8CAC78F19B101769E310B301B28BD38CA836AF72A641C50CAE383853856E79D11445AA373E81C33E94E1D137684213CB00EC3216
0207650836131EF5AF267E9386BE82221370504326FABA5FE0586E5A974A835FB0BA959C92250D3DEA21F7AA225D6902A5472CDAC81BDE4095E5CD945652F9C1
0CB98934BC2AD19BF5AB926F7A62262891D874A6438DE706D22311F9E6C18E52D241FC88109C48A4389C31DD52F4B39632CD53AADA711A026CA240591DF35517
2519A548FA91677D14A839F0EEB3C6AA09189B19C3A683A80FD24052D32129FF4B3349AB43CA7C1031E00AC7387E585646E39AECFC40BE98CDD41BFC0B8AA5BC
611F94B3495F05F483C5722C2199986FB7224825E822E601A088866934A18CA8C6651FA0D607882D3426E9E60714A0DE07283638A8FE82BA1E70F84F1AF60187
193C4013D0A0276353BD8CBAC817D4D1C804421230EB37B887AF1216C81B18BB9037D4631F5212CAAE19DBE98D448318029AF524B487EA7D24761FB0C2D1A181
9D89763D60C1DE3C3459D5E05F504383AC3DD9C71B66B0E7392B23D93F48C0B8410D870428A4BFC906C5326625DF245D3B3F70A8479C91428C5413C3ACC0F208
92D0BB6BC1F2250D9A902CA81B1C6F6FEF63196AE0097D4B338607B47BBEB4FF5CC8C9410D40DAC24BC7B7D34734BAB5B46ED9D7260ED004B4890928C1FE40E7
505B5A05E41BEB584DA8020C5288031AAE0387A0DA9B1B9C29602C2B9050809B9EE5BC8A1E673D60F9767A4DF4D8874002EB1484D40314D7D4F94FBDCD240C9B
E4D6D096C1A231A40350B349E75ED139B81D4009501BBB8B1F7F831A3E1A13C666C2DF8255551A1AAE09A7856B206A00770E801E1104E81C0EEE29B67B2A3089
686822BD8B76CD3E28A1DA8568221AEEB34B62DDE35FB9E200EFF969784272BE0F3205F6F3C59E50A441918349CC3752BA4400637BA4F301D7E4F5FAD0C41846
DC9319FC601FC4207126D2E090315C7BE1C56733CA6FA38C657C14C315159EFF8E96A2F6CCB9EECFB5CF5C0E68FD03681083E64B13C83EF4017FE63D353F3A97
88DA276C21C176864E1C944D09A00FFBE00032607903761578870309B07ECAA011DD176F09287FA08000E6910399500F3F80009107077C046A9A400194100D25
17119C9678CAE05F1C7368C2D63C024180FBE07C82A55A709706FEC64E07E27B6AE00063907802215FD47758D0B6110907622938100ED0815127104F77165C07
260A756BD130288B754B932776A8F16CCBD01416671733305F0C387909787CDE9425FB90096D9203FEE51448027B39005720436B32602269405FD3B30FD03003
02715FAAB20CCA00429B312043E663B9B10CD14060E72784418703F25504B3FFF6582D6534396007B5B759D0431008D05762537ECF2510ED367219C5367D2258
53F651FF025848E85FF49179F2D683334316DEA60C99566E0D215F6F8003A82625E92158B4D683D477109A10597F180DF2B583024106DE460CB208620E2158D0
B00C0E90783F05847B531291F7060E006864E10091E68133608B9D046C2048645C9700A6011F9CA60681D157F33560DA830391966AFB400FBCA57361F615DDA7
0C0F176C0D518E6F90095CE619760640F62815F216173AE787D140096B316BD0E779336167CB000A03F9885A215766A586F3D57DCA771056481A5A913415A00F
CAC0522C155B02F131872642EE61042CA76E3C573AD9C188E0B65B5A052277FFF100C9B00FFA47829FE447F8C5604E612862812E1AE100B376787A076D0E9015
47F85A0DA7877BC17570E09303318F9B400C8DF7764B296F58537BCA500FCB567693070DA7376B62E0950282067E050AA1400CBAB87E24056ECBF00938027798
573045218F7F5815DF086DF611694EB11591A70994C057CA302C483983391259C616132788721C567C240558DEC4776247175CB76C193733F126610D377FE107
403E90003B19846350779430173A475F86D91332306B97A509D3F71597754B2C486F56781BCB70769BA00C8E0775C1E3178A2258142093CF278FB49603145009
CAC9720F508CF0F503BFE20302726846903497E41ED491039BC093EE8177F4FFA153F98100FE9606C9D710C1E32E9F9100F39500388000E809758B95033D3003
0D1058E3F9001590827E98470BB10F9B8000F7A11033A076F6784D34B10F25B771C7810314608FCB605940009857718611315BEBA70902E05FC1564D70A78E30
05138756669E447B66A56F72281099100D93609EEBE781B42458076022A7473D6042A007507CFA815F4E6172F590326F688F1ED97E9A9000C4C05893404BCFA7
0916988D957824CF2221F6F800762698B494714271623F719065370648590F9A603547327F09507269307DC37270E9A58762C019423A9EB6F131A620760E0404
B2080A9A50A79DA662020A07C9000A1266132D5A6EB3934C15500C3C993477FF915B61A1A2A0E07C24E95C6F4039F1669737708DEDB2956992513A970949E86D
C6287F8798037DC55E38F097FE97111F3701C7B7103E407BF2F78725D48370209FF3E7183A37062AF888FAF18491B1A115E09ED2C89A0C5A5A7B738D0D68223E
B00FA720208ACA101D681397574285E9526A2896FAA18457386FB1BA8033A00CEFF65AF987240E808C9F17795E29061510AE89279B6F864B032900A0E614BE47
0C0EC1AE67A94A49B10F9580A60EE5875DE04D6B28848B0A7AF7761066A2506A3250074174DDB2330FE000135B7C02A2738531AC3C77101FB728496364DE1626
D7611EA4B61127877A04D1B112C18E204810D1500C61E11E3909262CEB6DC9FFE610FB3683833129F5CA22CF39607BA80F3B58AD9F81856A0872031169390084
B3A68E0AF19C41F803E939032C481070376A70931F91C63113F200A1096A2D88B3304880CAE020395B6D933785751158A9A609CE856EEE2170834A93EFF166C9
07189106B4EBF100350B6E3635110E096A7F487339A08C9F271003E97BE5467DDE9406F48059046175A9461075A89C9EB941D24516D6B9347EB5B9B0031D55E9
73B4E74068741075B09C1F0B1F4F878895D2425F51669E715620C183B4D974FF41622AE25C62A160F6825C7A489BDB531046425B6DA60601695D024152045174
01F416A8743939566424A506B8FBAB0931038F566456B5123F201EFB611A49FF4158605A10D38B521DC2666C3626EA454B1D855C3A7613A9870364F00666A510
CADBBC73D145B0AB10ECD5446CB2B483453700E4660C018739764B63A664197956B08B4BC0F2516A300921D75E78D221C0719DF3952D80B26CDD57684B2B6F9A
B534FEF55811A273A1B0B1D8FA18E3894DAA6527A5821709804847B93DC7455BF059C17BF10016E81FEFE2BE39D55CEA57270791533FC5BD101148A7711F3E34
6402613510624958F74E517C2F8844C550582280312004117544611F84431735A2A0363210DE9528F59B26AE05AB3C31906C611F7285511EF92CBB154083843D
40915D5CB4C5928321A6B61145503236017782E58840300CD0576098F500A7FFAB33F0B533FE450C09F6677DF5800F84101D84365AF51FC4F55AACB55A8E542E
E9821F22942239422D3A05538B8424EB61C49E9C40CCFA282FA211898335A09127D342612ED436A0E4CAC475CBA9923BC16A2159B2439A2C3C121549A6A215AA
5CA46FF824E193BF9362575081B8B3C4C64DA45017B3C299F7B1D43906920B6C85D69F985501197834B9314715707AF2286A342747FD02221A86AC666429ACF1
19A4521E48CC47DA242F76C164D58403E768555F33CBC475449F6530684331C16C22E95347B0BCC51A644EA7B21A2E9C49A715BBE58355D9A4196305571255C7
7DF28BE9A51364E010648A267655A4024C1B4F312C6F15CDE30151B8423775FFC1B87A1C18C644016CF606CC5B3447637E219C34553162632A366A8447F44C27
6CF3C3D5F45AAEAC35FF31A217481EFC7CCF6FA11F8BD424351443243BC6A2882A2EE14E7A9316A012D6E564460FC14991523D8263C74E45CAEB017198E1C2B3
513DAE974AEB2110DE85BC3D8194017415DE354919493DBA44139FB327D8A451CA9459E6A71BDC7C7EF0112F17DC3A7B32C600A8D4FAE22DEC3164FE81D550E8
21433C8813211161A2BBF7372104ED305D162D7DB319112DCC03E17CD5B3D6B75C5538292A5D5CCCFB245496FD123A62C1A9D248A4714B5E415EDA2B3D5671C6
ED251459B13E05611ACBA2CC01D45665E55064B584B475A87E76418FBD33B4FF53BA2D15DE474D6A44863D5B432317E822D1A4214DF5D98601A0978D1E9A22C4
50B4395A0275F30D128F643D6D5DD6C3731912BD378FC1DB7CB367F3AD4F95E43080685507BD106FBC1A59E15D96724B206236CC7C51573128B8945EFED36475
E691669C1E0C4523CB2C3AF092D80A1447E7771D91E840E79C4CBD413B6FC44EBA15273EE41F47141633612D7C3161BD23A7880227A055C453C54444C11431D6
3C257B4EE85D38608D194EBE149B6DCB03EE22F6F410FD04424A3430AB435421C9A471834B56C81420C31568B0125922DDAF61173C1154EA71543F60363321E1
6B7C5111A7120339DAB83D9D8B8D3AA5FBB16F144C53833A1F835C8DF2595859EDCB78733EA496D8F2F14124E4D9FF97D8B4BCD5646EE751EC3CB0413E31F53C
ED24E06BDD5545F5496D4DDF66BDDF47F53661EDDBA8ADC761717C54F616636612E8C5CC4C6A67857DD8ECF513B3BE1A842D386636565FC1E1FF01B421D8D416
536304732AE8B2C32B670447D9D152E607DC3744E00913EAE21217A636B38401DAE70D265837221D36DD3B1230D8B3D0B53D548133237992EAB2B1D5FD74478D
62C45BA35578C4E5665D1EA6D174599472FC2B71A502751725D3EDFD137BAD562D9756624EEB0F7310651C84A6E14D72B68A74C22FE874F17C3310A9C91F9AF4
1F9A3BDA9EA210B5F58E58F51EE4D3101A8C40A8C22073E2201DF4DF5B51636134C5135D8DAE2CC4391154F79E2AE5912CB96C4366BDE54AEDC9E9CE440E45F3
E384D199F4D78D61D8734156AA111504FFF488621A064EC75913CDEC65C023BE63F066217E11365A7E387D332FF777F5067E4F177237555ECAFFBCCCDFA16415
A4A2D0F6611632E23B064120870351B8B15DFA6CCB3742E4ADCBDFF1DEDFB7EC185A02DDAA35F702832F5425CBFB544939B1D962E1D6D6553923AD35E2A35636
616799EFEBAD116725E1158D7B24272D144DE44469AED5F7585615802494FE54923ED73CCF2C18914D2502111AE6101FFFC29B8E2FC11D5D19A1214BAFE72601
1F265421B5B55A45A1E8302FF497DDCB21E6D658E62A4E824B5CAD7E465C55E544E08B5E3CA983DB7CD2E8520AFE50D26471A1DCAAD4CC54BF1A796EE1632671
75EC505981EB3D81CF6465E10C1BBBDA34A2008123478E1F0207FE189810218E823F1CF8788043A08F8439280E642890420E860E081EFC8810FFE4C790233F32
4C68502447830337E678C051A4C00A1823B20C6910C74D9518098EF92132A8C99525491E3D8950A851994D1BE64833308DD21F40A7023D28B020D18414958244
C9B422CA8B5B093EC02A542BCA855F732A9C1955EBC131238B8A59D9B6AED0BA1CA30EDC2B304DCB815EA172952AB52AC2BE1663EE34F898A3648273B362DCDA
B3A2E3C91039C21CE871EC678B9515E6102D9072D9B0864B3FA0581335C598A43D869D38F0C14CD10E964A66FB312AC2E10251329C7952F9D68BA68F5F5EBA99
EAE2E1048953B5FE9669D8E4DC2B17056F383AD2B04D7B9ADDBA728C8F31BE7388A99CF6231A8B7D115E2C5BB5BE5EC553E1039DEB07BC7EBAFF0F2B90A2A2E8
AF856492282597C0FA8822EED6AA2D870A9EC3ECB3E04A7BC9B4C57C0AEE2B8A74D0ACA5E61C5C4942877422C9339F92C3C922AD20C88840E13E5C0EA4AFD2CB
CEA8BCF242B1C7C3AA230EAA07AE5ACCC0A596F4512D92B0330F48928A78D2C78474782AA1A80094EBA331041B8DBEBA8E3C48A4A8D2A88BBDA608AC2B8D13F9
2A32070013530A87A806FC6B321C6A8AC93317299250B9CDC00222A3E6047A08A69D10BA2D870E098228C0D2567A4E25B6026CA9A19D287220A30AABC4813540
5143493687BA22CDC606DD023239F47C1234C5D3EA1C2A48A5869BEA071D8603EA87A9B8DAF049EFAA8C754DA5943CE922E3222C2CA98250122A8344FFAAF201
08ACDCFC5040FDAAC2610C034B230941902E02AAAE72BD1C884AA8BEF2F6302F7D882A20003B}}
\par\par \b \uc2 Following Discovery of New Superbug in U.S., Hatch, Bennet, to  \highlight22\uc2 Introduce \highlight\uc2  Amendment Supporting Development of New Antibiotics; Encourages Innovation in Antibiotic Research & Development to Combat Superbug Threat to Soldiers, Public Health; Sen. Orrin G. Hatch (R-UT) News Release\b0\par\par\uc2 513 \uc2 words\par \uc2 3 June 2016\par \uc2 Congressional Documents and Publications\par \uc2 CONGDP\par \uc2 English\par \uc2 (c) 2016 Federal Information & News Dispatch, Inc. \par \par \uc2 Washington, DC - Following the discovery of a bacteria resistant to colistin, an antibiotic of last resort, U.S. Senators Orrin Hatch (R-UT), and Michael Bennet (D-CO) will \b \highlight22\uc2 introduce\b0 \highlight\uc2  their bipartisan PATH Act as an amendment to the National Defense Authorization Act for Fiscal Year 2017. The measure would create a \b \highlight22\uc2 new drug\b0 \highlight\uc2  approval pathway to bolster innovation and encourage development of potentially life-saving antibiotic drugs for patients, including servicemembers serving overseas who are particularly at risk of exposure to antibiotic-resistant bacteria.\par \par \uc2 "Doctors and patients across the country increasingly face life-threatening bacteria that have grown resistant to even our most powerful antibiotics," said Senator Hatch. "More than 60 percent of infectious disease doctors have treated patients with infections that did not respond to any antibiotics. The discovery that the mcr-1 gene capable of spreading antibiotic resistance among bacterial species is now found in the U.S. makes the need for action imperative. This amendment would spur the urgently-needed innovation of new antibiotics to treat the most serious of superbugs."\par \par \uc2 "Superbugs are a growing threat to our public health and national security," Bennet said. "The colistin-resistant bacteria found in a patient in Pennsylvania underscores how vulnerable we are to a growing number of superbugs. Yet, research has lagged to the point where a truly novel antibiotic hasn't been discovered in more than 30 years. This bipartisan amendment would encourage researchers to find new antibiotics to treat otherwise unstoppable infections before it's too late."\par \par \uc2 "Superbugs"--or bacteria that are substantially resistant or unresponsive to any existing and available antibiotic--are an increasingly urgent public health threat, both at home and abroad. While antibiotic-resistant bacteria kills thousands of Americans each year, less than ten new antibiotics have made it to market since 2000. Antibiotic-resistant bacteria is also a significant concern to our troops, affecting more than a third of returning Iraq and Afghanistan veterans, according to the Department of Defense.\par \par \uc2 In an effort to address some of the significant regulatory obstacles hindering antibiotic development and patient access to life-saving treatments, the Promise for Antibiotics and Therapeutics for Health (PATH) Act would permit the \uc2 Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) to approve an antibacterial drug for a limited patient population upon determining that the drug treats a serious or life-threatening condition and addresses an unmet need. In addition, the bill includes several provisions to guide appropriate use of antibiotics approved under this pathway, such as labeling and promotional material requirements.\par \par \uc2 Hatch and Bennet introduced the Promise for Antibiotics and Therapeutics for Health (PATH) Act as a standalone bill early last year. The Senate Health, Education, Labor, and Pensions (HELP) Committee approved the bill in April.\par \par \uc2 Read this original document at: {\field{\*\fldinst{HYPERLINK "http://www.hatch.senate.gov/public/index.cfm/releases?ID=A742F00F-16F5-4AD3-91B9-0CC9BC2BD2CC"}}{\fldrslt{\cf2 \uc2 http://www.hatch.senate.gov/public/index.cfm/releases?ID=A742F00F-16F5-4AD3-91B9-0CC9BC2BD2CC}}}\par \par \uc2 Document CONGDP0020160606ec6300038\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic Cleocin solution\b0\par\par\uc2 80 \uc2 words\par \uc2 3 June 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Clindamycin Palmitate Hydrochloride for Oral Solution USP, 75 mg/5 mL, which is a generic version of \uc2 Pharmacia and Upjohn\uc2 's Cleocin(R) Solution. Mylan received final approval from the \uc2 FDA\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives are inappropriate. \par \par \uc2 Document FLYWAL0020160603ec630066a\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw388\pich38\picscaley100\picscalex100\picwgoal5820\pichgoal570
47
49463839618401260070000021F904010000FC002C0000000084012600870000000000330000660000990000CC0000FF002B00002B33002B66002B99002BCC00
2BFF0055000055330055660055990055CC0055FF0080000080330080660080990080CC0080FF00AA0000AA3300AA6600AA9900AACC00AAFF00D50000D53300D5
6600D59900D5CC00D5FF00FF0000FF3300FF6600FF9900FFCC00FFFF3300003300333300663300993300CC3300FF332B00332B33332B66332B99332BCC332BFF
3355003355333355663355993355CC3355FF3380003380333380663380993380CC3380FF33AA0033AA3333AA6633AA9933AACC33AAFF33D50033D53333D56633
D59933D5CC33D5FF33FF0033FF3333FF6633FF9933FFCC33FFFF6600006600336600666600996600CC6600FF662B00662B33662B66662B99662BCC662BFF6655
006655336655666655996655CC6655FF6680006680336680666680996680CC6680FF66AA0066AA3366AA6666AA9966AACC66AAFF66D50066D53366D56666D599
66D5CC66D5FF66FF0066FF3366FF6666FF9966FFCC66FFFF9900009900339900669900999900CC9900FF992B00992B33992B66992B99992BCC992BFF99550099
55339955669955999955CC9955FF9980009980339980669980999980CC9980FF99AA0099AA3399AA6699AA9999AACC99AAFF99D50099D53399D56699D59999D5
CC99D5FF99FF0099FF3399FF6699FF9999FFCC99FFFFCC0000CC0033CC0066CC0099CC00CCCC00FFCC2B00CC2B33CC2B66CC2B99CC2BCCCC2BFFCC5500CC5533
CC5566CC5599CC55CCCC55FFCC8000CC8033CC8066CC8099CC80CCCC80FFCCAA00CCAA33CCAA66CCAA99CCAACCCCAAFFCCD500CCD533CCD566CCD599CCD5CCCC
D5FFCCFF00CCFF33CCFF66CCFF99CCFFCCCCFFFFFF0000FF0033FF0066FF0099FF00CCFF00FFFF2B00FF2B33FF2B66FF2B99FF2BCCFF2BFFFF5500FF5533FF55
66FF5599FF55CCFF55FFFF8000FF8033FF8066FF8099FF80CCFF80FFFFAA00FFAA33FFAA66FFAA99FFAACCFFAAFFFFD500FFD533FFD566FFD599FFD5CCFFD5FF
FFFF00FFFF33FFFF66FFFF99FFFFCCFFFFFF00000000000000000000000008FF0073081C4890E00F81070FE648281047C187391C368448B1A2C58B032546C488
5121438F1C438AB4A870E1C893284D964CC9122443950861A65938E687C234206926AC990367CF85337FD44CF831E8D09E0F8CDAFCF9234D52A03A4DFA0C8AE3
60D58D3E22FEB8FA33A840AF5B23567510312BD98656C3660D5B756B58B70EDD2EAC1A3747561C641DE2D06BF7ECD60712F9EEDD48416C5FAD7CA3E21CCA732D
4C981F117A8C4C19B2E5981F2B27BC7A57ABDD8D9C3D77BE7B30EBE7814B377F866BF2AADCB497334715BA13E8C1993889D2F6D9B4E9429B407C067FA0E6A09A
DF0B75CC3C9E06C818203DA13B2F12BDE70FE7D77F1C2F1E5C47D3EEBD95DFFFD658B7605D1F0F6A8E71ECF0418E0A19DD5F7DE003877BC039DCC7BC5852E3DC
827FFDE05E5E02E5755005ED65E55E619E9D25917EA9DD66924A1A858598409DB135D146A77DE690690499661564FEA1B6D15B1B4E68D0442BA918A28939F567
626B324EF82186A755B813486FC0A812194241379373C9F994C31850DD94DA188BD126216D501DE71B1009E186831A5929F55B4DE269F7570E0EC03622436314
C193540D2526D10F33F8479E7D28A2E8986708719523872266A4278B81E9A9A14D645236D39A27FAA0C36AFB016A1710E7A195A85D258919116E26AD65678BA9
C574E98AE57944A84B6DEDA72288276A5ADA8A980D34157491F9541358BDA9FFB498753461D7A44DCFE9B65C0E459051411A3C018AE46E506AC79470B8397926
43822D8503B014E2FAD256F065852060F081E943B50F2C7521A21B7ABAE28111C1471E82F949842E83EE1D549843F00938D79868525AE77F33C6756389DE4E68
A18A99CE98694E9221D76F5957ED3B6268745926A1A80D5BC89588A1F9A816C06095298694D62149E591124A47EB41C1D904A44E3AF800244FCB35E5DD514D3D
D0E30F4072F75D4D40484925CD8036C92A90DE490C30A045D854746F80129DB4D136BDC1B4D34B331DF50F4514A12F8E2F9976238778BD882ED70DE72774605E
A17119A102C5EB59A402A38D1C4C8EBD8A5C552C7B8B62877EBA28EA6300AEFF1D138276FB8B990C3196FAEFDE8ED55699C141DDE65B8FCCC53413754BE59643
70BF31341553CFA50122B4C276BC259154A681D3E95036E8EFD43DB3EEA54DCDC10EE8CE482F4DFBC12DDE8929570DF35592690E72DD1A6AC1A269E94419BEA8
12BD1C8E387C7F3B166FD2B015DA78EA4B73755BA05BF855FC6F5D750D9B629F20F9E7BCBF9D4E146C953D1D375BD067CE262D638E5B1754714C5A17644291D3
06F3915F41887A2404AB97D1AC3DA8894BD26E77BBDCD42E6A69F855EB76969BD83D505C428B917D360298F3F18E43C2FB4198D2B590EE698E6F0AC95646AAA5
BC47B1ED6E85F3568F4E6730C1A5EA5E764B1F0EBC231FB1EDCD3535D15E0EFFB3879598804835E519489E54322CF1C14E80B379D5E4064840C79D6C5A81EACA
4B7882244AA5CE288F6959979C851E52FDA638B24BA3ED9286469CDC6E8D51A312EDB816990AD5053602290C7AF4529A6EA5AF791BDC900F82453767D18B2C98
3248124FB5C4D3B0E72B506A9CDC2233278025AA4F097B4C62E62411AFE0704605E214AA42C3BC1D21474A60D1C9FFDC6732E0144C95FEEB4A540492BF6921E9
2751111FB4C0C8392285483E4BB3A01A2AB040D72D245E6E6C5D84D4E8C012BA2871846A4F9FC2A51F0E39C03E8901CD67CC35A3990C0F4EFB9958027F87234B
DE10949409963A61D22873DAF05B5761E1B814B21619315253C034A2A3C675FF4798148F3723139264704206A8E0E65000C5A54241264B9A34749001641900FD
D545590AC5434A944CD48002074DC0A18215D44E11D49086A265AE381CED281A89E940670D0F448BAC1E0EBE862FF091B38323D4D3D67853998929C4355C918B
DE9EF710B9B8A663038B955251782F1A49845404A310680846D58CBE725E97FCE97EFE89A625B9844B9EF4E484BCF9933138C42BEAA1895E06A594B4FE400C13
826BE57A32C09810323F7B440DEBDEB08C7DD46319D0D88726D4A08950E480AFD1A88732A2E15765C0216AA0A84734E8110D7D2C43133691A0A2F6D92E01AD09
6D6E9217364BD22E106A2D2C79D1DE69FE25B11E0A043FFA914F35ADD2AEA0FF96505F2A1C48526EB3DBBAFA6845AAFD92BCD8C6220291273FADD19E134513CA
B374289B0DC18F28E994CA9B8CAC78F19B101769E310B301B28BD38CA836AF72A641C50CAE383853856E79D11445AA373E81C33E94E1D137684213CB00EC3216
0207650836131EF5AF267E9386BE82221370504326FABA5FE0586E5A974A835FB0BA959C92250D3DEA21F7AA225D6902A5472CDAC81BDE4095E5CD945652F9C1
0CB98934BC2AD19BF5AB926F7A62262891D874A6438DE706D22311F9E6C18E52D241FC88109C48A4389C31DD52F4B39632CD53AADA711A026CA240591DF35517
2519A548FA91677D14A839F0EEB3C6AA09189B19C3A683A80FD24052D32129FF4B3349AB43CA7C1031E00AC7387E585646E39AECFC40BE98CDD41BFC0B8AA5BC
611F94B3495F05F483C5722C2199986FB7224825E822E601A088866934A18CA8C6651FA0D607882D3426E9E60714A0DE07283638A8FE82BA1E70F84F1AF60187
193C4013D0A0276353BD8CBAC817D4D1C804421230EB37B887AF1216C81B18BB9037D4631F5212CAAE19DBE98D448318029AF524B487EA7D24761FB0C2D1A181
9D89763D60C1DE3C3459D5E05F504383AC3DD9C71B66B0E7392B23D93F48C0B8410D870428A4BFC906C5326625DF245D3B3F70A8479C91428C5413C3ACC0F208
92D0BB6BC1F2250D9A902CA81B1C6F6FEF63196AE0097D4B338607B47BBEB4FF5CC8C9410D40DAC24BC7B7D34734BAB5B46ED9D7260ED004B4890928C1FE40E7
505B5A05E41BEB584DA8020C5288031AAE0387A0DA9B1B9C29602C2B9050809B9EE5BC8A1E673D60F9767A4DF4D8874002EB1484D40314D7D4F94FBDCD240C9B
E4D6D096C1A231A40350B349E75ED139B81D4009501BBB8B1F7F831A3E1A13C666C2DF8255551A1AAE09A7856B206A00770E801E1104E81C0EEE29B67B2A3089
686822BD8B76CD3E28A1DA8568221AEEB34B62DDE35FB9E200EFF969784272BE0F3205F6F3C59E50A441918349CC3752BA4400637BA4F301D7E4F5FAD0C41846
DC9319FC601FC4207126D2E090315C7BE1C56733CA6FA38C657C14C315159EFF8E96A2F6CCB9EECFB5CF5C0E68FD03681083E64B13C83EF4017FE63D353F3A97
88DA276C21C176864E1C944D09A00FFBE00032607903761578870309B07ECAA011DD176F09287FA08000E6910399500F3F80009107077C046A9A400194100D25
17119C9678CAE05F1C7368C2D63C024180FBE07C82A55A709706FEC64E07E27B6AE00063907802215FD47758D0B6110907622938100ED0815127104F77165C07
260A756BD130288B754B932776A8F16CCBD01416671733305F0C387909787CDE9425FB90096D9203FEE51448027B39005720436B32602269405FD3B30FD03003
02715FAAB20CCA00429B312043E663B9B10CD14060E72784418703F25504B3FFF6582D6534396007B5B759D0431008D05762537ECF2510ED367219C5367D2258
53F651FF025848E85FF49179F2D683334316DEA60C99566E0D215F6F8003A82625E92158B4D683D477109A10597F180DF2B583024106DE460CB208620E2158D0
B00C0E90783F05847B531291F7060E006864E10091E68133608B9D046C2048645C9700A6011F9CA60681D157F33560DA830391966AFB400FBCA57361F615DDA7
0C0F176C0D518E6F90095CE619760640F62815F216173AE787D140096B316BD0E779336167CB000A03F9885A215766A586F3D57DCA771056481A5A913415A00F
CAC0522C155B02F131872642EE61042CA76E3C573AD9C188E0B65B5A052277FFF100C9B00FFA47829FE447F8C5604E612862812E1AE100B376787A076D0E9015
47F85A0DA7877BC17570E09303318F9B400C8DF7764B296F58537BCA500FCB567693070DA7376B62E0950282067E050AA1400CBAB87E24056ECBF00938027798
573045218F7F5815DF086DF611694EB11591A70994C057CA302C483983391259C616132788721C567C240558DEC4776247175CB76C193733F126610D377FE107
403E90003B19846350779430173A475F86D91332306B97A509D3F71597754B2C486F56781BCB70769BA00C8E0775C1E3178A2258142093CF278FB49603145009
CAC9720F508CF0F503BFE20302726846903497E41ED491039BC093EE8177F4FFA153F98100FE9606C9D710C1E32E9F9100F39500388000E809758B95033D3003
0D1058E3F9001590827E98470BB10F9B8000F7A11033A076F6784D34B10F25B771C7810314608FCB605940009857718611315BEBA70902E05FC1564D70A78E30
05138756669E447B66A56F72281099100D93609EEBE781B42458076022A7473D6042A007507CFA815F4E6172F590326F688F1ED97E9A9000C4C05893404BCFA7
0916988D957824CF2221F6F800762698B494714271623F719065370648590F9A603547327F09507269307DC37270E9A58762C019423A9EB6F131A620760E0404
B2080A9A50A79DA662020A07C9000A1266132D5A6EB3934C15500C3C993477FF915B61A1A2A0E07C24E95C6F4039F1669737708DEDB2956992513A970949E86D
C6287F8798037DC55E38F097FE97111F3701C7B7103E407BF2F78725D48370209FF3E7183A37062AF888FAF18491B1A115E09ED2C89A0C5A5A7B738D0D68223E
B00FA720208ACA101D681397574285E9526A2896FAA18457386FB1BA8033A00CEFF65AF987240E808C9F17795E29061510AE89279B6F864B032900A0E614BE47
0C0EC1AE67A94A49B10F9580A60EE5875DE04D6B28848B0A7AF7761066A2506A3250074174DDB2330FE000135B7C02A2738531AC3C77101FB728496364DE1626
D7611EA4B61127877A04D1B112C18E204810D1500C61E11E3909262CEB6DC9FFE610FB3683833129F5CA22CF39607BA80F3B58AD9F81856A0872031169390084
B3A68E0AF19C41F803E939032C481070376A70931F91C63113F200A1096A2D88B3304880CAE020395B6D933785751158A9A609CE856EEE2170834A93EFF166C9
07189106B4EBF100350B6E3635110E096A7F487339A08C9F271003E97BE5467DDE9406F48059046175A9461075A89C9EB941D24516D6B9347EB5B9B0031D55E9
73B4E74068741075B09C1F0B1F4F878895D2425F51669E715620C183B4D974FF41622AE25C62A160F6825C7A489BDB531046425B6DA60601695D024152045174
01F416A8743939566424A506B8FBAB0931038F566456B5123F201EFB611A49FF4158605A10D38B521DC2666C3626EA454B1D855C3A7613A9870364F00666A510
CADBBC73D145B0AB10ECD5446CB2B483453700E4660C018739764B63A664197956B08B4BC0F2516A300921D75E78D221C0719DF3952D80B26CDD57684B2B6F9A
B534FEF55811A273A1B0B1D8FA18E3894DAA6527A5821709804847B93DC7455BF059C17BF10016E81FEFE2BE39D55CEA57270791533FC5BD101148A7711F3E34
6402613510624958F74E517C2F8844C550582280312004117544611F84431735A2A0363210DE9528F59B26AE05AB3C31906C611F7285511EF92CBB154083843D
40915D5CB4C5928321A6B61145503236017782E58840300CD0576098F500A7FFAB33F0B533FE450C09F6677DF5800F84101D84365AF51FC4F55AACB55A8E542E
E9821F22942239422D3A05538B8424EB61C49E9C40CCFA282FA211898335A09127D342612ED436A0E4CAC475CBA9923BC16A2159B2439A2C3C121549A6A215AA
5CA46FF824E193BF9362575081B8B3C4C64DA45017B3C299F7B1D43906920B6C85D69F985501197834B9314715707AF2286A342747FD02221A86AC666429ACF1
19A4521E48CC47DA242F76C164D58403E768555F33CBC475449F6530684331C16C22E95347B0BCC51A644EA7B21A2E9C49A715BBE58355D9A4196305571255C7
7DF28BE9A51364E010648A267655A4024C1B4F312C6F15CDE30151B8423775FFC1B87A1C18C644016CF606CC5B3447637E219C34553162632A366A8447F44C27
6CF3C3D5F45AAEAC35FF31A217481EFC7CCF6FA11F8BD424351443243BC6A2882A2EE14E7A9316A012D6E564460FC14991523D8263C74E45CAEB017198E1C2B3
513DAE974AEB2110DE85BC3D8194017415DE354919493DBA44139FB327D8A451CA9459E6A71BDC7C7EF0112F17DC3A7B32C600A8D4FAE22DEC3164FE81D550E8
21433C8813211161A2BBF7372104ED305D162D7DB319112DCC03E17CD5B3D6B75C5538292A5D5CCCFB245496FD123A62C1A9D248A4714B5E415EDA2B3D5671C6
ED251459B13E05611ACBA2CC01D45665E55064B584B475A87E76418FBD33B4FF53BA2D15DE474D6A44863D5B432317E822D1A4214DF5D98601A0978D1E9A22C4
50B4395A0275F30D128F643D6D5DD6C3731912BD378FC1DB7CB367F3AD4F95E43080685507BD106FBC1A59E15D96724B206236CC7C51573128B8945EFED36475
E691669C1E0C4523CB2C3AF092D80A1447E7771D91E840E79C4CBD413B6FC44EBA15273EE41F47141633612D7C3161BD23A7880227A055C453C54444C11431D6
3C257B4EE85D38608D194EBE149B6DCB03EE22F6F410FD04424A3430AB435421C9A471834B56C81420C31568B0125922DDAF61173C1154EA71543F60363321E1
6B7C5111A7120339DAB83D9D8B8D3AA5FBB16F144C53833A1F835C8DF2595859EDCB78733EA496D8F2F14124E4D9FF97D8B4BCD5646EE751EC3CB0413E31F53C
ED24E06BDD5545F5496D4DDF66BDDF47F53661EDDBA8ADC761717C54F616636612E8C5CC4C6A67857DD8ECF513B3BE1A842D386636565FC1E1FF01B421D8D416
536304732AE8B2C32B670447D9D152E607DC3744E00913EAE21217A636B38401DAE70D265837221D36DD3B1230D8B3D0B53D548133237992EAB2B1D5FD74478D
62C45BA35578C4E5665D1EA6D174599472FC2B71A502751725D3EDFD137BAD562D9756624EEB0F7310651C84A6E14D72B68A74C22FE874F17C3310A9C91F9AF4
1F9A3BDA9EA210B5F58E58F51EE4D3101A8C40A8C22073E2201DF4DF5B51636134C5135D8DAE2CC4391154F79E2AE5912CB96C4366BDE54AEDC9E9CE440E45F3
E384D199F4D78D61D8734156AA111504FFF488621A064EC75913CDEC65C023BE63F066217E11365A7E387D332FF777F5067E4F177237555ECAFFBCCCDFA16415
A4A2D0F6611632E23B064120870351B8B15DFA6CCB3742E4ADCBDFF1DEDFB7EC185A02DDAA35F702832F5425CBFB544939B1D962E1D6D6553923AD35E2A35636
616799EFEBAD116725E1158D7B24272D144DE44469AED5F7585615802494FE54923ED73CCF2C18914D2502111AE6101FFFC29B8E2FC11D5D19A1214BAFE72601
1F265421B5B55A45A1E8302FF497DDCB21E6D658E62A4E824B5CAD7E465C55E544E08B5E3CA983DB7CD2E8520AFE50D26471A1DCAAD4CC54BF1A796EE1632671
75EC505981EB3D81CF6465E10C1BBBDA34A2008123478E1F0207FE189810218E823F1CF8788043A08F8439280E642890420E860E081EFC8810FFE4C790233F32
4C68502447830337E678C051A4C00A1823B20C6910C74D9518098EF92132A8C99525491E3D8950A851994D1BE64833308DD21F40A7023D28B020D18414958244
C9B422CA8B5B093EC02A542BCA855F732A9C1955EBC131238B8A59D9B6AED0BA1CA30EDC2B304DCB815EA172952AB52AC2BE1663EE34F898A3648273B362DCDA
B3A2E3C91039C21CE871EC678B9515E6102D9072D9B0864B3FA0581335C598A43D869D38F0C14CD10E964A66FB312AC2E10251329C7952F9D68BA68F5F5EBA99
EAE2E1048953B5FE9669D8E4DC2B17056F383AD2B04D7B9ADDBA728C8F31BE7388A99CF6231A8B7D115E2C5BB5BE5EC553E1039DEB07BC7EBAFF0F2B90A2A2E8
AF856492282597C0FA8822EED6AA2D870A9EC3ECB3E04A7BC9B4C57C0AEE2B8A74D0ACA5E61C5C4942877422C9339F92C3C922AD20C88840E13E5C0EA4AFD2CB
CEA8BCF242B1C7C3AA230EAA07AE5ACCC0A596F4512D92B0330F48928A78D2C78474782AA1A80094EBA331041B8DBEBA8E3C48A4A8D2A88BBDA608AC2B8D13F9
2A32070013530A87A806FC6B321C6A8AC93317299250B9CDC00222A3E6047A08A69D10BA2D870E098228C0D2567A4E25B6026CA9A19D287220A30AABC4813540
5143493687BA22CDC606DD023239F47C1234C5D3EA1C2A48A5869BEA071D8603EA87A9B8DAF049EFAA8C754DA5943CE922E3222C2CA98250122A8344FFAAF201
08ACDCFC5040FDAAC2610C034B230941902E02AAAE72BD1C884AA8BEF2F6302F7D882A20003B}}
\par\par \b \uc2 With Superbug Discovered in U.S., Blumenthal to  \highlight22\uc2 Introduce \highlight\uc2  Amendment to Support Development of New Antibiotics; This amendment would encourage innovation in antibiotic research and development to combat superbug threat to soldiers, public health; Sen. Richard Blumenthal (D-CT) News Release\b0\par\par\uc2 456 \uc2 words\par \uc2 2 June 2016\par \uc2 Congressional Documents and Publications\par \uc2 CONGDP\par \uc2 English\par \uc2 (c) 2016 Federal Information & News Dispatch, Inc. \par \par \uc2 [WASHINGTON, DC] - Following the discovery of a bacteria resistant to colistin, an antibiotic of last resort, U.S. Senator Richard Blumenthal (D-CT, along with Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT), will \b \highlight22\uc2 introduce\b0 \highlight\uc2  the bipartisan Promise for Antibiotics and Therapeutics for Health (PATH) Act as an amendment to the National Defense Authorization Act for Fiscal Year 2017. The measure would create a \b \highlight22\uc2 new drug\b0 \highlight\uc2  approval pathway to bolster innovation and encourage development of potentially life-saving antibiotic drugs for patients, including servicemembers serving overseas who are particularly at risk of exposure to antibiotic-resistant bacteria.\par \par \uc2 "This critical legislation will help develop new drugs to combat the deadly threat of superbugs. These antibiotic resistant infections are a menace that mandate urgent action-- including a streamlined path to approval of new antibiotics to fight them. ?The alarming arrival of this superbug signals the potential emergence of a truly dangerous bacteria resistant to all antibiotics, and a looming public health crisis that we cannot ignore," said Blumenthal.\par \par \uc2 Earlier this week, Blumenthal joined Dr. Jack Ross, the Director of Infectious Disease at Hartford Hospital, to call for action to fight the spread of antibiotic-resistant bacteria and for passage of the PATH Act. Blumenthal has also previously led bipartisan efforts to spur development of new drugs to treat increasing cases of bacterial infections resistant to conventional antibiotics.\par \par \uc2 "Superbugs"--or bacteria that are substantially resistant or unresponsive to any existing and available antibiotic--are an increasingly urgent public health threat, both at home and abroad. While antibiotic-resistant bacteria kills thousands of Americans each year, less than ten new antibiotics have made it to market since 2000. Antibiotic-resistant bacteria is also a significant concern to our troops, affecting more than a third of returning Iraq and Afghanistan veterans, according to the Department of Defense.\par \par \uc2 In an effort to address some of the significant regulatory obstacles hindering antibiotic development and patient access to life-saving treatments, the PATH Act would permit the \uc2 Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) to approve an antibacterial drug for a limited patient population upon determining that the drug treats a serious or life-threatening condition and addresses an unmet need. In addition, the bill includes several provisions to guide appropriate use of antibiotics approved under this pathway, such as labeling and promotional material requirements.\par \par \uc2 Read this original document at: {\field{\*\fldinst{HYPERLINK "https://www.blumenthal.senate.gov/newsroom/press/release/with-superbug-discovered-in-us-blumenthal-to-introduce-amendment-to-support-development-of-new-antibiotics"}}{\fldrslt{\cf2 \uc2 https://www.blumenthal.senate.gov/newsroom/press/release/with-superbug-discovered-in-us-blumenthal-to-introduce-amendment-to-support-development-of-new-antibiotics}}}\par \par \uc2 Document CONGDP0020160603ec620004z\par }\page {\par\fs20\uc2 Generics News\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  New Strength of Generic Doryx\b0\par\par\uc2 Da Hee Han, PharmD \par \uc2 150 \uc2 words\par \uc2 1 June 2016\par \uc2 MPR, Monthly Prescribing Reference\par \uc2 MPRMPR\par \uc2 English\par \uc2 \u169\'00\'A9 2016 Haymarket Media. All Rights Reserved. \par \par \uc2 Mylan \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Doxycycline Hyclate Delayed-Release Tablets 50mg, the generic version of Mayne's Doryx.\par \par {\field{\*\fldinst{HYPERLINK "http:"}}{\fldrslt{\cf2 \uc2 Mylan}}}\b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of Doxycycline Hyclate Delayed-Release Tablets 50mg, the generic version of Mayne's {\field{\*\fldinst{HYPERLINK "http://www.empr.com/doryx/drug/653/"}}{\fldrslt{\cf2 \uc2 Doryx}}}\uc2 . The final approval from the \uc2 Food and Drug Administration\uc2  (\uc2 FDA\uc2 ) for the supplemental Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application (sANDA) grants 180 days of marketing exclusivity.\par \par \uc2 This marks the first generic version in this dosage strength; Mylan also {\field{\*\fldinst{HYPERLINK "http://www.empr.com/mylan-launches-generic-doryx-200mg-tablets/article/498101/"}}{\fldrslt{\cf2 \uc2 recently announced}}}\uc2  the launch of Doxycycline Hyclate Delayed-Release 200mg. [HMICMS RELATED ARTICLES]\par \par \uc2 Doryx is a tetracycline antibiotic indicated as adjunctive therapy for severe acne. It works by inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram- negative bacteria.\par \par \uc2 For more information call (800) RX-MYLAN or visit {\field{\*\fldinst{HYPERLINK "http://www.mylan.com/"}}{\fldrslt{\cf2 \uc2 Mylan.com}}}\uc2 .\par \par \uc2 Document MPRMPR0020160602ec6100002\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  first generic of doxycycline hyclate delayed-release tablets\b0\par\par\uc2 103 \uc2 words\par \uc2 1 June 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Doxycycline Hyclate Delayed-Release Tablets USP, 50 mg, a generic version of Mayne's Doxteric, which is being marketed as Doryx. Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its supplemental Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application and was awarded 180 days of marketing exclusivity for this product. Mylan also recently \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of the 200 mg strength of this product with 180 days of exclusivity. Doxycycline Hyclate DR Tablets are a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.\par \par \uc2 Document FLYWAL0020160601ec61005xx\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 Cannabis & Legal Marijuana Sector Continues To See Steady Growth As Companies  \highlight22\uc2 Launch \highlight\uc2  Newest Innovative Products; Company to Develop First Ever MMJ Plant to Paper Product\b0\par\par\uc2 1,215 \uc2 words\par \uc2 1 June 2016\par 08:30\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 CORAL SPRINGS, Florida, June 1, 2016 /PRNewswire/ --\par \par \uc2 As legal & medical marijuana uses evolves and becomes more accepted in US society, companies continue to push the industry forward with increased research and the development of \b \highlight22\uc2 new products\b0 \highlight\uc2  and services. With Legal Marijuana Sales expected to top $20 Billion within five years, innovative and emerging MMJ/Cannabis companies in the sector race to develop newest products for states currently online with production and sales.\par \par \uc2 Newest innovation of importance in the sector of note today in the markets: \uc2 Freedom Leaf, Inc\uc2 . (OTC: FRLF) of Las Vegas, NV, announces it is a equity partner in Plants to Paper, LLC of Woodbridge, NJ - First Ever Marijuana Rolling Papers - Plants to Paper, LLC (PTP) will create the first marijuana rolling papers to be sold domestically and worldwide. John Ostrander, Managing Partner of PTP and \uc2 Clifford Perry\uc2 , CEO of \uc2 Freedom Leaf, Inc\uc2 . signed a contract that includes an investment in PTP and for FRLF to Incubate PTP. Another example of how the Freedom Leaf Magazine, its website ({\field{\*\fldinst{HYPERLINK "http://www.freedomleaf.com"}}{\fldrslt{\cf2 \uc2 http://www.freedomleaf.com}}}\uc2 ) and other media platforms create a funnel to bring important Cannabis Industry deals to FRLF. Mr. Ostrander, a Freedom Leaf Magazine reader stated: "It was with confidence that I selected Freedom Leaf to guide Plants to Paper through the maze of the Cannabis Industry. Freedom Leaf's experience within the Industry will aid in the success of Plants to Paper."\par \par \uc2 Read the full Freedom Leaf (FRLF) Press Release at: {\field{\*\fldinst{HYPERLINK "http://www.financialnewsmedia.com/profiles/frlf.html"}}{\fldrslt{\cf2 \uc2 http://www.financialnewsmedia.com/profiles/frlf.html}}}\par \par \uc2 Mr. Perry remarks: "The time is ripe to license and invest in this innovative product from PTP. Working within current state laws and mandatory regulations, PTP aims at producing a product that provides an enhanced feeling of elation, as well as a toxin-free, natural experience." The papers will be sold within the medical marijuana industry, and within the recreational industry in states, as legalization occurs. Licenses will be sold to major Cannabis Industry "pre-roller" and other well-known brands of rolling paper companies in each state that has legalized marijuana sales. It is important that each state's licensee manufacturers, under strict guidelines, its own PTP rolling papers since the product cannot cross state lines. Likewise, Mr. Ostrander noted the product's distinct advantages: "Many rolling papers contain toxins, flavored dyes, colored dyes, asbestos, glue, and harsh fire retardant chemicals are not clean for the body or the environment. Our products address these important concerns."\par \par \uc2 In other sector related developments of note: \uc2 22nd Century Group, Inc\uc2 . (NYSE: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced last week the receipt of an initial purchase order for MAGIC 0 Very Low Nicotine cigarettes from French distributor, Royal Distribution. Beginning in June, Royal Distribution will promote and sell the MAGIC brand in France as the world's lowest nicotine tobacco cigarette. Before the end of 2016, Royal Distribution projects it will have placed MAGIC 0 cigarettes in more than 750 tobacco stores throughout France.\par \par \uc2 Cara Therapeutics, Inc\uc2 . (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, recently announced that it was selected to deliver a presentation titled "Kappa Opioid Receptor Agonists (KORAs), a Novel Pharmacology for the Treatment of Acute and Chronic Pain" at the International Conference on Opioids, which will be held June 5-7, 2016 in Boston.\par \par \uc2 Terra Tech Corp\uc2 . (OTC: TRTC) (OTCQX: TRTC) will present at the 5th Annual Marcum MicroCap Conference at 9:30am ET Today, June 1, 2016 at the Grand Hyatt Hotel in New York City. \uc2 Terra Tech Corp\uc2 . (TRTC), recently announced that its subsidiary, Edible Garden, a retail seller of locally grown hydroponic produce, herbs, and floral products, has shipped its first order of nutritionally-enhanced lettuce to ShopRite Supermarkets.\par \par \uc2 FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at financialnewsmedia.com. Follow us on \uc2 Facebook\uc2 : facebook.com/financialnewsmedia and \uc2 Twitter\uc2 : twitter.com/FNMgroup.\par \par \uc2 DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated three thousand seven hundred dollars for news coverage of recent press releases issued by \uc2 Freedom Leaf, Inc\uc2 . by a non-affiliated third party. FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.\par \par \uc2 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the \uc2 Securities and Exchange Commission\uc2 . You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.\par \par \uc2 Contact Information:\par \par \uc2 Company: FN Media Group, LLC\par \par \uc2 Contact email: editor@financialnewsmedia.com\par \par \uc2 U.S. Phone: +1-954-345-0611\par \par \uc2 URL: {\field{\*\fldinst{HYPERLINK "http://www.financialnewsmedia.com"}}{\fldrslt{\cf2 \uc2 http://www.financialnewsmedia.com}}}\par \par \uc2 SOURCE FN Media Group, LLC\par \par \uc2 Document PRN0000020160601ec61000d4\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Provectus Biopharma Files 8K - Regulation FD >PVCT\b0\par\par\uc2 230 \uc2 words\par \uc2 1 June 2016\par 06:12\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Provectus Biopharmaceuticals Inc\uc2 . (PVCT) filed a Form 8K - Regulation FD Disclosure - with the \uc2 U.S Securities and Exchange Commission\uc2  on June 01, 2016.\par \par \uc2 On June 1, 2016, \uc2 Provectus Biopharmaceuticals, Inc\uc2 . (the "Company"), issued a press release (the "Press Release") announcing the launch of its newly redesigned website as well as the Company's official \uc2 Facebook\uc2  page. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 Pursuant to the rules and regulations of the \uc2 Securities and Exchange Commission\uc2 , the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be "filed" under the Securities Exchange Act of 1934.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/315545/000119312516609098/d193190d8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/315545/000119312516609098/d193190d8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/315545/000119312516609098/0001193125-16-609098-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/315545/000119312516609098/0001193125-16-609098-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 June 01, 2016 06:12 ET (10:12 GMT)\par \par \uc2 Document DJDN000020160601ec61001ba\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Titan Pharmaceuticals Files 8K - Other Events >TTNP\b0\par\par\uc2 271 \uc2 words\par \uc2 31 May 2016\par 17:14\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Titan Pharmaceuticals Inc\uc2 . (TTNP) filed a Form 8K - Other Events - with the \uc2 U.S Securities and Exchange Commission\uc2  on May 26, 2016.\par \par \uc2 On May 26, 2016, \uc2 Titan Pharmaceuticals, Inc\uc2 . (the "Company") announced that the \uc2 U.S. Food and Drug Administration\uc2  has approved Probuphine(R) (buprenorphine) implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine. The Probuphine subdermal implant, which utilizes the Company's proprietary ProNeura(tm) technology, delivers buprenorphine continuously for up to six months. The product is expected to be commercially available this summer.\par \par \uc2 In connection with the \uc2 FDA\uc2  approval, the Company will receive a $15 million milestone payment from its commercialization partner, \uc2 Braeburn Pharmaceuticals\uc2 , double-digit tiered royalties on product sales, and is eligible for sales milestones of up to $165 million\par \par \uc2 A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\par \par \uc2 The full text of this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/910267/000114420416105951/v441357_8k.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/910267/000114420416105951/v441357_8k.htm}}}\par \par \uc2 Any exhibits and associated documents for this \uc2 SEC\uc2  filing can be retrieved at: {\field{\*\fldinst{HYPERLINK "http://www.sec.gov/Archives/edgar/data/910267/000114420416105951/0001144204-16-105951-index.htm"}}{\fldrslt{\cf2 \uc2 http://www.sec.gov/Archives/edgar/data/910267/000114420416105951/0001144204-16-105951-index.htm}}}\par \par \uc2 Public companies must file a Form 8-K, or current report, with the \uc2 SEC\uc2  generally within four days of any event that could materially affect a company's financial position or the value of its shares.\par \par \uc2 (END) Dow Jones Newswires\par \par \uc2 May 31, 2016 17:14 ET (21:14 GMT)\par \par \uc2 Document DJDN000020160531ec5v003x5\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw205\pich40\picscaley100\picscalex100\picwgoal3075\pichgoal600
47
4946383961CD002800F7FF00C5E8F54AB8E09CD8EEF9FAFAF3FAFDFDFEFF81CEEAD8F0F8F5F6F664767A1CA7D96EC6E671C8E7E4F5FA8E9B9E2AACDB89D1EB4C
616652666B495E64C5CCCE76CAE8BAE4F3A9DDF09AA6A9B6E2F35EC0E43EB4DE203A41E9F6FB0E2A313C5359A4DCF07DCCE9E1E4E5ADDFF1F5FBFDB0E0F2EAED
EDC1C8CAC0E6F416A4D720A8D9AEE0F1CAEAF61B363CBDE5F45A6D7219A5D855696E7E8D906D7E829ED9EFAAB4B6364D53D6EFF8758589D4D9DBE3F4FAD4EEF8
2CADDBA0DAEF40565CB1BABC8CD2EC46B7E040B5DFEEF9FC92D4EC5BBFE3BEE6F459BEE3E1F3FA3DB3DEE5E8E97FCDE96BC5E68ED3ECA2DBEF82919479888C34
B0DD53BCE2D1EDF744B6DF60C1E4B6BFC11BA6D89DA8AB9AD8EE96D6ED98D7EE87D0EBB5E2F236B1DD2FAEDCCAD0D2FDFDFDECF8FC4F646923A9DA3AB2DED1D6
D789979A2E474D48B8E02A43496CC6E6465B604FBAE1697A7F324A5039505557BDE2153037122D3413A3D732AFDC51BBE290D4ECC7E9F524A9DADAF1F968C4E5
64C2E5F6FBFDF9FDFE8F9CA0C9EAF6D9DEDF1FA8D938B1DD27ABDAB3E1F274C9E77BCBE9F7FCFE607377D8DDDE43B6DFFAFDFE70C7E726ABDAF1FAFDD3EEF7AD
B6B914A3D7B9C1C333B0DC738387B2E1F228ABDBBBE5F4F9FCFE586B7057BEE3EDEFF0C2E7F595D6ED26AADADDE1E2DBF1F9C6E9F5FBFEFE87959855BDE225AA
DAF2F3F4F0F9FCA7DDF0BBC3C5274046AEB7BAABDEF1F8FCFEDADEDFC7E9F694D5EDC8EAF691D4EC7ACBE86F808466C3E5BFC6C8ECEEEF5F7276D2D7D8E7F6FB
31AFDC28414784CFEACCD2D3E0E3E45CC0E3CCEBF6DCF1F971828665C3E54BB9E14DBAE1F6F7F8DBDFE0EFF1F1DEF2F91D373EBDC5C696A2A531494FC4CBCCEB
F7FCE4E7E8A2ADB0E5F5FBECF7FC77CAE8384F5539B2DD8B989C19A6D8DCE0E1DEE2E3CEECF7EAF7FBD7DCDD5C6F74708185C8CFD0FBFCFCA6B0B3A0ABADE7EA
EBD2EDF7F1F2F3F3F4F498A4A78F9C9FC3E8F5D3D8D9D6DBDCDFF2FA183339E8EBEC7F8E92B7E3F3CFD4D667C4E5CDD3D4B3BCBE42B5DFE6E9EA2B444A334B51
DDF2F9ACB5B850BBE1FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F786170
2F312E302F2220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F6D6D2F2220786D6C6E733A7374526566
3D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75726365526566232220786D703A43726561746F72546F6F
6C3D2241646F62652050686F746F73686F70204343203230313520284D6163696E746F7368292220786D704D4D3A496E7374616E636549443D22786D702E6969
643A34434136463534303530463531314536393838464545313643313433353536382220786D704D4D3A446F63756D656E7449443D22786D702E6469643A3443
413646353431353046353131453639383846454531364331343335353638223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443413646353345353046353131453639383846454531364331343335353638222073745265663A646F63756D656E744944
3D22786D702E6469643A3443413646353346353046353131453639383846454531364331343335353638222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000CD00280040
08FF008DD51948B0A0C1825EDA84B044E29FC38710234A7CB84EC2980913665889C84A020735E1B63954142197C3011258399C14E1CFC4873F226079F86D462F
0E9AEE3D843626D1C37663C239FC21414284081322E072682F018755C4A4BD9C4AB5AAD5AB2FEBD0D9BA550A56872402701DDBE1EBBF171E564D60E3C183BE01
0E7DB44D10A3EDB48738DA3EF987A0AD074E13E5CA49D476E63F0C6D3511F630C1610D0F361C366BFBCCE1190F1CD6B299B0545DDB310998794860B6B4E9D35A
C7DA39CDBAB5EBD7B063CB369D9AEB6AD386C6D221E4E7EB9EB10F221EDA2A00229EAD41AE36DABAE26116AE981E1AD80AE421091874522C8BE86B6BF0871AB6
76FF92CE15D2C3055B5341BCB31502C43E79E8A898C8646B318800B61EB16A64EB17898B6CB5406D5BB5E1C7810766520044A3B8D2411755E8C61508A5FD4607
850E51B11526251067DC566960758080DDA540C03F805027051D8E607543105B09D2DB43A26C158235747CB2607F74CCB2011D3C48C41E1DEE3D049F7C0FE527
DF10132959446B2E38A21F8112566925570C9C4698030F55E2C119FF9CE0C1070FFDE2811A0EB1E2810CC8F8254F5F6854F587079538C48107AF3C64830760FC
138907177940419B91FD33273336D8B00F98FFA8E2970FD99C32DBA46651795B697648380AA59C76EAE9A795EA76A959B98DC5DB57060C32882F1335A1EA0810
75FF739041253C6481AA4556C5C42051980751274528C0551D1030129113AA3A7195068350A2C343C80E52DC43880861102F946C60CB051309336B4116480402
15926C25C92218FE63E9692AE8B68159168E97C256C338341C1DD33A741C1D64F0E1EFBFFE0210112574C080CA3F5CD0F14513E9FD03CB561A4484097055DCC1
C24B8808AB4D43CB09B1C55646FCD3211D4C443464AEFF1C09030315B45C011F577085047E5B5D0230C0173F04C158D830D1C30D10515965B80F2561A50AE39D
6661BA0ED13056BEFFECEB052054570D082CD148F4F156642CE8500763250D517D3686E20722806848878C112DC1D52010ED30D60E42B6F75E7C829CF8500182
6CFFE549444A2EC282D554CB2206445F6C95020DD4303244219F4C79E5E4122AD0436B84E160063D737A60C63FF1B4F5473EAF44E081260E5DE3C10FFF10D356
3AFFEC23285573D6F98FE91280A2C4136D01F6675B8A340A99437326A0882281E40097261ED4328E34A64301EAF4EAEA96871DD867AF7DF641907125936611E6
9243B57840CA3FB77800C7438A78D0CB4972B4D08B0703942FFBF85321468C43A229F1D033B3FB1399E4E101D1ACCF50A301850201F30F49FD831BE4988007D8
403D50ADAB34F3905030CCA284407830100E8C483226710B7444240C81C893431010081350E5179370874494D18C49000322A70884082012881BFE83131FFCE0
38FF1E8280134C428515FCD40593C8C4263A31894B348B2702608C2A1AA308C67AA216B7E8C4287EA5545C3915562C44076348E45E50DBD79594E5908CE52822
1DD0C1232032223A0801221918CB2084D0AEAD440122D4D88A1722420D1DE8CD210FA3C37E1E72B2BB510E6E349B1CACC8A3B80D6C605E5B6944F554739A0AE8
E61333BACA6F52D088BEC100110F41E387EC78951AD12162FF28401FE990848778612B3373882B844507595C65045B598343C480493A94A28DC282C121FFD148
23E1AD2111B9C0569E94A4AE58851D5B310555BC681561542903F0DA0A1BA5448742FC0347F85AE595B61091E9D0611EFF98D721FE2196E0848039132981318A
C9FF156A42043D7410C63FB6128B7FFC6811FFB0C556506032BB39F36865688544947425A639E40E65A85213363939733EE40194A38669960691E53C6D9577C4
CA31C6521D87AC612CD688482BB8321118D14114031B4BBA4A319610D48D488ECCDB43C0B615174C742BA37A8985421491026493725B99A44362C61515144360
AEC9141DB4201135B6D4213CBA524123120DAED02022B4E0DA4B1AF0A32AF9542275A403D11E12213AFC51226EA34305204202AECC3122C6D8CA0636E590894D
EE7210B1C02CC72209895215AA5772440876E11AB6F8A52DD27388032EEB81397CE31FB8680B378457287078000754918107C0E1105D70D603CE70483930EB10
2BFF78400E0E512D676F4881D78A848BB0111A64AD6408D610C63067F10097C414A7D69EC92133F00006FEA186B66CA477B4A3939D3C008A87ACC203E2F0935F
2263A642CDE97C11A98B1B20E242E0BE46B8C3B512B74AB3A58744371BFF808607AEF1107178A0B9EDD3046270B00A1B4C633472D2EE3FEE948387BCC103BF10
AF1BCC91967B0C0F81977DC143542197B6C8A1C1EE750D953681150280800755D264F83C60182554572539F0003CA4F28FCD1EF01F6368CB3EFED10FBF406322
3878417849E181F5FE030DB01D891C3C900CF19269C16D79F29CF01B9108C0632FE8C34C88452C2AD3104242ECFC0A5A321C8F872843027E81077A1DD2630FE8
C2FF21CCBB714494D0610F98E421F258726210E018F53D241717DE2C67776828D1B42506C8D8726BB87915148F85128A8EB4A451D365D31CC00298C6B411BC36
E94E7B7A228CFEB4A847CD9A5093FAD4A8DE66A54B53D7B16442D1842D0DA72122861D4C811F2F99F557740DDC064C610ACF0ADAAA49A51B315E250E5C798744
C8360B88A080725C75488AE85006AB20822B657908C3AA14856C3BA410D6ACCAB5B7E28A8774870EF3B40EE5F0518D8884D54A6C048F9536C851A49E068C5B31
B655C84807A34244950FD91736F440F082EBE1007F754860E970808784020692B844B91D32B23D40A4AD49F0152AB6468778FF8317053B241E522089BB3A2416
5BFFA1C57A1CEA902329600A06970518A5FA0F25A521140627F8010E590DAED4A3010ED18149E9A0075353059D610CE5BEB3C3952CFCDB4301DF4A4AABE289AD
6CD421C1E0CA12E85AD4A16EE50A1261440F68305F87DC930E77784880FCF690859F63E5407DA85023F26C3A90B89A7448EA442CB195BB43040934A0810B8C3E
954DE8E63B63DCCA0D9C460715FF03E0FA42CE55883AC8A8D14112BCA4AC37F23D6BB53D0013599CCA0D24FF8F1564073B0AE84D1D110A77941D693E848CC256
0C10C9455205155C3986AF2442F889E4752C8E17E5562E87723ABCEB1F694D67D4273756AED30116FFD0901418D1375BFCE33974B83A447626A13A1061220BDF
0EFF8A1730503A6C3DAFCD6EBD2327E7F4485E09B10F31BC848260098750290E6699073FB7E2085E5385A4FF9041BBF10FDB96465B51078590800A680925904B
0F3132A9A0035BD105FFC07D43C0005BD1706B950121B07004151155470723C0025BD10DFF704F57F0085A156C8CC47229131F57D00A5D60098E167C9194045D
A08009C8802235117A900A0C60345CE12DBA01039740084848088EC0500FD1069F801D56524B15B215E9120AFE111ECA1779AC741599D03782D037C7F0102896
07ED120011110A1770015805118CE03D7400345EC722DE731FFF8008DA40070FD02EFED48271D7727873483C55464D626F55210A69582F74B7153C005F633157
FFFF208456C28453782110E1075008755A981C58317401F510D2C415F0E710B8B7155C1011A3101F74B07B0ED16A74C082B3301665C787AEF787107176410238
FA61152EC01538F52B35C3885CE188903816554059AC018010017298687993735611210B5C510511D1563090700F410097602AA630161E47715C115310015205
034DEA2777CBF40F7CB715D64851F2051190301629F0007DC31537C0050C6008F8988FFAC80070E81040D00887100BF3003EAF7107D8E36F111102D8034E0F71
03DBF390083936D8E36D0E3105D88332124103FEC00382A00251500C62131199700476500AE40856D8E38C113102D8138B99A0017650047D20113A2005764005
0E17B8030FB93D6BF810DE00018B400882600A49400B881810003B}}
\par\par \b \uc2 Press Release: Lilly Details Robust R&D Pipeline to Investment Community\b0\par\par\uc2 1,467 \uc2 words\par \uc2 24 May 2016\par 06:30\par \uc2 Dow Jones Institutional News\par \uc2 DJDN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9 2016, Dow Jones & Company, Inc.   \par \par \uc2 Lilly Details Robust R&D Pipeline to Investment Community\par \par \uc2 Company has potential to \b \highlight22\uc2 launch\b0 \highlight\uc2  20 \b \highlight22\uc2 new products\b0 \highlight\uc2  in 10 years\par \par \uc2 PR Newswire\par \par \uc2 INDIANAPOLIS, May 24, 2016\par \par \uc2 INDIANAPOLIS, May 24, 2016 /PRNewswire/ -- In a presentation to the investment community today, \uc2 Eli Lilly and Company\uc2  (NYSE: LLY) stated it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023. In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period.\par \par \uc2 "We're pleased to share with investors the breadth and depth of the Lilly pipeline, which showcases our progress across our key therapeutic areas. This includes recent launches as well as a robust lineup of assets in late-stage development or already under regulatory review," said \uc2 John C. Lechleiter, Ph.D\uc2 ., Lilly's chairman, president and chief executive officer. "There are no guarantees given the nature of science and of our business; however, in looking at our recent launches and current pipeline, we believe we are in the midst of the most prolific period of new launches in our company's 140-year history."\par \par \uc2 Lilly's R&D efforts focus on five therapeutic areas where the company has assets and capabilities that enable it to compete successfully. These include four core areas--diabetes, oncology, immunology and neurodegeneration--and one emerging area--pain. Building upon a similar investment community meeting in December 2015 focused on neurodegeneration -- specifically Alzheimer's disease -- as well as animal health, today's presentation highlighted the company's R&D strategy and progress in diabetes, oncology, immunology and pain.\par \par \uc2 "We have improved the productivity and success of our pipeline through discrete actions aimed at enhancing focus, quality and speed, and by positioning ourselves as an attractive partner for external innovation opportunities," said \uc2 Jan Lundberg, Ph.D\uc2 ., executive vice president of science and technology and president of Lilly Research Laboratories. "These improvements have led to the potential for unprecedented R&D output."\par \par \uc2 Diabetes\par \par \uc2 Lilly's long-standing commitment to diabetes care dates to 1923, when it was the first company to bring insulin to patients. Today, the company has the broadest range of diabetes therapies in the industry. Lilly's R&D efforts in diabetes focus on differentiated therapeutics and delivery devices within three key areas of unmet need: glucose control, metabolic control and end-organ protection. The company aims to combine its strong in-house diabetes R&D capabilities with a comprehensive external network to deliver continued innovation in this important area of therapy.\par \par \uc2 Oncology\par \par \uc2 Lilly has a long history of leadership in oncology. The company has a balanced R&D approach across three key areas of disease modification: tumor cell signaling, tumor microenvironment and immuno-oncology. This approach allows for testing of combinations of internally-derived agents to address tumor heterogeneity and drug resistance. Lilly has a portfolio of differentiated assets across these approaches, including Cyramza(R) (ramucirumab), Portrazza(TM) (necitumumab), olaratumab and abemaciclib. Lilly's immuno-oncology portfolio will have five differentiated molecules in clinical testing by the end of 2016, and as many as 11 by the end of 2018.\par \par \uc2 Immunology\par \par \uc2 With the recent launch of Taltz(R) (ixekizumab) and the submission of baricitinib for regulatory review, Lilly has designated immunology as the company's newest core therapeutic area. While these assets represent the foundational first wave of innovation, Lilly has built a robust emerging pipeline of both internal assets and partnered molecules focusing on key pathways and interventions in multiple autoimmune diseases.\par \par \uc2 Neurodegeneration\par \par \uc2 Lilly's commitment to Alzheimer's disease is demonstrated by its more than 25 years of research and development in the field. As a result of this sustained effort and deep understanding of the disease, Lilly today has one of the industry's most comprehensive Alzheimer's portfolios, with seven molecules already in human testing. The company's Alzheimer's research includes disease prevention, detection and treatment.\par \par \uc2 Pain\par \par \uc2 Pain is an emerging research area for Lilly, focusing on non-opioid treatment for chronic pain. The two late-stage innovative medicines currently in development are galcanezumab (CGRP Ab), being studied for cluster headache and migraine, and tanezumab, being studied for osteoarthritis pain, chronic lower back pain and cancer pain in partnership with \uc2 Pfizer\uc2 .\par \par \uc2 A live audio webcast of today's presentation is available on the "Webcasts & Presentations" section of Lilly's investor website at {\field{\*\fldinst{HYPERLINK "http://investor.lilly.com/events.cfm"}}{\fldrslt{\cf2 \uc2 http://investor.lilly.com/events.cfm}}}\uc2 . A replay will be available for approximately 90 days.\par \par \uc2 About \uc2 Eli Lilly and Company\par \par \uc2 Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at {\field{\*\fldinst{HYPERLINK "http://www.lilly.com"}}{\fldrslt{\cf2 \uc2 www.lilly.com}}}\uc2  and newsroom.lilly.com/social-channels. F-LLY\par \par \uc2 This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as "may," "will," "estimate," "project," "intend," "expect, " "believe," "target," "anticipate," "plan," and similar expressions. Actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. Among other things, there can be no guarantees that pipeline products will succeed in clinical testing, will receive the necessary clinical and manufacturing regulatory approvals or will prove to be commercially successful. The company's results may also be affected by such factors as the timing of anticipated regulatory approvals and launches of new products; market uptake of recently launched products; competitive developments affecting current products; the expiration of intellectual property protection for certain of the company's products; the company's ability to protect and enforce patents and other intellectual property; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals, including U.S. health care reform; regulatory compliance problems or government investigations; regulatory actions regarding currently marketed products; unexpected safety or efficacy concerns associated with the company's products; issues with product supply stemming from manufacturing difficulties or disruptions; regulatory changes or other developments; changes in patent law or regulations related to data-package exclusivity; litigation involving current or future products; the extent to which third-party indemnification obligations relating to product liability litigation and similar matters will be performed; unauthorized disclosure of trade secrets or other confidential data stored in the company's information systems and networks; changes in tax law and regulations; changes in inflation, interest rates, and foreign currency exchange rates; asset impairments and restructuring charges; changes in accounting standards promulgated by the \uc2 Financial Accounting Standards Board\uc2  and the \uc2 U.S. Securities and Exchange Commission\uc2  (SEC); acquisitions and business development transactions and related integration considerations; and the impact of exchange rates and global macroeconomic conditions. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the \uc2 United States Securities and Exchange Commission\uc2 . Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. \par \par \uc2 \f2 \par  \par Refer to:  Molly McCully; mccully_molly@lilly.com; 317-478-5423 (Media) \par            Philip Johnson; johnson_philip_l@lilly.com; 317-655-6874 \par            (Investors) \par  \f28 \par \par \uc2 \f2 Logo - \f28 {\field{\*\fldinst{HYPERLINK "http://photos.prnewswire.com/prnh/20031219/LLYLOGO"}}{\fldrslt{\cf2 \uc2 http://photos.prnewswire.com/prnh/20031219/LLYLOGO}}}\uc2 \f2 \f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/lilly-details-robust-rd-pipeline-to-investment-community-300273485.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/lilly-details-robust-rd-pipeline-to-investment-community-300273485.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Eli Lilly and Company\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 /Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.lilly.com"}}{\fldrslt{\cf2 \uc2 http://www.lilly.com}}}\uc2 \f2 \f28 \par \par \uc2 \f2 24 May 2016 06:31 ET *Lilly Details Robust R&D Pipeline To Investment Community\f28 \par \par \uc2 \f2 24 May 2016 06:31 ET *\f28 \uc2 \f2 Eli Lilly\f28 \uc2 \f2  Sees Potential to Launch 20 New Products in 2014-2023 Span >LLY\f28 \par \par \uc2 \f2 24 May 2016 06:32 ET *\f28 \uc2 \f2 Eli Lilly\f28 \uc2 \f2  Could Launch Average of Two New Indications or Line Extensions for Already-Approved Products Each Year\f28 \par \par \uc2 \f2 24 May 2016 06:33 ET *\f28 \uc2 \f2 Eli Lilly\f28 \uc2 \f2  R&D to Focus on Diabetes, Oncology, Immunology, Neurodegeneration and Pain\f28 \par \par \uc2 \f2 (MORE TO FOLLOW) Dow Jones Newswires (212-416-2800)\f28 \par \par \uc2 \f2 May 24, 2016 06:33 ET (10:33 GMT)\f28 \par \par \uc2 Document DJDN000020160524ec5o00169\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw174\pich40\picscaley100\picscalex100\picwgoal2610\pichgoal600
47
4946383961AE002800F7FF005451528A88888E8C8CA3A1A1868485CFCECEB1B0B0949293E1E0E06B6869656262ACABABB5B3B4C5C4C4B7B6B67F7D7E5B585957
5454BAB9B93531324643444C494A262223373334231F206E6B6CFCFCFC5653547270702B2728484546E9E8E84F4C4D5F5C5C8583844A4747343131A7A5A6FCFB
FCD7D7D7242021FDFDFDE8E7E7454142514E4EFBFBFBF5F4F5EFEFEF5D5A5BB2B1B1D2D1D2A19FA03632336D6B6B605D5ECBCACBF6F6F6474445EDEDEDF7F7F7
F1F1F17C797AE7E6E74642432C28296764654946468B898AE3E2E2F0F0F0999798DCDBDB3F3C3DC7C6C65A5758F8F8F8F9F9F9F3F3F35F5C5D9A989939353668
6566A8A6A7322E2FCECDCD2E2A2B393637757273423F3F2925264D4A4BCCCBCBF2F2F2FAFAFA2F2B2CBFBEBEC6C5C5D1D0D1A9A7A8EEEDEE2C292A7371717977
77413E3F716E6F333031C4C3C4D9D8D9C2C1C1E4E4E4EAEAEA4C4849DFDEDF504D4D3834353D393A3E3A3B332F30A5A4A4CAC9CACDCCCC9B999A444041888686
939192595657787677807E7E817F7FE3E3E32A2627A6A5A5E2E1E19896973B3838D6D6D6434040F4F4F4E5E5E5E6E6E65E5B5BDCDCDC898787A4A3A3D5D4D49E
9C9C7472724B4748EFEEEE929091DEDEDEC0BFBF969494979595312D2E848182D3D2D2CAC9C9C8C7C7B3B2B2BBBABA3A37386A6768BDBBBC272324777475B6B4
B5B8B7B7F6F5F52521226C6A6A615E5F696667AAA8A8B0AEAFB0AFAF524F505C595A2D2A2A828080918F8F7B7979636061787576535051D0CFCF918F90DBDADA
ABAAAABEBDBDEBEBEBAAA9A9C3C2C3ECECEC767374E0DFE0D0D0D0ADACAC9C9A9A6F6C6DA4A2A2625F60585556838181302C2D9D9B9B666464848283C3C2C28C
8A8B726F70524E4F4E4B4C7E7B7CDAD9D97D7A7B8D8B8C3F3B3CE9E9E99796969F9D9EDDDDDD9E9D9DD6D5D5AEACAD585555646162908E8E403D3E7A7878C9C8
C8B4B3B3BDBCBDB7B5B6D4D3D33C38397E7C7D706D6E282425656363D8D7D8A7A6A7A09E9F959393C1C0C0727071AFADAEB9B8B89D9B9CF5F5F5888687231F21
9C9A9B9E9C9D828081FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A46443746313137343037323036383131383038334435314630433333393636372220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A37314432413841433531453031314536383342314337334644453946314437322220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A37314432413841423531453031314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3936353832434644323145343131453642323641433635413536343534384435222073745265663A646F63756D656E744944
3D22786D702E6469643A3936353832434645323145343131453642323641433635413536343534384435222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000AE00280040
08FF004B641097230B86837414D00AF3AFA1C32D689C204A7510C304469BD838DCB85197212CEFB8701CF94F1590722453AA5CC9B2A5CB97305F92382882A492
83677034CC7090D1C836340E0E48C901038A130D9B55C4367204860D0E9D615821D2E1978A9C1AD2EAC95145150C003832093AEB9F0B2418426C2C70905FC35E
07A1E8E0D8074316221CCB60C0E55083070C1D3E38AC70B0C44657A61A3AB5C1B1C4411A456662A8E99267DA8D94E61C5CB14365D1A32A831CD454E769C36885
538AC020D861B983A7C661D0F8EFC6C14F833024E0D8A20547680727546D68E0E01F5E931BE2D06C8B88DDE10DFD026EFD0F44EA91510E424B192255CCEFE0C3
8BFF1F4FBEBCF9F3E8535AD305C809863C0EF96030B0110E063AFF7A1C44C3E39F2D0C6260E0CF4648C4E1180518F4E200063134D404089E3435C346EF48414C
580D2D538643D218F1CF2A9B6C44C086FFC0330E20216020C53F85ECD6101E2168F00F0CF3FC7309052948461947DB54B4DD3F96A935D23C15A943523D18D0C0
42459DA8E4145424B9A04267E99154840A4B545965111F30C19164B8B0B749250C1C9192652CFC4308160705E1D26748D527CB4114F4F7CF930D4D53D141A478
900101BF6C61898C0D11322729BB34F408068E207350030D2571D01A1BFDB1672C908E04C041E03434CC530B1C54E33F3C7881811D1B49179843D6616018471F
A4FFB1270664B070C5109FE4A2C23FA66250CA4BA21CD407496B58505112D81D84474BB96190A643479C31EB4135F836522307FD3012040725C6D10D5F6100C4
0AE1FA9152AB877034C4418090B483B459F8E0D01B42A9540033D362208096FCAAC4441BA8A4A4812F599AA042300E5112F03F452CD28543452C6C16C00D2542
C40B1C69E0432223A950C4483CB8E1901B1873F4822F232DD1864E26A3DCEFCB2BBD4203041BF420020DCB3AE48DB1186C024916933091892007ED9B000660FC
C34628074530CC3FB221F3CF820C566A850D14D86042439184E284165A20F0CF28C336E4C8AF0DDD329424C948120E2E73A8D1502B13C402400F0458A1CD2B68
38FF7443145BFF13C8A90D4D7110011BA91089AC1878916E43351CF4CE462E1403C54182E492925E150DC1D224184400F3E8A4B3A423493254C4C74E0709C9D1
55073539525118F8F08226073DDB94690EC191C341725851D1030E8D72D0148A8C3403069472740E6CFFA45017067184D041D10D8D112E3A231D828131238D51
DA350D2D810806825027C30A0731B3C2F5B735B405EE1864334145A34A1604279E401303204111176D583715233C81166610C241E2802CCF18254E0DB1C14150
203787E0E91FA8D103475CE083D56060040E89C041E4B111091EC4730E61070640101D05026825B2C180283662848AC0602331380821FAF2975535A455AFE288
68FF9CC0111D04223B18B8C5E92AC315455504552B8113492251913DFC833050D2931260628A8384851280F1D20F308084869CCF1B29B9C44D1EB3438720E07A
B210D9A69276858314E01FD7D04DC67A481D208E245618B0E24A96D892208D840015810F49A4A8124B488677FF7847B6BAB1113B1CC41523A14645FED0918A90
610C1B699633369208B4546024FA39480E36028C3D316024AAEAE3754642AFB4CCA5212910C0412254BA97EDA008D682190E8AF0B05E8207073C48813197C9CC
663AF399CDC842275220034DD0C7218EC0C0146A500572DCC00258F8871630308464606011755C83F730B00A58608019FFC8C34116F08F6554AD210520C320FE
01FF092098E11F8A2083005AE0066ADC300C1880800E5C604E1150930490D24B005EC005564C201F2C72C716FE410532702F40B518032A84A08A7FD422160E01
44D99E091E15648397FF2847591A923A10F826183C181C145200079D180303E050611260800186FCA3159309101B7251916BFEE30DF870C83736048300382405
7AE00431B4E09059947427F0E1C0161DA28409D101180EC9C00158E4A686788211325A02040C60833BB0F4AE784DC906D8511E13B4C00968E3D541DC410110B0
601D7B528225361239BBE4200E2CF801292A2204088E84151571914A5A900D67E5F5B3E0910CE238B20BF8E9CE328CE1081CC285A1D9CD8A172BB9206867DB12
42FF6EC41C15F110905A471250542469AE85C21A3670900BB42125B28D8E185880020C40210A03FC870EC2C089E38E840B78214937A880B07F9860064EC1401D
1200DC7F2C0112903842E038D2089671841054C8EE3F40618C4F100A979078822D2AE00146A001AD0E494426108481391C43060EB1AD4318D05402BA6E23FD38
08129AB0C807FEE31E15C9004964AB820B60E00DD66808288070107D346407C2C3003D394254DD6E44186474C13F1E7090574AF777F7BCC54148B4919F2A6024
BF38C846BDFB1741ECAA21E138082C7CA38163CCF31F9DA0C82AE4F58F5FF06C4592B12A47EA083D02CE70236AB81C391D089A86D0F8C91BB9E0160E620F541E
44FF90C438081016EB10C7D87123CFC300150447B4B13A040CADF05243F47090736CA41114C1001A1DD28439558287D361D5418A4192E2E8792444C5C00C1E39
AD1F6002941BB1CCB47A20329630B2212F1823FA12A518DE1115020528C1032220E68A70C021CD6AAD0A48918A9908C1212D10DEA31BF2848AD4A07923491D06
D240E57F88F07E1880A01F3090DAE8F051D2AE1A8909FE628630CC40182C30DC9E3291E59758A6AD27805F3B5A726AAB54441C0D011D94ACB302577C431B8256
89380EF28486A4E810BB3888969F71198E0003741581807C1B32808324A3213DB2A21C30008B865C0505A5B676A47F384B87F8A0344AF8C21182B1DE8D285825
86FF7488689415C57D947924043F8801220725A2D6A1642369C216D6CB03CD90A20518BE42433671906FBCE020C953C925C4FDCF8D480503A060020642B13509
1CA419FFA0838AF6B8F1EA74BC21DBC6800754E283309CFC4CBCDD88F10EA259D7BE7C245DC0F141A0649BA953C72197F82047EEB0990ED0804AFF589210E8B5
228704C2037A58F83F9441AB4560467872088A5D1B62A97564E7D65CF7A1D7B33D921C62201C2469B82A1837DA42A69D239B3AC8282AFC7692A8A12250026800
4901815248435A322409910E32F986ACA122EBDEC822A05D8DC049E2208507734586ED90BF60C010CACC980235DFAAE47F6BB2E25A85301230F13163A20766B8
C4FF4B4C510A3F509A24BDF04300A2708A917CE11998B8254B62508D5770C404BCB04128A67086639497247B0004AD3012AF00054150720E31064FA00CD7E305
09105D1C510C13602E1CD10D6F300259311229200973600B32D610B3800858400F2BC103DC100B72500739500B08465B2EF88230188332388334588336383AC8
30022B8008DB30128F703F53800D320004F88100E3840168B08118802C37807009705C95103A0DB10718F0086056012B70068EE01077000B3F80083DB0357810
0D33E001175013668005562035FFC007AD10091480044E00070EC10D3AF8039120623310097A600857A04C92D040FFA0021A76830D8109E9E010D5200C0E913A
42FFD0198740051F403D8BF07C9DD11F92640E29A239FFB03C8E1020187006FFB02E0DD210D4403E16776BC78079FF80037270048D60088ED786E10439586706
1AE41071E02143E02DFF8006D1104F86E01049302C44F00366F20FB8005B86F80F8350050950085480063B221FA5D810F621070D11035AF749751420CFB011E4
0002528001AE000342604FD7A40371D0821BF10656E81051C00DEAC055945788FF5003F0E104CB2022D2F00F76E00535F0049D200A99C022AC408C302023F130
09FFE00C3DD08CD285040ED010AF800185202218A00919E005391067D3700416810DE35400D3660D08850141C078F0546CA8E24EE6E810469006DAD010110001
FFA0A006A49033B7B00263B34A0D510B09D910ACD06FD9D429FFF00869D0041A400E89F80FC8611899B00A7FA60CC5440BA4F05512A92698D07EB511081CB104
C320125D300C8AA04C5D80002EE3068D40251A4004D4F1024740610065091FE81090C007BDC0113E6004F6D5105D4097AD78972E90254E6055BF300338F70F08
300FA0D01077B02B1C037693591B5840095B99992E5103FB421E8D30012020980101003B}}
\par\par \b \uc2 New Study Outlines Pharmaceutical Industry Spending for  \highlight22\uc2 New Product Launch \highlight\uc2  Activities Before and During a  \highlight22\uc2 Launch \highlight\b0\par\par\uc2 503 \uc2 words\par \uc2 20 May 2016\par 18:30\par \uc2 PR Newswire\par \uc2 PRN\par \uc2 English\par \uc2 Copyright \u169\'00\'A9  2016  PR Newswire Association LLC.  All Rights Reserved.   \par \par \uc2 CHAPEL HILL, N.C., May 20, 2016 /PRNewswire/ -- The \b \highlight22\uc2 launch\b0 \highlight\uc2  landscape for new pharmaceutical products continues to evolve. To keep up with market and technology changes, the pharmaceutical industry has to continually shift its investment patterns for the activities that support a \b \highlight22\uc2 new product launch\b0 \highlight\uc2 .\par \par \uc2 For instance, medical affairs, digital marketing, health economics, & payer activities are growing in importance while field-based promotional investments such as samples and \b \highlight22\uc2 launch\b0 \highlight\uc2  meetings are being reduced, according to a new \b \highlight22\uc2 launch\b0 \highlight\uc2  study by research and consulting leader \uc2 Best Practices, LLC\uc2 .\par \par \uc2 Almost half of the study participants -- 44 percent - are expecting a decrease in funding for samples over the next two years while 30 percent are expecting a decrease in funding for launch/kickoff meetings.\par \par \uc2 "Winning Necessary Resources for a Successful Product Launch" will help pharmaceutical companies develop effective launch and pre-launch activity budgets to ensure successful U.S. market entry for new products. This comprehensive benchmark study investigates current costs as well as budget and staffing allocations required for a successful drug launch. The data in the study will serve as a reference or comparison point for brand and marketing leaders as they develop budgets and allocate funds for their new brands.\par \par \uc2 Key insights and metrics in the study include:\par \par \uc2 \f2 \par    -- Industry average cost for new pharmaceutical product launch \par  \par    -- Average cost for multiple specialty, single specialty and primary product \par       launches \par  \par    -- Percentage of budget allocated to 12 key marketing, education and market \par       access activities during and prior to launch \par  \par    -- Timing for conducting 50+ activities \par  \par    -- FTE Allocated to key launch activities \par  \par    -- Anticipated budget & activity trends \par  \par    -- Top 3 success factors for launch \f28 \par \par \uc2 \f2 This report provides exclusive new data on the cost of launching a pharmaceutical product in today's market. The study identifies current investment levels needed for marketing programs, educational activities and market-access efforts required to bring a new successful drug to market.\f28 \par \par \uc2 \f2 For this study, \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  engaged 34 marketing & commercial leaders from 27 leading pharmaceutical, biotech, and life sciences companies.\f28 \par \par \uc2 \f2 To access the full 120-page report or to download a complimentary summary: \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com/rr1428.htm"}}{\fldrslt{\cf2 \uc2 http://www.best-in-class.com/rr1428.htm}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 For related research, visit our \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  website at \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com/"}}{\fldrslt{\cf2 \uc2 www.best-in-class.com/}}}\uc2 \f2 .\f28 \par \par \uc2 \f2 ABOUT BEST PRACTICES, LLC\f28 \par \par \uc2 \f2 \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  is a leading benchmarking and advisory services firm serving pharmaceutical and medical device companies worldwide. \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 's clients include all the top 10 and most of the top 50 pharmaceutical companies. \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2  believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.\f28 \par \par \uc2 \f2 To view the original version on PR Newswire, visit:\f28 {\field{\*\fldinst{HYPERLINK "http://www.prnewswire.com/news-releases/new-study-outlines-pharmaceutical-industry-spending-for-new-product-launch-activities-before-and-during-a-launch-300272630.html"}}{\fldrslt{\cf2 \uc2 http://www.prnewswire.com/news-releases/new-study-outlines-pharmaceutical-industry-spending-for-new-product-launch-activities-before-and-during-a-launch-300272630.html}}}\uc2 \f2 \f28 \par \par \uc2 \f2 SOURCE \f28 \uc2 \f2 Best Practices, LLC\f28 \uc2 \f2 \f28 \par \par \uc2 \f2 Web site: \f28 {\field{\*\fldinst{HYPERLINK "http://www.best-in-class.com"}}{\fldrslt{\cf2 \uc2 http://www.best-in-class.com}}}\uc2 \f2 \f28 \par \par \uc2 Document PRN0000020160520ec5k000f0\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw226\pich40\picscaley100\picscalex100\picwgoal3390\pichgoal600
47
4946383961E2002800F7000091A2D21D61AEEFF0F8005BAA6681C0C4CCE81460ADF8F8FC3468B2DADEF0125FADACB8DEC7CEE9758CC79EACD88599CE5A8BC3E8
EAF64871B7DEE2F28D9ED0F3F4FA8094CB2D66B1FCFCFE99A9D6E7E9F5889BCFB2BCE05576BA456EB62163AF6A84C2A0AED9788FC8BCC5E45F7DBEC0C8E6CAD0
EAF4F5FB014EA21860AE6C86C32C61AE0A5EAC7088C4D4D9EE9CAAD796A6D54485C08295CC005DACF1F2F9397EBDCCD2EBD0D6EC3066B1607EBE6883C1386AB3
2964B0C2CAE7EDEDF75A7ABC7C91C92562AEC8CFE93168B2406DB54C73B83E6CB40058A8BBC3E395A4D4F0F1F9F6F8FCE0E3F3EDEEF88FA0D2638CC5BEC7E5B8
C1E3B5BFE2D5DAEFD2D8EDA8B5DCD9DDF07990C8B0BBE0E3E6F45778BC4A72B8A6B2DBD2D7EDE4E7F4F8FAFDCFD5EC5879BC5376BAE1E4F34282BF426EB64180
BD427EBCC8D0EAFEFEFEF5F8FBD6DBEFB6C0E27E92CAE5E8F55478BB4E74B98A9CD0AAB6DD1A5FADA4B0DA0D5FAD3D82BF5174B9BFC8E63A6BB44681BE627EBF
4670B76380C06E88C4054DA2DCE0F28497CD055EACC1CAE6BDC6E52263AFA2AFDA738AC6F5F7FBF0F5FA5175BA7C92CA0A4CA1748BC60E5CABABB8DE5B7BBD0A
5CAB7289C54169B20057A80054A60053A50056A80056A70051A4F2F6FB0055A70055A64183BF0052A4005CAB788EC7004FA30052A5DCE0F195A6D5FBFCFEF6F7
FBFAFAFDF2F3F9E2E5F45275BAF7F7FBEEEFF8F2F6FA2764B0C6CDE8F2F3FAB4BEE14182BEF3F7FBEAECF6EBECF7034EA2DDE1F1D8DCEFEBEDF7ACB7DDB9C2E3
FAFBFDADB9DE95A5D43C6BB4F6F6FBC3CBE8FAF9FC416EB6FBFBFD2563AFC4CBE7BBC4E4CDD3EBDADDF0A9B6DDB0BADFABB7DEA6B3DCA5B2DBB6BFE1D7DCEFA7
B4DC97A7D55073B8EAECF7DEE1F24E7DBD6480C0416DB55D7CBE4181BD5C7CBD96A4D34183BE607CBD11499FF3F5FB4B6FB67187C3909ED0085DAC436FB6065A
AA5176BA5175B9EEF3F9A7B3DB95A8D40059A9F1F6FAD9DEF0FCFCFDA5B4DBFDFDFE93A3D3EBF1F8637ABCF1F3FA557DBDAFBBDFE5EAF55573B894A5D47389C5
597ABC045BAAFFFFFF0058A921F90400000000002C00000000E20028000008FF00C9F51B48B0A0C18308132A5CC8B0A1C38710234A9C48B1E24381FF326ADCC8
B1A3C78F20438A1C49B2A4C9932853AA5C597220CB973063CA9C49B3664D973673EADCC9B3674F9C3E830A1D4A5428D0A248932A5D2AF228D3A750A3FEEC27B5
AAD5AB2F9D62DDCAB5EB3FAD5EC38A5D0A76ACD9B353D1AA5DBBB32CDBB7704DBA8D4BB72EC7B976F3C6C5ABB7AF5ABE7E038B052CB8F056C255295D5A4CE9A4
E2C62B296DAA44B91226C886432A5E7C097347B09C2C59E284A9B4E98FA6535FDE7829B5E78C98448BBEC49192A5509406E8BE14AA92E64AA132E9E6146AD3A6
4CC8932B4F2E2A23254F982EC041A74842804CBE35DA96CD9DB676EEE02BBDFFFE175BF4269095928B5ECEDE136D4CC97D3F4F4EDB52724EFF3685B2A45BB7A7
F31E69C58E076F745046001F2498A028967897D1001728A860218EB8F70F25C51492602103784609025A882186161760E25C259FEC210D1651B488853461B033
5E7E9C6C61813352ECA28B3446EC000428400629242822E8400926971080C514A89C608A0F4238B183258D51624088228AD8011C823478E10C6F6429E6963378
B68911216AC1C3788D656301284090708D08430A29C221C56C32C49B226CC1490A4482B24821FFECD1062816F0210A0E6D44D3621448BC8000807751559B0CA5
D0904B2A6E68E0A91B5D0050CE009D65148712A9A412012D11B89145081260FF52C91E59A4E20514AF7DE8C50927DC528E6F9B7C620113ABF863ECB1FEC45266
479C4860022AC81AAB8203D1566B6C159EE4510031D6FAD3840C32FE334014AB28D1E40907C0E2C6023B984849062728418329A61CB0CA01A6FCBA1126AE8081
4A051310612247980C3386B4C578D1EDB11684220817C60E220A250F180B4E009584D184B12450404BB54A8861498096B236AEB1A754B3062E599C72EC0D3948
C6091F07F8734A173D74A184B1AB5C53C9002EFB238283CE0D4087B1058867C93026F813CF180B3400820E1B20E18F211D727449113BFB63853A873CC0863F16
B0720B033DE06185B14ABCD24330C9F8734D1F0EA8A003087D6C0046B5CE0CFFB009257B18EB83210E18E303DBE888878DB1A558D14501361C2C46761A7122C2
B16B0441B946A184E04F2ABF540283B15EBC1DCC206B1C7BCC0C9678606C044658528EB119B0B3C907B8F883C4D1FEA0D24B033A88F0CC186F8CFC59C91BD9C2
4DC4AECC5007027DBC3001CA4EB0630936ACF893C50A8CB0A3C82BAFF36149CDFE6C335E2516183B426F9050E38F30717C9089259489928916905C581B15C61A
12C47E9EC8C41B64D0880F882214DFA047C42A618B5028C0092AF0473436B1850C0021009C185DB41CC08E1A196B1928C8842724400863754110989883B1A690
820114C71500E0037E5823016411C26F1CF10405FCE1025770421AC67A4003FF43810273F4C258072887253E110B63C9E00F3930961642A3859D956014FE5845
0BE65709D16C010103AB944742410A63C9E112A4E184282A7181231A0B089520C2CEC610002465020758F4870CC667AC98752413E250DF1FF210017F1CA00F9C
98E14646D3914B0CA16627E0C1E644310051FCED1F96204129FCC1804FD4C711A9EB010B3660AC510460056B8B560B2C11417F48E13C94C8840776260C1D7822
05C662C011684309F1B0A3917088963EF4A7914C38C11FB8B8C00F8318464B04617AFE08442C2FA73B51E8C21FAFA8A327E2F0B92AE4321398E925A5C4D81132
1AAB17E1720E27D8B1006301C3158540C6E73E30305B3C8376FF00461FC7E3FF891618EB188CE04010393123D410A166ABE081229DB34812C483939EFC4726A8
C90003C8C058F128033B7A502D64D4A195AFCCC82678E00263492213B8F4870006B0114A8CE712C1AC052E36E98F2B8451A2C7BC05022A01447F6CE0A6A29087
B190F1894AFC220BFEF0023A4AEA045160620623F047012EEA8F2928607321018B39FD81CE5C29207BFE9087019A960A7A5E481451F5070030D1857D76A49F1F
C4062CFC818C148C732497C001F9A2C183FF7C24930FEDE46266300863BD420115F3C70406C0875C582B1B2005502526514853F4411429F5C7004A4334AD0553
09122800E3BCE189621E73143BED692FC679893CD0940897A8C4318C650C25FF34A108A39140CD0ED14A7F38C00099B82BC9C65846AEA6B3A5DC54EC0584304F
1365A20327F047053A60093CB89523A20081B1B000046325211429A104734B69810F40A7238085686C8B00D6571840123488852248204F6B852070AE84652500
60AC60FCE3129935400A52F009E301D358457045028CD584709416A7FE402D4F8DC5813F84E2C2E7B94461FD4181D0F4D61F42B80C2502914516F0600A2F0302
0F3271D3E311F79CC7D5C8266AE80F0D1441B4A92804272E1186839DE21004E5A83FFCC8114B686193AF78813FC091030377C4A52ED5DA0E14762C266480083B
6E68603DE989DEBA570B7130E643BB2584C5B9B21297A803B5FC61021CE027FFB3C918C528AC0004276B04A6C63A4728B6500B6351C1871096704F59610213D8
A0071240337E99E0C93AF4D9581BC8C43F04913B2C1C2163D0AAB2211050AAE196B3B85DEDC826CCAC84064021C25B7840D334D08B58B954C8445EA4188AA581
92A2E20758D5C8003AA00210F063A1FFE0442162F18568456307944BAF60E16A58034082093CE0C182BB450323182B164540C209E231085090EA429985052A68
E08F6648FAC97930962ABAD802F26181CBA74D2DE3C0018E038003120DBA40659B7C09CFF94309C570E90E8CB587F778A004D13D561A1C3084D59093235B0D35
C1D2FDEF469CDA053AA880B11A608B815102D6E3B104248CE506FEC102DF1FFFD94477D90C5EAD6D02127428E4B1601186192A9BCBFE6CB616B88A892D80F504
1CA0405A6147613F182B1793408176321B0631DCC1022F3877473EA16EDF6CF3584E8865BC270C6238A8220CBED8827828E10B63A90337AA301613F0B35F7F44
A0E1B0E1441FEEB1B16369400CC2D52AA8632C521AD7E2071CD5C005D2A73D04CCF0E31CE367CEA161357F0041EA1CA9C40E0E668296D7668D79B8C2B4FDE106
C363D2A1EA15850E8EC58014ECDC1F710805081EDAB04994C0B0D6F6070738D14E3607004094C86C2F2BE189AC79640655BF102578E78F063062EB3D8D0576E8
97354BFC609356B8001B916884F330C11FBE88B273C0598E405C5FED85788DFFDE613C1E4C50950963FDF71D36D144BA16C35D42064167FFC1EC1EF474178AF1
C848F9577990F4F24FCE702C91F6795B165B12F031AE3400A7E70F2090090D000A9EB00532E70F19F00BC6220577044D0E9035B9772C2CC5501F017CFEB06E19
710906706AFE000C454062827681B80719973000A2E50F2A100A8D208028A00AA620370FD65295B009018005C7D2029D357EC6F51A2688546A957E21230AFAF6
4F91801FE0E30F4E205CF5A702D1150F90D01CA276622C371298C00228F802E075738B31008D270F05337390001D39A001C8020714F74A96900DE4E30B04F50F
99F581222182249811953004D3060663D382F935463BC45503F07AC6620228FFE0395DF001C27567828080005084C8C3397BE71997600910632C0810004D1332
3F080941C30CB6D37E37E0701AC16C36F00933D805C5006CF9E185426079FF956BFF100AE3E05D65087A822551FBE0349142078FB60A7B80029B9058C66203E4
3087E761096D702C22201E7BF8642DE6879B6309D32000281361F27688B55109AEB03134D00215600AD1150192C05C2FF06089E41195C0888780892FE60F0BF0
5F50761E7130661450091FC05CA4D84BA4642C1480092BE70F6D402550460947B066C7F007D3500FB4B5535096119C40523C1451FF350461D0200DC909018006
FFA608BE6186FA3385C87200DE100A040046405033F190039E107BB1004B98FFB066A570059C60001ED890F9B703C4F40FDA5864A3772C86280504D590981009
17E00951602C1FF30A19200C35362F5A303294200689D619505609D8406E4D10700FB711A1900414F609FD21081DC000C7220575600946D0674A6092175209EA
702C818003B7C03881C002BAF1093C505CC567099BA00341E30332F0019F20238D41040B960029E07101200050400229C002E460007C3083EA603CA2900D9B24
049F30309B500670782C02400294B07A4C500694000AA71008964102C67203D9914228E80FA0E093C6C298FD31035B300286808B82107C04338DA5B45365E70F
23F0096A39009F6000D9F00A0D100AB6792C21A0004AF839FA630951840561FFC002E4690087808040D0625F918917C209CA602C02200572C00CBDB079ACE004
8E202B1E5033A7A0032D971BD7642C0E700DDDD90451500523B083C6927D22F506D0A09A05200D322003BD20730960006174098D57012E00068FE69C01001999
D04AE0900F5C981F1ED09D54D00C503066A890005DA002E7B109D4C40A060020405842027A2CB7A20CF4393D07400006B6091D2045B9D6184AE60F09300499D0
7EF1E002F2F90825002DB7902703B00B6C13067FE04D9036439C80007DE90FB9B006567038C60200DF761731D0096CDAA666E007C5B23050700567200B9D5003
CDE90F83B0057AC0A6DA10036E692CBB700528662DD4B00EDA60A76C7A0610FF000F99D62D4C0001DAD0A664B066D5F208DD30A99D4006807A2C78600764E0A6
10D034DDF20E1960069B6A0D2525A03510AA9D600610E00E0B832C1110038A4A067610A06CA007AEDAA6AF1A0337C0794F600FC5B6302370069DA00D4F903A09
60AB100008C6F2048A2A0B7A3036D5020BFA200B9AEAAB9D10039AF0ADE0AA09AD9006B36A48AD00AEE9102DA5B004E03A0BE4632CA6C02DD6520A6A70AEE1DA
0A883066DD8201B310AE9AA0A0D57200F6FAADADA0AFF1000EFEDA0AEF5A2D69B004E73A0BF5A0AF079008FDFAADB3C00BE56A2CC2A006E1DA0EC5CA0B89E0AF
E0DA0A18EB0FF8D0350B73021CAB09B3506C34F0052C5BB2F310AE8800B0C808120F152BB2DF1A10003B}}
\par\par \b \uc2 Natrol  \highlight22\uc2 introduces \highlight\uc2  first  \highlight22\uc2 new products \highlight\uc2  since Aurobindo Pharma USA acquisition\b0\par\par\uc2 470 \uc2 words\par \uc2 18 May 2016\par \uc2 Drug Store News\par \uc2 DRSN\par \uc2 English\par \uc2 \u169\'00\'A9 2016, Lebhar-Friedman, Inc. All Rights Reserved. \par \par \uc2 CHATSWORTH, Calif. - Natrol on Wednesday \b \highlight22\uc2 introduced\b0 \highlight\uc2  three \b \highlight22\uc2 new products\b0 \highlight\uc2 , including Natrol Skin, Hair & Nails, Natrol Biotin Plus and Natrol Extra Strength Turmeric. These represent the first product introductions since being under new ownership by Aurobindo Pharma USA.\par \par \uc2 The \b \highlight22\uc2 new products\b0 \highlight\uc2  will be on store shelves in May at select retailers nationwide, such as \uc2 Walgreens\uc2 , Sprouts and other health food retailers.\par \par \uc2 Skin, Hair & Nails and Biotin Plus are the newest additions to Natrol's growing suite of beauty products.\par \par \uc2 Focusing on skin health and vitality, both products are anchored with clinical strength lutein. Clinical research has shown that the daily intake of 10 mg of clinical strength lutein can help to improve skin hydration and elasticity. This nutrient helps protect the skin against exposure to sunlight and the environment, per research published in Skin Pharmacology and Physiology.\par \par \uc2 "To date, lutein has primarily been associated with eye health, but it has been shown to have a significant effect on skin. Most beauty supplements available in the marketplace do not include this essential ingredient for skin health. Natrol is the first to apply it in the beauty segment," said Michelle Baron, brand manager, innovation, Natrol.\par \par \uc2 Natrol Skin, Hair & Nails focuses on skin health by helping protect against free radicals and oxidative damage from pollution and UV rays. The lutein ingredient helps by hydrating and improving skin elasticity.\par \par \uc2 In addition to the clinical strength lutein, the new product contains 5,000 mcg biotin, a B-vitamin that helps strengthen hair and nails, and complexion enhancing ingredients collagen and hyaluronic acid. Rounding out the quality and value of this product, Vitamins A, C, D, B12, B6, and minerals copper and zinc, alpha-lipoic acid and horsetail have all been added to help improve overall health of skin, hair and nails.\par \par \uc2 Natrol extends its focus on beauty and skin health with its Biotin Plus product. Featuring 10 mg of lutein and 5,000 mcg of biotin, Biotin Plus helps revive hair, strengthen nails and hydrate skin.\par \par \uc2 Natrol Extra Strength Turmeric provides support for a normal healthy inflammation response, heart and joint health. Natrol Extra Strength Turmeric features CurcuWIN, a proprietary form of curcumin that increases absorption of curcuminoids. Turmeric derives its power from curcuminoids. Those found in CurcuWIN are retained at higher levels in the body than standard extracts. CurcuWIN has been clinically shown to be absorbed 46 times more than 95% standardized curcumin extract. It has demonstrated longer sustained periods of curcuminoid availability at high levels of concentration that gives the body potent antioxidant protection for cellular health.\par \par \uc2 "The majority of turmeric products in the market place are not easily absorbed by the body. Natrol uses CurcuWIN delivery method to allow consumers to get the most out of their turmeric supplement," Baron said.\par \par {\field{\*\fldinst{HYPERLINK "http://www.drugstorenews.com/article/natrol-introduces-first-new-products-aurobindo-pharma-usa-acquisition?utm_term=DSN204846"}}{\fldrslt{\cf2 \uc2 Read more...}}}\par \par \uc2 Document DRSN000020160518ec5i0002t\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw133\pich40\picscaley100\picscalex100\picwgoal1995\pichgoal600
47
494638396185002800F7FF00FBEAEAE6797CEB9EA1919191F0F0F0828282EEA4A6F2F2F2ADADAD9E9E9EB5B5B5D0D0D06E6E6E3333332C2C2CD8282CFBD5D6E3
696B898989F6D2D2F0AAABD30103F2B8B9A9A9A9CDCDCD9B9B9B7E7E7EFEFAFAF6D6D6B1B1B1E36165141414F4F4F4A2A1A1DEDEDEF1B5B6FAEDED666666E573
76BFBFBF8E8E8EFCF2F2C4C4C43B3B3B4A4A4AE8E8E8DD4E50BABABAFEF8F8F0B0B1DD5154DADADA616161EEEEEEDCDCDCECECECF1C2C3EAEAEAFDF4F4696969
E15B5EFDF6F6CACACAF5C9CAF8D9DA5E5E5EC8C8C8404040CE0000FBE6E6FCF0F0E88184BCBCBCB8B8B84444440C0C0CE3E3E3E88385D2D2D2D9252AF4C5C6E5
777AF9E0E0959595E9888AF8DCDDE6E6E6E36468F9DEDED8D8D8DE484C767676EBBBBCDB4448E1555AC2C2C27A7A7AE7AFB1DC3D415A5A5AEEA2A41D1D1D7070
70E77E80D72C31DF6264F4C1C2C6C6C6575757E88486A6A6A6181818E0E0E0505050E49597212121868686787878DB4045E4E4E4F5CDCE262626EEA8AAF4C7C8
C90000EEADAFD5D5D5EB9495EA9192E46E71C40000DA3136CD1619FAE4E4FFDFE0FCEDEEE25F62D6D6D6EC9597EB9798EEA6A7D41418EEA1A2737373C0C0C0FD
FBFAEA8C8EEC999AD1090D000000F6D0D1F7DEDEE77B7EE98A8DE88082F1CCCDDD3A3FFAE7E7F0AFB1EA8E90EB9C9ED51D22F2C5C7F0A7AAF2BABBEA9395FDFE
FE060606DA353AF9E6E7FAE2E2F2BDBEF2B7B8F8E4E4F8D8D9F5C2C4E04A4FF0B2B4EC9A9CFFFFFFFBFBFBFEFEFEFDFDFDFCFCFCFFFEFEFAFAFAF9F9F9FFFDFD
F8F8F8F6F6F6F7F7F7FEFDFDFDF8F8F9E1E2FEFCFCFEFFFFFDF7F7FAE5E6FBEBEBFFFEFFF9E3E3FCEEEEFFFCFCE4A8AAEFABADEC5C5FCF2025FEDADBABC0BF9B
B1B0080909F3C3C4FFE3E30F1010F1D3D2D20F12DF5A5DE8B7B9FFFEFDE04C50DF6D6FEA8487FDF5F5F5BEBFFCF1F1F3BBBDF9E5E6707D7CD8464AE78C8EF4A2
A4768786F6D3D4FAE3E4EC9294F4BFC0F8DADCEDC1C3F9DDDEF9DFDFE9AAAADA7C7EFEFBFBFBE1E1FCEFF0535453F3D8D9E68789E1575BFFFDFCF9ECEC8E9393
E8282D232323E8999BFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A45324541463245354338373545323131413343304437443032394336463539432220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A32463439334235323531303231314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A45314543363134303531303131314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F70204353352E312057696E646F7773223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E6365
49443D22786D702E6969643A4533454146324535433837354532313141334330443744303239433646353943222073745265663A646F63756D656E7449443D22
786D702E6469643A4532454146324535433837354532313141334330443744303239433646353943222F3E203C2F7264663A4465736372697074696F6E3E203C
2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEB
EAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACAB
AAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B
6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B
2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000850028004008FF
006DE9A245B020AD5CBA66D5F255EB9F4387B374D9FA372B572E83B4784D7CC89162BE591C73E570020744C78B1DFFD962A872A0C15B1C6FE94AB9B021C759BD
4072B4C5CB66CA9F401F12A8B4A3E3964A493A3AA904E6DF824A1A66499DAAD3612D79527578E133E15F824A2B6A3CACE5A6D292890D2A4DB1396B46A54A13EB
54F2F15042A5062069F5AB34D32192B7952EFC1351E90D0A3088252CA974E09F864A2A66DD2268D167D094B36000AB4A952A4712449EC4F2E4C800050AF366ED
AD14A4EA974A05FE0DADC4C087930574DECE8C5349C1BF1780C53A6C51A9DABF036F1324C8C07C409659652A0D58CE7C0A827F3B2A6D4182408182016F277EFF
A8B4E01F83B765723D6452C9CCBF5A792AD53BB1C0CFD74A4E1C1671D1A8118F4E0E5D2041552901D344139824884900819833CC3E0558F68F1075A8F0101C1A
34504D0328F8124206FF28508708836DD14247076830C03FB948A0811930C2C84002B52000C6230CC498632F428071C74D12B0D1D8612776A081491CB5B0C509
0F1D80C210D538B0058F412043C53FF820D24D009AE0A1493783A0124514BF3C44C6208E50F1008097B54989096DC6091417686812800B98E022E79EFA69C227
47BDD06654256E1C70430E3780B054534F3D22902EBAF8B211506154F0CC3F959C424B4A76CD80E9079B725440254C8E8AC14D8F90FA4F190E30514D25A7FEFF
734225D739948574FFF046C043A322F1E7AFC0062BECB0C412AB0711040E430404D000F6D60B1D81C6C93B58B8E3CE1E8550F4D6A6BD9C02EB5017D4F2964DD9
01F6C83F2520F5DB5C0ED1C01A08D27C70DC294B0821840A2A9C40A22D0E5482840FF87EE14343EE3AC0020B6F55D30248BAF45B9EBB24CE125F0220E0BAD80D
0E29E0EC29C576ECF1C72003E5CA19FF44D0032EB8C8B38B43F890D111007670808B307A7C224F171CCCD249397D440003317B6CE0CFCAF1B8FC8F0ED8EC6100
337A30934A1AF2E0420A108800300B1EADDCA38832EF14430C10DEFCC14D32F3781308370FC96189430180F2CF19B1EC5285144600D1430469F491C92E8560FF
118116B3786347307DE839822CC7C0F0C33B0138E4C21E6D66D08F030EBCF116E50EE401C214B476E44325254C78791EA4E7F1C614416D22881AEFC507150219
A4554916FFDCF2967A1C9DE79B19959451021B41B89B294CD1E1FA50129524C0D16B6FD1FED0791D7C3C54511C8151090B60C8A881BBB13D95C7233494504210
4905950D11D49852C9103F61C06E6104FE63976FB939FB5606BDFC43CB1C95C0F4542520604FADDC570F5D10A0172BA804C6FE312A68790C0473880D47063007
0B7144047958D10CF250865378D08377C1DD3FF4710D2210211480D093555E20BB4C49605742390F605640178764A00C357408081A200D38FC43090E10A143FF
425006261060091AC04C3DAA610B48F4E30D4BA88614ABB10448842C28B84847313AC1452E4AC11BFF60C20CFAF2105DF841382C9AC10B3280041B88B00659F0
C53F7CE107183EC4163660C27BE0600311F8D18F33D8550B66F04740FE880084F4631E5BD0188A0C523D378863476E910534DA42046B4C422278F1905208A20D
96B0442004318A7FD4A31290F8C2094ED00132FE033483D8C30FA0B0073500415B79E08512A0E210E08460168B09D54FD8A02EE0B4E02973E0247BDE30AF53BC
205F274082A76C9116044013092A20186466618B5AD82207D1D95474CA138453E882736380091C2A21817FF4EB443FE9011F02F19059440059E3905750F441FF
0458C0E09F3090C706E4510B69544298C4794B3B3FD71BDCDD213ACA4B575280931F88C8CE01C7C9140826438B5BF8A227D1B9014727D38B5A6447080FF91C13
F5E7B07FB80B9EFA034C1203953C4E1E272D2CB8A24E77CAD39EFAF4A7404D091064F18F409C011054E88AE35ED1113BB88223A5A9533114D10D7174E10731E0
0431D2100555E0031D0FD98018FE410C7CFC2305A84047150261842B50A010F8408628B631017C30E31268E0400C52208A41B08311247808174CF0030BA80110
B388850726000B5630E21AEC300038A6318809444106BF10C008CE108A48F0C003AAB084175461010AC8030DA490021A8C112790CC6217B0DD854EA402147AFF
8091ACE498850E5448566240E4B70EE12D4440020C703C0417C9E08811789B027940C408DAB80967F4348B64F0D6086572483256F60F5C1897221D49C106804B
DBCBA4EA2DA79883E500438017BCC1820F994119DA9985328CC77E5B080A0708B136FDB9E155806100896A37870608D3210378035D125086C500A61A60D8952D
E2F0860410C8071F702044D8200D061028C1F015962D6C310BE47878C413B11E4A93C414A754020598090A1788B0B6C7D04084B340DE413F756006AACA5437D1
DD3F34E4AD5AFDE335469E8534DEB04E8CF2CA5FD2234A47AC673FC0D0C1C5550EC265965181F455220E3FB9155D2AF10121FE23374CCA8D036810871D30C0FF
72FDA805742AF18F8A41E61F6BE81C45DE700A98F0E22E4FF695C7A637A81C0EA7127570F18AF87409414000539530F33FE4E2A94A48237EE942E9633AC0CDA5
CC4127FBAB841C656516B908E61F09AC72537C1C6262D5E07A1D09829E1FE23E1AE0F92D799883AEE750863808D31E4410831D88208807088322B2AEC4180EB3
9853E4C02139F0D60724300084F5C621E9F20D441258006E7ACBA60EE15C6FC45509983AC40F95C8C32C46758A0F7CD08382FE1537E3578B5BC44F320DE1268A
F72DA159C80306F173C82D0E500302B8922386AA01082645117B77443230A98584042E1598FC443252E9A6C4374EE2A07AFCE320FF93314CC88792975C10CDFF
F8C7AB5640A0BF306038C5034C19E03984C0FC03016FF10347ACF016D978ABCA6C585595DF320B19DA6F09D09A85E550CA9B25D871309508FA716AEE2C69C097
149430E13558F78F1038C083D2F0D6021DA20F3E5CE127B5F8C01CE2B3039D40E2C5E822544714F001BA8CA19895E85725F2F70F9E33133965F8092DC60394BB
0FF821BC11CB38B1238DB4BC4127EC4934CE73CA9105CC210800E003233862002228E31C4BB80C0928510193F341108D7048CF67319EEB2CA595990A95081210
020424E1D9B29E6825ACE0E33270B330C7B9AFB398F9C3A137265D80F9C06A125D8BC5BB0B26A7CC69C550F716181280F61778C102624184EC3A2412443044FF
344E810209D00105E67E251F3C80F66D1D1A746A41357E1C420B02D42204F197E8BACA53BB7439A01A739051C4D711B4603985471E147103D2500DB8C30B2DE5
2EBCF70FBC8053B0611EF1F71E04700B79B602FFB0077C100A07D2087CF0687B11700FD1097C60422A48047CC00FEA13691CE116A043111A831E6F6150EE9116
21D07577F610B7906AFFF06A4397078337740A942ED10311A9520D52F11616921687771CAF2275186050BDE3609912724161825A08325CD8856018866238861E
370BE3D503D48205C1A003C1500546600CEC2005C27508316001CE452C3A708757F40B9D500555500C5F382CB8305E7BC20180F00F54700C299106E1D01196FF
2003DC050069A003EC30029FD00DBE150C02A00829F00FC1100399B00E1D410AB1000AC9F50FEF700454C001FF200FEA00089E0012D320000600125060008AB0
01B3600106300984F80F02100C0FA10500F00F7A4006AC4011E1C00864706C6AE008A320156A400131508C2460014405055490093DB0015730029200566DC201
6E6302459002D8F51032F00D1D21034CF5104D600072F010FB15016AB00A927009380012F020000F210994100E9E4004C2B009D6F010AE10050F310CCEA008AC
300264B0015030098C9002C2E0098B100BC020586D100C92100A0E410E2330027DB0082960017F100306B20823600147900C161003EF1005A9D007208109DEAC
D70947E01026200A6D020E31F00F4D20035780082E80050EC1085090128520063CE0021EA027E47005262006EEF00F9E100126300AB880032B13063FE01002B0
0A1C91093AF00A32900626800BC6D0057FA303FFB020F8600CC0800F47700624900C2E400567508C0ED10EACD85DB0200FF2C003478008E04002DBF00967600C
BF600267E00152900251A0094D7004298007D4150857A0053F00037AE010A5500540850B7E4986A8F9130101003B}}
\par\par \b \uc2 Mederi Therapeutics Inc\uc2 . Mederi To  \highlight22\uc2 Launch \highlight\uc2  Improved Stretta RFT3 Technology, Highlight New Data at Digestive Disease Week 2016\b0\par\par\uc2 308 \uc2 words\par \uc2 16 May 2016\par \uc2 Journal of Engineering\par \uc2 JOENG\par 67\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016 Journal of Engineering via VerticalNews.com   \par \par \uc2 2016 MAY 16 (VerticalNews) -- By a News Reporter-Staff News Editor at Journal of Engineering -- \uc2 Mederi Therapeutics Inc\uc2 ., manufacturers of Stretta Therapy for gastroesophageal reflux disease (GERD), \b \highlight22\uc2 announced the launch\b0 \highlight\uc2  of RFT3, the third generation of Stretta technology. The \b \highlight22\uc2 new product\b0 \highlight\uc2  will be \b \highlight22\uc2 launched\b0 \highlight\uc2  at Digestive Disease Week(R) (DDW) 2016, to be held May 21-24 in San Diego. Additionally, Stretta 10-year follow-up data on special patient populations with GERD will be presented in several DDW poster sessions.\par \par {\field{\*\fldinst{HYPERLINK "https://photos.prnewswire.com/prnvar/20160502/362660"}}{\fldrslt{\cf2 \uc2 https://photos.prnewswire.com/prnvar/20160502/362660}}}\par \par \uc2 The New Stretta RFT3 is a re-generation of the clinically proven Stretta system. While the procedure remains the same, new aesthetic, functional, and material improvements will further facilitate ease of use and optimal delivery of Stretta treatment for chronic GERD sufferers.\par \par \uc2 "We are constantly listening to our worldwide users and utilizing that feedback to make incremental improvements to our system," said Bob Knarr, CEO of Mederi. "The third generation of Stretta offers improved interfaces, and automation of certain features to enhance usability and optimize treatment. The new RFT3 catheters are compatible with the existing MDRF1 Generator, allowing maximum versatility of the updated technology. These enhancements demonstrate Mederi's ongoing commitment to quality products."\par \par \uc2 About 30% of adults suffer from chronic GERD. Many of these patients don't completely respond to proton pump inhibitors (PPIs), the most common medication for this condition, and many more are concerned about the risks associated with long-term PPI use, or anti-reflux surgery. Stretta provides a non-surgical, middle option for this patient.\par \par \uc2 Keywords for this news article include: Technology, Gastroenterology, \uc2 Mederi Therapeutics Inc\uc2 ., Digestive System Diseases.\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document JOENG00020160516ec5g000br\par }\page {\par\fs20\b \uc2 Best Practices, Llc\uc2 ; Optimizing a New Pharmaceutical Product's Market Entry through Targeted  \highlight22\uc2 Launch \highlight\uc2  Training for District Sales Managers\b0\par\par\uc2 368 \uc2 words\par \uc2 13 May 2016\par \uc2 Drug Week\par \uc2 DRGW\par 143\par \uc2 English\par \uc2 \u169\'00\'A9 Copyright 2016, Drug Week via NewsRx.com   \par \par \uc2 2016 MAY 20 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- With so much riding on the success of a \b \highlight22\uc2 new product launch\b0 \highlight\uc2 , savvy biopharmaceutical companies are beginning to focus more attention on preparing and measuring performance of the front-line District Sales Managers (DMs) who oversee \b \highlight22\uc2 launch\b0 \highlight\uc2 -related activities in the field.\par \par \uc2 To help sales leaders better understand this rising issue, \uc2 Best Practices, LLC\uc2  conducted a study that identifies the extent, content, channels, venues, and timing of training to prepare DMs for \b \highlight22\uc2 launch\b0 \highlight\uc2 . The study also looks at performance metrics companies are using to ensure these front-line managers are accountable for field results.\par \par \uc2 Interestingly, blended learning (classroom and online) was deemed a highly effective delivery approach for training by 50 percent of the study participants, signaling that while in-person training is viewed as the most effective approach, it is not always feasible because of cost and time.\par \par \uc2 "We are trying to effect a shift in 2016 because to spend $3 million to $4 million on a live meeting every time a product launches...we no longer have that kind of money to spend. So live meetings have been effective, but we believe that if we do it the right way and if we message it the right way, we can be almost as effective with virtual meetings, in cases where it is appropriate. We are trying to essentially boost net sales by not spending this amount of money on things like live meetings," said an Executive Director of Sales for a Top 20 pharma company.\par \par \uc2 "New & Effective Front-Line Management Training Practices to Optimize Performance & Grow Accountability at Launch" uses external benchmarks and executive interviews to ascertain the most appropriate manager training amount and topics for a new product launch. Likewise, the research gathered qualitative and quantitative data to surface current practices and tactics to make front-line managers more accountable for launch performance.\par \par \uc2 Keywords for this news article include: \uc2 Best Practices Llc\uc2 .\par \par \uc2 Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC\par \par \uc2 Document DRGW000020160513ec5d0003w\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw181\pich40\picscaley100\picscalex100\picwgoal2715\pichgoal600
47
4946383961B5002800F7FF00344BAC8293CCB6C1DF6B82C5E1E6F100007D00008DF2F4F8F6F8FA7B91CAB0BBDDDDE2EFE5E9F20011948C9ACD000083CDD5EA52
6DBBF8F9FBA8B5DCFBFCFD000090FAFAFC868AC82345AC425DB3889DD07283C3EDF0F73D5BB35D73BC283CA5ADBADE3455B19DACD8ECEEF6B2BDE10022A00028
A291A1D2D4DAEDBFC9E3EEF0F7001D9D8598CE000994A1AED70930A2FBFCFC7C8DC8C5CEE60000890B299C00049295A6D5A6B2D9BAC4E1D6DCEEAAB8DDDDE2F0
A5B4DA5B76C0001597F4F6FA5571BCF0F2F8B9C1E1A2B2DACAD4E94B69BA000E95C8D1E6B0BCDEDAE0EE011A96000B982B4AACC1CAE56D7CC0F6F6FA00119A00
06954664B800199DA9B6DA3654AFC0CAE3E8EBF48B92CB99ABD6E6EAF41D3BA404299DFDFDFD002DA40B249A9EA6D50025A21436A36A79BD7388C56479BF778F
C9001D99002AA3F4F6F9E3E8F3143BA6CBD1E9AAB2DA4362B50024A24E66B97289C81E40AA9CAAD7637BC1C1CDE5B8BDDF7B8AC6010A8E0029A4000D91E9ECF4
92A3D6152B9D00219FEEF0F8F8FAFCD0D6EA000891768BC9EFF1F700199800169C00048E6474BD0024A098A7D69AA5D29FACD594A0D22E50AE2B46AD4454B0F3
F4F9082BA0EBEEF5707CC1DEE3F0D8DEEDDADDEDD8DCED012099EBEEF698A1D29BADD69EAAD8D4DDEC6781C3D2D9EAC6CBE64859B2E8ECF6E6E9F40D309DD8DE
EED8DDEEA5B0D71C34A101249C1C349F2E40A77487CA001F9FA6B4DC5966B801259BDBE0F0D6DCEC072D9FC8CDE6BCC6E205229700019306259C062098535FB6
7884C5052BA0FFFFFFFEFEFE0026A1E5E9F4FEFFFFFFFFFEFDFEFEFEFFFE0028A0002BA3EAEDF5F8F9FC05279B979DD1C2CCE3979ACDD9DEF04769B84862B5CE
D9ED93A4D395A7D34757AF385BB2EFF3F74F68B4607CBEA6B3DBC1C7E290A4D3B1BEDB96AAD4CDD2E8F5F5FAA7B8DAACBBDCECF0F5081D96BBC8E3ADBDDE1B3E
A8405FB7012BA000139BDFE4EF5769B6D3DCEC9BACD39EA8D2B6C1E07178BEACB4D8EBEDF6C7CFE8D2DAECE5EAF5D9DBEB6D86C699A9D7E3EAF5B4BFDF041D9A
C3CFE8FEFEFF04239AFFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A446F63756D656E74
49443D22786D702E6469643A32444645324438453531453231314536383342314337334644453946314437322220786D704D4D3A496E7374616E636549443D22
786D702E6969643A32444645324438443531453231314536383342314337334644453946314437322220786D703A43726561746F72546F6F6C3D2241646F6265
2050686F746F73686F702043432032303135204D6163696E746F7368223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E6365
49443D224339364446334439334332383038353032384632363733414539413943314243222073745265663A646F63756D656E7449443D224339364446334439
334332383038353032384632363733414539413943314243222F3E203C2F7264663A4465736372697074696F6E3E203C2F7264663A5244463E203C2F783A786D
706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEEDECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDB
DAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEADACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B
9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D6C6B6A696867666564636261605F5E5D5C5B
5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D2C2B2A292827262524232221201F1E1D1C1B
1A191817161514131211100F0E0D0C0B0A090807060504030201000021F904010000FF002C00000000B50028004008FF00FF091C48B0A0C183087D215CC8B0A1
C38710234A9C48F1609C282B567831444B61C57F2C0CB83261628A240A1F53AA5CC9B2A1A507642AFAC26060D4C06A518E45E9003189810A0B04E668016C0517
9408177C795043489782BFBCDDAA91CE0024400D17D528F08880C7811236458112A5021883BE2C4848D0C244181F8C2225B38080D0A9465B2AE0AA2148542582
BE22316AF1C644143A0CE3543884EADB57B41B0C186006F5438512080AA23080419841184A56A0A900C4A096198590121C0AAC840F0E0411AC18590184C44885
FC9830204320880A265CADF8215104F015C62C100C66E48D6BD80E77080A63A2C6008321A27831C0E29FAF2A0FC449FFF445C6409863795A1C1285E271C10C15
30B82F0801389A122D4ACD5F4DB4FA09A8622C710C7E2A40F4491486280103415A1850421E4B8400511799B86280190691D29C6B84381440055E2CF1C5530871
D0C01B35F03191080F0CB3D0013EE0771D41303C920E4906A4C0922F72DC68420B1EB8D8D290441699902A0F18818685937CF4C903B6E960804E6E5064CB0C3E
F8F2075153F4A29A916086B9A326BB14F0DF479A18608E670315538A21684421E1422A1C224810FC1595496605015101303EF0E9900615A091C80C0C1064811E
532C510444C5F491CE312DC8579086CEBDE6500639BD31C329040DA30C14C01890689F0568F010048798B044950881FF2241413670C6A6411CD4709E01E108A4
C50334ECF70F6BD51D4150103EE866C81A423EE44B08509820882C021987A36D11A9A147188688F1CB721B6AEA1004359054C1340899818B095030D112216350
E58517B898A3501707E8935B1E460031C2820BB1304326241EE40B0281D0B002496818510629CA15A48D1E152C514300820AE4CB021F1450830B0DFD4289014B
44A14413DF12448102061440030107C17045073E7A61442A387080402457D8B2C1193318D0C026C430E4CB379500608809FCC6C041C40F8540B212A17CE50B33
2D18300E9F123CF0800F18B8710E13FECC904F4B383C404B15628BE1C30C33642CE6DC742F240116A2C0128A4A2400FF674209461CB0D2007E4F814EC17527AE
F8420A4411450F1FB552C002A7181022061F51F1400447AC008C495F2E2EBAE8BEB0A207E21245F080150229A6D39C10E5308311C4A1409451A11F2441281E9C
7108DC35F801C722971433D108A800D0800141EB21061D0A8C40E7328A6433C1F513BC22023EDC0FA18310103090FB3F385C20C22BD84F3004252C34FBCF2F01
F0C2830ED98B70010E0279004F1A0621D0C62AB7D84229F090891E60C15805A140218C9132EFD0020A3AE14943F6708843406758B78B45320E02010340A105C8
6848A45A402F5D14CD201E98C1120020AC812C2078799841020EA28570FD6121C3088001FE6680753CA60B8530841FFF0285900E3CC05D0D19C60B8C5001901D
A41B0FE81041D4500139DC4A2030C8C414D050032920E40078D083DC58E38A33C88D0585BA98448010853C18E20529FBC50BD211062304232230984D1E2A1083
82302753176448358C608244E8417003F105130464803A10A40805200244FA2106231C630A4610420B0982831974E6200868802BD060802110441D0FD807EA84
4294302C815A03D9417FD418115F38225A15E08140061105B71801661121801E12E1873344025C807CC8017263022344E0207EF2C20A3C500825347022761044
05FC8006349800178760C7410660AB852C60875EA8001592300339B4905815D041417A50AEDDCC23220870852B22E4FF11099C6124AE5002D41CF21B52DEC08F
E10AE442A4B0041318820BD72488894A50034514491C3E104D05E620513DA4630D9BFC872D0A050531843407F5ACC1200ED28E193CA802DC68882F3865809818
E41796D94803F8C7107134600906F0040D8D409D0AB06E21966880219670087A34640427AAC10C25B20741E8C11A5F3C910102C18C664C00040A08AB02903001
FBFDE5201458054F0F92820B0C01044810AB5875D00916ACF21F16A8450C1EE1830AE2E10C701082DC1E4288789441127A30C0211A40830DCC22A203F9C509C0
A003B98A1504EACB86029A200BC73C040558989F6541400530D800B209B147003A50880A36600B9B901E60D411095FFFD8D6B61450037156E28B3468A10B0AB9
AD050830BED119F7B804E9823C5010031F18201DE930440B9AC412E34C211D5030803F1C700A158414B9E08548069214850798F223E0F05B0B1EB51202F80D70
880CAF7C79CB003BC0A10625A880343E728228508794595089057C309292D0E2AEF34D7045623083D254A41506884115A6B047045244813E90C30B4A7212057B
5825FC2840133E12870240C017FE589A0180399E523C401D0888C2E73AFCE11A4BE40E914C490F1EA08F7FC0E00C0B3340506AB9861960C8195CF2522D292001
045000B513F9050C10900C0AB8CFC609C94001788C107C3DEDCA0539C70CA221902B4CC704155003446C3903F6B206FF770CA1800BF450003D44E004D970C100
4AF08019D4E003B5F8EE3F908188071440150398C30DA40187163CC0007A40C4150E828302006F2FB8F09A640C60684B0BE20B0E98344104C0E90754A006B8A8
C00C00E0802B122306A9F84905BC36831E7BE7206D10440110A1862E7401025F089A35A1D28B253C612044D8E16ECEDA10373CA0081E79732C064A107254C000
BA90E2412C408D1AA4F30BF12D882FC61034275CB120983082214A30830DEC470DBAF24303A82D905F040200978982011CE09E0F510A720891002B66800A875C
6909E70065030257901F0802A4A336001A805181532DE4199BCBD30A54B1C18248A00586A8C0369469048D54001B06FF01C70CC250833D3C84139663372C91F9
9C8638604ABB99EA40C261B90A7CE22057A88020147A1002E081E222087801982D907A18C08A05E101CE57BC907B3CE01E0521E39E0A7205F34001760E9140B2
461307826C634A06183144C861803CE4C100B34068321BC281E9C4C9118FB182E5A2803982300035276C08035A058C1A4812229578FAB9FF01F363B0DCE20401
4201309475A2F8A110784A2406A2858B5748A43E2678831142F88F05B4EAF2E17648111ADAAEC7FCB1E60EE181DF0C60EB81CC42E286F00152D2F00000484406
0F088334AD72899026FB930649C0945CE1036A9FE3010136086B440FF92B34A73A498F48175E300534CB1324E52A01FFE63F5F2EE1EC5620AF17574308112357
3DB320C8A8C01BA690095FA4205514F14564A6708C63FCC800BB40740231019EB478026106856208B910781D5000E48010AC010C2D9003A74454AEE26011710E
D16200EF201009200824617812A105DBB202984173EAC7109AD0002560181E701007A0070F020533E04829A10217D00015701E5E000587A00906A143C87710D9
710C86B00F0AE1080EB810C46200024010BF400BDD3744C70411BF200686504658F10FF3D076EE271181D02A2D8081E897500FC1087E73084C47103B5003C080
0BAA322497500846E00568B6863DC0199BE4082DE04DB33103870781B3C45104C1065392075140860D910435404ADFFF27107988066FD71B10410751E00A3B25
77AE51200D114A25B01DFB552251A52212710A368810E5001C51507603D105BDC0779BE40B2F000579404AF8C310A7304B0E60100420125E5003D0F010698007
16725404810D96B31B81C810545001E9A007F4F64761A007A2B61049001C55A1050C612228428A11610A05D02B08610125B00215100004A108DBD47C21130B53
407B0ED18C2461081FB01F0E300353E00715500B0BA17FD7E604F3A11016601968D002A9707E0671005F6000354019076109E66102E9C00AE36301EE80072D50
017DC0620B210B6E0805BE271130900815300E6B45102E5016F632085EF36835706A86360378000A08B10305A04B0892410587A0692F590130E935A580141E11
0958E00FB376081DC0028A100011A00496C60BD4E51098000B6FF300994007D26003835005875000FBD006ABF40BD7406B65E1933530035BD66731A907000006
55B810B5D06933509699069400B37E005003CCF302F7C0029FC00505600094302B2B410C829612BEF00B140003C0C512C3D00516F06487896506D30530209906
1110003B}}
\par\par \b \uc2 Moody's\uc2  Affirms Amneal's Ratings; Outlook Stable\b0\par\par\uc2 2,340 \uc2 words\par \uc2 12 May 2016\par \uc2 Moody's Investors Service Press Release\par \uc2 MOODPR\par \uc2 English\par \uc2 (c) 2016   \par \par \uc2 Moody's Investors Service\uc2 , ("\uc2 Moody's\uc2 ") affirmed the ratings of Amneal Pharmaceuticals LLC ("Amneal") including the B1 Corporate Family Rating and the B1-PD Probability of Default Rating. \uc2 Moody's\uc2  also affirmed the B1 on the senior secured credit facility. The affirmation follows the announcement that the company will upsize its existing term loan by $225 million to fund a shareholder dividend and repay amounts outstanding on the ABL facility. The outlook is stable.\par \par \uc2 Despite increasing adjusted debt/EBITDA to around 4.5x to fund a shareholder dividend, the affirmation reflects \uc2 Moody's\uc2  expectation leverage will decline back to the 4.0x range by the end of 2016 due to EBITDA expansion fueled by \b \highlight22\uc2 new product launches\b0 \highlight\uc2 .\par \par \uc2 Ratings affirmed:\par \par \uc2 Corporate Family Rating, at B1\par \par \uc2 Probability of Default Rating, at B1-PD\par \par \uc2 Senior secured term loan, at B1 (LGD4)\par \par \uc2 The outlook is stable.\par \par \uc2 RATINGS RATIONALE\par \par \uc2 The B1 Corporate Family Rating reflects Amneal's modest scale by revenue in the highly competitive generic pharmaceutical industry. The rating is also constrained by the company's limited cash flow which has been constrained by high expansion-related capital expenditures and working capital investment as well as Amneal's high distributions for shareholder taxes. The rating is also constrained by the expectation that the company will continue to pay dividends to shareholders from time to time.\par \par \uc2 The ratings are supported by Amneal's moderate financial leverage with debt/EBITDA expected to remain around 4.0x or below. The ratings are also supported by Amneal's significant manufacturing capacity in the US and India, its diverse dosage-form development and manufacturing capabilities, including in-house active pharmaceutical ingredient (API) production, as well as the company's proven ability to launch and supply difficult-to-manufacture products. The company has a significant portfolio of new drugs on file with the \uc2 FDA\uc2  and in development that will drive future growth. The ratings are also supported by the company's strong quality track record and good liquidity.\par \par \uc2 Though not anticipated in the near-term, \uc2 Moody's\uc2  could upgrade the ratings if Amneal continues to expand revenue and EBITDA and successfully executes its growth strategy. An upgrade could be considered if the company is expected to maintain adjusted debt to EBITDA below 3.5 times and generate free cash flow to debt of at least 10%.\par \par \uc2 The ratings could be downgraded if \uc2 Moody's\uc2  expects adjusted debt to EBITDA to be sustained above 4.5x. This could occur from acquisitions, shareholder dividends or operating disruption from supply issues or difficulty in getting new products approved and launched. The weakening of liquidity due to an overly aggressive growth strategy could also lead to a downgrade.\par \par \uc2 Amneal Pharmaceuticals LLC ("Amneal"), founded in 2002 and headquartered in Bridgewater, NJ, is a generic pharmaceutical manufacturer with facilities in New York, New Jersey, and India. The company generates most of its revenue in the US but is actively pursuing expansion into international generic markets. Amneal recorded net revenue of $875 million for the twelve months ended March 30, 2016. The company is owned by the founders of \uc2 Amneal Pharmaceuticals\uc2  and the principals of Tarsadia Investments, LLC.\par \par \uc2 The principal methodology used in these ratings was Global Pharmaceutical Industry published in December 2012. Please see the Ratings Methodologies page on {\field{\*\fldinst{HYPERLINK "http://www.moodys.com"}}{\fldrslt{\cf2 \uc2 www.moodys.com}}}\uc2  for a copy of this methodology.\par \par \uc2 REGULATORY DISCLOSURES\par \par \uc2 For ratings issued on a program, series or category/class of debt, this announcement provides certain regulatory disclosures in relation to each rating of a subsequently issued bond or note of the same series or category/class of debt or pursuant to a program for which the ratings are derived exclusively from existing ratings in accordance with \uc2 Moody's\uc2  rating practices. For ratings issued on a support provider, this announcement provides certain regulatory disclosures in relation to the rating action on the support provider and in relation to each particular rating action for securities that derive their credit ratings from the support provider's credit rating. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating. For further information please see the ratings tab on the issuer/entity page for the respective issuer on {\field{\*\fldinst{HYPERLINK "http://www.moodys.com"}}{\fldrslt{\cf2 \uc2 www.moodys.com}}}\uc2 .\par \par \uc2 For any affected securities or rated entities receiving direct credit support from the primary entity(ies) of this rating action, and whose ratings may change as a result of this rating action, the associated regulatory disclosures will be those of the guarantor entity. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.\par \par \uc2 Regulatory disclosures contained in this press release apply to the credit rating and, if applicable, the related rating outlook or rating review.\par \par \uc2 Please see {\field{\*\fldinst{HYPERLINK "http://www.moodys.com"}}{\fldrslt{\cf2 \uc2 www.moodys.com}}}\uc2  for any updates on changes to the lead rating analyst and to the \uc2 Moody's\uc2  legal entity that has issued the rating.\par \par \uc2 Please see the ratings tab on the issuer/entity page on {\field{\*\fldinst{HYPERLINK "http://www.moodys.com"}}{\fldrslt{\cf2 \uc2 www.moodys.com}}}\uc2  for additional regulatory disclosures for each credit rating.\par \par \uc2 Jessica Gladstone\par \par \uc2 Senior Vice President\par \par \uc2 Corporate Finance Group\par \par \uc2 Moody's Investors Service, Inc.\par \par \uc2 250 Greenwich Street\par \par \uc2 New York, NY 10007\par \par \uc2 U.S.A.\par \par \uc2 JOURNALISTS: 212-553-0376\par \par \uc2 SUBSCRIBERS: 212-553-1653\par \par \uc2 Peter H. Abdill, CFA\par \par \uc2 MD - Corporate Finance\par \par \uc2 Corporate Finance Group\par \par \uc2 JOURNALISTS: 212-553-0376\par \par \uc2 SUBSCRIBERS: 212-553-1653\par \par \uc2 Releasing Office:\par \par \uc2 Moody's Investors Service, Inc.\par \par \uc2 250 Greenwich Street\par \par \uc2 New York, NY 10007\par \par \uc2 U.S.A.\par \par \uc2 JOURNALISTS: 212-553-0376\par \par \uc2 SUBSCRIBERS: 212-553-1653\par \par \uc2 \u169\'00\'A9 2016 \uc2 Moody's Corporation\uc2 , Moody's Investors Service, Inc., Moody's Analytics, Inc. and/or their licensors and affiliates (collectively, "\uc2 MOODY'S\uc2 "). All rights reserved.\par \par \uc2 CREDIT RATINGS ISSUED BY MOODY'S INVESTORS SERVICE, INC. AND ITS RATINGS AFFILIATES ("MIS") ARE \uc2 MOODY'S\uc2  CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND CREDIT RATINGS AND RESEARCH PUBLICATIONS PUBLISHED BY \uc2 MOODY'S\uc2  ("\uc2 MOODY'S\uc2  PUBLICATIONS") MAY INCLUDE \uc2 MOODY'S\uc2  CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES. \uc2 MOODY'S\uc2  DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY MAY NOT MEET ITS CONTRACTUAL, FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS AND \uc2 MOODY'S\uc2  OPINIONS INCLUDED IN \uc2 MOODY'S\uc2  PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. \uc2 MOODY'S\uc2  PUBLICATIONS MAY ALSO INCLUDE QUANTITATIVE MODEL-BASED ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY'S ANALYTICS, INC. CREDIT RATINGS AND \uc2 MOODY'S\uc2  PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND CREDIT RATINGS AND \uc2 MOODY'S\uc2  PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. NEITHER CREDIT RATINGS NOR \uc2 MOODY'S\uc2  PUBLICATIONS COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. \uc2 MOODY'S\uc2  ISSUES ITS CREDIT RATINGS AND PUBLISHES \uc2 MOODY'S\uc2  PUBLICATIONS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.\par \par \uc2 MOODY'S CREDIT RATINGS AND \uc2 MOODY'S\uc2  PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS OR \uc2 MOODY'S\uc2  PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER.\par \par \uc2 ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT \uc2 MOODY'S\uc2  PRIOR WRITTEN CONSENT.\par \par \uc2 All information contained herein is obtained by \uc2 MOODY'S\uc2  from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided "AS IS" without warranty of any kind. \uc2 MOODY'S\uc2  adopts all necessary measures so that the information it uses in assigning a credit rating is of sufficient quality and from sources \uc2 MOODY'S\uc2  considers to be reliable including, when appropriate, independent third-party sources. However, \uc2 MOODY'S\uc2  is not an auditor and cannot in every instance independently verify or validate information received in the rating process or in preparing the Moody's Publications.\par \par \uc2 To the extent permitted by law, \uc2 MOODY'S\uc2  and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability to any person or entity for any indirect, special, consequential, or incidental losses or damages whatsoever arising from or in connection with the information contained herein or the use of or inability to use any such information, even if \uc2 MOODY'S\uc2  or any of its directors, officers, employees, agents, representatives, licensors or suppliers is advised in advance of the possibility of such losses or damages, including but not limited to: (a) any loss of present or prospective profits or (b) any loss or damage arising where the relevant financial instrument is not the subject of a particular credit rating assigned by \uc2 MOODY'S\uc2 .\par \par \uc2 To the extent permitted by law, \uc2 MOODY'S\uc2  and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability for any direct or compensatory losses or damages caused to any person or entity, including but not limited to by any negligence (but excluding fraud, willful misconduct or any other type of liability that, for the avoidance of doubt, by law cannot be excluded) on the part of, or any contingency within or beyond the control of, \uc2 MOODY'S\uc2  or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising from or in connection with the information contained herein or the use of or inability to use any such information.\par \par \uc2 NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY SUCH RATING OR OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY \uc2 MOODY'S\uc2  IN ANY FORM OR MANNER WHATSOEVER.\par \par \uc2 Moody's Investors Service, Inc., a wholly-owned credit rating agency subsidiary of \uc2 Moody's Corporation\uc2  ("MCO"), hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody's Investors Service, Inc. have, prior to assignment of any rating, agreed to pay to Moody's Investors Service, Inc. for appraisal and rating services rendered by it fees ranging from $1,500 to approximately $2,500,000. MCO and MIS also maintain policies and procedures to address the independence of MIS's ratings and rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities who hold ratings from MIS and have also publicly reported to the \uc2 SEC\uc2  an ownership interest in MCO of more than 5%, is posted annually at {\field{\*\fldinst{HYPERLINK "http://www.moodys.com"}}{\fldrslt{\cf2 \uc2 www.moodys.com}}}\uc2  under the heading "Investor Relations -- Corporate Governance -- Director and Shareholder Affiliation Policy."\par \par \uc2 Additional terms for Australia only: Any publication into Australia of this document is pursuant to the Australian Financial Services License of \uc2 MOODY'S\uc2  affiliate, Moody's Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody's Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to "wholesale clients" within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to \uc2 MOODY'S\uc2  that you are, or are accessing the document as a representative of, a "wholesale client" and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to "retail clients" within the meaning of section 761G of the Corporations Act 2001. \uc2 MOODY'S\uc2  credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail investors. It would be reckless and inappropriate for retail investors to use \uc2 MOODY'S\uc2  credit ratings or publications when making an investment decision. If in doubt you should contact your financial or other professional adviser.\par \par \uc2 Additional terms for Japan only: Moody's Japan K.K. ("MJKK") is a wholly-owned credit rating agency subsidiary of Moody's Group Japan G.K., which is wholly-owned by Moody's Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody's SF Japan K.K. ("MSFJ") is a wholly-owned credit rating agency subsidiary of MJKK. MSFJ is not a Nationally Recognized Statistical Rating Organization ("NRSRO"). Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJKK and MSFJ are credit rating agencies registered with the \uc2 Japan Financial Services Agency\uc2  and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.\par \par \uc2 MJKK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJKK or MSFJ (as applicable) have, prior to assignment of any rating, agreed to pay to MJKK or MSFJ (as applicable) for appraisal and rating services rendered by it fees ranging from JPY200,000 to approximately JPY350,000,000.\par \par \uc2 MJKK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.\par \par \uc2 Document MOODPR0020160512ec5c004ed\par }\page {\par\fs20\uc2 Business\par \b \uc2 Mylan  \highlight22\uc2 Launches \highlight\uc2  Generic Frova Tablets In U.S. - Quick Facts\b0\par\par\uc2 164 \uc2 words\par \uc2 12 May 2016\par \uc2 RTT News\par \uc2 RTTNEW\par \uc2 English\par \uc2 \u169\'00\'A9 2016 NoticiasFinancieras. All Rights Reserved. \par \par \uc2 (RTTNews) - Pharmaceutical company \uc2 Mylan N.V\uc2 . (MYL) said it \b \highlight22\uc2 launched\b0 \highlight\uc2  Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova Tablets, in the U.S.\par \par \uc2 Mylan received final approval from the \uc2 U.S. Food and Drug Administration\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application or ANDA for this product, which is used to treat acute migraine headaches in adults.\par \par \uc2 According to \uc2 IMS Health\uc2 , Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of about $88.3 million for the 12 months ending March 31, 2016.\par \par \uc2 Currently, Mylan has 260 ANDAs pending \uc2 FDA\uc2  approval, representing $109.1 billion in annual brand sales, according to \uc2 IMS Health\uc2 . Forty-seven of these pending ANDAs are potential first-to-file opportunities, representing $37.5 billion in annual brand sales, for the 12 months ending December 31, 2015.\par \par \uc2 For comments and feedback: contact editorial@rttnews.com\par \par \uc2 Copyright(c) 2016 RTTNews.com. All Rights Reserved\par \par \uc2 Document RTTNEW0020160512ec5c003ux\par }\page {\par\fs20{\*\shppict{\pict\pngblip\picw114\pich40\picscaley100\picscalex100\picwgoal1710\pichgoal600
47
494638396172002800F7000006080907090A090B0CFEFEFEFDFDFDFCFCFCEDEDEEF5F5F5FBFBFB0A0C0DF8F8F8F1F1F1F6F6F60E10110B0D0E828383F0F0F0F7
F7F7F2F2F21E20210C0E0F121415080A0B131516FAFAFABCBDBD0D0F1027292AF3F3F31A1B1C111314212324303233232526EFEFF018191A151717CCCCCD1B1C
1D101213F4F4F4696A6B3C3D3EB7B8B8A6A6A7313334D5D5D53638382B2D2E161818141617CECECF292B2CF9F9F9A9A9AAE8E9E9E6E7E7BFC0C0585A5A4D4E4F
191A1BEAEBEBCBCBCC777878A7A7A8AEAEAFC1C2C2ACACAD2C2E2FDBDBDB7A7B7BD7D7D78C8D8E2628298081811E1F203F4041BBBCBC2D2F30C0C1C1ECEDED7D
7E7EE5E5E5E9EAEAEEEEEFC7C8C89798984041420F11123537375F6061E7E8E8D3D3D34344454A4B4C6F7071BABBBBC2C3C3989999EBECECA2A3A3B2B2B23436
362224253335363A3C3C2E3031E4E4E4B5B6B6E1E1E1626364282A2B7B7C7C727374CFCFD0DFDFDFCDCDCE48494A969797B4B5B5B8B9B9171919444546CACACB
A5A6A65C5E5E252728DADADAE6E6E69FA0A0D8D8D84546476667681D1E1FAAAAAB1C1D1E4748493739399596968B8C8DC4C5C5A1A2A29D9E9ED1D1D17F80805D
5F5F575959999A9AADADAE68696A616263414243707172AFAFB0555757747575595B5B525455646566E3E3E3C9CACAE0E0E08A8B8C8283846364655052537374
74BEBFBF4E4F502A2C2DDDDDDDD2D2D2B9BABA535555ABABAC6A6B6CBDBEBE9192939293939E9F9F242627494A4B6E6F709A9B9B9C9D9DDCDCDCC3C4C4C5C6C6
868788B1B1B2383A3A6D6E6F1F21229B9C9C8788895051525B5D5D797A7A515354848586323435E2E2E24B4C4D202223A4A5A5676869A8A8A9898A8B9394943B
3C3D3D3E3FC8C9C97E7F7FB0B0B19495959091925E6060B3B3B3D0D0D18E8F90A0A1A17879795456567576766B6C6D5A5C5CDEDEDEB4B4B4C6C7C76C6D6E4F50
51D9D9D9D4D4D48F9091A3A4A4656667B6B7B77C7D7D71727388898A424344393B3B4C4D4E2F31325658588384853E3F40767777D6D6D6464748858687606162
8D8E8F818282050708FFFFFF21FF0B584D502044617461584D503C3F787061636B657420626567696E3D22EFBBBF222069643D2257354D304D7043656869487A
7265537A4E54637A6B633964223F3E203C783A786D706D65746120786D6C6E733A783D2261646F62653A6E733A6D6574612F2220783A786D70746B3D2241646F
626520584D5020436F726520352E362D633131312037392E3135383332352C20323031352F30392F31302D30313A31303A32302020202020202020223E203C72
64663A52444620786D6C6E733A7264663D22687474703A2F2F7777772E77332E6F72672F313939392F30322F32322D7264662D73796E7461782D6E7323223E20
3C7264663A4465736372697074696F6E207264663A61626F75743D222220786D6C6E733A786D704D4D3D22687474703A2F2F6E732E61646F62652E636F6D2F78
61702F312E302F6D6D2F2220786D6C6E733A73745265663D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F73547970652F5265736F75
726365526566232220786D6C6E733A786D703D22687474703A2F2F6E732E61646F62652E636F6D2F7861702F312E302F2220786D704D4D3A4F726967696E616C
446F63756D656E7449443D22786D702E6469643A30323830313137343037323036383131383038334146373433433236323731452220786D704D4D3A446F6375
6D656E7449443D22786D702E6469643A42384642314346413530463531314536393838464545313643313433353536382220786D704D4D3A496E7374616E6365
49443D22786D702E6969643A42384642314346393530463531314536393838464545313643313433353536382220786D703A43726561746F72546F6F6C3D2241
646F62652050686F746F73686F702043533620284D6163696E746F736829223E203C786D704D4D3A4465726976656446726F6D2073745265663A696E7374616E
636549443D22786D702E6969643A3443454533314539313945393131453341463330383738423534393031323445222073745265663A646F63756D656E744944
3D22786D702E6469643A3443454533314541313945393131453341463330383738423534393031323445222F3E203C2F7264663A4465736372697074696F6E3E
203C2F7264663A5244463E203C2F783A786D706D6574613E203C3F787061636B657420656E643D2272223F3E01FFFEFDFCFBFAF9F8F7F6F5F4F3F2F1F0EFEEED
ECEBEAE9E8E7E6E5E4E3E2E1E0DFDEDDDCDBDAD9D8D7D6D5D4D3D2D1D0CFCECDCCCBCAC9C8C7C6C5C4C3C2C1C0BFBEBDBCBBBAB9B8B7B6B5B4B3B2B1B0AFAEAD
ACABAAA9A8A7A6A5A4A3A2A1A09F9E9D9C9B9A999897969594939291908F8E8D8C8B8A898887868584838281807F7E7D7C7B7A797877767574737271706F6E6D
6C6B6A696867666564636261605F5E5D5C5B5A595857565554535251504F4E4D4C4B4A494847464544434241403F3E3D3C3B3A393837363534333231302F2E2D
2C2B2A292827262524232221201F1E1D1C1B1A191817161514131211100F0E0D0C0B0A090807060504030201000021F90400000000002C000000007200280040
08FF00FF091C48B0A0C18308132A5CC8B0A1C3870409B878E1AFA2C50B3F92112038458D3F07162B8E8048B2A4C987AE2CEA108861D8453A03415DB0E865E3C2
31E70E28A404C4C5B993FFA414B16912829C02734221E412B269C56E03C7D0C1C384D5C194FE02C01458E419B73DCEA6E060B1EB1F9E67A28214A806EB5F1320
08C0045081E21F032B90B2FD1B736BC6BF6A4D06547950CD87A102E7C424FB97AD5EBA55FF7C582910CACA9A7FA01EA8A3E4A38D2205E3D8212CA190C106A7A8
43F23000B4B5EBD727677CA8186900ECDBB80B8AB39884E139D6B200580CD42E41EEE3B915A44AED2F5319194E4D401058057A0717030764ABE04097297FAD94
01FF78A7C91F377BFE64918071279A3F7416B0F1F167C35FAA200D6885F10763933F62CCF8A3C71D5AF8F30B45542CC1C313147442C421B878F041300E08530D
1F51F8A30410FE18B0410B067D61110FAA0C440007FF0CC15C451310144E48883080DC8C34FEF3842D963C51E38E3CBE36C01E6968D3E390348671454809E041
E492084DA3814594484010065BB802831D04F5804553B130E925416458140C418B38F08941112C635108380834CD97700A44414514B0924C6A62F0621100A2FD
13481D061541833FFF44114006DA2030D01E53FCE3C204CB809208A150FC43C0020BFC03410911FC53C07447F4F04F04FE70C280261E2CE0C3401CF85097043A
71FFF02A8A7FC82190231D7E989004C0A496C46202E1338245291484424501E828D0271B60F1CF0301E8C28A3F9AE811C023103C7204307AFCC304A1EDF89300
3578F843C83F4900F0843FA6FC63C215FFF863CB3F9D6870402CFE64E00F3280F4A0CA01FE08B0CF1B16C83045009E1CE14F39F57908624103D861414500E4F0
0F19003820C08AFE24A140411C56548A6D40DD1007207122B48870FED090294244709CDA2D29D7EC6653F52CD0C6386EA042030C5E8C824E5D36176DF4D13C2E
A013D24C1B9B21325434DDF402DB5814001252F308051FB338C2C29909153353481AB4993572B7B0EC4F17FCB000043FAD7CA0033E03F9D0C810833425C9D9C8
2DFF272E100AF1420D06A39A61110527F88332DFB8CD571124052D6DD01A1E5874EE2EC6309E5B23166D3350110DF873461805C11152109ACF28C58884CFE294
220370E08B452408448094051170835F3FF8B302420520E2CF3215104AD21C6DFCE3853FB89B64853F507410C242E404409313A9390052459C287A849A589B08
0700000C428A3F1F54108201508010C008A3AC03400297508444213E6833410AB3146241087B98C104D0508142D061360EA845250460820AB442013E58823F42
1004275CE100C8C807074060861424200134D882EB1CA6905B6C0C35E110081B12D094DF0DC4162223482E3ED0807F2821007B38853F6A71097F84CE1F814802
22FFBC45286450201C2308843F5027097FE8100EFF380113E2F5837FB44200FF9085EF7C58110D20C102F038830054E08F23B40300D07945C37485905730C713
052902F6FC70038334D11FF3B00901EA203A526880116048C02B98B1257F744001210054171CF08F64584000A7F8070C024681454C2300F7F807B7FE3113277C
E10207B04600D8100516FA031CFF4043B2E21080674C615832A000265C01000310E10508418345CE500DB511EB1F9628840C6290872A1A641C14AB876BAA3027
74306D0CBDAA882606428D57D84166CF28881F2C12A3D491A45C14EBD24156F043D434401DDFE8845352E84D8810E00F3BF0872E12C2850EC8CC2985E8543B8F
331D001034E503DF4A8D174AB44F1A59A178FEA800410BCAD0863A546A0101003B}}
\par\par \b \uc2 Mylan  \highlight22\uc2 launches \highlight\uc2  generic Frova tablets\b0\par\par\uc2 96 \uc2 words\par \uc2 12 May 2016\par \uc2 Theflyonthewall.com\par \uc2 FLYWAL\par \uc2 English\par \uc2 (c) 2016. Theflyonthewall.com.  All Rights Reserved.   \par \par \uc2 Mylan announced the U.S. \b \highlight22\uc2 launch\b0 \highlight\uc2  of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova Tablets. Mylan received final approval from the \uc2 FDA\uc2  for its Abbreviated \b \highlight22\uc2 New Drug\b0 \highlight\uc2  Application for this product, which is used to treat acute migraine headaches in adults. Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of approximately $88.3M for the 12 months ending March 31, according to \uc2 IMS Health\uc2 . Currently, Mylan has 260 ANDAs pending \uc2 FDA\uc2  approval representing $109.1B in annual brand sales, according to \uc2 IMS Health\uc2 . \par \par \uc2 Document FLYWAL0020160512ec5c0028n\par }\par \b \uc2 Search Summary: gizem2\b0\par \par  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Text\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 ns=C22 and (hlp=((new device or new devices or new drug or new drugs or new product or new products) and (announced the launch or announces the launch or launch or launches or launched or announced new or announces new or announces launch or introduce or introduces or introduced)) or ns=(CDINN or CGVFIL)) and in=(I257 or I372) and fmt=article and date from 01/01/2013 to 12/31/2016 and roo=USA and re=USA and la=en not (ns=(CMARKR or c01 or CIPROF or C41 or C18 or C133 or NRMF or NNAM or NOBT or NLIST or NHOC or C1521 or NAMT) or in=IDDTECH or Drug Administration announced approval)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Date\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Dates\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Source\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 Not US Food and Drug Administration News (Abstracts)\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Author\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Authors\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Company\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2  Not U.S. Food and Drug Administration\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Subject\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Subjects\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Industry\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 All Industries\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Region\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 United States Not China Not Japan Not Europe\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Language\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 English\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Results Found\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 1,392\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row } \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \uc2 Timestamp\cell \pard \ql \li0\ri0\widctlpar\intbl\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \li50\uc2 30 April 2019 15:03\cell \pard \ql \li0\ri0\widctlpar\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {  \trowd\trgaph15\trqc\trleft-15 \clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx2000\clvertalt\clbrdrt\brdrs\clbrdrl\brdrs\clbrdrb\brdrs\clbrdrr\brdrs \cellx9360\row }\par }}